Michael Andreeff, M.D., Ph.D.

Peer-Reviewed Articles

1. Akiyama H, Nishida Y, Chang KH, Bedoy A, Muftuoglu M, Ma W, Basyal M, Alaniz Z, Honma D, Tsutsumi S, Wang J, Zhang W, Rampal RK, Oluwole OO, Bixby DL, Daver NG, Andreeff M. Dual Targeting of EZH1 and EZH2 Drives Exit of Leukemia Stem Cells from quiescence and Potentiates Chemotherapy in Acute Myeloid Leukemia. Blood Cancer J. e-Pub 2025.
2. Sankalparrora, Yilmaz M, Jen WY, Deshmukh IA, Loghavi S, Issa GC, Short NJ, Kadia TM, DiNardo C, Borthakur G, Pemmaraju N, Andreeff M, Takahashi K, Bhalla K, Popat UR, Shpall E, Oran B, Abbas HA, Garcia-Manero G, Ravandi-Kashani F, Kantarjian HM, Daver N. Characteristics and Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia with FLT3-Tyrosine Kinase Domain (TKD) mutations. e-Pub 2025.
3. Jen W, Montalban-Bravo G, Wang X, Loghavi S, Lavu S, Short N, Chien K, Issa G, Pemmaraju N, Yilmaz M, Andreeff PM, Borthakur G, Kadia T, Daver N, Garcia-Manero G, Mill C, Su X, Fiskus W, Bhalla K, DiNardo C. Phase 1b/2 study of omacetaxine and venetoclax for patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome (MDS) harboring mutant RUNX1. e-Pub 2025.
4. Battula VL, Anand V, El-Dana F, Baran N, Borgman J, Yin Z, Zhao H, Wong S, Andreeff M. GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function. e-Pub 2025.
5. Daver N, Senapati J, Kantarjian HM, Wang B, Reville P, Loghavi S, Yilmaz M, DiNardo C, Kadia T, Mhd Y, Maiti A, Arora S, Montalban-Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez G, Ning J, Issa G, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas H. Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis Corresponding Author. e-Pub 2025.
6. Khanna, P, Ostermann, LB, Khazaei, S, Zhao, R, Andreeff, M, Pourebrahim, R. Protocol for monitoring clonal hematopoiesis in transgenic mouse models using multispectral imaging. STAR Protocols 5(4), 2024. e-Pub 2024. PMID: 39423122.
7. Cuglievan, B, Kantarjian, HM, Rubnitz, JE, Cooper, T, Zwaan, CM, Pollard, J, DiNardo, C, Kadia, TM, Guest, E, Short, NJ, McCall, DC, Daver, N, Nunez, CA, Haddad, FG, Garcia, MB, Bhalla, K, Maiti, A, Catueno, S, Fiskus, WC, Carter, BZ, Gibson, A, Roth, M, Khazal, SJ, Tewari, P, Abbas, HA, Bourgeois, W, Andreeff, M, Shukla, N, Truong, D, Connors, JS, Ludwig, JA, Stutterheim, J, Salzer, E, Juul-Dam, KL, Sasaki, K, Mahadeo, KM, Tasian, SK, Borthakur, G, Dickson, S, Jain, N, Jabbour, EJ, Meshinchi, S, Garcia-Manero, G, Ravandi, F, Stein, EM, Kolb, EA, Issa, GC. Menin inhibitors in pediatric acute leukemia. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
8. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109(8):2660-2664, 2024. e-Pub 2024. PMID: 38572554.
9. Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad FG, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. Int J Hematol 120(2):203-211, 2024. e-Pub 2024. PMID: 38748089.
10. Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of Dasatinib and Venetoclax in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
11. DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, Sumi H, Hizukuri Y, Hong Y, Patel P, Seki T, Duan T, Lesegretain A, Andreeff M. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Med 13(14):e70028, 2024. e-Pub 2024. PMID: 39030997.
12. Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C Mutations in Patients with Myeloid Malignancies. Leuk Lymphoma:1-5. e-Pub 2024. PMID: 38856690.
13. Yu G, Zhang W, Basyal M, Nishida Y, Mizumo H, Ly C, Zhang H, Rice WG, Andreeff M. The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases. Leuk Lymphoma:1-16. e-Pub 2024. PMID: 38871487.
14. Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. Venetoclax and cobimetinib in relapsed/refractory AML: a phase 1b trial. Clin Lymphoma Myeloma Leuk 24(6):364-374, 2024. e-Pub 2024. PMID: 38378362.
15. Pourebrahim R, Montoya RH, Akiyama H, Ostermann L, Khazaei S, Muftuoglu M, Baran N, Zhao R, Lesluyes T, Liu B, Khoury JD, Gagea M, Van Loo P, Andreeff M. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice. Cell Rep Med 5(5):101558, 2024. e-Pub 2024. PMID: 38733986.
16. Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia 38(4):729-740, 2024. e-Pub 2024. PMID: 38148395.
17. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9(48):eadh1436, 2023. e-Pub 2023. PMID: 38019903.
18. Figueroa M, Ma H, Alfayez M, Morales-Mantilla DE, Wang F, Lu Y, Estecio MR, King KY, Kleinerman E, Moghaddam SJ, Daver N, Andreeff M, Konopleva M, DiNardo C, Chandra J. Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. Blood Adv 7(21):6624-6629, 2023. e-Pub 2023. PMID: 37486624.
19. Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108(10):2626-2638, 2023. e-Pub 2023. PMID: 37078252.
20. Ebner J, Schmoellerl J, Piontek M, Manhart G, Troester S, Carter BZ, Neubauer H, Moriggl R, Szakács G, Zuber J, Köcher T, Andreeff M, Sperr WR, Valent P, Grebien F. ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. Nat Commun 14(1):5709, 2023. e-Pub 2023. PMID: 37726279.
21. Carter BZ, Mak PY, Tao W, Ostermann LB, Mak DH, Ke B, Ordentlich P, McGeehan GM, Andreeff M. Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica 108(9):2513-2519, 2023. e-Pub 2023. PMID: 36727398.
22. Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Epichaperome inhibition targets TP53-mutant AML and AMl stem/progenitor cells. Blood 142(12):1056-1070, 2023. e-Pub 2023. PMID: 37339579.
23. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
24. Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A Phase 1/2 Study of Azacitidine, Venetoclax and Pevonedistat in Newly Diagnosed Secondary AML and in MDS or CMML after Failure of Hypomethylating Agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
25. Glytsou C, Chen X, Zacharioudakis E, Al-Santli W, Zhou H, Nadorp B, Lee S, Lasry A, Sun Z, Papaioannou D, Cammer M, Wang K, Zal T, Zal MA, Carter BZ, Ishizawa J, Tibes R, Tsirigos A, Andreeff M, Gavathiotis E, Aifantis I. Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia. Cancer Discov 13(7):1656-1677, 2023. e-Pub 2023. PMID: 37088914.
26. Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J 13(1):101, 2023. e-Pub 2023. PMID: 37386016.
27. Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
28. Bhattacharya S, Piya S, Ma H, Sharma P, Zhang Q, Baran N, Ruvolo VR, McQueen T, Davis RE, Pourebrahim R, Konopleva M, Kantarjian H, Cosford NDP, Andreeff M, Borthakur G. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) overcomes adaptive drug resistance in acute myelogenous leukemia. Mol Cancer Res 21(6):548-563, 2023. e-Pub 2023. PMID: 36787422.
29. Zhang W, Yu G, Zhang H, Basyal M, Ly C, Yuan B, Ruvolo V, Piya S, Bhattacharya S, Zhang Q, Borthakur G, Battula V, Konopleva M, Rice WG, Andreeff M. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through inhibition of autophagy. Haematologica 108(6):1500-1514, 2023. e-Pub 2023. PMID: 36226489.
30. Jia Y, Zhang W, Basyal M, Chang KH, Ostermann L, Burks JK, Ly C, Mu-Mosley H, Zhang Q, Han X, Fogler WE, Magnani JL, Lesegretain A, Zal AA, Zal T, Andreeff M. FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia 37(6):1379-1383, 2023. e-Pub 2023. PMID: 37085610.
31. Pourebrahim R, Heinz Montoya R, Alaniz Z, Ostermann L, Lin PP, Liu B, Ayoub E, Burks JK, Andreeff M. Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. Cell Death Dis 14(6):371, 2023. e-Pub 2023. PMID: 37353528.
32. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):80, 2023. e-Pub 2023. PMID: 37193700.
33. Akiyama H, Carter BZ, Andreeff M, Ishizawa J. Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia. Cells 12(8):1128, 2023. e-Pub 2023. PMID: 37190037.
34. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):57, 2023. e-Pub 2023. PMID: 37088806.
35. Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
36. Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood 141(11):1265-1276, 2023. e-Pub 2023. PMID: 36265087.
37. Yu G, Zhang W, Zhang H, Ly C, Basyal M, Rice WG, Andreeff M. The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases. Res Sq, 2023. e-Pub 2023. PMID: 36865133.
38. Zhang, Q, Riley-Gillis, B, Han, L, Jia, Y, Lodi, A, Zhang, H, Ganesan, S, Pan, R, Konoplev, SN, Sweeney, SR, Ryan, J, Jitkova, Y, Dunner, K, Grosskurth, SE, Vijay, P, Ghosh, S, Lu, C, Ma, W, Kurtz, S, Ruvolo, VR, Ma, H, Weng, C, Ramage, CL, Baran, N, Shi, C, Cai, T, Davis, RE, Battula, VL, Mi, YC, Wang, J, DiNardo, C, Andreeff, M, Tyner, JW, Schimmer, AD, Letai, AG, Padua, RA, Bueso-Ramos, CE, Tiziani, S, Leverson, JD, Popovic, R, Konopleva, M. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduction and Targeted Therapy 7(1), 2022. e-Pub 2022. PMID: 35185150.
39. Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma doi: 10.1080/10428194.2022.2118533. Online ahead of print(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
40. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):3848-3857, 2022. e-Pub 2022. PMID: 35704787.
41. Nishida, Y, Scruggs, DA, Ayoub, E, Patsilevas, T, Ruvolo, VR, Mak, PY, Carter, BZ, Boettcher, S, Maiti, A, Zhou, Q, Yang, Z, Yan, H, Ma, L, Andreeff, M. AML-147 C-MYC Targeting by Degradation. Clinical Lymphoma, Myeloma and Leukemia 22:S218, 2022. e-Pub 2022. PMID: 36163775.
42. Akiyama, H, Zhao, R, Nishida, Y, Ostermann, LB, Mak, PY, Ayoub, E, Piya, S, Carter, BZ, Andreeff, M, Ishizawa, J. AML-250 Mitochondrial Respiration Regulates GPX4 Inhibition-Induced Ferroptosis in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S229, 2022. e-Pub 2022. PMID: 36163797.
43. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
44. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
45. Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36(9):2228-2232, 2022. e-Pub 2022. PMID: 35941212.
46. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
47. Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica 107(6):1311-1322, 2022. e-Pub 2022. PMID: 34732043.
48. Carter BZ, Mak PY, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, Jabbour EJ, Hughes PE, Chen X, Morrow PK, Andreeff M. Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Mol Cancer Ther 21(6):879-889, 2022. e-Pub 2022. PMID: 35364607.
49. Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun 13(1):2801, 2022. e-Pub 2022. PMID: 35589701.
50. Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
51. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. e-Pub 2022. PMID: 35484266.
52. Piya S, Yang Y, Bhattacharya S, Sharma P, Ma H, Mu H, He H, Ruvolo V, Baran N, Davis RE, Jain AK, Konopleava M, Kantarjian H, Andreeff M, You MJ, Borthakur G. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia 36(5):1261-1273, 2022. e-Pub 2022. PMID: 35173274.
53. Li L, Muftuoglu M, Liang S, Basyal M, Lv J, Akdogan ME, Chen K, Andreeff M, Flowers CR, Parmar S. In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight 7(7), 2022. e-Pub 2022. PMID: 35230977.
54. Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 7(1):110, 2022. e-Pub 2022. PMID: 35365596.
55. Yamatani, K, Ai, T, Saito, K, Suzuki, K, Hori, A, Kinjo, S, Ikeo, K, Ruvolo, VR, Zhang, W, Mak, PY, Kaczkowski, B, Harada, H, Katayama, K, Sugimoto, Y, Myslinski, J, Hato, T, Miida, T, Konopleva, M, Hayashizaki, Y, Carter, BZ, Tabe, Y, Andreeff, M. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Translational Oncology 18, 2022. e-Pub 2022. PMID: 35114569.
56. Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, Ikeo K, Ruvolo V, Zhang W, Mak P, Kaczkowski B, Harada H, Katayama K, Sugimoto Y, Myslinski J, Hato T, Miida T, Konopleva M, Andreeff M. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Translational Oncology 18, 2022. e-Pub 2022.
57. Ganan Gomez, I, Yang, H, Ma, F, Montalban Bravo, G, Thongon, N, Marchica, V, Richard-Carpentier, G, Chien, KS, Manyam, GC, Wang, F, Alfonso Pierola, A, Chen, S, Class, CA, Kanagal Shamanna, R, Ingram, JP, Ogoti, Y, Rose, A, Loghavi, S, Lockyer, P, Cambo, B, Muftuoglu, M, Schneider, S, Ademà Llobet, V, McLellan, MD, Garza, J, Marchesini, M, Giuliani, N, Pellegrini, M, Wang, J, Walker, J, Li, Z, Takahashi, K, Leverson, JD, Bueso-Ramos, CE, Andreeff, M, Dwyer, KC, Garcia-Manero, G, Colla, S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature medicine 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
58. Jaggupilli A, Ly S, Nguyen K, Anand V, Yuan B, El-Dana F, Yan Y, Arvanitis Z, Piyarathna DWB, Putluri N, Piwnica-Worms H, Manning HC, Andreeff M, Battula VL. Metabolic stress induces GD2+ cancer stem cell-like phenotype in triple-negative breast cancer. Br J Cancer 126(4):615-627, 2022. e-Pub 2022. PMID: 34811508.
59. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):672-675, 2022. e-Pub 2022. PMID: 34668451.
60. Shao C, Anand V, Andreeff M, Battula VL. Ganglioside GD2: A Novel Therapeutic Target in Triple-Negative Breast Cancer. Ann N Y Acad Sci 1508(1):35-53, 2022. e-Pub 2022. PMID: 34596246.
61. Andreeff M. Biochim Biophys Acta Mol Cell Res 1869(4):119207. e-Pub 2022. PMID: 35101696.
62. Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and Safety of Enasidenib and Azacitidine Combination in Patients with IDH2 mutated Acute Myeloid Leukemia and Not Eligible for Intensive Chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
63. Mu-Mosley H, Ostermann L, Muftuoglu M, Vaidya A, Bonifant CL, Velasquez MP, Gottschalk S, Andreeff M. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models. Front Immunol 13:880108, 2022. e-Pub 2022. PMID: 35615350.
64. Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N. Single-cell Polyfunctional Proteomics of CD4 Cells from Patients with AML Predicts Responses to Anti-PD-1-based therapy. Blood Adv 5(22):4569-4574, 2021. e-Pub 2021. PMID: 34555853.
65. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
66. Saito K, Zhang Q, Yang H, Yamatani K, Ai T, Ruvolo V, Baran N, Cai T, Ma H, Jacamo R, Kuruvilla V, Imoto J, Kinjo S, Ikeo K, Moriya K, Suzuki K, Miida T, Kim YM, Vellano CP, Andreeff M, Marszalek JR, Tabe Y, Konopleva M. Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition. Blood Adv 5(20):4233-4255, 2021. e-Pub 2021. PMID: 34507353.
67. Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127(20):3761-3771, 2021. e-Pub 2021. PMID: 34171128.
68. Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 12(21):2231, 2021. e-Pub 2021. PMID: 34676056.
69. Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in Patients with Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia with or without Venetoclax-Based Therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
70. Carter BZ, Tao W, Mak PY, Ostermann LB, Mak D, McGeehan G, Ordentlich P, Andreeff M. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood 138(17):1637-1641, 2021. e-Pub 2021. PMID: 34232981.
71. Gorombei P, Guidez F, Ganesan S, Chiquet M, Pellagatti A, Goursaud L, Tekin N, Beurlet S, Patel S, Guerenne L, Le Pogam C, Setterblad N, de la Grange P, LeBoeuf C, Janin A, Noguera ME, Sarda-Mantel L, Merlet P, Boultwood J, Konopleva M, Andreeff M, West R, Pla M, Adès L, Fenaux P, Krief P, Chomienne C, Omidvar N, Padua RA. BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. Int J Mol Sci 22(19):10658, 2021. e-Pub 2021. PMID: 34638998.
72. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
73. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):2768-2778, 2021. e-Pub 2021. PMID: 34043428.
74. Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Therapeutic Implications of Menin Inhibition in Acute Leukemias. Leukemia 35(9):2482-2495, 2021. e-Pub 2021. PMID: 34131281.
75. Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA, Whitesell L, Andreeff M, Ishizawa J. Inhibition of Translation Initiation Factor eIF4a Inactivates Heat Shock Factor 1 (HSF1) and Exerts Anti-Leukemia Activity in AML. Leukemia 35(9):2469-2481, 2021. e-Pub 2021. PMID: 34127794.
76. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
77. Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, Mirali S, Wang X, Gronda M, Jitkova Y, MacLean N, Arruda A, Alaniz Z, Konopleva MY, Andreeff M, Minden MD, Zhang L, Schimmer AD. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood 138(3):234-245, 2021. e-Pub 2021. PMID: 34292323.
78. Muftuoglu M, Li L, Liang S, Mak D, Lin AJ, Fang J, Burks JK, Chen K, Andreeff M. Extended Live-cell Barcoding Approach for Multiplexed Mass Cytometry. Sci Rep 11(1):12388, 2021. e-Pub 2021. PMID: 34117319.
79. Haines E, Nishida Y, Carr MI, Montoya RH, Ostermann LB, Zhang W, Zenke FT, Blaukat A, Andreeff M, Vassilev LT. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia. Sci Rep 11(1):12148, 2021. e-Pub 2021. PMID: 34108527.
80. Zeng Z, Ly C, Daver N, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Ann Hematol 100(6):1485-1496, 2021. e-Pub 2021. PMID: 33787984.
81. Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission. Cancer 127(11):1894-1900, 2021. e-Pub 2021. PMID: 33449377.
82. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 12(1):2823, 2021. e-Pub 2021. PMID: 33972555.
83. Post SM, Andreeff M, DiNardo C, Khoury JD, Ruvolo PP. TAM kinases as regulators of cell death. Biochim Biophys Acta Mol Cell Res 1868(6):118992, 2021. e-Pub 2021. PMID: 33647320.
84. Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer 127(8):1246-1259, 2021. e-Pub 2021. PMID: 33270904.
85. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
86. Valent, P, Orfao, A, Kubicek, S, Staber, PB, Haferlach, T, Deininger, M, Kollmann, K, Lion, T, Virgolini, I, Winter, G, Hantschel, O, Kenner, L, Zuber, J, Grebien, F, Moriggl, R, Hoermann, G, Hermine, O, Andreeff, M, Bock, C, Mughal, TI, Constantinescu, SN, Kralovics, R, Sexl, V, Skoda, R, Superti-Furga, G, Jaeger, U. Precision Medicine in Hematology 2021. HemaSphere 5(3):E536, 2021. e-Pub 2021. PMID: 33623882.
87. Lovat F, Gasparini P, Nigita G, Larkin K, Byrd JC, Minden MD, Andreeff M, Carter BZ, Croce CM. Loss of expression of both miR-15/16 loci in CML transition to Blast Crisis. Proc Natl Acad Sci U S A 118(11), 2021. e-Pub 2021. PMID: 33836616.
88. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary Action Score Identifies a Subset of TP53-Mutated Myelodysplastic Syndrome with Favorable Prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
89. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
90. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia After Frontline Hypomethylating Agent and Venetoclax Regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
91. Alotaibi A, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia T, DiNardo C, Bortakhur G, Konopleva M, Pierce S, Wang S, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short N, Issa G, Ohanian M, Garcia-Manero G, Bhalla K, Patel K, Takahashi K, Andreeff M, Cortes J, Kantarjian H, Ravandi F, Daver N. Patterns of Secondary Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3-inhibitors. Blood Cancer Discovery 2(2):125-134, 2021. e-Pub 2021. PMID: 33681815.
92. Ly S, Anand V, El-Dana F, Nguyen K, Cai Y, Cai S, Piwnica-Worms H, Tripathy D, Sahin AA, Andreeff M, Battula VL. The Anti-GD2 Antibody Dinutuximab Inhibits Triple-Negative Breast Tumor Growth by Targeting GD2+ Breast Cancer Stem-like Cells. J Immunother Cancer 9(3), 2021. e-Pub 2021. PMID: 33722905.
93. Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu" SN, Kralovics R, Sexl V, Skoda R Superti-Furga G, Jäger U, Valent P. Precision Medicine in Hematology 2020: Definitions, Tools, Perspectives and Open Questions. HemaSphere 5(3):p e536, 2021. e-Pub 2021.
94. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Cancer Discov 2(2):125-134, 2021. e-Pub 2021. PMID: 34238762.
95. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
96. Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, Ruvolo V, Tan L, Cidado J, Drew L, Andreeff M. Targeting MCL-1 Dysregulates Cell Metabolism and Leukemia-stroma Interactions and Re-sensitizes acute myeloid leukemia to BCL-2 Inhibition. Haematologica 107(1):58-76, 2020. e-Pub 2020. PMID: 33353284.
97. Shen X, Wang R, Jong M, Hu Q, Hsu CC, Yao J, Klages-Mundt N, Tian Y, Lynn E, Zhang Y, Arun B, Gan B, Andreeff M, Takeda S, Chen J, Park JI, Shi X, Brewer TF, Chang CJ, Jung SY, Qin J, Li L. A surge of DNA damage links transcriptional reprogramming and hematopoietic deficit in Fanconi anemia. Molecular Cell 80(6):1013-1024.e6, 2020. e-Pub 2020. PMID: 33338401.
98. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
99. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun 11(1):5996, 2020. e-Pub 2020. PMID: 33214561.
100. Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris MA, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol 13(1):148, 2020. e-Pub 2020. PMID: 33148342.
101. Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff M. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol 95(11):1296-1303, 2020. e-Pub 2020. PMID: 32697348.
102. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
103. Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, Ott M, Mascarenhas J, Andreeff M. MDM2 inhibition: an important step forward in cancer therapy. Leukemia 34(11):2858-2874, 2020. e-Pub 2020. PMID: 32651541.
104. Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
105. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
106. Martin M, Mayer IA, Walenkamp AME, Lapa C, Andreeff M, Bobirca A. At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. J. Leukoc. Biol 109(5):953-967, 2020. e-Pub 2020. PMID: 33089889.
107. Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Post SM, Andreeff M. LGALS1 acts as a pro-survival molecule in AML. Biochim Biophys Acta Mol Cell Res 1867(10):118785, 2020. e-Pub 2020. PMID: 32590026.
108. Major CK, Kantarjian HM, Borthakur G, Kadia T, Pemmaraju N, DiNardo CD, Short N, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leukemia and Lymphoma, 2020. e-Pub 2020.
109. Wang X, Mak PY, Mu H, Tao W, Rao A, Visweswaran R, Ruvolo V, Pachter JA, Weaver DT, Andreeff M, Xu B, Carter BZ. Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances anti-leukemia activity of venetoclax in acute myeloid leukemia. Mol Cancer Ther 19(8):1636-1648, 2020. e-Pub 2020. PMID: 32404407.
110. Kim BR, Jung SH, Han AR, Park G, Kim HJ, Yuan B, Battula VL, Andreeff M, Konopleva M, Chung YJ, Cho BS. CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32629802.
111. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical Value of Event-Free Survival in Acute Myeloid Leukemia. Blood Adv 4(8):1690-1699, 2020. e-Pub 2020. PMID: 32330243.
112. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1 mutated AML: Current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
113. Méndez-Ferrer S, Bonnet D, Steesma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS. Bone marrow niches in haematological malignancies. Nat Rev Cancer, 2020. e-Pub 2020. PMID: 32112045.
114. Rytelewski M, Harutyunyan K, Baran N, Mallampati S, Zal MA, Cavazos A, Butler JM, Konoplev S, El Khatib M, Plunkett S, Marszalek JR, Andreeff M, Zal T, Konopleva M. Inhibition of oxidative phosphorylation reverses bone marrow hypoxia visualized in imageable syngeneic B-ALL mouse model. Front Oncol Front. Oncol., 30 June 2020 | https://doi.org/10.3389/fonc.2020:991, 2020. e-Pub 2020. PMID: 32695673.
115. Yuan B, El Dana F, Ly S, Yan Y, Ruvolo V, Shpall EJ, Konopleva M, Andreeff M, Battula VL. Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway. PLoS One 15(11):e0242809, 2020. e-Pub 2020. PMID: 33253299.
116. Young KH, Deng M, Zhang M, Pham VL, Tzankov A, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, His ED, Choi WWL, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, van Krieken JH, Piris AM, Winter JM, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu-Monette ZY, Xu B. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor 13(1):148, 2020. e-Pub 2020. PMID: 33148342.
117. Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 targets the orphan G protein-coupled receptor GPR132 in acute myeloid leukemia. Leukemia 33(12):2805-2816, 2019. e-Pub 2019. PMID: 31127149.
118. Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke JE, Young PR, Beckett P, Zhang X, Carter BZ, Andreeff M, Halene S, Xu T, Rothberg J, Lichenstein H. LAM-003, a New Drug for Treatment of Tyrosine Kinase Inhibitor-Resistant FLT3-ITD Positive AML. Blood Adv 3(22):3661-3673, 2019. e-Pub 2019. PMID: 31751472.
119. Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y. Correction: Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 10(63):6842, 2019. e-Pub 2019. PMID: 31827726.
120. Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic Significance of Baseline FLT3- ITD Mutant Allele Level in Acute Myeloid Leukemia Treated with Intensive Chemotherapy With/Without Sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
121. Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T, Andreeff M. Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica. e-Pub 2019. PMID: 31371419.
122. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855-1866, 2019. e-Pub 2019. PMID: 30811597.
123. Ruvolo PP, Hu CW, Qiu Y, Ruvolo VR, Go RL, Hubner SE, Coombes KR, Andreeff M, Qutub AA, Kornblau SM. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine 44(2019):126–137, 2019. e-Pub 2019. PMID: 31105032.
124. Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant Targeting of BCL2 with Venetoclax and MAPK Signaling with Cobimetinib in Acute Myeloid Leukemia Models. Haematologica. e-Pub 2019. PMID: 31123034.
125. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality. Cancer Cell 35(5):721-737, 2019. e-Pub 2019. PMID: 31056398.
126. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470-1481, 2019. e-Pub 2019. PMID: 30500073.
127. Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest 130(5):1878-1894, 2019. e-Pub 2019. PMID: 30829648.
128. Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M. An ARC-regulated IL1β/Cox-2/PGE2/β-catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML. Cancer Res 79(6):1165-1177, 2019. e-Pub 2019. PMID: 30674535.
129. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2019. PMID: 30530801.
130. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2019. PMID: 30409776.
131. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
132. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):37-48, 2019. e-Pub 2019. PMID: 29741984.
133. Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, Do KA, Ueno NT, Andreeff M, Battula VL. ST8SIA1 regulates tumor growth and metastasis in TNBC by activating the FAK-AKT-mTOR signaling pathway. Mol Cancer Ther 12(12):2689-2701, 2018. e-Pub 2018. PMID: 30237308.
134. Le PM, Andreeff M, Battula VL. Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica 103(12):1945-1955, 2018. e-Pub 2018. PMID: 30337364.
135. Tabe Y, Saitoh K, Yang H, Sekihara K, Yamatani K, Ruvolo V, Taka H, Kaga N, Kikkawa M, Arai H, Miida T, Andreeff M, Spagnuolo PA, Konopleva M. Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Sci Rep 8(1):16837, 2018. e-Pub 2018. PMID: 30442990.
136. Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer J 8(11):98, 2018. e-Pub 2018. PMID: 30341277.
137. Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol 93(10):1245-1253, 2018. e-Pub 2018. PMID: 30051599.
138. Zhang W, Ly C, Ishizawa J, Mu H, Ruvolo V, Shacham S, Daver N, Andreeff M. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103(10):1642-1653, 2018. e-Pub 2018. PMID: 29773601.
139. Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, Kadia T, Pierce S, Burger J, Richie MA, Patel K, Andreeff M, Estrov Z, Cortes J, Kantarjian H, Ravandi F. Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML). Am J Hematol 93(93):1136-1141, 2018. e-Pub 2018. PMID: 30028037.
140. Boddu P, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Andreeff M, Jabbour EJ, Benton CB, DiNardo CD, Konopleva M, Daver N, Patel K, Takahashi K, Kanagal-Shamanna R, Cortes J, Kadia T. Outcomes with Lower Intensity Therapy in TP53-Mutated Acute Myeloid Leukemia. Leuk Lymphoma 59(9):2238-2241, 2018. e-Pub 2018. PMID: 29338567.
141. Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P, Zhar AA, Wu CJ, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Mendoza M, Thompson E, Zhang J, DiNardo CD, Jain N, Ravandi F, Cortes JE, Garcia-Manero G, Kornblau S, Andreeff M, Jabbour E, Bueso-Ramos C, Takaori-Kondo A, Konopleva M, Patel K, Kantarjian H, Futreal PA. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9(1):2670, 2018. e-Pub 2018. PMID: 29991687.
142. Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC derived Galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865(7):959-969, 2018. e-Pub 2018. PMID: 29655803.
143. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol 36(18):1788-1797, 2018. e-Pub 2018. PMID: 29702001.
144. Sanchez M, Xia Z, Rico-Bautista E, Cao X, Cuddy M, Castro DJ, Correa RG, Chen L, Yu J, Bobkov A, Ruvolo V, Andreeff M, Oshima RG, Matsuzawa SI, Reed JC, Zhang XK, Hansel D, Wolf DA, Dawson MI. Oxidized Analogs of Di(1H-indol-3-yl)methyl-4-substituted Benzenes are NR4A1-dependent UPR Inducers with Potent and Safe Anti-Cancer Activity. Oncotarget 9(38):25057-25074, 2018. e-Pub 2018. PMID: 29861853.
145. Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ. Disruption of Wnt/β-catenin exerts anti-leukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia. Clin Cancer Res 24(10):2417-2429, 2018. e-Pub 2018. PMID: 29463558.
146. Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N, Konopleva M, Andreeff M. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103(5):810-821, 2018. e-Pub 2018. PMID: 29545342.
147. Kornblau SM, Ruvolo PP, Wang RY, Battula VL, Shpall EJ, Ruvolo VR, McQueen T, Qui Y, Zeng Z, Pierce S, Jacamo R, Yoo SY, Le PM, Sun J, Hail N, Konopleva M, Andreeff M. Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103(5):810-821, 2018. e-Pub 2018. PMID: 29545342.
148. Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese LE, Ma W, Ma MCJ, DiNardo CD, Pierce SA, Patel KP, Tse A, Davis RE, Rao A, Andreeff M. Predictive gene signatures determine tumor sensitivity to MDM2 inhibition. Cancer Res 78(10):2721-2731, 2018. e-Pub 2018. PMID: 29490944.
149. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol 5(4):e136-e146, 2018. e-Pub 2018. PMID: 29550383.
150. Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon R. Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9(4):4354-4365, 2018. e-Pub 2018. PMID: 29435107.
151. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
152. Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol 7:26, 2018. e-Pub 2018. PMID: 30323983.
153. Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Mu H, Schober W, Hernandez I, Gallardo M, Khoury JD, Cortes J, Andreeff M, Post SM. Anexelekto/MER Tyrosine Kinase inhibitor ONO-7475 growth arrests and kills FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Mutant Acute Myeloid Leukemia cells by diverse mechanisms. Haematologica 102(12):2048-2057, 2017. e-Pub 2017. PMID: 28912176.
154. Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, Konopleva M, Andreeff M. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32(6):748-760.e6, 2017. e-Pub 2017. PMID: 29232553.
155. Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B. Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with Inhibitions of cFLIP Expression and PI3K/AKT/mTOR Activities. Oncotarget 8(60):102150-102160, 2017. e-Pub 2017. PMID: 29254232.
156. Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res 23(22):7034-7046, 2017. e-Pub 2017. PMID: 28855350.
157. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica 102(10):1709-1717, 2017. e-Pub 2017. PMID: 28729302.
158. Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE, Yang J. The imipridone ONC201 induces apoptosis and overcomes chemotherapy resistance by upregulation of Bim in multiple myeloma. Neoplasia 19(10):772-780, 2017. e-Pub 2017. PMID: 28863346.
159. Jacamo R, Davis RE, Ling X, Sonnylal S, Wang Z, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, McQueen T, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M. Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8(48):83354-83369, 2017. e-Pub 2017. PMID: 29137349.
160. Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitorresistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia 31(10):2065-2074, 2017. e-Pub 2017. PMID: 28321124.
161. Zeng Z, Liu W, Tsao T, Qiu Y, Zhao Y, Samudio I, Sarbassov DD, Kornblau SM, Baggerly KA, Kantarjian HM, Konopleva M, Andreeff M. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102(9):1537-1548, 2017. e-Pub 2017. PMID: 28659338.
162. Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica 102(9):1519-1529, 2017. e-Pub 2017. PMID: 28596283.
163. Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S, Andreeff M, Ravandi F, Cortes J, Kornblau SM. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group. Blood Adv 1(19):1546-1550, 2017. e-Pub 2017. PMID: 29296796.
164. Zhou F, Pan Y, Wei Y, Zhang R, Bai G, Shen Q, Meng S, Le XF, Andreeff M, Claret FX. Jab1/Csn5-thioredoxin signaling in relapsed acute monocytic leukemia under oxidative stress. Clin Cancer Res 23(15):4450-4461, 2017. e-Pub 2017. PMID: 28270496.
165. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv 1(17):1312-1323, 2017. e-Pub 2017. PMID: 29296774.
166. Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RE, Harrington MA, Cahill CW, Bueso-Ramos C, Andreeff M. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight 2(13). e-Pub 2017. PMID: 28679949.
167. Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M. Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate, in acute myeloid leukemia. Clin Cancer Res 23(13):3385-3395, 2017. e-Pub 2017. PMID: 28096272.
168. Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R. A Phase I Clinical Trial of Single-Agent Selinexor in Acute Myeloid Leukemia. Blood 129(24):3165-3174, 2017. e-Pub 2017. PMID: 28336527.
169. Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M. IKK Inhibition by BMS-345541 Suppresses Breast Tumorigenesis and Metastases by Targeting GD2+ Cancer Stem Cells. Oncotarget 8(23):36936-36949, 2017. e-Pub 2017. PMID: 28415808.
170. Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16(6):1133-1144, 2017. e-Pub 2017. PMID: 28270436.
171. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J, Daver N, Takahashi K, DiNardo C, Jabbour E, Borthakur G, Konopleva M, Pierce S, Bueso-Ramos C, Patel K, Kornblau S, Kantarjian H, Young KH, Garcia-Manero G, Andreeff M. Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129(18):2584-2587, 2017. e-Pub 2017. PMID: 28246192.
172. Sekihara K, Saitoh K, Han L, Ciurea S, Yamamoto S, Kikkawa M, Kazuno S, Taka H, Kaga N, Arai H, Miida T, Andreeff M, Konopleva M, Tabe Y. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8(21):34552-34564, 2017. e-Pub 2017. PMID: 28388555.
173. Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B cell acute leukemia. Blood 129(14):1958-1968, 2017. e-Pub 2017. PMID: 28143883.
174. Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
175. Uy GL, Rettig MP, Stone RM, Konopleva MY, Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades W, Stockerl-Goldstein K, Abboud CN, Jacoby MA, Westervelt P, DiPersio JF. A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia. Blood Cancer J 7(3):e542, 2017. e-Pub 2017. PMID: 28282031.
176. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2017. PMID: 28003274.
177. Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo V, Ishizawa J, Hail N, Kazuno S, Igarashi M, Matsushita H, Yamanaka Y, Arai H, Nagaoka I, Miida T, Hayashizaki Y, Konopleva M, Andreeff M. Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. Cancer Res 77(6):1453-1464, 2017. e-Pub 2017. PMID: 28108519.
178. Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Sci Rep 7:43013, 2017. e-Pub 2017. PMID: 28220839.
179. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence Of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is Highly Prognostic In Younger Patients With Acute Myeloid Leukemia. Cancer 123(3):426-435, 2017. e-Pub 2017. PMID: 27657543.
180. Piya S, Andreeff M, Borthakur G. Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia. Autophagy 13(1):214-215, 2017. e-Pub 2017. PMID: 27797294.
181. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2017. PMID: 27673440.
182. Zeng Z, Konopleva M, Andreeff M. Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells. Methods Mol Biol 1633:75-86, 2017. e-Pub 2017. PMID: 28735481.
183. Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M. Peripheral blood blast clearance is an independent prognostic factor for survival and response to AML induction chemotherapy. Am J Hematol 91(12):1221-1226, 2016. e-Pub 2016. PMID: 27474808.
184. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 7(45):74380-74392, 2016. e-Pub 2016. PMID: 27602582.
185. Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, Szulc ZM, Ruvolo P, Kornblau S, Andreeff M, Ogretmen B. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood 128(15):1944-1958, 2016. e-Pub 2016. PMID: 27540013.
186. Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE, Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood 128(9):1260-9, 2016. e-Pub 2016. PMID: 27268264.
187. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med 8(355):355ra117, 2016. e-Pub 2016. PMID: 27605552.
188. Kojima K, Ishizawa J, Andreeff M. Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp Hematol 44(9):791-8, 2016. e-Pub 2016. PMID: 27327543.
189. Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. Oncotarget 7(34):55083-55097, 2016. e-Pub 2016. PMID: 27391151.
190. Rau RE, Rodriguez BA, Luo M, Jeong M, Rosen A, Rogers JH, Campbell CT, Daigle SR, Deng L, Song Y, Sweet S, Chevassut T, Andreeff M, Kornblau SM, Li W, Goodell MA. DOT1L As a Therapeutic Target for the Treatment of DNMT3A-Mutant Acute Myeloid Leukemia. Blood 128(7):971-81, 2016. e-Pub 2016. PMID: 27335278.
191. Velez J, Pan R, Lee JT, Enciso L, Suarez M, Duque JE, Jaramillo D, Lopez C, Morales L, Bornmann W, Konopleva M, Krystal G, Andreeff M, Samudio I. Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport. Oncotarget 7(32):51435-51449, 2016. e-Pub 2016. PMID: 27283492.
192. Eckstein OS, Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE. Mixed Phenotype Acute Leukemia (MPAL) Exhibits Frequent Mutations in DNMT3A and Activated Signaling Genes. Exp Hematol 44(8):740-4, 2016. e-Pub 2016. PMID: 27208809.
193. Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G, Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva M. A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia. Am J Hematol 91(8):800-5, 2016. e-Pub 2016. PMID: 27169385.
194. Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, Borthakur G, Jabbour E, Konopleva M, Daver NG, Dinardo C, Pierce S, Kanagal-Shamanna R, Patel K, Estrov Z, Cortes J, Kantarjian HM. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. e-Pub 2016. PMID: 27463065.
195. Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med 13(2):248-59, 2016. e-Pub 2016. PMID: 27458532.
196. Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget 7(15):20054-67, 2016. e-Pub 2016. PMID: 26956049.
197. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekoffer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LaBoeuf N, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 29(4):574-86, 2016. e-Pub 2016. PMID: 27070704.
198. Han X, Medeiros LJ, Zhang YH, You MJ, Andreeff M, Konopleva M, Bueso-Ramos CE. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. e-Pub 2016. PMID: 27155969.
199. Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE, Bankson JA, Cortes JE, Hart CP, Andreeff M, Konopleva M. Hypoxia-activated prodrug TH-302 targets hypoxic bone marrow niches in pre-clinical leukemia models. Clin Cancer Res 22(7):1687-98, 2016. e-Pub 2016. PMID: 26603259.
200. Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N, Davis RE, Andreeff M. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochim Biophys Acta 1863(4):562-71, 2016. e-Pub 2016. PMID: 26704388.
201. Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M. The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations. Cancer Res 76(6):1-10, 2016. e-Pub 2016. PMID: 26822154.
202. Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, Kadia T, Andreeff M, Konopleva M, DiNardo C, Daver N, Cortes J, Estrov Z, Futreal A, Kantarjian H, Garcia-Manero G. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget 7(12):14172-87, 2016. e-Pub 2016. PMID: 26871476.
203. Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, Andreeff M, Ravandi F, Cortes J. Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients. Clin Lymphoma Myeloma Leuk 16(3):163-8.e1-2, 2016. e-Pub 2016. PMID: 26752456.
204. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2016. e-Pub 2016. PMID: 26884599.
205. Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K. Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia. Clin Cancer Res 22(4):868-76, 2016. e-Pub 2016. PMID: 26459177.
206. Tabe Y, Hatanaka Y, Nakashiro M, Sekihara K, Yamamoto S, Matsushita H, Kazuno S, Fujimura T, Ikegami T, Nakanaga K, Matsumoto H, Ueno T, Aoki J, Yokomizo T, Konopleva M, Andreeff M, Miida T, Iwabuchi K, Sasai K. Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cells. Int J Radiat Biol 92(1):24-34, 2016. e-Pub 2016. PMID: 26809544.
207. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep 13(12):2715-27, 2015. e-Pub 2015. PMID: 26711339.
208. Nishida Y, Maeda A, Chachad D, Ishizawa J, Qiu YH, Kornblau SM, Kimura S, Andreeff M, Kojima K. Preclinical activity of the novel BMI-1 inhibitor PTC-209 in acute myeloid leukemia: implications for leukemia therapy. Cancer Sci 106(12):1705-13, 2015. e-Pub 2015. PMID: 26450753.
209. Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation of GSK3 α/β correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clin 4:59-68, 2015. e-Pub 2015. PMID: 26674329.
210. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
211. Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget 6(31):30487-99, 2015. e-Pub 2015. PMID: 26431162.
212. Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF. Mesenchymal Stem Cells Isolated from Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells through the IL-6/gp130/STAT3 pathway. Stem Cells 33(8):2400-15, 2015. e-Pub 2015. PMID: 25966666.
213. Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood 126(3):363-72, 2015. e-Pub 2015. PMID: 26045609.
214. Cho BS, Zeng Z, Mu H, Wang Z, McQueen T, Protopopova M, Cortes J, Marszalek JR, Peng SB, Ma W, Davis RE, Thornton DE, Andreeff M, Konopleva M. Anti-leukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood 126(2):222-32, 2015. e-Pub 2015. PMID: 26031918.
215. Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant 50(7):939-946, 2015. e-Pub 2015. PMID: 25867648.
216. Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
217. Jacamo R, Andreeff M. Bone Marrow Microenvironment-mediated Resistance to Chemotherapy in AML. Journal of Nature and Science 1(8):e145. e-Pub 2015.
218. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
219. Mallampati S, Leng X, Ma H, Zeng J, Li J, Wang H, Lin K, Lu Y, Yang Y, Sun B, Gong Y, Lee JS, Konopleva M, Andreeff M, Arlinghaus RB, Cai Z, Fang B, Shen H, Han X, Hirsch-Ginsberg CF, Gao X, Paranjape AN, Mani SA, Clise-Dwyer K, Sun X. Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia. Blood 125(19):2968-73, 2015. e-Pub 2015. PMID: 25712988.
220. Sphyris N, Sarkar TR, Battula VL, Andreeff M, Mani SA. GD2 and GD3 synthase: novel drug targets for cancer therapy. Molecular and Cellular Oncology 2(3), 2015. e-Pub 2015.
221. Carter BZ, Andreeff M. Targeting AML stem/progenitor cells by combinational therapy with SMAC mimetics and demethylating agents. Stem Cell Epigenetics:1-6. e-Pub 2015.
222. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A 87(4):346-56, 2015. e-Pub 2015. PMID: 25598437.
223. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II Trial of the Combination of Midostaurin (PKC412) and 5-Azacytidine for Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Am J Hematol 90(4):276-81, 2015. e-Pub 2015. PMID: 25530214.
224. Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, Dullin C, Alves F, Andreeff M, Weissman IL, Longaker MT, Schallmoser K, Majeti R, Strunk D. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood 125(2):249-60, 2015. e-Pub 2015. PMID: 25406351.
225. Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE, Wang Z, Ma W, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M. Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. PLoS One 10(9):e0137210, 2015. e-Pub 2015. PMID: 26340096.
226. Zhang Y, Nowicka A, Solley TN, Wei C, Parikh A, Court L, Burks JK, Andreeff M, Woodward WA, Dadbin A, Kolonin MG, Lu KH, Klopp AH. Stromal Cells Derived from Visceral and Obese Adipose Tissue Promote Growth of Ovarian Cancers. PLoS One 10(8):e0136361, 2015. e-Pub 2015. PMID: 26317219.
227. Ishizawa J, Kojima K, McQueen T, Ruvolo V, Chachad D, Nogueras-Gonzalez GM, Huang X, Pierceall WE, Dettman EJ, Cardone MH, Shacham S, Konopleva M, Andreeff M. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs. PLoS One 10(9):e0138377, 2015. e-Pub 2015. PMID: 26375587.
228. Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M. MDM2 inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP kinase Activation. PLoS One 10(10):e0139254, 2015. e-Pub 2015. PMID: 26440941.
229. Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One 10(11):e0139851, 2015. e-Pub 2015. PMID: 26556047.
230. Chae YK, Dimou A, Pierce S, Kantarjian H, Andreeff M. The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk Lymphoma 55(12):2822-9, 2014. e-Pub 2014. PMID: 24628293.
231. Wu T, Ye Y, Min SY, Zhu J, Khobahy E, Zhou J, Yan M, Hemachandran S, Pathak S, Zhou XJ, Andreeff M, Mohan C. Targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid prevents murine lupus nephritis. Arthritis Rheumatol 66(11):3129-39, 2014. e-Pub 2014. PMID: 25047252.
232. Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol 167(3):376-84, 2014. e-Pub 2014. PMID: 25079338.
233. Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N, Konopleva M, Calin G, Kornblau SM, Andreeff M. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta 1843(9):1969-77, 2014. e-Pub 2014. PMID: 24858343.
234. Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol 166(6):862-74, 2014. e-Pub 2014. PMID: 24942980.
235. Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Peña EQ, Taube JH, Chang JT, Miura N, Porter W, Sphyris N, Andreeff M, Mani SA. GD3 Synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene 0. e-Pub 2014. PMID: 25109336.
236. Velez J, Enciso LJ, Suarez M, Fiegl M, Grismaldo A, López C, Barreto A, Cardozo C, Palacios P, Morales L, Duque JE, Carmona JU, Konopleva M, Andreeff M, Samudio I. Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment. Cancer Microenviron 7(1-2):79-90, 2014. e-Pub 2014. PMID: 25112275.
237. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer 120(14):2142-9, 2014. e-Pub 2014. PMID: 24737502.
238. Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs 23(7):943-54, 2014. e-Pub 2014. PMID: 24749672.
239. Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Final report of phase II study of sorafenib, cytarabine, and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 28(7):1543-5, 2014. e-Pub 2014. PMID: 24487412.
240. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K. Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma. Cancer Sci 105(7):795-801, 2014. e-Pub 2014. PMID: 24766216.
241. Zhang W, Ruvolo VR, Gao C, Zhou L, Bornmann W, Tsao T, Schober WD, Smith P, Guichard S, Konopleva M, Andreeff M. Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myeloid Leukemia Cells. Mol Cancer Ther 13(7):1848-59, 2014. e-Pub 2014. PMID: 24739393.
242. Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M. Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies. Clin Cancer Res 20(9):2363-74, 2014. e-Pub 2014. PMID: 24619500.
243. Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol 73(5):961-74, 2014. e-Pub 2014. PMID: 24619497.
244. Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, Nguyen MH, Strunk D, Bueso-Ramos CE, Konoplev S, Davis RE, Konopleva M, Andreeff M. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood 123(17):2691-702, 2014. e-Pub 2014. PMID: 24599548.
245. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res 20(8):2226-35, 2014. e-Pub 2014. PMID: 24583795.
246. Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R. Implications of the miR-10 family in chemotherapy response of NPM1 mutated AML. Blood 123(15):2412-5, 2014. e-Pub 2014. PMID: 24596420.
247. Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest 124(4):1512-24, 2014. e-Pub 2014. PMID: 24590286.
248. Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis 19(4):698-707, 2014. e-Pub 2014. PMID: 24337870.
249. Lu H, Kojima K, Battula VL, Korchin B, Shi Y, Chen Y, Spong S, Thomas DA, Kantarjian H, Lock RB, Andreeff M, Konopleva M. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia pre-clinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. Ann Hematol 93(3):485-92, 2014. e-Pub 2014. PMID: 24154679.
250. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG. Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia. Cancer Discov 4(3):362-75, 2014. e-Pub 2014. PMID: 24346116.
251. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M. Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. J Natl Cancer Inst 106(2):djt440, 2014. e-Pub 2014. PMID: 24526787.
252. Tabe Y, Jin L, Konopleva M, Shikami M, Kimura S, Andreeff M, Raffeld M, Miida T. Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematol 131(1):59-69, 2014. e-Pub 2014. PMID: 24052005.
253. Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A. The Combinatorial Complexity of Cancer Precision Medicine. Oncoscience 1(7):504-9, 2014. e-Pub 2014. PMID: 25594052.
254. Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. J Mol Med (Berl) 91(12):1383-97, 2013. e-Pub 2013. PMID: 23955073.
255. Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M. BH3 Profiling Discriminates Response to Cytarabine-based Treatment of Acute Myeloid Leukemia. Mol Cancer Ther 12(12):2940-9, 2013. e-Pub 2013. PMID: 24092807.
256. Konoplev S, Lin P, Yin CC, Lin E, Nogueras González GM, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(6):686-92, 2013. e-Pub 2013. PMID: 24035716.
257. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
258. Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, Fan AC, Felsher DW, Whetton A, Pla M, West R, Fenaux P, Chomienne C, Padua RA. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood 122(16):2864-76, 2013. e-Pub 2013. PMID: 23943652.
259. Russell KC, Tucker HA, Bunnell BA, Andreeff M, Schober W, Gaynor AS, Strickler KL, Lin S, Lacey MR, O'Connor KC. Cell-Surface Expression of Neuron-Glial Antigen 2 (NG2) and Melanoma Cell Adhesion Molecule (CD146) in Heterogeneous Cultures of Marrow-Derived Mesenchymal Stem Cells. Tissue Eng Part A 19(19-20):2253-66, 2013. e-Pub 2013. PMID: 23611563.
260. Spaeth EL, Labaff AM, Toole BP, Klopp A, Andreeff M, Marini FC. Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res 73(17):5347-59, 2013. e-Pub 2013. PMID: 23838935.
261. Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE. XIAP Downregulation Promotes Caspase-dependent Inhibition of Proteasome Activity in AML Cells. Leuk Res 37(8):974-9, 2013. e-Pub 2013. PMID: 23669290.
262. Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM. PhaseI/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 13(4):430-4, 2013. e-Pub 2013. PMID: 23763920.
263. Battula VL, Chen Y, Cabreira Mda G, Ruvolo V, Wang Z, Ma W, Konoplev S, Shpall E, Lyons K, Strunk D, Bueso-Ramos C, Davis RE, Konopleva M, Andreeff M. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood 122(3):357-66, 2013. e-Pub 2013. PMID: 23741006.
264. Zhou L, Ruvolo VR, McQueen T, Chen W, Samudio IJ, Conneely O, Konopleva M, Andreeff M. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia 27(6):1358-68, 2013. e-Pub 2013. PMID: 23247046.
265. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase II Study of Azacytidine Plus Sorafenib in Patients with Acute Myeloid Leukemia and FLT-3 Internal Tandem Duplication Mutation. Blood 121(23):4655-62, 2013. e-Pub 2013. PMID: 23613521.
266. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long term outcome of relapsed or refractory AMLin patients with FLT3-ITD. Br J Haematol 161(5):659-66, 2013. e-Pub 2013. PMID: 23530930.
267. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest 123(6):2395-407, 2013. e-Pub 2013. PMID: 23676502.
268. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121(20):4166-74, 2013. e-Pub 2013. PMID: 23564911.
269. Shinojima N, Hossain A, Takezaki T, Fueyo J, Gumin J, Gao F, Nwajei F, Marini FC, Andreeff M, Kuratsu J, Lang FF. TGF-β Mediates Homing of Bone Marrow-Derived Human Mesenchymal Stem Cells to glioma Stem Cells. Cancer Res 73(7):2333-44, 2013. e-Pub 2013. PMID: 23365134.
270. Velez J, Hail Jr N, Konopleva M, Zeng Z, Kojima K, Samudio I, Andreeff M. Mitochondrial uncoupling and the reprogramming of intermediary metabolism in leukemia cells. Frontiers in Oncology 3(67), 2013. e-Pub 2013.
271. Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, Schmidt S, Kadam S, Brandt JT, Van Bockstaele D, Andreeff M. Safety and Pharmacokinetics of the Antisense Oligonucleotide (ASO) LY2181308 as a Single-Agent or in Combination with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML). Invest New Drugs. e-Pub 2013. PMID: 23397500.
272. Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, Andreeff M, Konopleva M. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett 329(1):45-58, 2013. e-Pub 2013. PMID: 23036488.
273. Valent P, Bonnet D, Wöhrer S, Andreeff M, Copland M, Chomienne C, Eaves C. Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional and Clinical Implications. Cancer Res 73(3):1037-45, 2013. e-Pub 2013. PMID: 23345162.
274. Dembinski JL, Wilson SM, Spaeth EL, Studeny M, Zompetta C, Samudio I, Roby K, Andreeff M, Marini FC. Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy 15(1):20-32.e2, 2013. e-Pub 2013. PMID: 23260083.
275. Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. Molecular characterization of de novo Ph+ Acute Myeloid Leukemia. Leuk Lymphoma 54(1):138-44, 2013. e-Pub 2013. PMID: 22691121.
276. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Correction: Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression. PLoS One 8(3), 2013. e-Pub 2013. PMID: 23555550.
277. Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One 8(6):e62785, 2013. e-Pub 2013. PMID: 23826077.
278. Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, Coombes KR. Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells. PLoS One 8(10):e78453, 2013. e-Pub 2013. PMID: 24223100.
279. Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, Hail N, Konopleva M, Andreeff M. The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo. PLoS One 8(3):e58426, 2013. e-Pub 2013. PMID: 23484027.
280. Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K, Konopleva M. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol 91(12):1861-70, 2012. e-Pub 2012. PMID: 22893484.
281. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12(11):767-75, 2012. e-Pub 2012. PMID: 23051844.
282. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 12(5):355-62, 2012. e-Pub 2012. PMID: 22658895.
283. Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. J Mol Med (Berl) DOI 10.1007/s00109-012-0886-z(10):1133-44, 2012. e-Pub 2012. PMID: 22399013.
284. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML under conditions mimicking the bone marrow microenvironment. Blood 120(13):2679-89, 2012. e-Pub 2012. PMID: 22826565.
285. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1α signaling and chemoresistance in Acute Lymphocytic Leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 13(10):858-70, 2012. e-Pub 2012. PMID: 22785211.
286. Cheng X, Quintás-Cardama A, Golemovic M, Zingaro R, Gao MZ, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. The Organic Arsenic Derivative GMZ27 Induces PML-RARα-Independent Apoptosis in Myeloid Leukemia Cells. Anticancer Res 32(7):2871-80, 2012. e-Pub 2012. PMID: 22753750.
287. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 120(1):173-80, 2012. e-Pub 2012. PMID: 22645176.
288. Pan J, Chen C, Jin Y, Fuentes-Mattei E, Velazquez-Tores G, Benito JM, Konopleva M, Andreeff M, Lee MH, Yeung SC. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle 11(12):2314-26, 2012. e-Pub 2012. PMID: 22659796.
289. Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J, Nagata K, Hashimoto N, Honda H, Kanno M, Miwa M, Okada S, Andreeff M, Saya H. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene 31(23):2849-61, 2012. e-Pub 2012. PMID: 21986948.
290. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M. "Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis". J Clin Invest 122(6):2066-78, 2012. e-Pub 2012. PMID: 22585577.
291. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res 18(12):3396-3406, 2012. e-Pub 2012. PMID: 22634319.
292. Chen Y, Jacamo R, Shi YX, Wang RY, Battula VL, Konoplev S, Strunk D, Hofmann NA, Reinisch A, Konopleva M, Andreeff M. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood 119(21):4971-80, 2012. e-Pub 2012. PMID: 22490334.
293. Ravandi F, Patel K, Luthra R, Faderl S, Konopleva M, Kadia T, Brandt M, Pierce S, Kornblau S, Andreeff M, Wang X, Garcia-Manero G, Cortes J, Kantarjian H. Prognostic Significance of Alterations in IDH Enzyme Isoforms in Patients With AML Treated with High Dose Cytarabine and Idarubicin. Cancer 118(10):2665-73, 2012. e-Pub 2012. PMID: 22020636.
294. Tabe Y, Jin L, Iwabuchi K, Wang RY, Ichikawa N, Miida T, Cortes J, Andreeff M, Konopleva M. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia 26(5):883-92, 2012. e-Pub 2012. PMID: 22005789.
295. Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M. MEK Inhibition Enhances ABT-737-Induced Leukemia Cell Apoptosis via Prevention of ERK activated MCL-1 induction and Modulation of MCL-1/BIM Complex. Leukemia doi10.1038/leu.2011.287(4):778-87, 2012. e-Pub 2012. PMID: 22064351.
296. Bernstein SH, Venkatesh S, Li M, Lee J, Lu B, Hilchey SP, Morse KM, Metcalfe HM, Skalska J, Andreeff M, Brookes PS, Suzuki CK. The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives. Blood 119(14):3321-9, 2012. e-Pub 2012. PMID: 22323447.
297. Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ. Activation of Apoptosis Signaling Eliminates CD34+ Progenitor Cells in Blast Crisis CML Independent of Response to Tyrosine Kinase Inhibitors. Leukemia 26(4):788-94, 2012. e-Pub 2012. PMID: 22033489.
298. Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia 26(3):443-50, 2012. e-Pub 2012. PMID: 21904380.
299. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer doi: 10.1002/cncr.26360(4):1023-31, 2012. e-Pub 2012. PMID: 21761401.
300. Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward W, Schmandt R, Broaddus R, Lu K, Kolonin MG. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res 18(3):771-82, 2012. e-Pub 2012. PMID: 22167410.
301. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood doi:10.1182. e-Pub 2012. PMID: 22275381.
302. Tabe Y, Konopleva M, Andreeff M, Ohsaka A. Effects of PPARγ Ligands on Leukemia. PPAR Res 2012:483656, 2012. e-Pub 2012. PMID: 22685453.
303. Hofmann NA, Ortner A, Jacamo RO, Reinisch A, Schallmoser K, Rohban R, Etchart N, Fruehwirth M, Beham-Schmid C, Andreeff M, Strunk D. Oxygen Sensing Mesenchymal Progenitors Promote Neo-Vasculogenesis in a Humanized Mouse Model In Vivo. PLoS One 7(9):e44468, 2012. e-Pub 2012. PMID: 22970226.
304. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M, Marini FC. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 7(2):e30563, 2012. e-Pub 2012. PMID: 22363446.
305. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant 17(12):1874-7, 2011. e-Pub 2011. PMID: 21767516.
306. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, Kornblau SM. Low expression of PP2A regulatory subunit B55a is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia doi:10.1038/leu.2011.146(11):1711-7, 2011. e-Pub 2011. PMID: 21660042.
307. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1{alpha}-mediated down-regulation of CXCL12. Blood 118(16):4431-9, 2011. e-Pub 2011. PMID: 21868571.
308. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer doi:10.1002/cancr.26113(20):4689-95, 2011. e-Pub 2011. PMID: 21456010.
309. Havelange V, Stauffer N, Heaphy CC, Volinia S, Andreeff M, Marcucci G, Croce CM, Garzon R. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer doi: 1002/cncr.206096(20):4696-706, 2011. e-Pub 2011. PMID: 21455993.
310. Abel EL, Bubel JD, Simper MS, Powell L, McClellan SA, Andreeff M, MacLeod MC, DiGiovanni J. Protection against 2-chloroethyl ethyl sulfide (CEES) - induced cytotoxicity in human keratinocytes by an inducer of the glutathione detoxification pathway. Toxicol Appl Pharmacol doi:10.1016/j.taap.2011.06.012(2):176-83, 2011. e-Pub 2011. PMID: 21723306.
311. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16(1):67-74, 2011. e-Pub 2011. PMID: 20938744.
312. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase 1 study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96(1):62-8, 2011. e-Pub 2011. PMID: 20952518.
313. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 117(3):780-787, 2011. e-Pub 2011. PMID: 21041716.
314. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells 29(1):11-9, 2011. e-Pub 2011. PMID: 21280155.
315. Jin L, Tabe Y, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Konopleva M, Andreeff M, Miida T. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. Br J Cancer 104(1):91-100, 2011. e-Pub 2011. PMID: 21139584.
316. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS One 6(8):e23108, 2011. e-Pub 2011. PMID: 21853076.
317. Saha PK, Reddy VT, Konopleva M, Andreeff M, Chan L. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem 285(52):40581-40592, 2010. e-Pub 2010. PMID: 20956520.
318. Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, Clise-Dwyer K, R-Y W, Zhang W, Yuan X, Lu H, Caldwell L, Andreeff M. Mesenchymal stem cells overexpressing IFN-beta inhibit breast cancer growth and metastases through Stat3 signaling in a syngeneic tumor model. Cancer Microenvironment 3(1):83-95, 2010. e-Pub 2010. PMID: 21209776.
319. Carter BZ, Mak DH, Cortes J, Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?. Semin Hematol 47(4):362-370, 2010. e-Pub 2010. PMID: 20875553.
320. Dasgupta SK, Argaiz ER, Mercado JE, Maul HO, Garza J, Enriquez AB, Abdel-Monem H, Prakasam A, Andreeff M, Thiagarajan P. Platelet senescence and phosphatidylserine exposure. Transfusion 50(10):2167-75, 2010. e-Pub 2010. PMID: 20456701.
321. Yip KW, Kim I, Garrison J, Cortez A, Cheung N, Aza-Blanc P, Konopleva M, Andreeff M, Reed JC. Development and Validation of an RNAi Screen for ABT-737 Sensitizers. International Journal of High Throughput Screening 1:163-170, 2010. e-Pub 2010.
322. Kang SG, Shinojima N, Hossain A, Gumin J, Yong RL, Colman H, Marini F, Andreeff M, Lang FF. Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery 67(3):711-720, 2010. e-Pub 2010. PMID: 20651630.
323. Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 9(9):2545-2557, 2010. e-Pub 2010. PMID: 20736344.
324. Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M, Andreeff M, Marini FC. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12(5):615-625, 2010. e-Pub 2010. PMID: 20230221.
325. Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, Mani SA. Epithelial-mesenchymal transition-derived cells exhibit multi-lineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28(8):1435-1445, 2010. e-Pub 2010. PMID: 20572012.
326. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28(24):3880-3889, 2010. e-Pub 2010. PMID: 20660823.
327. Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, Konopleva M, Andreeff M, Safe S. Methyl 2-Cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) Decreases Specificity Protein (Sp) Transcription Factors and Inhibits Pancreatic Tumor Growth: Role of MicroRNA-27a. Mol Pharmacol 78(2):226-236, 2010. e-Pub 2010. PMID: 20488920.
328. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Study Group AOC, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109-121, 2010. e-Pub 2010. PMID: 20708153.
329. Fiegl M, Samudio I, Mnjoyan Z, Korchin B, Fritsche H, Andreeff M. Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells. Leukemia 24(7):1364-1367, 2010. e-Pub 2010. PMID: 20508615.
330. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, Kardassis D, Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. Role of Peroxisome Proliferator-Activated Receptor-{gamma} and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia. Cancer Res 70(12):4949-60, 2010. e-Pub 2010. PMID: 20501850.
331. Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC. Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer. Cancer Res 70(11):4709-18, 2010. e-Pub 2010. PMID: 20484037.
332. Thompson T, Andreeff M, Studzinski GP, Vassilev LT. 1,25-Dihydroxyvitamin D3 Enhances the Apoptotic Activity of MDM2 Antagonist Nutlin-3a in Acute Myeloid Leukemia Cells Expressing Wild-type p53. Mol Cancer Ther 9(5):1158-1168, 2010. e-Pub 2010. PMID: 20406950.
333. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. J Clin Oncol 28(11):1856-1862, 2010. e-Pub 2010. PMID: 20212254.
334. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 17(4):1-9, 2010. e-Pub 2010. PMID: 19876078.
335. Zhang W, Konopleva M, Burks JK, Dywer KC, Schober WD, Yang JY, McQueen TJ, Hung MC, Andreeff M. Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim. Cancer Res 70(6):2424-2434, 2010. e-Pub 2010. PMID: 20215498.
336. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120(1):142-156, 2010. e-Pub 2010. PMID: 20038799.
337. Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia 24(1):33-43, 2010. e-Pub 2010. PMID: 19946262.
338. Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 115(2):306-314, 2010. e-Pub 2010. PMID: 19897582.
339. Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M, Lang FF. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery 66(1):144-156; discussion 156-157, 2010. e-Pub 2010. PMID: 20023545.
340. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA. Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells. PLoS One 5(8 (e12180)):1-9, 2010. e-Pub 2010. PMID: 20808935.
341. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM. MicroRNA 29b functions in acute myeloid leukemia. Blood 114(26):5331-5341, 2009. e-Pub 2009. PMID: 19850741.
342. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 69(23):8932-8940, 2009. e-Pub 2009. PMID: 19920199.
343. Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia 23(10):1755-1762, 2009. e-Pub 2009. PMID: 19458629.
344. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia. J Clin Oncol 27(28):4741-4746, 2009. e-Pub 2009. PMID: 19652057.
345. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M, Marini FC. Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescence Imaging. Stem Cells 27(10):2614-2623, 2009. e-Pub 2009. PMID: 19650040.
346. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 8(9):2509-2516, 2009. e-Pub 2009. PMID: 19723894.
347. Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci 100(6):1128-1136, 2009. e-Pub 2009. PMID: 19385969.
348. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113(25):6411-6418, 2009. e-Pub 2009. PMID: 19211935.
349. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113(24):6215-6224, 2009. e-Pub 2009. PMID: 18955566.
350. Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 23(4):784-790, 2009. e-Pub 2009. PMID: 19225536.
351. Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113(7):1504-1512, 2009. e-Pub 2009. PMID: 18957686.
352. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 15(4):1326-1334, 2009. e-Pub 2009. PMID: 19228734.
353. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional proteomic profiling of AML predicts response and survival. Blood 113(1):154-164, 2009. e-Pub 2009. PMID: 18840713.
354. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4(4):e4992, 2009. e-Pub 2009. PMID: 19352430.
355. Elsawa SF, Novak AJ, Grote D, Konopleva M, Andreeff M, Witzig TE, Ansell SM. CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia. Leuk Res 32(12):1895-1902, 2008. e-Pub 2008. PMID: 18468679.
356. Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, Berger M, Viallet J, Borthakur G. A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in patients with Advanced Hematologic Malignancies. Clin Cancer Res 14(24):8295-8301, 2008. e-Pub 2008. PMID: 19088047.
357. Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, Konopleva M, Andreeff M, Radomski MW, Ruvolo PP. Ceramide promotes apoptosis in Chronic Myelogenous leukemia-derived K562 Cells by a mechanism involving caspase-8 and JNK. Cell Cycle 7(21):3362-3370, 2008. e-Pub 2008. PMID: 18948750.
358. Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, Chen W, Kornblau S, Barón AE, Drabkin HA. HOX expression patterns identify a common signature for favorable AML. Leukemia 22(11):2041-2047, 2008. e-Pub 2008. PMID: 18668134.
359. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 112(7):2886-2895, 2008. e-Pub 2008. PMID: 18633130.
360. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The Dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22(9):1728-1736, 2008. e-Pub 2008. PMID: 18548093.
361. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The Warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 68(13):5198-5205, 2008. e-Pub 2008. PMID: 18593920.
362. Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka R, Andreeff M, Taniwaki M, Maekawa T. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol 87(5):507-515, 2008. e-Pub 2008. PMID: 18415656.
363. Kong G, Wang D, Wang H, Wu J, Bielawski J, Konopleva M, Andreeff M, Ruvolo PP, Maurer BJ. Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells. Leukemia 22(6):1258-1262, 2008. e-Pub 2008. PMID: 18033322.
364. Xu Y, Tabe Y, Jin L, Watt J, McQueen T, Ohsaka A, Andreeff M, Konopleva M. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 142(2):192-201, 2008. e-Pub 2008. PMID: 18492113.
365. Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC. Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res 14(10):3011-3021, 2008. e-Pub 2008. PMID: 18483366.
366. Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M, Dunner K, Kondo S, Andreeff M, Konopleva M. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther 7(5):1130-1139, 2008. e-Pub 2008. PMID: 18483301.
367. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M. Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax). Cancer Res 68(9):3413-3420, 2008. e-Pub 2008. PMID: 18451169.
368. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 111(7):3742-3750, 2008. e-Pub 2008. PMID: 18187663.
369. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 22(4):808-818, 2008. e-Pub 2008. PMID: 18200035.
370. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111(6):3183-3189, 2008. e-Pub 2008. PMID: 18187662.
371. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100(3):184-198, 2008. e-Pub 2008. PMID: 18230792.
372. Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 140(2):181-190, 2008. e-Pub 2008. PMID: 18028486.
373. Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 7(1):48-58, 2008. e-Pub 2008. PMID: 18202009.
374. Mori S, Kantarjian H, Zhang W, Andreeff M, Ravandi F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leukemia and Lymphoma 49(12):2246-2255, 2008. e-Pub 2008.
375. Andreeff M, Zeng Z, Tabe Y, Samudio I, Fiegl M, Watt J, Dietrich M, McQueen T, Frolova O, Battula L, Mnjoyan Z, Y-X S, Konoplev S, Burks J, Konopleva M. Microenvironment and leukemia: Yin and yang. Ann Hematol 87 Suppl 1:S94-S98, 2008. e-Pub 2008.
376. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 67(24):11687-11695, 2007. e-Pub 2007. PMID: 18089798.
377. Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther 6(12):1967-1977, 2007. e-Pub 2007. PMID: 18075297.
378. Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Müller-Tidow C, Serve H, Tenen DG. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood 110(10):3695-3705, 2007. e-Pub 2007. PMID: 17671235.
379. Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 14(9):1667-1677, 2007. e-Pub 2007. PMID: 17510658.
380. Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, Xu Y, Tsutusmi-Ishii Y, Miyake K, Miyake N, Kondo S, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ 14(8):1443-1456, 2007. e-Pub 2007. PMID: 17464329.
381. Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P, Vignetti M, Vitale A, Mancini M, Cimino G, Palmieri S, Di Raimondo F, Specchia G, Fabbiano F, Cantore N, Mosna F, Camera A, Luppi M, Annino L, Miraglia E, Fioritoni G, Ronco F, Meloni G, Mandelli F, Andreeff M, Milella M, Foà R, Tafuri A, Working Party GAL. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 109(12):5473-5476, 2007. e-Pub 2007. PMID: 17351113.
382. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, Conneely OM. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med 13(6):730-735, 2007. e-Pub 2007. PMID: 17515897.
383. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 13(11):3380-3387, 2007. e-Pub 2007. PMID: 17545546.
384. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, Calin GA, Liu CG, Andreeff M, Croce CM. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 26(28):4148-4157, 2007. e-Pub 2007. PMID: 17260024.
385. Sun K, Li M, Konopleva M, Konoplev S, Stephens LC, Kornblau SM, Frolova O, Wilkins DE, Ma W, Welniak LA, Andreeff M, Murphy WJ. The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality. Biol Blood Marrow Transplant 13(5):521-525, 2007. e-Pub 2007. PMID: 17448911.
386. Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL, Andreeff M. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res 67(9):4210-4218, 2007. e-Pub 2007. PMID: 17483332.
387. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells. Cancer Res 67(7):3210-3219, 2007. e-Pub 2007. PMID: 17409429.
388. Mak DH, Schober WD, Chen W, Heller J, Andreeff M, Carter BZ. Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma 48(4):774-785, 2007. e-Pub 2007. PMID: 17454637.
389. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109(8):3509-3512, 2007. e-Pub 2007. PMID: 17179228.
390. Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foà R, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood 109(5):2121-2129, 2007. e-Pub 2007. PMID: 17077328.
391. Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang H, Andreeff M, Garcia-Manero G. Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation. Oncogene 26(10):1439-1448, 2007. e-Pub 2007. PMID: 16936778.
392. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer 109(6):1152-1156, 2007. e-Pub 2007. PMID: 17315232.
393. Brookes PS, Morse K, Ray D, Tompkins A, Young SM, Hilchey S, Salim S, Konopleva M, Andreeff M, Phipps R, Bernstein SH. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore. Cancer Res 67(4):1793-1802, 2007. e-Pub 2007. PMID: 17308122.
394. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67(2):684-694, 2007. e-Pub 2007. PMID: 17234779.
395. Kress CL, Konopleva M, Martínez-García V, Krajewska M, Lefebvre S, Hyer ML, McQueen T, Andreeff M, Reed JC, Zapata JM. Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS One 2(6):e559, 2007. e-Pub 2007. PMID: 17593960.
396. Lapotko DO, Lukianova-Hleb EY, Zhdanok SA, Hafner JH, Rostro BC, Scully P, Konopleva M, Andreeff M, Li C, Hanna EY, Myers JN, Oraevsky AA. LANTCET: laser nanotechnology for screening and treatment tumor ex vivo and in vivo. Proc SPIE 6735:673516, 2007. e-Pub 2007.
397. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M, Meli M, Colombo G, Altieri DC. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 98(15):1068-1077, 2006. e-Pub 2006. PMID: 16882944.
398. Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, Pond GR, Konopleva M, Gurfinkel D, Mawji IA, Brown E, Reed JC. Identification of small-molecules that sensitize resistant tumor cells to TNF-family death receptors. Cancer Res 66:2367-2375, 2006. e-Pub 2006.
399. Kurinna S, Konopleva M, Palla SL, Chen W, Kornblau S, Contractor R, Deng X, May WS, Andreeff M, Ruvolo PP. Bcl2 phosphorylation and active PKC alpha are associated with poor survival in AML. Leukemia 20(7):1316-1319, 2006. e-Pub 2006. PMID: 16642043.
400. Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J, Andreeff M. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 107(4):1546-1554, 2006. e-Pub 2006. PMID: 16223781.
401. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Jr, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66:3737-3746, 2006. e-Pub 2006. PMID: 16585200.
402. Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 5:3113-3121, 2006. e-Pub 2006. PMID: 17172414.
403. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12:5165-5173, 2006. e-Pub 2006. PMID: 16951235.
404. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'Brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 30:813-822, 2006. e-Pub 2006. PMID: 16478631.
405. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O'Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma 47:1062-1068, 2006. e-Pub 2006. PMID: 16840198.
406. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5:2512-2521, 2006. e-Pub 2006. PMID: 17041095.
407. Tabe Y, Konopleva M, Kondo Y, Contractor R, Jin L, Ruvolo V, Tsutsumi-Ishii Y, Miyake K, Miyake N, Ohsaka A, Nagaoka I, Issa JP, Andreeff M. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Ann Hematol 85:689-704, 2006. e-Pub 2006. PMID: 16832676.
408. Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res 12:1828-1838, 2006. e-Pub 2006. PMID: 16551868.
409. Samudio I, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann W, Ying Y, Evans R, Contractor R, Andreeff M. A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol Pharmacol 69:1182-1193, 2006. e-Pub 2006. PMID: 16410408.
410. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107:2517-2524, 2006. e-Pub 2006. PMID: 16293603.
411. Sah NK, Munshi A, Hobbs M, Carter BZ, Andreeff M, Meyn RE. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys 66:852-859, 2006. e-Pub 2006. PMID: 17011457.
412. Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 20:610-619, 2006. e-Pub 2006. PMID: 16482209.
413. Ling X, Wang Y, Dietrich MF, Andreeff M, Arlinghaus RB. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene 25:4483-4490, 2006. e-Pub 2006. PMID: 16547503.
414. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108:2358-2365, 2006. e-Pub 2006. PMID: 16763210.
415. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M. Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle 5:2769-2777, 2006. e-Pub 2006. PMID: 17172852.
416. Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther 5:317-328, 2006. e-Pub 2006. PMID: 16505105.
417. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388, 2006. e-Pub 2006. PMID: 17097560.
418. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 5(23):2778-2786, 2006. e-Pub 2006. PMID: 17172851.
419. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108:993-1000, 2006. e-Pub 2006. PMID: 16543464.
420. Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM, Andreeff M. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 5:2223-2229, 2006. e-Pub 2006. PMID: 16969080.
421. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 108:630-637, 2006. e-Pub 2006. PMID: 16556893.
422. Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, Chen W, Andreeff M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 107:1555-1563, 2006. e-Pub 2006. PMID: 16254145.
423. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce CM. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A 103(13):5078-5083, 2006. e-Pub 2006. PMID: 16549775.
424. Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff M, Konopleva M. Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 19(11):1977-1984, 2005. e-Pub 2005. PMID: 16151469.
425. Takada Y, Andreeff M, Aggarwal BB. Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 106:641-649, 2005. e-Pub 2005. PMID: 15811958.
426. Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, Sebolt-Leopold J, Konopleva M, Andreeff M. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 19(9):1543-1549, 2005. e-Pub 2005. PMID: 16001087.
427. Okcu MF, Wang RY, Bueso-Ramos C, Schober W, Weidner D, Andrassy R, Blakely M, Russell H, Ozkan A, Kuttesch J, Andreeff M, Chan KW, Ater J. Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow. Pediatr Blood Cancer 45(6):787-795, 2005. e-Pub 2005. PMID: 15929127.
428. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65(8):3307-3318, 2005. e-Pub 2005. PMID: 15833864.
429. Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, Ruvolo PP. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19(8):1350-1354, 2005. e-Pub 2005. PMID: 15931262.
430. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106(9):3150-3159, 2005. e-Pub 2005. PMID: 16014563.
431. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088, 2005. e-Pub 2005. PMID: 15767648.
432. Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104(3):541-546, 2005. e-Pub 2005. PMID: 15977212.
433. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130(4):501-510, 2005. e-Pub 2005. PMID: 16098063.
434. Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva M. A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res 65(7):2890-2898, 2005. e-Pub 2005. PMID: 15805291.
435. Chintharlapalli, S, Papineni S, Konopleva M, Andreeff M, Samudio I, Safe S. 2-cyano-3,12-dioxoolean-1,9-dien-28 oic acid (CDDO) and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor-g-dependent and –independent pathways. . Mol Pharmacol 68(1):119-128, 2005. e-Pub 2005.
436. Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, Schober WD, Nefzi A, Pond GR, Mawji IA, Houghten RA, Ostresh J, Brandwein J, Minden MD, Schuh AC, Wells RA, Messner H, Chun K, Reed JC, Schimmer AD. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 105(10):4043-4050, 2005. e-Pub 2005. PMID: 15687241.
437. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 11(19 Pt 1):6916-6923, 2005. e-Pub 2005. PMID: 16203783.
438. Samudio I, Konopleva M, Hail N, Shi YX, McQueen T, Hsu T, Evans R, Honda T, Gribble GW, Sporn M, Gilbert HF, Safe S, Andreeff M. 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 280(43):36273-36282, 2005. e-Pub 2005. PMID: 16118208.
439. Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res 65(21):9962-9970, 2005. e-Pub 2005. PMID: 16267021.
440. Samudio I, Konopleva M, Safe S, McQueen T, Andreeff M. Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 4(12):1982-1992, 2005. e-Pub 2005. PMID: 16373713.
441. Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff M. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64(21):7927-7935, 2004. e-Pub 2004. PMID: 15520199.
442. Jiffar T, Kurinna S, Suck G, Carlson-Bremer D, Ricciardi MR, Konopleva M, Andreeff M, Ruvolo PP. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia 18(3):505-12, 2004. e-Pub 2004. PMID: 14737078.
443. Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in mycosis fungoides/Sezary syndrome cells. J Invest Dermatol 123(2):380-387, 2004. e-Pub 2004. PMID: 15245439.
444. Jr HN, Konopleva M, Sporn M, Lotan R, Andreeff M. Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO). J Biol Chem 279(12):11179-87, 2004. e-Pub 2004. PMID: 14711815.
445. Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10(9):2908-17, 2004. e-Pub 2004. PMID: 15131024.
446. Monaco G, Belmont JW, Konopleva M, Andreeff M, Tavor S, Petit I, Kollet O, Lapidot T. Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia. Cancer Res 64(18):6832 author reply 6832-3, 2004. e-Pub 2004. PMID: 15375005.
447. Chen JS, Konopleva M, Andreeff M, Multani AS, Pathak S, Mehta K. Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J Cell Physiol 200(2):223-34, 2004. e-Pub 2004. PMID: 15174092.
448. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100(12):2583-91, 2004. e-Pub 2004. PMID: 15197800.
449. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18(2):267-75, 2004. e-Pub 2004. PMID: 14628071.
450. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103(12):4396-4407, 2004. e-Pub 2004. PMID: 14551133.
451. Tacke F, FCrd M, Zhao S, McQueen T, Konopleva M, Ruvolo PP, Hu SX, Xu HJ, Andreeff M. Expression of inducible Bcl-X(S) in myeloid leukemia: compensatory upregulation of Bcl-X(L) and Bcl-2 prevents apoptosis and chemosensitization. Cancer Biol Ther 3(3):340-7, 2004. e-Pub 2004. PMID: 14726688.
452. Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, McQueen T, Tsao T, Zhao S, Pierce S, Igari J, Estey EH, Andreeff M. PML-RARalpha is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 103(5):1815-22, 2004. e-Pub 2004. PMID: 14630813.
453. Tabe Y, Konopleva M, Igari J, Andreeff M. Spontaneous migration of acute promyelocytic leukemia cells beneath cultured bone marrow adipocytes with matched expression of the major histocompatibility complex. Rinsho Byori 52(8):642-648, 2004. e-Pub 2004. PMID: 15478619.
454. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96(21):1593-603, 2004. e-Pub 2004. PMID: 15523088.
455. Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 100(7):1459-71, 2004. e-Pub 2004. PMID: 15042680.
456. Norwood K, Wang RY, Hirschmann-Jax C, Andreeff M, Brenner MK, Goodell MA, Wulf GG. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res 28(3):295-9, 2004. e-Pub 2004. PMID: 14687625.
457. Munshi A, Kurland JF, Nishikawa T, Chiao PJ, Andreeff M, Meyn RE. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol Cancer Ther 3(8):985-92, 2004. e-Pub 2004. PMID: 15299081.
458. Monaco G, Konopleva M, Munsell M, Leysath C, Wang RY, Jackson CE, Korbling M, Estey E, Belmont J, Andreeff M. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 22(2):188-201, 2004. e-Pub 2004. PMID: 14990858.
459. Yotnda P, Zompeta C, Heslop HE, Andreeff M, Brenner MK, Marini F. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther 15(12):1229-42, 2004. e-Pub 2004. PMID: 15684699.
460. Melichar B, Konopleva M, Hu W, Melicharova K, Andreeff M, Freedman RS. Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. Gynecol Oncol 93:149-54, 2004. e-Pub 2004. PMID: 15047229.
461. Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Targeted therapy of AML new concepts. Ann Hematol 83 Suppl 1:S51-S53, 2004. e-Pub 2004. PMID: 15124670.
462. Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther 3(10):1249-62, 2004. e-Pub 2004. PMID: 15486192.
463. Konopleva M, Cheng SC, Cortes JE, Hayes KJ, Pierce SA, Andreeff M, Giles FJ, O'Brien S, Kantarjian HM, Estey EH. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. Haematologica 88(7):733-6, 2003. e-Pub 2003. PMID: 12857550.
464. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98(3):522-8, 2003. e-Pub 2003. PMID: 12879469.
465. Takahashi S, Mok H, Parrott MB, FCrd M, Andreeff M, Brenner MK, Barry MA. Selection of chronic lymphocytic leukemia binding peptides. Cancer Res 63(17):5213-7, 2003. e-Pub 2003. PMID: 14500347.
466. Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 9(12):4570-7, 2003. e-Pub 2003. PMID: 14555532.
467. Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, Madden T, Andreeff M. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 63(18):5926-39, 2003. e-Pub 2003. PMID: 14522919.
468. O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98(5):888-93, 2003. e-Pub 2003. PMID: 12942553.
469. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-5, 2003. e-Pub 2003. PMID: 12522009.
470. Eksioglu-Demiralp E, Kitada S, Carson D, Garland J, Andreef M, Reed JC. A method for functional evaluation of caspase activation pathways in intact lymphoid cells using electroporation-mediated protein delivery and flow cytometric analysis. J Immunol Methods 275(1-2):41-56, 2003. e-Pub 2003. PMID: 12667669.
471. Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97(5):1234-41, 2003. e-Pub 2003. PMID: 12599230.
472. Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M, Suh N, Sporn M, Reed JC. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 17(11):2122-9, 2003. e-Pub 2003. PMID: 12931220.
473. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Jr, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63(14):4174-80, 2003. e-Pub 2003. PMID: 12874023.
474. Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2(5):488-93, 2003. e-Pub 2003. PMID: 12963850.
475. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 17(11):2081-9, 2003. e-Pub 2003. PMID: 12970762.
476. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, Sung HG, Reed JC, Andreeff M. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 102(12):4179-86, 2003. e-Pub 2003. PMID: 12920030.
477. Schimmer AD, Pedersen IM, Kitada S, Eksioglu-Demiralp E, Minden MD, Pinto R, Mah K, Andreeff M, Kim Y, Suh WS, Reed JC. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res 63(6):1242-8, 2003. e-Pub 2003. PMID: 12649183.
478. Bolontrade, MF, Worth LL, R-R Z, Marini FC, Andreeff M, Kleinerman ES. Bone marrow side population cells contribute to neovessel formation in Ewing’s sarcoma. Stem Cell and Cell Therapy 1:14-20, 2003. e-Pub 2003.
479. Biagi E, Yvon E, Dotti G, Amrolia PJ, Takahashi S, Popat U, Marini F, Andreeff M, Brenner MK, Rousseau RF. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther 14(6):545-59, 2003. e-Pub 2003. PMID: 12718765.
480. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. Low levels of ABCG2 expression in adult AML blast samples. Blood 100(13):4594-601, 2002. e-Pub 2002. PMID: 12393637.
481. Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC, Jr. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 62(24):7264-72, 2002. e-Pub 2002. PMID: 12499268.
482. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1(12):989-97, 2002. e-Pub 2002. PMID: 12481421.
483. Clodi K, Asgari Z, Younes M, Palmer JL, Cabanillas F, Carbone A, Andreeff M, Younes A. Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer 94(1):1-5, 2002. e-Pub 2002. PMID: 11815953.
484. Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clin Cancer Res 8:2123-33, 2002. e-Pub 2002. PMID: 12114412.
485. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 20(3):656-64, 2002. e-Pub 2002. PMID: 11821445.
486. Gu J, Andreeff M, Roth JA, Fang B. hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther 9(1):30-7, 2002. e-Pub 2002. PMID: 11850720.
487. Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M, Glassman A, Arlinghaus RB. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 16(12):2447-53, 2002. e-Pub 2002. PMID: 12454751.
488. Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8(7):2177-87, 2002. e-Pub 2002. PMID: 12114418.
489. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16(9):1713-24, 2002. e-Pub 2002. PMID: 12200686.
490. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99(1):326-35, 2002. e-Pub 2002. PMID: 11756188.
491. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff M. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 118(2):521-34, 2002. e-Pub 2002. PMID: 12139741.
492. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res 26(6):551-9, 2002. e-Pub 2002. PMID: 12007503.
493. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99(9):3461-4, 2002. e-Pub 2002. PMID: 11964319.
494. O'Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer 94(7):2024-32, 2002. e-Pub 2002. PMID: 11932905.
495. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 100(8):2965-72, 2002. e-Pub 2002. PMID: 12351409.
496. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62(13):3603-8, 2002. e-Pub 2002. PMID: 12097260.
497. Tacke F, Trautwein C, Zhao S, Andreeff M, Manns MP, Ganser A, Schoffski P. Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. Liver 22(3):205-12, 2002. e-Pub 2002. PMID: 12100570.
498. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma 43(4):767-72, 2002. e-Pub 2002. PMID: 12153163.
499. Tsimberidou AM, Thomas D, O'Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 50(3):237-42, 2002. e-Pub 2002. PMID: 12203106.
500. Korbling M, Giralt S, Khouri I, Mirza N, Donato M, Anderlini P, Fischer H, Andreeff M, McMannis J, Champlin R. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher 16(2):82-7, 2001. e-Pub 2001. PMID: 11746533.
501. Pachmann K, Zhao S, Schenk T, Kantarjian H, El-Naggar AK, Siciliano MJ, Guo JQ, Arlinghaus RB, Andreeff M. Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification. Br J Haematol 112(3):749-59, 2001. e-Pub 2001. PMID: 11260080.
502. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98(4):1166-73, 2001. e-Pub 2001. PMID: 11493466.
503. Varella-Garcia M, Hogan CJ, Odom LF, Murata-Collins JL, Ai H, Chen L, Richkind K, Paskulin G, Andreeff M, Brizard A, McGavran L, Gemmill RM, Berger R, Drabkin HA. Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia 15(9):1408-14, 2001. e-Pub 2001. PMID: 11516101.
504. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108(6):851-9, 2001. e-Pub 2001. PMID: 11560954.
505. Takahashi S, Rousseau RF, Yotnda P, Mei Z, Dotti G, Rill D, Hurwitz R, Marini F, Andreeff M, Brenner MK. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 12(6):659-70, 2001. e-Pub 2001. PMID: 11426465.
506. Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer 91(11):1964-72, 2001. e-Pub 2001. PMID: 11391574.
507. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 97(9):2784-90, 2001. e-Pub 2001. PMID: 11313272.
508. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 67(4):227-33, 2001. e-Pub 2001. PMID: 11443634.
509. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97(3):631-7, 2001. e-Pub 2001. PMID: 11157478.
510. Gisslinger H, Kurzrock R, Gisslinger B, Jiang S, Li S, Virgolini I, Woloszczuk W, Andreeff M, Talpaz M. Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood 97(9):2791-7, 2001. e-Pub 2001. PMID: 11313273.
511. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S, Lopez-Berestein G, Andreeff M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 95(12):3929-38, 2000. e-Pub 2000. PMID: 10845930.
512. Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 6(4):1401-9, 2000. e-Pub 2000. PMID: 10778970.
513. Liu Y, Kleine HD, Engel H, Andreeff M. Cytokine expression of T cells in chronic myeloid leukemia. Chin Med J (Engl) 113(3):232-5, 2000. e-Pub 2000. PMID: 11775253.
514. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 6(1):250-9, 2000. e-Pub 2000. PMID: 10656456.
515. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6(5):1796-803, 2000. e-Pub 2000. PMID: 10815900.
516. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18(3):547-61, 2000. e-Pub 2000. PMID: 10653870.
517. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96(2):393-7, 2000. e-Pub 2000. PMID: 10887097.
518. Clodi K, Kliche KO, Zhao S, Weidner D, Schenk T, Consoli U, Jiang S, Snell V, Andreeff M. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes. Cytometry 40(1):19-25, 2000. e-Pub 2000. PMID: 10754513.
519. Engel H, Drach J, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Goodacre A, Andreeff M. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Leukemia 13(4):568-77, 1999. e-Pub 1999. PMID: 10214863.
520. Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17(9):2819-30, 1999. e-Pub 1999. PMID: 10561358.
521. Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth AB. Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma 32(3-4):279-88, 1999. e-Pub 1999. PMID: 10037025.
522. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao S. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13(11):1881-92, 1999. e-Pub 1999. PMID: 10557066.
523. Aboul-Nasr R, Estey EH, Kantarjian HM, Freireich EJ, Andreeff M, Johnson BJ, Albitar M. Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol 111(6):753-8, 1999. e-Pub 1999. PMID: 10361510.
524. Ruan S, Okcu MF, Pong RC, Andreeff M, Levin V, Hsieh JT, Zhang W. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Clin Cancer Res 5(1):197-202, 1999. e-Pub 1999. PMID: 9918219.
525. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 10(4):433-40, 1999. e-Pub 1999. PMID: 10370786.
526. Weinkauff R, Estey EH, Starostik P, Hayes K, Huh YO, Hirsch-Ginsberg C, Andreeff M, Keating M, Kantarjian HM, Freireich EJ, Albitar M. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 111(6):733-40, 1999. e-Pub 1999. PMID: 10361507.
527. Marini FC, Snell V, Yu Q, Zhang X, Singletary SE, Champlin R, Andreeff M. Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation. Clin Cancer Res 5(6):1557-68, 1999. e-Pub 1999. PMID: 10389945.
528. O'Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood 93(12):4149-53, 1999. e-Pub 1999. PMID: 10361112.
529. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 5(7):1758-66, 1999. e-Pub 1999. PMID: 10430080.
530. Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A. Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br J Haematol 106(3):827-32, 1999. e-Pub 1999. PMID: 10468881.
531. Kornblau SM, Konopleva M, Andreeff M. Apoptosis regulating proteins as targets of therapy for haematological malignancies. Expert Opin Investig Drugs 8(12):2027-2057, 1999. e-Pub 1999. PMID: 11139839.
532. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 93(5):1668-76, 1999. e-Pub 1999. PMID: 10029596.
533. Konopleva M, Andreeff M. Regulatory pathways in programmed cell death. Cancer Mol Biol 6:1229-1260, 1999. e-Pub 1999.
534. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 106(4):995-1004, 1999. e-Pub 1999. PMID: 10520003.
535. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 17(1):284-92, 1999. e-Pub 1999. PMID: 10458244.
536. Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F, Gluckman E, Andreeff M, Champlin RE. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 67(1):124-30, 1999. e-Pub 1999. PMID: 9921808.
537. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93(8):2478-84, 1999. e-Pub 1999. PMID: 10194425.
538. Schenk TM, Keyhani A, Bottcher S, Kliche KO, Goodacre A, Guo JQ, Arlinghaus RB, Kantarjian HM, Andreeff M. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 12(5):666-74, 1998. e-Pub 1998. PMID: 9593263.
539. Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, Rosenblum MG. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res 4(8):1971-6, 1998. e-Pub 1998. PMID: 9717827.
540. Wang MW, Consoli U, Lane CM, Durett A, Lauppe MJ, Champlin R, Andreeff M, Deisseroth AB. Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ 9(2):105-12, 1998. e-Pub 1998. PMID: 9486846.
541. Kobayashi T, Ruan S, Jabbur JR, Consoli U, Clodi K, Shiku H, Owen-Schaub LB, Andreeff M, Reed JC, Zhang W. Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ 5(7):584-91, 1998. e-Pub 1998. PMID: 10200513.
542. Kobayashi T, Ruan S, Clodi K, Kliche KO, Shiku H, Andreeff M, Zhang W. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 16(12):1587-91, 1998. e-Pub 1998. PMID: 9569026.
543. Liu, YR, Drach J, Drach D, Andreeff M, S-S C. Cytokine mRNA expression of normal CD34 positive bone marrow cells. J Exp Hematol 6:104-110, 1998. e-Pub 1998.
544. Ling YH, Consoli U, Tornos C, Andreeff M, Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer 75(6):925-32, 1998. e-Pub 1998. PMID: 9506539.
545. Lee HY, Dohi DF, Kim YH, Walsh GL, Consoli U, Andreeff M, Dawson MI, Hong WK, Kurie JM. All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway. J Clin Invest 101(5):1012-9, 1998. e-Pub 1998. PMID: 9486971.
546. Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92(11):4220-9, 1998. e-Pub 1998. PMID: 9834227.
547. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A, et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 4(11):2717-21, 1998. e-Pub 1998. PMID: 9829734.
548. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau SM. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92(9):3090-7, 1998. e-Pub 1998. PMID: 9787143.
549. Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth AB. Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia. Mol Med 4(3):158-64, 1998. e-Pub 1998. PMID: 9562974.
550. Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, Younes A. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 103(1):270-5, 1998. e-Pub 1998. PMID: 9792321.
551. Kornblau SM, Kantarjian H, O'Brien S, Andreeff M, Koller CA, Beran M, Keating M, Estey E. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma 28(3-4):371-5, 1998. e-Pub 1998. PMID: 9517508.
552. Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res 4(8):1955-63, 1998. e-Pub 1998. PMID: 9717825.
553. Schmitt T, Oehme L, Andreeff M, Foe Owono GD, Franke WG, Freyer R. [3D segmenting method for volume quantification of ECT (emission-computed tomography) data]. Biomed Tech (Berl) 43 Suppl:70-1, 1998. e-Pub 1998. PMID: 9859262.
554. Andreeff M, Kropp J, Beuthien-Baumann B, Oehme L, Hliscs R, Schellong S, Prescher Y, Franke WG, Daniel WG. [Equipment for modification of nuclear medicine lung diagnosis as triggered SPECT--presentation, phantom studies and clinical value]. Biomed Tech (Berl) 43 Suppl:76-7, 1998. e-Pub 1998. PMID: 9859265.
555. Foe Owono GD, Schmitt T, Oehme L, Andreeff M, Franke WG, Freyer R. [Effect of corrective procedures on volume quantification of SPECT data]. Biomed Tech (Berl) 43 Suppl:470-1, 1998. e-Pub 1998. PMID: 9859447.
556. Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol 103(1):217-9, 1998. e-Pub 1998. PMID: 9792311.
557. Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine HD, Brown W, Robinson JR, DiRaimondo F, Plunkett W, Andreeff M. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 91(5):1742-8, 1998. e-Pub 1998. PMID: 9473241.
558. Konopleva M, Estrov Z, Zhao S, Andreeff M, Mehta K. Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. J Immunol 161(9):4702-8, 1998. e-Pub 1998. PMID: 9794400.
559. Ruan S, Okcu MF, Ren JP, Chiao P, Andreeff M, Levin V, Zhang W. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 58(7):1538-43, 1998. e-Pub 1998. PMID: 9537261.
560. Munker R, Zhao S, Jiang S, Snell V, Andreeff M, Andersson BS. Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line. Leuk Res 22(11):1073-7, 1998. e-Pub 1998. PMID: 9783811.
561. DeLima M, Albitar M, O'Brien S, Pierce S, Kantarjian H, Andreeff M, Fayad L, Keating M, Estey E. Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia. Am J Med 104(3):246-51, 1998. e-Pub 1998. PMID: 9552087.
562. Munker R, Kantarjian H, O'Brien S, Keating M, Andreeff M, Estey EH. Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol 99(2):106-8, 1998. e-Pub 1998. PMID: 9554461.
563. Perez-Soler R, Neamati N, Zou Y, Schneider E, Doyle LA, Andreeff M, Priebe W, Ling YH. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Int J Cancer 71(1):35-41, 1997. e-Pub 1997. PMID: 9096663.
564. Rondon G, Giralt S, Pereira M, Van Besien K, Mehra R, Champlin R, Andreeff M. Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma 25(5-6):463-7, 1997. e-Pub 1997. PMID: 9250816.
565. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99(3):618-24, 1997. e-Pub 1997. PMID: 9401075.
566. Younes A, Consoli U, Snell V, Clodi K, Kliche KO, Palmer JL, Gruss HJ, Armitage R, Thomas EK, Cabanillas F, Andreeff M. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 15(11):3355-62, 1997. e-Pub 1997. PMID: 9363866.
567. Younes A, Zhao S, Zhang X, Snell V, Clodi K, Kliche KO, Thomas E, Cabanillas F, Andreeff M. CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease. Ann Oncol 8 Suppl 2:97-100, 1997. e-Pub 1997. PMID: 9209650.
568. Yousuf HM, Englund J, Couch R, Rolston K, Luna M, Goodrich J, Lewis V, Mirza NQ, Andreeff M, Koller C, Elting L, Bodey GP, Whimbey E. Influenza among hospitalized adults with leukemia. Clin Infect Dis 24(6):1095-9, 1997. e-Pub 1997. PMID: 9195063.
569. Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M, McConkey DJ. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood 90(9):3673-81, 1997. e-Pub 1997. PMID: 9345052.
570. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89(4):1133-42, 1997. e-Pub 1997. PMID: 9028934.
571. Clodi K, Younes A, Goodacre A, Roberts M, Palmer J, Younes M, Cabanillas F, Andreeff M. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. Br J Haematol 98(4):913-21, 1997. e-Pub 1997. PMID: 9326189.
572. Consoli, U, Li H, Huang P, Kobayashi T, Andreeff M, Levin V, Zhang W. Enhancement of apoptosis in irradiated glioblastoma cells by pentoxifylline. Oncology Reports 4:673-678, 1997. e-Pub 1997.
573. Consoli U, Van NT, Neamati N, Mahadevia R, Beran M, Zhao S, Andreeff M. Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines. Leukemia 11(12):2066-74, 1997. e-Pub 1997. PMID: 9447822.
574. Engel H, Goodacre A, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Andreeff M. Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. Br J Haematol 99(1):64-75, 1997. e-Pub 1997. PMID: 9359505.
575. Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M, Deisseroth AB. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 89(17):1271-6, 1997. e-Pub 1997. PMID: 9293917.
576. Kobayashi, T, Clodi K, Yang Y, Ruan S, Shiku H, Andreeff M, Shay JW, Zhang W. Inhibition of telomerase activity correlates with a decrease in the RNA component of telomerase during differentiation. Intl J Oncol 11:13-17, 1997. e-Pub 1997.
577. Konishi H, Steinbach G, Terry NH, Fujita K, Lee JJ, Ruifrok A, Spaulding D, Lynch PM, Dubin JA, Andreeff M, Goodacre AM, Hattori T, Hittelman WN. S phase determination in intact colonic crypts by histone H3 messenger RNA in situ hybridization and confocal microscopy. Cancer Epidemiol Biomarkers Prev 6(7):531-6, 1997. e-Pub 1997. PMID: 9232341.
578. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15(5):1796-802, 1997. e-Pub 1997. PMID: 9164187.
579. Mehta K, McQueen T, Manshouri T, Andreeff M, Collins S, Albitar M. Involvement of retinoic acid receptor-alpha-mediated signaling pathway in induction of CD38 cell-surface antigen. Blood 89(10):3607-14, 1997. e-Pub 1997. PMID: 9160665.
580. Munker R, Marini F, Jiang S, Savary C, Owen-Schaub L, Andreeff M. Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing. Hematol Cell Ther 39(2):75-8, 1997. e-Pub 1997. PMID: 9168303.
581. Munker R, Younes A, Cabanillas F, Andreeff M. Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations. Leuk Lymphoma 27(5-6):517-21, 1997. e-Pub 1997. PMID: 9477134.
582. Nowak R, Oelschlaegel U, Schuler U, Zengler H, Hofmann R, Ehninger G, Andreeff M. Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Cytometry 30(1):47-53, 1997. e-Pub 1997. PMID: 9056742.
583. Hanania, EG, Giles RE, Kavanagh J, Ellerson D, Zu Z, Wang M, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton C, Vachier C, Thall P, Cheng S, Hester J, Ostrove J, Byrd R, Cheng A, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Bast R, Andreeff M, Champlin R, Deisseroth AB. Results of MDR-1 modification trial indicate that granulocyte/ macrophage colony-forming unit cells do not contribute to post transplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 93(26):15346-15351, 1996. e-Pub 1996.
584. Beran M, Kantarjian H, O'Brien S, Koller C, al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88(7):2473-9, 1996. e-Pub 1996. PMID: 8839838.
585. Jiang S, Munker R, Andreeff M. Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2. Nat Immun 15(6):312-7, 1996. e-Pub 1996. PMID: 9523282.
586. Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O'Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma 21(1-2):85-92, 1996. e-Pub 1996. PMID: 8907274.
587. Tari AM, Andreeff M, Kleine HD, Lopez-Berestein G. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides. J Mol Med 74(10):623-8, 1996. e-Pub 1996. PMID: 8912183.
588. Konishi H, Steinbach G, Hittelman WN, Fujita K, Lee JJ, Glober GA, Levin B, Andreeff M, Goodacre AM, Terry NH. Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence. Gastroenterology 111(6):1493-500, 1996. e-Pub 1996. PMID: 8942727.
589. Munker R, Andreeff M. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma. Cytokines Mol Ther 2(3):147-59, 1996. e-Pub 1996. PMID: 9384699.
590. Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10(10):1563-9, 1996. e-Pub 1996. PMID: 8847890.
591. Zhao S, Consoli U, Arceci R, Pfeifer J, Dalton WS, Andreeff M. Semi-automated PCR method for quantitating MDR1 expression. Biotechniques 21(4):726-31, 1996. e-Pub 1996. PMID: 8891227.
592. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W, Andreeff M, Koeffler HP. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 88(6):2201-9, 1996. e-Pub 1996. PMID: 8822940.
593. Zhang W, Piatyszek MA, Kobayashi T, Estey E, Andreeff M, Deisseroth AB, Wright WE, Shay JW. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 2(5):799-803, 1996. e-Pub 1996. PMID: 9816233.
594. Younes A, Sarris A, Consoli U, Rodriguez A, McLaughlin P, Huh Y, Starry S, Cabanillas F, Andreeff M. A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results. Blood 87(5):1698-703, 1996. e-Pub 1996. PMID: 8634414.
595. Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 88(10):3987-97, 1996. e-Pub 1996. PMID: 8916965.
596. Consoli U, Priebe W, Ling YH, Mahadevia R, Griffin M, Zhao S, Perez-Soler R, Andreeff M. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 88(2):633-44, 1996. e-Pub 1996. PMID: 8695811.
597. Younes A, Consoli U, Zhao S, Snell V, Thomas E, Gruss HJ, Cabanillas F, Andreeff M. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 93(3):569-71, 1996. e-Pub 1996. PMID: 8652374.
598. Mehta K, McQueen T, Neamati N, Collins S, Andreeff M. Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 7(2):179-86, 1996. e-Pub 1996. PMID: 8822201.
599. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreeff M, Huber H. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88(5):1747-54, 1996. e-Pub 1996. PMID: 8781431.
600. Munker R, Midis G, Owen-Schaub L, Andreeff M. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 10(9):1531-3, 1996. e-Pub 1996. PMID: 8751476.
601. Escudier SM, Albitar M, Robertson LE, Andreeff M, Pierce S, Kantarjian HM. Acute lymphoblastic leukemia following preleukemic syndromes in adults. Leukemia 10(3):473-7, 1996. e-Pub 1996. PMID: 8642864.
602. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, Pierce SA, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13(11):2827-34, 1995. e-Pub 1995. PMID: 7595745.
603. Chang KS, Fan YH, Andreeff M, Liu J, Mu ZM. The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 85(12):3646-53, 1995. e-Pub 1995. PMID: 7780148.
604. Tafuri, A, DeFelice L, Goodacre A, Fenu S, Petrucci M, Mascolo M, Alimena G, Petti M, Meloni G, Mandelli F, Andreeff M. Interleukin-3 priming in acute myeloid leukaemia patients. Br J Haematol 91(1):234-44, 1995. e-Pub 1995. PMID: 7577641.
605. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 9(9):1444-9, 1995. e-Pub 1995. PMID: 7658710.
606. Del Giglio A, Drach J, Kornblau SM, Patel S, Novaes M, Khetan R, Sawaya N, Dorlhiac-Llacer P, Chamone DF, Andreeff M, et al. Quantitative expression of proliferating cell nuclear antigen by western blot (PCNAWB) in peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia. Leuk Lymphoma 19(3-4):235-41, 1995. e-Pub 1995. PMID: 8535214.
607. Drach D, Zhao S, Drach J, Andreeff M. Low incidence of MDR1 expression in acute promyelocytic leukaemia. Br J Haematol 90(2):369-74, 1995. e-Pub 1995. PMID: 7794759.
608. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 3(3):198-202, 1995. e-Pub 1995. PMID: 7655781.
609. Estey E, Andreeff M. Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia. Leukemia 9(9):1440-3, 1995. e-Pub 1995. PMID: 7658709.
610. Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther 1(1):21-8, 1995. e-Pub 1995. PMID: 9384660.
611. Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB. PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Clin Cancer Res 1(6):583-90, 1995. e-Pub 1995. PMID: 9816019.
612. Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Korbling M, Hester J, Durett A, Andreeff M, Mechetner E, Holzmayer T, et al. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther 2(4):285-94, 1995. e-Pub 1995. PMID: 7552989.
613. Hegewisch-Becker S, Hanania EG, Fu S, Korbling M, Deisseroth AB, Andreeff M. Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol 90(4):876-83, 1995. e-Pub 1995. PMID: 7669666.
614. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 9(6):943-5, 1995. e-Pub 1995. PMID: 7596181.
615. Jakubowski A, Gordon M, Tafuri A, Schuster S, Andreeff M, Shieh JH, Vincent M, Gabrilove J. A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia. Leukemia 9(11):1799-804, 1995. e-Pub 1995. PMID: 7475265.
616. Jendiroba D, Younes A, Katz R, Hill D, Cabanillas F, Andreeff M. Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study. Leukemia 9(7):1144-6, 1995. e-Pub 1995. PMID: 7630187.
617. Kobayashi T, Consoli U, Andreeff M, Shiku H, Deisseroth AB, Zhang W. Activation of p21WAF1/Cip1 expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis. Oncogene 11(11):2311-6, 1995. e-Pub 1995. PMID: 8570182.
618. Preti HA, Huh YO, O'Brien SM, Andreeff M, Pierce ST, Keating M, Kantarjian HM. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer 76(9):1564-70, 1995. e-Pub 1995. PMID: 8635059.
619. Körbling, M, Engel H, van Besien K, Huh YO, Przepiorka D Giralt S, Kleine HD, Seong D, Deisseroth A, Andreeff M, Champlin R. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85(6):1659-65, 1995. e-Pub 1995. PMID: 7888684.
620. Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86(7):2842-8, 1995. e-Pub 1995. PMID: 7545476.
621. Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich JM, Raad II, Lewis V, Mirza N, Luna MA, Baxter B. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 21(2):376-9, 1995. e-Pub 1995. PMID: 8562747.
622. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86(9):3322-6, 1995. e-Pub 1995. PMID: 7579434.
623. Nguyen D, Diamond LW, Cherubino P, Koala WB, Imbert M, Andreeff M. A diagnostic workstation for neoplastic bone marrow diseases: evaluation on 526 cases. Medinfo 8 Pt 1:771-5, 1995. e-Pub 1995. PMID: 8591323.
624. Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia 9(10):1735-41, 1995. e-Pub 1995. PMID: 7564518.
625. Zhang W, Xu HJ, Kornblau SM, Drach J, Hu SX, Andreeff M, Benedict WF, Deisseroth AB. Growth-factor stimulation reveals two mechanisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. Leuk Lymphoma 16(3-4):191-8, 1995. e-Pub 1995. PMID: 7719226.
626. Younes A, Zhao S, Jendiroba D, Kleine HD, Cabanillas F, Andreeff M. Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma. Blood 85(10):2813-6, 1995. e-Pub 1995. PMID: 7742542.
627. Younes A, Jendiroba D, Katz R, Hill D, Cabanillas F, Andreeff M. Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization. Cancer Genet Cytogenet 82(1):23-9, 1995. e-Pub 1995. PMID: 7627930.
628. Wetzler M, Talpaz M, Yee G, Stass SA, Van Etten RA, Andreeff M, Goodacre AM, Kleine HD, Mahadevia RK, Kurzrock R. Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. Proc Natl Acad Sci U S A 92(8):3488-92, 1995. e-Pub 1995. PMID: 7724587.
629. Vadhan-Raj S, Broxmeyer HE, Andreeff M, Bandres JC, Buescher ES, Benjamin RS, Papadopoulos NE, Burgess A, Patel S, Plager C, Hittelman WN, McAlister I, Garrison L, Williams DE. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood 86(6):2098-105, 1995. e-Pub 1995. PMID: 7662957.
630. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12(4):671-8, 1994. e-Pub 1994. PMID: 7512125.
631. Younes A, Pugh W, Goodacre A, Katz R, Rodriguez MA, Hill D, Cabanillas F, Andreeff M. Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma. Genes Chromosomes Cancer 9(3):161-7, 1994. e-Pub 1994. PMID: 7515657.
632. Younes A, Jendiroba D, Engel H, Escudier S, Katz R, Rodriguez MA, Hill D, Cabanillas F, Andreeff M. High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement. Cancer Genet Cytogenet 77(1):39-44, 1994. e-Pub 1994. PMID: 7923081.
633. Younes, A, Drach J, Katz R, Jendiroba D, Sabourian M, Sarris A, Swan F, Hill D, Cabanillas F, Ford R, Andreeff M. Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3. Ann Oncol 5(3):265-8, 1994. e-Pub 1994. PMID: 7514436.
634. Tafuri A, Lemoli RM, Chen R, Gulati SC, Clarkson BD, Andreeff M. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. Leukemia 8(5):749-57, 1994. e-Pub 1994. PMID: 7514244.
635. Przepiorka, D, Ippoliti C, Giralt S, Van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, Estey E, Andreeff M, Champlin R. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 14(3):449-53, 1994. e-Pub 1994. PMID: 7994271.
636. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 330(5):319-22, 1994. e-Pub 1994. PMID: 7904047.
637. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia. Cytometry 17(1):84-93, 1994. e-Pub 1994. PMID: 8001461.
638. Korbling M, Drach J, Champlin RE, Engel H, Huynh L, Kleine HD, Berenson R, Deisseroth AB, Andreeff M. Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplant 13(5):649-54, 1994. e-Pub 1994. PMID: 7519938.
639. Drach J, McQueen T, Engel H, Andreeff M, Robertson KA, Collins SJ, Malavasi F, Mehta K. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. Cancer Res 54(7):1746-52, 1994. e-Pub 1994. PMID: 7511050.
640. Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia. Leuk Lymphoma 16(1-2):79-88, 1994. e-Pub 1994. PMID: 7535143.
641. Diamond LW, Nguyen DT, Andreeff M, Maiese RL, Braylan RC. A knowledge-based system for the interpretation of flow cytometry data in leukemias and lymphomas. Cytometry 17(3):266-73, 1994. e-Pub 1994. PMID: 7851162.
642. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 11(2):294-303, 1993. e-Pub 1993. PMID: 8426207.
643. Deisseroth, AB, Kantarjian H, Champlin R, Cabanillas F, Keating M, Reading C, Andersson B, Claxton D, Robertson B, Escudier S, Andreeff M, O'Brien S, Kornblau S, Ellerson D, Hanania E, Fu S. Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). Hum Gene Ther 4(6):821-34, 1993. e-Pub 1993. PMID: 8186294.
644. Escudier SM, Pereira-Leahy JM, Drach JW, Weier HU, Goodacre AM, Cork MA, Trujillo JM, Keating MJ, Andreeff M. Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 81(10):2702-7, 1993. e-Pub 1993. PMID: 7683927.
645. Deisseroth, A, Fu SQ, Hanania E, Randhawa G, Claxton D, Reading C, Champlin R, Andreeff M, Logothethis C, Hong WK, Holmes F, Hortobagyi G, Benedict W. Evolution of gene therapy: The M. D. Anderson experience. Contemporary Oncology 3:10-25, 1993. e-Pub 1993.
646. Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C. Genetic therapy of human neoplastic disease. J Hematother 2(3):373-5, 1993. e-Pub 1993. PMID: 7921999.
647. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M, Escudier S, Koller C, Kornblau S, Robertson L. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 11 Suppl 2:59-63, 1993. e-Pub 1993. PMID: 7510196.
648. Deisseroth, A, Kavanagh J, Hanania G, Fu S, Kornblau SM, Estey E, Talpaz M, Kantarjian HM, Claxton DF, Reading CL, Dixon DA, Anderson RW, Lopez-Berestein L, Holmes FA, Logothetis C, Andreeff M, Benedict W. Gene therapy: Chemoprotection, immunoenhancement, and modification of tumor cells. Cancer Bulletin 45(2):139-145, 1993. e-Pub 1993.
649. Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork A, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329(11):757-61, 1993. e-Pub 1993. PMID: 7688862.
650. Andreeff, M, Zhao S, Drach D, Hegewisch-Becker S, Rees J, Liu Y, Hanania E, Körbling M, Champlin R, Deisseroth A, Drach J. Expression of the multidrug resistance (mdr-1) and p53 genes in hematological cell systems: Implications for biology and gene therapy. Cancer Bulletin 45(2):131-138, 1993. e-Pub 1993.
651. Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid. Cancer Res 53(9):2100-4, 1993. e-Pub 1993. PMID: 8481912.
652. Valent P, Sillaber C, Geissler K, Andreeff M, Tafuri A, Vieder L, Schulz G, Lechner K, Bettelheim P. Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy. Cancer Invest 11(2):229-34, 1993. e-Pub 1993. PMID: 8462024.
653. Weiss, M, Telford P, Kempin S, Kritz A, Sogoloff H, Gee T, Berman E, Scheinberg D, Little C, Gaynor J, Belanger C, Bertino J, Andreeff M, McKenzie S, Clarkson B. Severe toxicity limites intensification of induction therapy for acute lymphoblastic leukemia. Leukemia 7(6):832-837, 1993. e-Pub 1993.
654. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80(10):2604-9, 1992. e-Pub 1992. PMID: 1421378.
655. Claxton DF, Plunkett W, Andreeff M, Deisseroth AB. Retinoids and cancer therapy. J Natl Cancer Inst 84(17):1306-7, 1992. e-Pub 1992. PMID: 1495098.
656. Fuks Z, Vlodavsky I, Andreeff M, McLoughlin M, Haimovitz-Friedman A. Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer 28A(4-5):725-31, 1992. e-Pub 1992. PMID: 1524892.
657. Valent P, Sillaber C, Geissler K, Andreeff M, Tafuri A, Vieder L, Schulz G, Lechner K, Bettelheim P. Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Med Pediatr Oncol Suppl 2:18-22, 1992. e-Pub 1992. PMID: 1306881.
658. Lichtman SM, Andreeff M. Flow cytometric analysis of cytokinetics of L3-acute lymphoblastic leukemia/lymphoma. Leuk Res 16(9):853-9, 1992. e-Pub 1992. PMID: 1405716.
659. Zhang W, Hittelman W, Van N, Andreeff M, Deisseroth A. The phosphorylation of retinoblastoma gene product in human myeloid leukemia cells during the cell cycle. Biochem Biophys Res Commun 184(1):212-6, 1992. e-Pub 1992. PMID: 1567429.
660. Zhang W, Drach J, Andreeff M, Deisseroth A. Proliferation of hematopoietic cells is accompanied by suppressed expression of heat shock protein 70. Biochem Biophys Res Commun 183(2):733-8, 1992. e-Pub 1992. PMID: 1550580.
661. Deisseroth, A, Zhang W, Cha Y, Yuan T, Chen H, Sims S, Wedrychowski A, Gao P, Huston L, Filaccio M, Claxton D, Kornblau S, Johnson E, Howard O, Andersson B, Giglio A, Gressot L, Kantarjian H, Talpaz M, Khouri I, Champlin R, Andreeff M, Gaozza E, Seong D, Suh S, Ellerson D, Hu G, Chou M. New directions in the biology and therapy of chronic myeloid leukemia. Leukemia and Lymphoma 6:89-95, 1992. e-Pub 1992.
662. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80(11):2729-34, 1992. e-Pub 1992. PMID: 1360266.
663. Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, Gee T, Straus D, Gansbacher B, Filippa D, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 79(5):1305-10, 1992. e-Pub 1992. PMID: 1536954.
664. Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol 20(5):558-64, 1992. e-Pub 1992. PMID: 1587302.
665. Gulati, S, Acaba L, Yahalom J, Reich L, Motzer R, Crown J, Doherty M, Clarkson B, Berman E, Atzpodien J, Andreeff M, Gee T. Autologous bone marrow transplantation for acute myelogenous leukemia using 4 hydroperoxy cyclophosphamide and VP-16 purged bone marrow. Bone Marrow Transpl 10:129-134, 1992. e-Pub 1992.
666. Przepiorka D, Giralt S, Huh YO, Andreeff M, Luna M, Reading C, Thomas M, Champlin RE. T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma. Transplant Proc 24(6):2906-7, 1992. e-Pub 1992. PMID: 1465994.
667. Kornblau SM, Xu HJ, del Giglio A, Hu SX, Zhang W, Calvert L, Beran M, Estey E, Andreeff M, Trujillo J, et al. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Res 52(17):4587-90, 1992. e-Pub 1992. PMID: 1511426.
668. Lemoli RM, Tafuri A, Strife A, Andreeff M, Clarkson BD, Gulati SC. Proliferation of human hematopoietic progenitors in long-term bone marrow cultures in gas-permeable plastic bags is enhanced by colony-stimulating factors. Exp Hematol 20(5):569-75, 1992. e-Pub 1992. PMID: 1587303.
669. Tafuri A, Meyers J, Lee BJ, Andreeff M. DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. Cancer 67(2):449-54, 1991. e-Pub 1991. PMID: 1985738.
670. Chouaib S, Mahe Y, Mechri S, Andreeff M, Welte K. Differential sensitivity of CD4+ and CD8+ T lymphocytes to phorbol myristate acetate upon anti-CD3 stimulation: Evidence for a distinct signaling pathway. Intl J Immunopathol and Pharmacol 4:19-32, 1991. e-Pub 1991.
671. Crown JP, Jhanwar S, Haimi J, Andreeff M, Gee T. Acquired cyclic hematopoiesis and infections associated with a radiotherapy induced chromosomal abnormality with clonal, morphologically normal circulating leucocytes. Acta Haematological 86:103-106, 1991. e-Pub 1991.
672. Jr WR, Frankel SR, Jr MW, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324(20):1385-93, 1991. e-Pub 1991. PMID: 1850498.
673. Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B, Andreeff M. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77(4):818-25, 1991. e-Pub 1991. PMID: 1993221.
674. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77(4):700-11, 1991. e-Pub 1991. PMID: 1993213.
675. Kempin, S, Arlin Z, Berman E, Gee T, Mertelsmann R, Andreeff M, Kolitz J, Jhanwar S, Meyers J, Clarkson B. Treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in blast crisis and Ph+ acute leukemia with high dose cytosine arabinoside (HDARAC). . Leukemia and Lymphoma 4:111-116, 1991. e-Pub 1991.
676. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77(8):1666-74, 1991. e-Pub 1991. PMID: 2015395.
677. Herrmann F, Andreeff M, Gruss HJ, Brach MA, Lübbert M, Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood 78(8):2070-4, 1991. e-Pub 1991. PMID: 1912585.
678. Bettelheim P, Muhm M, Valent P, Geissler K, Andreeff M, Haimi J, Sillaber C, Hinterberger W, Vieder L, Schulz G, et al. GM-CSF in combination with cytotoxic chemotherapy in AML patients. Bone Marrow Transplant 6 Suppl 1:127-30, 1990. e-Pub 1990. PMID: 2202464.
679. Andreeff M, Tafuri A, Hegewisch-Becker S. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside. Haematol Blood Transfus 33:747-62, 1990. e-Pub 1990. PMID: 2323674.
680. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suryanarayan K, Homge M, Redner A, Gray J, Pinkel D. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 250(4980):559-62, 1990. e-Pub 1990. PMID: 2237408.
681. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4(12):826-34, 1990. e-Pub 1990. PMID: 2243506.
682. Shalinsky DR, Andreeff M, Howell SB. Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro. Cancer Res 50(23):7537-43, 1990. e-Pub 1990. PMID: 1979245.
683. Redner A, Hegewisch S, Haimi J, Steinherz P, Jhanwar S, Andreeff M. A study of multidrug resistance and cell kinetics in a child with near-haploid acute lymphoblastic leukemia. Leuk Res 14(9):771-7, 1990. e-Pub 1990. PMID: 2232849.
684. Andreeff M, Bressler J, Verbeek W, Bokemeyer C, Hegewisch-Becker S, Haimi J, Rehermann B, Smith M, Squires J, Tafuri A, Redner A. Oncogene expression in leukemia: assessment by flow cytometry, immunoprecipitation, fluorescence in situ hybridization and DNA polymerase chain reaction. Jap J Flow Cytometry - Cell Biology 2:6-31, 1990. e-Pub 1990.
685. Paietta E, Racevskis J, Stanley ER, Andreeff M, Papenhausen P, Wiernik PH. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res 50(7):2049-55, 1990. e-Pub 1990. PMID: 2156611.
686. Berman E, Raymond V, Gee TS, Kempin SJ, Gulati S, Andreeff M, Gabrilove J, Young CW, Clarkson BD, Wiernik PH. Idarubicin in acute leukemia: results of US trials. Bone Marrow Transplant 4 Suppl 1:49, 1989. e-Pub 1989. PMID: 2713561.
687. Gulati SC, Gaynor J, Esseesse I, Gee T, Little C, Andreeff M, Berman E, Kempin S, Clarkson B. Use of prognostic factors in deciding therapy for adult acute lymphoblastic leukemia: new approaches at Memorial Sloan-Kettering Cancer Center (MSKCC). Bone Marrow Transplant 4 Suppl 1:86-9, 1989. e-Pub 1989. PMID: 2653525.
688. Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Heller G, Young CW, et al. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol 16(1 Suppl 2):30-4, 1989. e-Pub 1989. PMID: 2928808.
689. Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 4(11):1363-74, 1989. e-Pub 1989. PMID: 2682463.
690. Berman E, Arlin ZA, Gaynor J, Miller W, Gee T, Kempin SJ, Mertelsmann R, Andreeff M, Reich L, Nahmias N, et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia 3(2):115-21, 1989. e-Pub 1989. PMID: 2911205.
691. Kreis W, Chan K, Budman DR, Schulman P, Allen S, Weiselberg L, Henderson V, Freeman J, Deere M, Vinciguerra V, Andreeff M. Effect of tetrahydrouridine (THU) on the clinical pharmacology of 1-B-D-arabinofuranosylcytosine when both drugs are co-infused over 3 hours. Cancer Res 48:1337-1342, 1988. e-Pub 1988.
692. Haluska FG, Russo G, Andreeff M, Croce CM. Molecular analysis of an AIDS-associated Burkitt's lymphoma: near-identity with endemic cases. Curr Top Microbiol Immunol 141:75-9, 1988. e-Pub 1988. PMID: 3215057.
693. Gaynor J, Chapman D, Little C, McKenzie S, Miller W, Andreeff M, Arlin Z, Berman E, Kempin S, Gee T, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 6(6):1014-30, 1988. e-Pub 1988. PMID: 3163722.
694. Chouaib S, Bensussan A, Termijtelen AM, Andreeff M, Marchiol-Fournigault C, Fradelizi D, Dupont B. Allogeneic T cell activation triggering by MHC class I antigens. J Immunol 141(2):423-9, 1988. e-Pub 1988. PMID: 2838549.
695. Kong XB, Andreeff M, Fanucchi MP, Fox JJ, Watanabe KA, Vidal P, Chou TC. Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells. Leuk Res 11(11):1031-9, 1987. e-Pub 1987. PMID: 3480397.
696. Benedetto P, Mertelsmann R, Szatrowski TH, Andreeff M, Gee T, Arlin Z, Kempin S, Clarkson B. Prognostic significance of terminal deoxynucleotidyl transferase activity in acute nonlymphoblastic leukemia. J Clin Oncol 4(4):489-95, 1986. e-Pub 1986. PMID: 3958762.
697. Andreeff M, Hansen H, Cirrincione C, Filippa D, Thaler H. Prognostic value of DNA/RNA flow cytometry of B-cell non-Hodgkin's lymphoma: development of laboratory model and correlation with four taxonomic systems. Ann N Y Acad Sci 468:368-86, 1986. e-Pub 1986. PMID: 2425690.
698. Andreeff M, Slater DE, Bressler J, Furth ME. Cellular ras oncogene expression and cell cycle measured by flow cytometry in hematopoietic cell lines. Blood 67(3):676-81, 1986. e-Pub 1986. PMID: 3511984.
699. Koziner B, Stavnezer J, Al-Katib A, Gebhard D, Mittelman A, Andreeff M, Clarkson BD. Surface immunoglobulin light chain expression in pre-B cell leukemias. Ann N Y Acad Sci 468:211-26, 1986. e-Pub 1986. PMID: 2425686.
700. Redner A, Melamed MR, Andreeff M. Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA. Ann N Y Acad Sci 468:241-55, 1986. e-Pub 1986. PMID: 2425687.
701. Ciobanu N, Paietta E, Andreeff M, Papenhausen P, Wiernik PH. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation. Exp Hematol 14(7):626-35, 1986. e-Pub 1986. PMID: 3525202.
702. Sordillo PP, Andreeff M, Helson L, Steinmetz J, Melamed MR. Cytokinetics of a human neuroblastoma cell line following treatment with dianhydrogalactitol. Cancer Invest 3(4):321-5, 1985. e-Pub 1985. PMID: 4027754.
703. Suarez C, Miller DR, Steinherz PG, Melamed MM, Andreeff M. DNA and RNA determination in 111 cases of childhood acute lymphoblastic leukemia (ALL) by flow cytometry: correlation of FAB classification with DNA stemline and proliferation. Br J Haematol 60(4):677-86, 1985. e-Pub 1985. PMID: 3861195.
704. Andreeff M, Bartal A, Feit C, Hirshaut Y. Clonal stability and heterogeneity of hybridomas: analysis by multiparameter flow cytometry. Hybridoma 4(3):277-87, 1985. e-Pub 1985. PMID: 2412947.
705. Wustrow TP, Andreeff M, Fernandes G, Good RA. DNA and RNA analysis by flow cytometry of the leukemia in AKR mice. Leuk Res 9(10):1283-91, 1985. e-Pub 1985. PMID: 2415780.
706. Andreeff M, Bressler J, Higgins P. [Oncogens and cancer. Review and a new method for measuring the gene expression in relation to the cell cycle]. Dtsch Med Wochenschr 110(1):30-5, 1985. e-Pub 1985. PMID: 3855293.
707. Suarez CR, Andreeff M, Miller DR. Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma. Med Pediatr Oncol 12(2):89-92, 1984. e-Pub 1984. PMID: 6583472.
708. Welte K, Andreeff M, Platzer E, Holloway K, Rubin BY, Moore MA, Mertelsmann R. Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med 160(5):1390-403, 1984. e-Pub 1984. PMID: 6092510.
709. Blumenreich MS, Chou TC, Andreeff M, Vale K, Clarkson BD, Young CW. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia. Cancer Res 44(2):825-30, 1984. e-Pub 1984. PMID: 6692380.
710. Blumenreich MS, Woodcock TM, Andreeff M, Hiddemann W, Chou TC, Vale K, O'Hehir M, Clarkson BD, Young CW. Effect of very high-dose thymidine infusions on leukemia and lymphoma patients. Cancer Res 44(5):2203-7, 1984. e-Pub 1984. PMID: 6713407.
711. Hiddemann W, Schumann J, Andreef M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF, Sandberg AA. Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet 13(2):181-3, 1984. e-Pub 1984. PMID: 6478442.
712. Redner A, Andreeff M, Miller DR, Steinherz P, Melamed M. Recognition of central nervous system leukemia by flow cytometry. Cytometry 5(6):614-8, 1984. e-Pub 1984. PMID: 6596184.
713. Hiddemann W, Buchner T, Andreeff M, Arlin Z, Wormann B, Clarkson BD. [Comparison of the therapeutic efficacity of 2 induction protocols in acute myeloid leukemia using exact quantification of bone marrow cellularity]. Onkologie 6(4):179-83, 1983. e-Pub 1983. PMID: 6355946.
714. Feldman SP, Mertelsmann R, Venuta S, Andreeff M, Welte K, Moore MA. Sodium azide enhancement of interleukin-2 production. Blood 61(4):815-8, 1983. e-Pub 1983. PMID: 6600947.
715. Shank B, Andreeff M, Li D. Cell survival kinetics in peripheral blood and bone marrow during total body irradiation for marrow transplantation. Int J Radiat Oncol Biol Phys 9(11):1613-23, 1983. e-Pub 1983. PMID: 6358155.
716. Dorner MH, Broxmeyer HE, Silverstone A, Andreeff M. Biosynthesis of ferritin subunits from different cell lines of HL-60 human promyelocytic leukemia cells and the release of acidic isoferritin-inhibitory activity against normal granulocyte-macrophage progenitor cells. Br J Haematol 55(1):47-58, 1983. e-Pub 1983. PMID: 6576806.
717. Anger B, Bockman R, Andreeff M, Erlandson R, Jhanwar S, Kameya T, Saigo P, Wright W, Beattie EJ, Jr, Oettgen HF, Old LJ. Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma. Cancer 50(8):1518-29, 1982. e-Pub 1982. PMID: 7116286.
718. Hiddemann W, Buchner T, Andreeff M, Wormann B, Melamed MR, Clarkson BD. Cell kinetics in acute leukemia: a critical reevaluation based on new data. Cancer 50(2):250-8, 1982. e-Pub 1982. PMID: 7083131.
719. Hiddemann W, Clarkson BD, Buchner T, Melamed MR, Andreeff M. Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia. Blood 59(2):216-25, 1982. e-Pub 1982. PMID: 7055637.
720. Hiddemann W, Buchner T, Andreeff M, Wormann B, Melamed MR, Clarkson BD. Bone marrow biopsy instead of 'marrow juice' for cell kinetic analysis. Comparison of bone marrow biopsy and aspiration material. Leuk Res 6(4):601-12, 1982. e-Pub 1982. PMID: 6183535.
721. Melamed DE, Fogh J, Andreeff M. Characterization of cultured human tumor cell lines by flow cytometry DNA stemline. Anal Quant Cytol 3(1):67-72, 1981. e-Pub 1981. PMID: 7015945.
722. Darzynkiewicz Z, Andreeff M. Multiparameter flow cytometry. Part I: application in analysis of the cell cycle. Clin Bull 11(2):47-57, 1981. e-Pub 1981. PMID: 6173142.
723. Lu L, Broxmeyer HE, Pelus LM, Andreeff M, Moore MA. Detection of luxol-fast-blue positive cells in human promyelocytic leukemia cell line HL-60. Exp Hematol 9(9):887-92, 1981. e-Pub 1981. PMID: 6175532.
724. Chiao JW, Freitag WF, Steinmetz JC, Andreeff M. Changes of cellular markers during differentiation of HL-60 promyelocytes to macrophages as induced by T lymphocyte conditioned medium. Leuk Res 5(6):477-89, 1981. e-Pub 1981. PMID: 6977076.
725. Hiddemann W, Andreeff M, Clarkson BD. Quantitation of chemotherapy-induced cytoreduction in acute leukemia. Haematol Blood Transfus 26:73-6, 1981. e-Pub 1981. PMID: 7319296.
726. Andreeff M, Darzynkiewicz Z. Multiparameter flow cytometry. Part II. application in hematology. Clin Bull 11(3):120-30, 1981. e-Pub 1981. PMID: 6175445.
727. Andreeff M, Clarkson BD. [Pro and con: Aggressive or conventional treatment of chronic myelogenous leukemia. Arguments in favor of aggressive treatment]. Internist (Berl) 21(7):371-5, 1980. e-Pub 1980. PMID: 7007271.
728. Koziner B, Mertelsmann R, Andreeff M, Arlin Z, Hansen H, De Harven E, McKenzie S, Gee T, Good RA, Clarkson B. Heterogeneity of cell lineages in L3 leukemias. Blood 55(4):694-8, 1980. e-Pub 1980. PMID: 6244017.
729. Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 55(2):282-93, 1980. e-Pub 1980. PMID: 6928106.
730. Barlogie B, Latreille J, Freireich EJ, Fu CT, Mellard D, Meistrich M, Andreeff M. Characterization of hematologic malignancies by flow cytometry. Blood Cells 6(4):719-44, 1980. e-Pub 1980. PMID: 7008871.
731. Hellriegel KP, Andreeff M. [Summary: Therapy of chronic myelogenous leukemia--prognosis]. Internist (Berl) 21(7):380-1, 1980. e-Pub 1980. PMID: 7007273.
732. Beck JD, Andreeff M, Haghbin M, Miller D, Good RA, Gupta S. Surface marker analysis and flow cytometric studies of acute nonlymphocytic leukemias in children and young adults. Clin Immunol Immunopathol 14(3):275-83, 1979. e-Pub 1979. PMID: 291503.
733. Darzynkiewicz Z, Traganos F, Andreeff M, Sharpless T, Melamed MR. Different sensitivity of chromatin to acid denaturation in quiescent and cycling cells as revealed by flow cytometry. J Histochem Cytochem 27(1):478-85, 1979. e-Pub 1979. PMID: 86572.
734. Drapkin RL, Adreeff M, Koziner B, Strife A, Wisniewski D, Darzynkiewicz Z, Melamed MR, Clarkson B. Subpopulations of human peripheral blood cells: analysis of granulocytic progenitor cells by flow cytometry and immunologic surface markers. Am J Hematol 7(2):163-72, 1979. e-Pub 1979. PMID: 94243.
735. Andreeff M, Beck JD, Darzynkiewicz Z, Traganos F, Tan C, Clarkson B, Melamed MR. Blastic chronic myeloid leukemia: cell proliferation in vivo and in tissue culture, and after desacetyl vinblastine amide (DVA). Verh Dtsch KrebsGes:351, 1979. e-Pub 1979.
736. Andreeff, M, Beck JD, Darzynkiewicz Z, Arlin Z, Melamed MR, Clarkson B. DNA, RNA and chromatin structure assayed in situ by flow cytometry: A means for the classification of human leukemias. Verh Dtsch KrebsGes:348, 1979. e-Pub 1979.
737. Darzynkiewicz Z, Andreeff M, Traganos F, Sharpless T, Melamed MR. Discrimination of cycling and non-cycling lymphocytes by BUdR-suppressed acridine orange fluorescence in a flow cytometric system. Exp Cell Res 115(1):31-5, 1978. e-Pub 1978. PMID: 79494.
738. Andreeff M, Beck JD, Darzynkiewicz Z, Traganos F, Gupta S, Melamed MR, Good RA. RNA content in human lymphocyte subpopulations. Proc Natl Acad Sci U S A 75(4):1938-42, 1978. e-Pub 1978. PMID: 306108.
739. Andreeff M, Stoffner D, Dayss U, Abenhardt W. [Autoregulatory growth inhibition in experimental tumors]. Verh Dtsch Ges Inn Med 81:1615-8, 1975. e-Pub 1975. PMID: 1227034.
740. Andreeff M. Die Wirkung von Bleomycin auf die DNS-Reduplikation und die Proliferationskinetik am Modell des Ehrlich-Ascites-Tumors. Drug Res 25:566-571, 1975. e-Pub 1975.
741. Andreeff M. [Effect of various new cytostatic agents on DNA reduplication and proliferation kinetics in the Ehrlich-Lettre ascites tumor model]. Verh Dtsch Ges Inn Med 80:1678-80, 1974. e-Pub 1974. PMID: 4454511.
742. Bothmann G, Rummel HH, Andreeff M, Gailus F. [The value of impulse cytophotometry in the examination of ascitic fluid, contents of cysts and secretions from the cul-de-sac]. Geburtshilfe Frauenheilkd 33(6):483-91, 1973. e-Pub 1973. PMID: 4730615.
743. Goerttler K, Rummel H, Haag D, Bothmann G, Andreeff M. [Interpretation of differencies in the DNA-values of exfoliated cells in gynecologic smears (author's transl)]. Verh Dtsch Ges Pathol 57:217-22, 1973. e-Pub 1973. PMID: 4142180.
744. Andreeff M, Mono G, Kohn R, Kuhn E. [Heart involvement in hemochromatosis]. Verh Dtsch Ges Inn Med 77:436-8, 1971. e-Pub 1971. PMID: 4265150.
745. Skwarska A, Moujalled DM, Panis PF, Zhang Q, Herbrich SM, Kurvilla VM, Baran N, Pomilio G, Halilovic E, Ruvolo PP, Ruvolo V, Morris E, Derreal A, Banquet S, Daver N, Andreeff M, Wei A, Konopleva M. Synergistic activity of the MCL-1 inhibitor S63845 with FLT3 inhibitors in preclinical human models of FLT3-ITD mutated acute myeloid leukemia (AML).
746. Cuglievan B, Kantarjian H, Armstrong S, Rubnitz J, Zwaan M, Dinardo C, Cooper T, Pollard J, Kadia T, Guest E, Short N, McCall D, Daver N, Nunez C, Haddad F, Garcia M, Bhalla K, Maiti A, Catueno S, Fiskus W, Gibson A, Roth M, Khazal S, Tewari P, Abbas H, Bourgeois W, Andreeff M, Gruber T, Shukla N, Truong D, Connors J, Joseph Ludwig J, Stutterheim J, Salzer E, Dam KJ, Sasaki K, Mahadeo K, Tasian S, Borthakur G, Dickson S, Faulk K, Jain N, Jabbour E, Meshinchi S, Garcia Manero G, Ravandi F, Stein E, Kolb A, Issa G. Menin Inhibitors in Pediatric Acute Leukemia: A Comprehensive Review and Recommendations to Accelerate Progress in Collaboration with Adult Leukemia and the International Community.
747. Post SM, Ma H, Aitken MJL, Zhang X, Ruvolo VR, Yasuhiro T, Kozaki R, Ostermann LB, Kornblau SM, Konopleva M, Kantarjian H, DiNardo C, Andreeff M, Khoury JD, Ruvolo PP. Proteomic and genetic profile of AML FLT3 ITD Sorafenib resistant cell line reveals activation of distinct survival networks.
748. John MV, Schneeweiss-Gleixner M, Eisenwort G, Peter B, Berger D, Stefanzl G, Konopleva M, Andreeff M, Isalm W, Schwaab J, Reiter A, Sperr WR, Arock M, Valent P, Gleixner K. The synthetic triterpenoid CDDO-Me synergizes with midostaurin, avapritinib and nintedanib in counteracting growth and survival of neoplastic mast cells in advanced systemic mastocytosis.
749. Anand V, El-Dana F, Baran N, j B, Shaw KR, Yin Z, Zhao H, Wong STC, Andreeff M, Battula VL. GD3 Synthase Opposes Wildtype P53-Mediated Tumor Suppression but is Required for Tumor Growth in Breast Cancer with Mutant P53.
750. Bouligny I, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo C, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Kantarjian H, Garcia-Manero G. A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome. Clinical Cancer Research.
751. Ganesan S, Kappel C, Gou P, Mlayah B, Chiquet M, Hontonnou F, Zassadowski F, Cassinat B, Pla M, Sarda-Mantel L, Hosten B, Konopleva M, Andreeff M, Ades L, Setterblad N, Krief P, Omidvar N, Chomienne C, Fenaux P, Padua RA. Efficacy of ABT-199 and MEK inhibitors in myelodysplasia / acute myelogenous leukemia (MDS/AML) progression. IJMC.
752. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov ZE, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for Anemia of Myelofibrosis: a Phase 2 Investigator-initiated.

Invited Articles

1. Carter BZ, Andreeff M. Targeting survivin in leukemia. Oncol Rev 1:195-204, 2008. e-Pub 2008.
2. Konopleva M, Andreeff M. Targeting the leukemia microenvironment. Curr Drug Targets 8(6):685-701, 2007. e-Pub 2007. PMID: 17584025.
3. Hail N, Carter BZ, Konopleva M, Andreeff M. Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis 11(6):889-904, 2006. e-Pub 2006. PMID: 16547589.
4. Milella M, Kornblau SM, Andreeff M. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 7:160-190, 2003. e-Pub 2003.
5. Konopleva M, Andreeff M. Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. Curr Opin Hematol 9:294-302, 2002. e-Pub 2002.
6. Marini FC, Shayakhmetov D, Gharwan H, Lieber A, Andreeff M. Advances in gene transfer into hematopoietic stem cells by adenoviral vectors. Expert Opin Biol 2:847-856, 2002. e-Pub 2002.

Other Articles

1. Konopleva, MY, Milella, M, Ruvolo, P, Watts, JC, Ricciardi, MR, Korchin, B, Teresa, M, Bornmann, W, Tsao, T, Bergamo, P, Mak, D, Chen, W, McCubrey, JA, Tafuri, A, Andreeff, M Retraction note. Leukemia 38(9):2072, 2024. PMID: 39025987.
2. Akiyama, H, Zhao, R, Ostermann, LB, Li, Z, Tcheng, M, Yazdani, SJ, Moayed, A, Pryor, ML, Slngh, S, Baran, N, Ayoub, E, Nishida, Y, Mak, PY, Ruvolo, VR, Carter, BZ, Schimmer, AD, Andreeff, M, Ishizawa, J Correction to. Leukemia 38(4):926, 2024. PMID: 38459170.
3. Garzon, R, Pichiorri, F, Palumbo, T, Visentini, M, Aqeilan, RI, Cimmino, A, Wang, H, Sun, HL, Volinia, S, Alder, H, Calin, GA, Liu, C, Andreeff, M, Croce, CM Correction to. Oncogene 41(25):3452-3453, 2022. PMID: 35546352.
4. Tabe Y, Konopleva M, Andreeff M Fatty acid metabolism, bone marrow adipocytes, and AML. Front Oncol 10:155, 2020. PMID: 32133293.
5. Daver N, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G First Report of Sorafenib in Patients with Acute Myeloid Leukemia Harboring Non- canonical FLT3-mutations. Front Oncol 10:1538, 2020. PMID: 32984009.
6. Forte D, Krause DS, Andreeff M, Bonnet D, Méndez-Ferrer S Updates on the hematologic tumor microenvironment and its therapeutic targeting. Haematologica 104(10):1928-1934, 2019. PMID: 31515356.
7. Parker Kerrigan BC, Shimizu Y, Andreeff M, Lang FF Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy 19(4):445-457, 2017. PMID: 28233640.
8. Ishizawa J, Kojima K, Hail N, Tabe Y, Andreeff M Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther 153:25-35, 2015. PMID: 26048327.
9. Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations. Leuk Lymphoma 55(6):1431-4, 2014. PMID: 24033106.
10. Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, Jiffar T, Kornblau S, Konopleva M, Andreeff M Targeting PKC Mediated Signal Transduction pathways Using Enzastaurin to Promote Apoptosis in Acute Myeloid Leukemia-Derived Cell Lines and Blast Cells. J Cell Biochem 112(6):1696-707, 2011. PMID: 21360576.
11. Samudio I, Fiegl M, Andreeff M Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 69(6):2163-2166, 2009. PMID: 19258498.
12. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer 8:106, 2009. PMID: 19922650.
13. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22(6):1095-1105, 2008. PMID: 18323801.
14. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15(10):730-738, 2008. PMID: 18401438.
15. Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B, Marini FC The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 10(7):657-667, 2008. PMID: 18985472.
16. Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, Marini F Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol 86(1):8-16, 2007. PMID: 17675260.
17. Inoue S, Shanker M, Miyahara R, Gopalan B, Patel S, Oida Y, Branch CD, Munshi A, Meyn RE, Andreeff M, Tanaka F, Mhashilkar AM, Chada S, Ramesh R MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic. Curr Gene Ther 6:73-91, 2006. PMID: 16475947.
18. Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM, Tafuri A, Andreeff M Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 11(21):2779-2795, 2005. PMID: 16101455.
19. Milella M, Kornblau SM, Andreeff M The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 7(2):160-90, 2003. PMID: 14763161.
20. Konopleva M, Andreeff M Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. Curr Opin Hematol 9(4):294-302, 2002. PMID: 12042703.
21. Lin H, Guo JQ, Andreeff M, Arlinghaus RB Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia 16(2):294-7, 2002. PMID: 11840298.
22. Marini FC, Shayakhmetov D, Gharwan H, Lieber A, Andreeff M Advances in gene transfer into haematopoietic stem cells by adenoviral vectors. Expert Opin Biol Ther 2(8):847-56, 2002. PMID: 12517264.
23. Ueno NT, Anagnostopoulos A, Rondon G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 119(1):131-4, 2002. PMID: 12358917.
24. FCrd M, Yu Q, Wickham T, Kovesdi I, Andreeff M Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther 7(6):816-25, 2000. PMID: 10880011.
25. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M Apoptosis. Molecules and mechanisms. Adv Exp Med Biol 457:217-36, 1999. PMID: 10500797.
26. Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage RJ, Andreeff M Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 100(1):135-41, 1998. PMID: 9450802.
27. Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia 11(8):1386-90, 1997. PMID: 9264399.
28. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56(13):3010-20, 1996. PMID: 8674056.
29. Rondon G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18(3):669-72, 1996. PMID: 8879640.
30. Drach J, Zhao S, Drach D, Korbling M, Engel H, Andreeff M Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis. Leuk Lymphoma 16(5-6):419-24, 1995. PMID: 7540457.
31. San-Miguel JF, Bartram C, Campana D, Andreeff M Minimal residual disease in hematologic malignancies. Rev Invest Clin Suppl:147-52, 1994. PMID: 7886299.
32. Huh YO, Andreeff M Flow cytometry. Clinical and research applications in hematologic malignancies. Hematol Oncol Clin North Am 8(4):703-23, 1994. PMID: 7961287.
33. Anderlini P, Przepiorka D, Luna M, Langford L, Andreeff M, Claxton D, Deisseroth AB Acanthamoeba meningoencephalitis after bone marrow transplantation. Bone Marrow Transplant 14(3):459-61, 1994. PMID: 7994273.
34. Duque RE, Andreeff M, Braylan RC, Diamond LW, Peiper SC Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 14(5):492-6, 1993. PMID: 8354121.
35. Haluska FG, Russo G, Kant J, Andreef M, Croce CM Molecular resemblance of an AIDS-associated lymphoma and endemic Burkitt lymphomas: implications for their pathogenesis. Proc Natl Acad Sci U S A 86(22):8907-11, 1989. PMID: 2682665.
36. Arlin ZA, Hagenbeek A, Feldman EJ, Andreeff M Implications of 'cell kill' for the treatment of acute myelogenous leukemia: can the cure rate be increased?. Acta Haematol 82(4):175-8, 1989. PMID: 2511718.
37. Paietta E, Andreeff M, Papenhausen P, Gucalp R, Wiernik PH Distinct antigen expression related to DNA ploidy in a case of biphenotypic leukemia. Leukemia 3(1):76-8, 1989. PMID: 2909810.
38. Andreeff M, Welte K Hematopoietic colony-stimulating factors. Semin Oncol 16(3):211-29, 1989. PMID: 2471272.
39. Clarkson BD, Gee T, Arlin ZA, Mertelsmann R, Kempin SJ, Dinsmore RE, O'Reilly RJ, Andreeff M, Berman E, Little C Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. Crit Rev Oncol Hematol 4(3):221-48, 1986. PMID: 3513984.
40. Redner A, Grabowski E, Al-Katib A, Andreeff M Common acute lymphoblastic leukemia characterized by four different DNA stemlines with heterogeneity in RNA content, antigen expression and sensitivity to chemotherapy. Leuk Res 10(6):671-6, 1986. PMID: 3458978.
41. Andreeff M Cell kinetics of leukemia. Semin Hematol 23(4):300-14, 1986. PMID: 3535084.
42. Clarkson B, Ellis S, Little C, Gee T, Arlin Z, Mertelsmann R, Andreeff M, Kempin S, Koziner B, Chaganti R, et al Acute lymphoblastic leukemia in adults. Semin Oncol 12(2):160-79, 1985. PMID: 2409604.
43. Mintzer DM, Andreeff M, Filippa DA, Jhanwar SC, Chaganti RS, Koziner B Progression of nodular poorly differentiated lymphocytic lymphoma to Burkitt's-like lymphoma. Blood 64(2):415-21, 1984. PMID: 6547626.
44. Jr WR, Krown SE, Koziner B, Andreeff M, Kempin SJ Acute non-lymphoblastic leukemia after treatment of nodular lymphoma with human leukocyte interferon. Ann Intern Med 98(4):482-3, 1983. PMID: 6340577.
45. Chaganti RS, Jhanwar SC, Arlin Z, Koziner B, Ambati A, Andreeff M, Clarkson BD Non-T, non-B acute lymphoblastic leukemia (L3) with t(8;22) and two 14q+ chromosomes. Cancer Genet Cytogenet 10(1):95-103, 1983. PMID: 6576853.
46. Ciobanu N, Andreeff M, Safai B, Koziner B, Mertelsmann R Lymphoblastic neoplasia in a homosexual patient with Kaposi's sarcoma. Ann Intern Med 98(2):151-5, 1983. PMID: 6572044.
47. Barlogie B, Raber MN, Schumann J, Johnson TS, Drewinko B, Swartzendruber DE, Gohde W, Andreeff M, Freireich EJ Flow cytometry in clinical cancer research. Cancer Res 43(9):3982-97, 1983. PMID: 6347364.
48. Chiao JW, Andreeff M, Freitag WB, Arlin Z Induction of in vitro proliferation and maturation of human aneuploid myelogenous leukemic cells. J Exp Med 155(5):1357-69, 1982. PMID: 6175721.
49. Kaur P, Miller DR, Andreeff M, Chaganti R, Meyers PA Acute myeloblastic leukemia following non-Hodgkin lymphoma in an adolescent. A report of a case with preleukemic syndrome, and review of the literature. Med Pediatr Oncol 9(1):69-80, 1981. PMID: 7007854.
50. Beck JD, Andreeff M, Mertelsmann R, Haghbin M, Tan C, Miller DR, Good RA, Gupta S Childhood CML in blastic stage: an analysis of cell markers and cell kinetics. Am J Hematol 9(3):337-44, 1980. PMID: 6165242.
51. Straus DJ, Andreeff M, Hansen HJ, Mertelsmann R, Koziner B, Chaganti R, Gee TS, McKenzie S, Melamed MR, Clarkson BD The coexistence of acute myeloblastic leukemia and diffuse histiocytic lymphoma in the same patient as demonstrated by multiparameter analysis. Blood 54(6):1428-33, 1979. PMID: 292459.
52. Andreeff M, Kuhn E [Diastolic murmur caused by a phaeochromocytoma (author's transl)]. Dtsch Med Wochenschr 100(29):1530-1, 1975. PMID: 1149633.
53. Tabe Y, Konopleva M, Andreeff M, Ohsaka A Effects of PPARץ ligands in leukemia.

Editorials

1. Griessinger E, Andreeff M. NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. Haematologica 103(6):921-923, 2018. PMID: 29866886.
2. Carter BZ, Andreeff M. Eradication of CML stem cells. Oncoscience 3(11-12):313-315, 2016. PMID: 28105453.

Abstracts

1. Kamachi K, Akiyama H, Otsuki Y, Zhao R, Zhang L, Ostermann L, Carter B, Saya H, Nagano O, Andreeff M, Ishizawa J. Targeting Ferroptosis-Apoptosis Interplay For Acute Myeloid Leukemia Therapy. Japanese Society of Hematology 2024, 2024. e-Pub 2024.
2. Nishida Y, Ayoub E, Scruggs D, Khazaei S, Munir F, Ostermann LB, Mak PY, Ke B, Carter BZ, Baran N, Maiti A, Mohanty V, Chen K, Navin N, Haferlach T, Ren Z, Tong Y, Chen D, Issa GC, Andreeff M. TP53 Mutant Acute Myeloid Leukemias comprise Stem-like Cell Enriched Cellular Hierarchy and are Vulnerable to Targeted Protein Degradation of c-MYC. 10th International MDM2 Workshop, Tokyo, Japan, 2023. e-Pub 2023.
3. Ayoub E, Li L, Muftuoglu M, Nishida Y, Mohanty V, Leighton JS, Patsilevas T, Basyal M, Bedoy A, i Takahashi K, Chen K, Navin N, Issa G, and Andreeff M. Integrated Single-Cell DNA and Mass Cytometry Analysis Reveals Treatment Induced Changes in Clonal Architecture and Immunophenotypes in TP53-mut AML. 10th International MDM2 Workshop, Tokyo, Japan, 2023. e-Pub 2023.
4. Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann LB, Montoya RH, Scruggs DA, Khazaei S, Muftuoglu M, Ruvolo VR, Yee Mak PY, Tao W, Carter BZ, Scruggs DA, Kojima K, Daver N, Seki T, Konopleva M, Mchael A. Enhanced TP53 Reactivation Disrupts MYC Transcriptional Program and Overcomes Venetoclax Resistance in Acute Myeloid Leukemias. 10th International MDM2 Workshop, Tokyo, Japan, 2023. e-Pub 2023.
5. Nishida Y, Scruggs DA, Ayoub E, Ostermann LB, Patsilevas T, Ruvolo VR, Mak PY, Carter BZ, Boettcher S, Maiti A, Sasaki K, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M. TP53 Independent Efficacy of Novel c-MYC Degrader in MYC-driven Acute Myeloid Leukemia and Lymphoma. 10th International MDM2 Workshop, Tokyo, Japan, 2023. e-Pub 2023.
6. Ishizawa J, Akiyama H, Otsuki Y, Zhao R, Yazdani S, Moayed A, Nishida Y, Ayoub E, Ostermann LB, Carter BZ, Saya H, Nagano O, Andreeff M. Targeting Aldehyde Dehydrogenase To Enhance Mitochondrial Ferroptosis in Acute Myeloid Leukemia. 85th Annual Japanese Society of Hematology Meeting, Tokyo, Japan, 2023. e-Pub 2023.
7. Nishida Y, Ishizawa J, Ayoub E, PatsilevasT, Ostermann LB, l Heinz Montoya R, Muftuoglu M, Ruvolo VR, Mak PY, Tao W, Carter BZ, Scruggs DA, Kojima K, Daver N, Lesegretain A, Seki T, Shacham S, Konopleva M, Andreeff M S. The Triple Inhibition of MDM2, XPO1 and BCL-2 Profoundly Induce Cell Kill in Ven/HMA Resistant AML. 10th Annual International MDM2 Workshop, Tokyo, Japan, 2023. e-Pub 2023.
8. Pourebrahim R, Montoya RH, Alaniz Z, Ostermann L, Lin PP, Liu B, Ayoub E, Burks JK, Andreeff M. Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damage. Res Sq, 2023. e-Pub 2023. PMID: 36909480.
9. Yu G, Zhang W, Zhang H, Ly C, Basyal M, Rice WG, Andreeff M. The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases. Res Sq, 2023. e-Pub 2023. PMID: 36865133.
10. Bidikian A, Short N, Ganesh R, Pike A, Sasaki K, Jabbour E, Andreeff M, Cortes J, Issa G. Early Results of a Phase II study evaluating the addition of Asciminib to eradicate minimal residual disease in chronic myeloid leukemia. EHA 2023, 2023. e-Pub 2023.
11. Sharma P, Ostermann L, Piya S, Baran N, Tyagi A, Hindley C, K-H D, Sims M, Battula L, Andreeff M, Borthakur G. ERK1/2 inhibition overcomes resistance to venetoclax in AML by altering mitochondrial metabolism. AACR 2023, 2023. e-Pub 2023.
12. Bidikian A, Basu S, Zhong H, Atluri H, Zarka J, Andreeff M, Sasaki K, Jabbour E, Cortes JE, Sharma P, Issa GC. T-cell Exhaustion and Immune Checkpoint VISTA Overexpression are Associated with Suboptimal Response to Tyrosine Kinase Inhibitors in Patients with CML. SOHO 2023, 2023. e-Pub 2023.
13. Sharma P, Piya S, Baran N, Zal A, Zhang Q, Munck J, Dao KH, Sims M, Andreeff M, Borthakur G. ERK1/2 Inhibition Overcomes Resistance to BCL2 Inhibition in acute myeloid leukemia by impact on mitochondrial dynamics and function. EHA 2023, 2023. e-Pub 2023.
14. Maiti A, Carter BZ, Andreeff M, Konopleva MY. Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. Clin Lymphoma Myeloma Leuk 22(9):652-658, 2022. e-Pub 2022. PMID: 35490155.
15. Battula VL, Nguyen K, Ly S, Applaraju J, Anand V, Andreeff M. Targeting Ganglioside GD2 in Breast Cancer Stem-like cells. Sialoglyco 2022, 2022. e-Pub 2022.
16. Bazinet A, Kadia T, Short N, Borthakur G, Wang S, Loghavi S, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad F, Pierce S, Andreeff M, Jabbour E, Konopleva M, Kantarjian H, Ravandi F. Achievement of Minimal Residual Disease Clearance is a Stronger Predictor of Patient Outcome Than Treatment Intensity in Newly Diagnosed Acute Myeloid Leukemia Patients. EHA Abstract 2022, 2022. e-Pub 2022.
17. Issa GC, Mohanty V, Ayoub E, Wang F, Leighton J, Wu X, Bidikian A, Patsilevas T, Alaniz Z, Zarka J, Kanagal-Shamanna R, Futreal A, Daver N, Konopleva M, Navin N, Zhang J, Chen K, Andreeff M. Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations. ASH 2022, 2022. e-Pub 2022.
18. Carter BZ, Mak PY, Tao W, Ostermann LB, Nishida Y, Pemmaraju N, Boettcher S, Shpall EJ, Chiosis G, Karras G, Wallner B, Morgan RA, Andreeff M. Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML. ASH 2022, 2022. e-Pub 2022.
19. Senapati J, Almanza EH, Kadia TM, Montalban-Bravo G, Faderl S, Sasaki K, Short N, Daver N, DiNardo CD, Masarova L, Ferrajoli A, Jabbour E, Borthakur G, Azzawi HA, Konopleva M, Garcia-Manero G, Andreeff M, Kantarjian H, Ravandi F, and Alvarado A. Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). ASH 2022, 2022. e-Pub 2022.
20. Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short N, Issa GC, Yilmaz M, Pierce SA, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia TM, Konopleva M, DiNardo CD, and Ravandi F. Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment. ASH 2022, 2022. e-Pub 2022.
21. Atluri H, Maiti A, Sasaki K, Daver N, Alvarado Y, Hossain F, Wang X, Pemmaraju N, Takahashi K, Borthakur G, Ferrajoli A, Short N, Abbas HA, Ravandi F, Jabbour E, Andreeff M, Garcia-Manero G, Kantarjian, H, Konopleva M, DiNardo CD. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia. ASH 2022, 2022. e-Pub 2022.
22. Akiyama H, Zhao R, Nishida Y, Baran N, Li Z, Ostermann LB, Mak PY, Ayoub E, Piya S, Carter, BZ, Andreeff M, and Ishizawa J. Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia. ASH 2022, 2022. e-Pub 2022.
23. Bidikian A, Basu S, PhD, Zhong H, Atluri H, MD, Zarka J, MD, Andreeff M, MD, PhD, Sasaki K, MD, Jabbour E, MD, Cortes JE, MD, Sharma P, MD, PhD, Issa GC. A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA. ASH 2022, 2022. e-Pub 2022.
24. Nishida Y, Scruggs DA, Ayoub E, Patsilevas T, Ruvolo V, Mak PY, Carter BZ, Boettcher S, Maiti A, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M. C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas. ASH 2022, 2022. e-Pub 2022.
25. Muftuoglu M, Yilmaz M, Basyal M, Li L, Seki T, Lesegretain A, Daver N, and Andreeff M. Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax. ASH 2022, 2022. e-Pub 2022.
26. Sharma P, Piya S, Baran N, Zal A, Hindley CJ, Dao KH, Sims M, Zal T, Ruvolo V, Andreeff M, Borthakur G. ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism. ASH 2022, 2022. e-Pub 2022.
27. Jia Y, Han L, Ramage CL, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla KN, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells. ASH 2022, 2022. e-Pub 2022.
28. Pourebrahim R, Heinz-Montoya R, Ostermann LB, Andreeff M. Traceable Mouse Models for Tracking p53-Mutant Subclones in Acute Myeloid Leukemia. ASH 2022, 2022. e-Pub 2022.
29. Sharma P, Piya S, Baran N, Muftuoglu M, Basyal M, Ruvolo V, Dao K-H HC, Sims M, Andreeff M, Borthakur G. Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia. ASH 2022, 2022. e-Pub 2022.
30. Desikan SP, Konopleva M, Takahashi K, Lachowiez CA, Loghavi S, MD, Xiao L, Kadia TM, MD, Daver N, MD, Short N, MD, Sasaki K, MD, Borthakur G, MD, Ghayas C Issa GC, Maiti A, Chien KS, Alvarado Y, Montalban-Bravo G, Masarova L, Yilmaz M, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian H, and DiNardo CD. Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia. ASH 2022 (Oral Presentation), 2022. e-Pub 2022.
31. Pourebrahim R, Heinz Montoya R, Ayoub E, Akiyama H, Baran N, Lesluyes T, Ostermann LB, Liu B, Ishizawa J, Khoury JD, Konopleva M, Van Loo P, Andreeff M. Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia. ASH 2022, 2022. e-Pub 2022.
32. Issa GC, Bidikian A, Ayoub E, Wang F, Mohanty V, Leighton J, Wu X, Patsilevas T, Alaniz ZB, Zarka J, Kanagal-Shamanna R, Daver N, Andy Futreal A, Konopleva M, Navin N, Zhang J, Chen K, Andreeff M. Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML, 2022. e-Pub 2022.
33. Carter BZ, Mak PY, Tao W, Ostermann LB, Mak D, Ke B, Ordentlich P, McGeehan GM, Andreeff M. Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3-ITD/-TKD Mutant AML in a PDX Model. ASH 2022, 2022. e-Pub 2022.
34. Daver N, Senapati J, Maiti A, Loghavi S, Kadia TM, DiNardo CD, Pemmaraju N, Jabbour E, Montalban-Bravo G, MD, Tang G, MD, PhD, Sasaki K, MD, Borthakur G, MD, Yilmaz M, MD, Alvarez J, Pierce SA, Nogueras González GM, Ning J, Issa GC, Andreeff M, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. ASH 2022 (Oral Presentation), 2022. e-Pub 2022.
35. Ong F, Garcia-Manero G, Montalban-Bravo G, Alvarado Y, Ohanian M, Konopleva M, Jabbour E, Jain N, Borthakur G, DiNardo CD, Daver N, Issa GC, Sasaki K, Chien KS, Takahashi K, Andreeff M, Muftuoglu M, Delumpa R, Mayor E, Loiselle C, Waller L, Banks G, Kantarjian H, Cortes JE, and Short N. A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure. ASH 2022, 2022. e-Pub 2022.
36. Bazinet A, Kadia TM, Short N, Borthakur G, Wang SA, Loghavi A, Jorgensen JL, Patel KP, DiNardo CD, Daver N, Alvarado Y, Haddad F, Pierce SA, Nogueras González GM, Maiti A, Andreeff M, Jabbour E, Konopleva M, Huang X, P Kantarjian H, Ravandi A, F. Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia. ASH 2022 (Oral Presentation), 2022. e-Pub 2022.
37. Reville PK, Kantarjian H, Borthakur G, Yilmaz M, Daver N, Short N, DiNardo CD, Kornblau SM, Pemmaraju N, Jain N, Alvarado Y, Bose P, Jabbour E, Chien KS, Abbas HA, Masarova L, Wang SA, Tidwell RSS, Andreeff M, Garcia-Manero G, Konopleva, M, Ravandi F, and Kadia TM. Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. ASH 2022 (Oral Presentation), 2022. e-Pub 2022.
38. Senapati J, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Issa GC, Dara KI, Pourebrahim R, Daver N, Jabbour EJ, Kornblau SM, Pemmaraju N, Garcia-Manero G, Ravandi F, Muftuoglu M, Khoury J, DiNardo C, Andreeff M. A Phase I/II Study of Milademetan (DS3032B) in Combination with Low Dose Cytarabine with or without Venetoclax in Acute Myeloid Leukemia. EHA 2022, Abstract 887, 2022. e-Pub 2022.
39. Sharma P, Andreeff M. Tolinapant (ASTX660) enhances the anti-leukemic activity of Venetoclax and Dexamethasone in T cell acute lymphoblastic leukemia (T-ALL). AACR 2022, 2022. e-Pub 2022.
40. Chang KH, Basyal M, Alaniz Z, Honma D, Tsutsumi S, Dos Santos CE, Daver, N, Andreeff M. Targeting EZH1/2 to Restore Chemosensitivity in Dormant Myeloid Leukemia Stem Cells. ASH 2021, 2021. e-Pub 2021.
41. Lachowiez C, DiNardo CD, Takahashi K, Loghavi S, L-C X, Kadia TM, Daver N, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa GC, Maiti A, Alvarado Y, Pemmaraju N, Montalban-Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau SM, Ravandi F, Jabbour EJ, Konopleva M, MD, and Kantarjian H. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. ASH 2021 (Oral Presentation), 2021. e-Pub 2021.
42. Piya S, PhD, Ma H, MS, Sharma P, PhD, Kojima K, MD, PhD, Ruvolo V, MS, Basyal M, BSc, Baran N, PhD, MD, Weetall M, PhD, Sheedy J, BS, MSc, Ray B, PhD, Andreeff M, MD, PhD, Borthakur G, MD. Inhibition of De Novo Pyrimidine Synthesis Depletes Acute Myleogenous Leukemia Stem Cells (LSCs) Burden and Triggers Apoptosis and Differentiation Associated with Oxidative Stress. ASH 2021, 2021. e-Pub 2021.
43. Skwarska A, Moujalled DM, Panis PF, Patel S, Zhang Q, Herbrich S, Kurvilla V, Baran N, Pomilio G, Halilovic Mistry P, Ruvolo V, Ruvolo PP, Derréal A, Banquet S, Niemira M, Kretowski A, Daver N, Andreeff M, Wei AH, Konopleva A, M. Combination Therapy of FLT3 Tyrosine Kinase Inhibitors and BH3 Mimetics Targeting Antiapoptotic MCL-1 Synergistically Eliminates FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and In Vivo. ASH 2021, 2021. e-Pub 2021.
44. Chang KH, PhD, Zal T, PhD, MSc, Basyal M, BSc, Ostermann L, Muftuoglu M, MD, Mak PY, Jia Y, Tao W, Zal MA, MSc, Fogler WE, PhD, Magnani JL, PhD, Zhang W, MD, PhD, Carter BZ, PhD, Andreeff M, MD, PhD. Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy. ASH 2021, 2021. e-Pub 2021.
45. Reville PK, MD, MPH, Kantarjian H, MD, Borthakur G, MD, Pemmaraju N, MD, DiNardo CD, MD, MSCE, Sasaki K, MD, PhD, Daver N, MD, Issa GC, MD, Ohanian M, DO, Montalban-Bravo G, MD, Short NJ, MD, Jain N, MD, Bhalla KN, MD, Jabbour EJ, MD, Ferrajoli A, MD, Takahashi K, MD, PhD, Rausch CR, PharmD, Malla R, RN, BSN, Marek K, Brandt M, BS, Popat UR, MD, Andreeff M, MD, PhD, Garcia-Manero G, MD, Konopleva M, MD, PhD, Ravandi F, MBBS, Kadia TM, MD. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). ASH 2021 (Oral Presentation), 2021. e-Pub 2021.
46. Yilmaz M, MD, Kantarjian H, MD, Short NJ, MD, Konopleva M, MD, PhD, Kadia TM, MD, DiNardo CD, MD, MSCE, Borthakur G, MD, Pemmaraju N, MD, Maiti A, MBBS, Jabbour EJ, MD, Issa GC, MD, Jain N, MD, Takahashi K, MD, PhD, Sasaki K, MD, PhD, Ohanian M, DO, Tang G, MD, PhD, Loghavi S, MD, Patel K, MD, PhD, Garcia-Manero G, MD, Andreeff M, MD, PhD, Ravandi F, MBBS, Daver N, MD. Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor “Triplet” Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. ASH 2021 (Oral Presentation), 2021. e-Pub 2021.
47. Maiti A, MBBS, DiNardo CD, MD, MSCE, Rausch CR, PharmD, Pemmaraju N, MD, Garcia-Manero G, MD, Ohanian M, DO, Daver N, MD, Issa GC, MD, Borthakur G, MD, Ravandi F, MBBS, Alvarado Y, MD, Kadia TM, MD, Short NJ, MD, Jabbour EJ, MD, Montalban-Bravo G, MD, Jain N, MD, Kornblau SM, MD, Masarova L, MD, Wierda WG, Sasaki K, MD, PhD, Takahashi K, MD, PhD, Yilmaz M, MD, Burger JA, MD, PhD, Estrov ZE, MD, Verstovsek S, MD, PhD, Andreeff M, MD, PhD, Bose P, MD, Ferrajoli A, MD, Thompson PA, Montalbano K, Vaughan K, RN, Bivins CA, RN, Pierce SA, BSN, BA, Qiao W, PhD, Ning J, Welch J, PhD MD, Kantarjian H, MD, Konopleva M, MD, PhD. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. ASH 2021, 2021. e-Pub 2021.
48. Short NJ, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour EJ, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo CD, Daver N, Issa GC, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien KS, Ravandi F, Kadia TM, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce SA, Waller L, Banks G, Kantarjian H, and Cortes JE. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. ASH 2021, 2021. e-Pub 2021.
49. Bose P, MD, Masarova L, MD, Pemmaraju N, MD, Bledsoe SD, Daver N, MD, Jabbour EJ, MD, Kadia TM, MD, Estrov ZE, MD, Kornblau SM, MD, Andreeff M, MD, PhD, Cortes JE, MD, Jain N, MD, Borthakur G, MD, Alvarado Y, MD, Huynh-Lu J, Assistant P, Nguyen-Cao MM, Assistant P, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, BSN, BA, Wang X, MS, Pike AM, RN, Garcia-Manero G, MD, Kantarjian H, MD, Verstovsek S, MD, PhD. Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. ASH 2021 (Oral Presentation), 2021. e-Pub 2021.
50. Maiti A, MBBS, DiNardo CD, MD, MSCE, Rausch CR, PharmD, Pemmaraju N, MD, Garcia-Manero G, MD, Ohanian M, DO, Daver N, MD, Issa GC, MD, Borthakur G, MD, Ravandi F, MBBS, Alvarado Y, MD, Kadia TM, MD, Jabbour EJ, MD, Short NJ, MD, Montalban-Bravo G, MD, Jain N, MD, Kornblau SM, MD, Masarova L, MD, Wierda WG, Sasaki K, MD, PhD, Takahashi K, MD, PhD, Yilmaz M, MD, Burger JA, MD, PhD, Estrov ZE, MD, Verstovsek S, MD, PhD, Andreeff M, MD, PhD, Bose P, MD, Ferrajoli A, MD, Thompson PA, Montalbano K, Vaughan K, RN, Bivins CA, RN, Pierce SA, BSN, BA, Qiao W, PhD, Ning J, Welch JS, MD, PhD, Kantarjian H, MD, Konopleva M, MD, PhD. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. ASH 2021 (Oral Presentation), 2021. e-Pub 2021.
51. Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo CD, Kadia TM, Konopleva M, Borthakur G, Pemmaraju N, Short NJ, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike AM, Loghavi S, Patel K, Tang G, Matthews JA, Kornblau SM, Jabbour EJ, MD, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) – RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. ASH 2021 (Oral Presentation), 2021. e-Pub 2021.
52. Muftuoglu M, MD, Li L, MD, Basyal M, BSc, Liang S, Ball CJ, Chen K, PhD, Kumar P, PhD, Lesegretain A, Daver N, MD, Andreeff M, MD, PhD. Single-Cell Proteomics Identifies Leukemia Landscape Associated with Clinical Outcomes in R/R AML Treated with MDM2i (Milademetan) and FLT3i (Quizartinib): Putative Role of CD68 and Diversity Index. ASH 2021, 2021. e-Pub 2021.
53. Jia Y, Zhang Q, Weng C, Ramage CL, Nishida Y, Chao M, Maute RL, Herbrich S, Zhang W, Andreeff M, Daver N, Konopleva M. Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models. ASH 2021 (Oral Presentation), 2021. e-Pub 2021.
54. Nishida Y, MD, PhD, Ishizawa J, MD, PhD, Ayoub E, PhD, Patsilevas T, BS, Ostermann L, Montoya RH, BS, Muftuoglu M, MD, Ruvolo V, MS, Mak PY, Tao W, Carter BZ, PhD, Kojima K, MD, PhD, Daver N, MD, Lesegretain A, Seki T, PhD, Shacham S, PhD, MBA, Konopleva M, MD, PhD, Andreeff M, MD, PhD. Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML. ASH 2021 (Oral Presentation), 2021. e-Pub 2021.
55. Venugopal S, MD, Issa GC, MD, Konopleva M, MD, PhD, DiNardo CD, MD, MSCE, Borthakur G, MD, Jabbour EJ, MD, Pemmaraju N, MD, Yilmaz M, MD, Short NJ, MD, Maiti A, MBBS, Sasaki K, MD, PhD, Masarova L, MD, Pierce SA, BSN, BA, Takahashi K, MD, PhD, Tang G, MD, PhD, Loghavi S, MD, Andreeff M, MD, PhD, Bhalla KN, MD, Garcia-Manero G, MD, Ravandi F, MBBS, Kantarjian H, MD, Daver N, MD. NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). ASH 2021, 2021. e-Pub 2021.
56. Jia Y, Basyal M, BSc, Ostermann LB, BS, Chang KH, PhD, Zhang Q, PhD, Fogler WE, PhD, Magnani JL, PhD, Konopleva M, MD, PhD, Zhang W, MD, PhD, Andreeff M, MD, PhD. FLT3 Inhibitors Upregulate CXCR4 and E-Selectin Ligands and CD44 Via ERK Suppression in AML Cells, and Blockade of CXCR4 and E-Selectin Signaling with GMI-1359 Overcomes AML Resistance to Quizartinib in Vitro and In Vivo. ASH 2021, 2021. e-Pub 2021.
57. Sharma P, PhD, Piya S, PhD, Ma H, MS, Baran N, PhD, MD, Zal MA, MSc, Hindley CJ, PhD, Dao K, DO, Sims M, PhD, Zal T, PhD, MSc, Ruvolo V, MS, Andreeff M, MD, PhD, Borthakur G, MD. ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics. ASH 2021, 2021. e-Pub 2021.
58. Piya S, PhD, Ma H, MS, Piya S, PhD, Ruvolo V, MS, Basyal M, BSc, Golas A, PhD, Windak R, PhD, Rzymski T, PhD, Andreeff M, MD, PhD, Borthakur G, MD. Inhibition of Cyclin Dependent Kinase 8(CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukaemia (T-ALL). ASH 2021, 2021. e-Pub 2021.
59. Ayoub E, PhD, Montoya RH, BS, Mohanty V, PhD, Walter W, PhD, Patsilevas T, BS, Issa GC, MD, Borthakur G, MD, Chen K, PhD, Konopleva M, MD, PhD, Navin N, PhD, Haferlach T, MD, Andreeff M, MD, PhD. Targeting Polo-like Kinase 4 Triggers Polyploidy and Apoptotic Cell Death in TP53-Mutant Acute Myeloid Leukemia. ASH 2021, 2021. e-Pub 2021.
60. Rivera D, MD, Kadia TM, MD, Montalban-Bravo G, MD, Faderl S, Sasaki K, MD, PhD, Short NJ, MD, Daver N, MD, DiNardo CD, MD, MSCE, Masarova L, MD, Ferrajoli A, MD, Jabbour EJ, MD, Borthakur G, Azzawi HA, Konopleva M, MD, PhD, Garcia-Manero G, MD, Andreeff M, MD, PhD, Kantarjian H, MD, Ravandi F, MBBS, Alvarado Y, MD. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). ASH 2021, 2021. e-Pub 2021.
61. Jia Y, Zhang Q, PhD, Zhang W, MD, PhD, Andreeff M, MD, PhD, Jain N, MD, Zhang P, MS, Zheng G, PhD, Zhou D, Konopleva M, MD, PhD. Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells. ASH 2021, 2021. e-Pub 2021.
62. Carter BZ, PhD, Mak PY, Tao W, Ostermann LB, BS, Boettcher S, Nishida Y, MD, PhD, Ayoub E, PhD, Ruvolo V, MS, Jabbour EJ, MD, Hughes P, Morrow PK, Andreeff M, MD, PhD. Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics. ASH 2021, 2021. e-Pub 2021.
63. Carter BZ, PhD, Tao W, Ostermann LB, BS, Mu-Mosley H, MD, PhD, Mak PY, Boettcher S, Nishida Y, MD, PhD, Tao R, Lang E, Zhai Y, Yang D, Andreeff M, MD, PhD. Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells. ASH 2021, 2021. e-Pub 2021.
64. Akiyama H, MD, PhD, Zhao R, BS, Rahhal A, BS, Nishida Y, MD, PhD, Ayoub E, PhD, Ostermann LB, BS, Andreeff M, MD, PhD, Ishizawa J, MD, PhD. Therapeutic Targeting of Ferroptosis Pathway in Combination with Mitochondrial Oxidative Stress Induction in Acute Myeloid Leukemia. ASH 2021, 2021. e-Pub 2021.
65. Pourebrahim R, MD, PhD, Montoya RH, BS, Ayoub E, PhD, Khoury JD, Andreeff M, MD, PhD. Mdm2 Maintains Cholesterol Biosynthesis in Hematopoietic Stem/Progenitor Cells Independent of p53. ASH 2021, 2021. e-Pub 2021.
66. Maiti A, Andreeff M, Konopleva M. Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. SOHO Abstract 2021. e-Pub 2021.
67. Yamatani K, Carter BZ, Konopleva M, Tabe Y, Andreeff M. BCL2A1: a novel target in refractory/relapsed acute myeloid leukemia with FLT3-ITD/D835 double mutations. SOHO Abstract 2021. e-Pub 2021.
68. Venugopal S, Takahashi K, Daver N, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa GC, Bueso-Ramos C, Yilmaz M, Kadia T, Andreef M, Ravandi F, Konopleva M, Kantarjian H, DiNardo C. Efficacy and Saftey of Enasidenib and Azacitidine Combination in Patients with IDH2 Mutated Acute Myeloid Leukemia and not Eligible for Intensive Chemotherapy. EHA 2021 Abstract 3228, 2021. e-Pub 2021.
69. John MV, Schneeweiss-Gleixner M, Eisenwort G, Peter B, Berger D, Stefanzl G, Konopleva M, Andreeff M, Sperr WR, Arock M, Valent P, Gleixner KV. The synthetic triterpenoid CDDO-Me blocks survival of neoplastic mast cells and synergizes with KIT D816V-targeting drugs in inducing growth inhibition. EHA 2021, 2021. e-Pub 2021.
70. Yilmaz M, Kantarjian H, Muftuoglu M, Dinardo C, Kadia T, Konopleva M, Borthakur G, Pemmaraju N, Short N, Alvarado Y, Maiti A, Montalban-Bravo G, Jurisprudencia C, Pike A, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with Decitabine and Venetoclax (Triplet) is Highly Active in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia. EHA 2021, 2021. e-Pub 2021.
71. Yilmaz M, Ravandi F, Loghavi S, Wang S, Borthakur G, Dinardo C, Kadia T, Kanagal-Shammanna R, Pemmaraju N, Oran B, Popat U, Pierce S, Jabbour E, Short N, Issa G, Ohanian M, Garcia-Manero G, Andreeff M, Patel K, Konopleva M, Kantarjian H, Daver N. Triple Combination of HMA, Venetoclax and FLT3 Inhibitor Produces Higher FLT3 PCR Clearance, Flow MRD Negativity, and Improved Median as Compared with Doublets of HMA with FLT3 Inhibitor. EHA 2021, 2021. e-Pub 2021.
72. Nishida Y, Heinz- Montoya R, Morita K, Tanaka T, Wang F, Takahashi K, Ishizawa J, Kumar P, Patel P, Dos Santos CE, DiNardo CD, Andreeff M. Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias. Blood 136 (Suppl 1):27-28, 2020. e-Pub 2020.
73. Heinz-Montoya R, Pourebrahim R, Alaniz Z, Ostermann LB, Burks JK, Andreeff M. Osterix Marks a Distinct Population of Circulatory Bone Marrow Mesenchymal Stem Cells That Is Increased upon Oncogenic Stress. Blood 136 (Suppl 1), 2020. e-Pub 2020.
74. Muftuoglu M, Mak PY, Ruvolo V, Nishida Y, Ruvolo P, Carter B, Andreeff M. High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML. Blood 136 (Suppl 1):15, 2020. e-Pub 2020.
75. Tyagi A, Yuan B, Ly S, El-Dana F, Kuruvilla V, Zhang Q, Peterson C, Zhou X, deCrombrugghe B, Andreeff M, Konopleva M, Amini B, Battula VL. AML Cells Alter Bone Homeostasis by Promoting the Formation of Immature Bone and Resorption of Mature Bone that Supports Leukemia Progression. Blood 136 (Suppl 1):27, 2020. e-Pub 2020.
76. Mu-Mosley H, Ostermann L, Zhao Y, Bonifant C, Gottschalk S, Velasquez MP, Andreeff M. Venetoclax enhances anti-leukemia activity of CD123-specific BiTE-secreting T-cells in AML. Blood 136 (Suppl 1):12-13, 2020. e-Pub 2020.
77. Yamatani K, Ai T, Saitoh K, Yang H, Kinjo S, Ikeo S, Ruvolo V, Mak PY, Harada H, Katayama K, Sugimoto Y, Miida T, Konopleva M, Zhang W, Carter BZ, Hayashizaki Y, Andreeff M, Tabe Y. BCL2A1: a novel target in refractory acute myeloid leukemia with FLT3-ITD/D835 dual mutations. Blood 136 (Suppl 1):12-13, 2020. e-Pub 2020.
78. Kanagal-Shamanna R, Montalban-Bravo G, Katsonis, P, Sasaki K, Class CA, Benton CB, Jabbour E, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis. Blood 136 (Suppl 1):23-24, 2020. e-Pub 2020.
79. Daver N, Basu S, Garcia-Manero G, Abbas HA, Konopleva M, Kadia TM DiNardo CD, Borthakur G, Alotaibi AS, Pemmaraju N, Jabbour E, Pierce SA, Brandt M, Takahashi K, Ning J, Kornblau SM, Sasaki K, Yilmaz M, Issa G, Short NJ, Matthews JA, Flores W, Andreeff M, Cortes JE, Ravandi F, Allison JP, Kantarjian HM, Sharma P. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. Blood 136 (Suppl 1):43-45, 2020. e-Pub 2020.
80. Chang KH, Alaniz Z, Nishida Y, Dos Santos C, Daver NG, Andreeff M. Inhibition of EZH1 and EZH2 Restores Chemosensitivity of Leukemia Stem Cells in Acute Myeloid Leukemia by Recruitment of Quiescent AML Stem/Progenitor Cells. Blood 136 (Suppl 1):27-28, 2020. e-Pub 2020.
81. Carter BZ, Mak PY, Ruvolo V, Tao W, Hughes PE, Chen X, Morrow PK, Andreeff M. Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML. Blood. e-Pub 2020.
82. Ayoub E, Zhang Y, Andreeff M, Perkins AS. MDS1-EVI1 Complex (MECOM) Activation Promotes Leukemic Stem Cell Quiscence By Upregulating CDKN1C/P57Kip2. Blood. e-Pub 2020.
83. Baran N, Lodi A, Dhungana Y, Sweeney, S, Pandey R, Herbrich S, Hof FW, Skwarska A, Kaplan M, Kuruvilla VM, Cavazos A, Ma H, Warmoes M, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Harutyunyan K, Daher M, Garcia LM, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Tomczak K, Kaminski M, Davis E, Herranz D, Ferando A, Jabbour EJ, DiFrancesco ME, Teachey DT, Horton TM, Rezvani K, Kornblau S, Iurascu MG, Takahashi K, Andreeff M, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konpleva M. Overcoming NOTCH1-driven chemoresistance in T-cell acute lymphoblastic leukemia via metabolic intervention with OxPhos inhibitor. Blood. e-Pub 2020.
84. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia T, DiNardo C, Borthakur G, Pierce S, Wang S, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short N, Issa G, Ohanian M, Garcia-Manero G, Bhalla K, Patel K, Takahashi K, Andreeff M, Cortes J, Konopleva M, Ravandi F, Kantarjian K, Daver N. Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I versus Type II FLT3-inhibitors (FLT3i’s). Blood. e-Pub 2020.
85. Kadia T, Garcia-Manero G, Yilmaz M, Dinardo C, Konopleva M, Montalban-Bravo G, Borthakur G, Jabbour E, Jain N, Andreeff M, Short M, Issa G, Ohanian M, Bose P, Daver N, Wang S, Tidwell RS, Estrov Z, Ravandi F, Kantarjian H. Ven (Ven) added to Intensive Chemo with Cladribine, Idarubicin, and AraC (CLIA) Achieves High Rates of Durable Complete Remission with Low Rates of Measurable Residual Disease (MRD) in Pts with Newly Diagnosed Acute Myeloid Leukemia (AML). ASCO Abstract 2020. e-Pub 2020.
86. Ruvolo PP, Qiu YH, Hu C, Ruvolo VR, Zhang N, Qutub AA, Andreeff M, Kornblau SM. Active Galectin 3/CD74 axis is associated with poor survival outcome in AML. SOHO 2020. e-Pub 2020.
87. Zhang X, Tao W, Mak PY, Qi Y, Ma W, Wang J, Ruvolo V, Andreeff M, Carter BZ. Cytokine crosstalk within the bone marrow microenvironment as a novel resistance mechanism of Bcl-2/Mcl-1 inhibitor resistance in AML. SOHO Abstract 2020. e-Pub 2020.
88. Chang KH, Zhang W, Basyal M, Ostermann L, Fogler WE, Magnani JL, Andreeff M. Targeting E-selectin with GMI-1271 Overcomes Microenvironment-mediated Resistance to Venetoclax/HMA Therapy. SOHO Abstract 2020. e-Pub 2020.
89. Dumbrava EEL, Damodaran S, Zheng X, Vukovic V, Pairawan SS, Hong DS, Piha-Paul SA, Rodon J, Pant S, Subbiah V, Yuan Y, Murthy R, Tapia C, Litton J, Ferrari D, Andreeff M, Tripathy D, Aivado M, Meric-Bernstam F. A Phase 1b Study of ALRN-6924 in Combination with Paclitaxel in Wild-type (WT) TP53 Metastatic Solid Tumors including Estrogen-Receptor Positive Breast Cancer. ASCO 2020 Abstract. e-Pub 2020.
90. Zal T, Zielinski R, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Zal MA, Andreeff M, Gil L, Shephard R, Priebe W. High Efficacy of Liposomal Annamycin (L-ANN) in combination with Cytarabine in Syngeneic p53-Null AML Mouse Model. Blood. e-Pub 2020.
91. Short N, Bose P, Dinardo C, Garcia-Manero G, Muftuoglu M, Alaniz Z, Patel K, Montalban-Bravo G, Jain N, Alvarado Y, Jabbour E, Andreeff M, Delumpa R, Kantarjian H, Cortes J. PRELIMINARY RESULTS OF A PHASE I/II STUDY OF AZACITIDINE, VENETOCLAX AND PEVONEDISTAT IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY. EHA Abstract 2020. e-Pub 2020.
92. Zal T, Zal MA, Rytelewski M, Chang KH, Jacamo R, Fogler WE, Magnani JL, Andreeff M. Dual CXCR4 and E-Selectin Inhibition (GMI-1359) Rapidly Increases AML Cellular Motility Prior to Intravasation and Vascular Niche Depletion Observed By Intravital Bone Marrow Two-Photon Microscopy. Blood. e-Pub 2020.
93. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia T, DiNardo C, Borthakur G, Pierce S, Wang S, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short N, Issa G, Ohanian M, Garcia-Manero G, Bhalla K, Patel K, Takahashi K, Andreeff M, Cortes J, Konopleva M, Ravandi F, Kantarjian H, Daver N. Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I versus Type II FLT3-inhibitors (FLT3i’s). Blood. e-Pub 2020.
94. Ayoub E, Zhang Y, Andreeff M, Perkins AS. MDS1-EVI1 Complex (MECOM) Activation Promotes Leukemic Stem Cell Quiescence By Upregulating CDKN1C/P57Kip2. Blood. e-Pub 2020.
95. Baran N, Lodi A, Dhungana Y, Sweeney S, Pandey R, Herbrich S, Hof FW, Skwarska A, Kaplan M, Kuruvilla VM, Cavazos A, Ma H, Warmoes M, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Harutyunyan K, Daher M, Garcia LM, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Tomczak K, Kaminski M, Davis E, Herranz D, Ferrando A, Jabbour EJ, Di Francesco ME, Teachey DT, Horton TM, Rezvani K, Kornblau S, Iurascu MG, Takahashi K, Andreeff M, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Overcoming NOTCH1-driven chemoresistance in T-cell acute lymphoblastic leukemia via metabolic intervention with OxPhos inhibitor. Blood. e-Pub 2020.
96. Bose P, Pemmaraju N, Masarova L, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Cortes JE, Jain N, Borthakur G, Alvarado Y, Huynh-Lu J, Henriquez M, Richie MA, Dobbins M, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept (ACE-011) for anemia of myelofibrosis: a phase 2 study. Blood. e-Pub 2020.
97. Carter BZ, Mak PY, Tao W, Ruvolo V, Zhang X, Nishida Y, Kornblau SM, Hughes PE, Chen X, Morrow PK, Andreeff M. Co-targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-resistant and TP53 mutated AML. Blood. e-Pub 2020.
98. Carter BZ, Mak PY, Ruvolo V, Tao W, Hughes PE, Chen X, Morrow PK, Andreeff M. Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML. Blood. e-Pub 2020.
99. Chang KH, Muftuoglu M, Zhang W, Basyal M, Ostermann L, Fogler WE, Magnani JL, Andreeff M. Targeting E-selectin with GMI-1271 Overcomes Microenvironment-mediated Resistance to Venetoclax/HMA Therapy. Blood. e-Pub 2020.
100. Issa GC, Andreeff M. Changes in Gene Expression Following treatment of Adverse Risk Acute Myeloid Leukemia. Blood. e-Pub 2020.
101. Chien KS, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Sheppard K, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy. Blood. e-Pub 2020.
102. Issa GC, Mohanty V, Wang Y, Alaniz Z, Zarka J, Leighton J, Navin N, Konopleva MY, Chen K, Andreeff M. Mapping the Architecture of Adverse Risk AML using Single-Cell RNA Sequencing. Blood. e-Pub 2020.
103. Maiti A, DiNardo CD, Wang S, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger J, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood. e-Pub 2020.
104. Muftuoglu M, Alaniz Z, Mak D, Lin AJ, Burks J, Carter BZ, Andreeff M. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML by Concomitant Analysis of Cell Surface antigens, Signaling Pathways and Anti-apoptotic Proteins. Blood. e-Pub 2020.
105. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ruvolo VR, Kojima K, Daver N, Kumar P, Lesegretain A, Shacham S, Andreeff M. Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-type p53 Acute Myeloid Leukemias. Blood. e-Pub 2020.
106. Piya S, Weetall M, Sheedy J, Ray B, Ma H, Kojima K, Ruvolo V, Basyal M, Konopleva M, Andreeff M, Borthakur G. The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia. Blood. e-Pub 2020.
107. Pourebrahim R, Montoya RH, Alaniz Z, Ostermann L, Ayoub E, Lin PP, Burks J, Andreeff M. Mdm2 Haplo-insufficiency in Hematopoietic and Mesenchymal Progenitor Cells Results in Cell Death. Blood. e-Pub 2020.
108. Pourebrahim R, Montoya RH, Alaniz Z, Ostermann L, Luong A, Khoury JD, Andreeff M. Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in Acute Myeloid Leukemia. Blood. e-Pub 2020.
109. Reville PK, Kantarjian HM, Borthakur G, Yilmaz M, Montalban-Bravo G, Dinardo CD, Andreeff M, Daver N, Jain N, Kornblau S, Jabbour E, Short NJ, Alvarado Y, Ohanian M, Bose P, Masarova L, Wang SA, Tidwell RSS, Estrov Z, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood. e-Pub 2020.
110. Reville PK, Nogueras-González GM, Ravandi F, Sasaki K, Borthakur G, Garcia-Manero G, Daver N, DiNardo C, Jabbour E, Pemmaraju N, Andreeff M, Verstovsek S, Ferrajoli A, Jain N, Ohanian M, Pierce S, Estrov Z, Konopleva M, Kantarjian H, Kadia TM. Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort. Blood. e-Pub 2020.
111. Rivera-Delgado D, Kantarjian H, Borthakur G, Konopleva M, Kanagal R, Pemmaraju N, Daver N, Dinardo C, Takahashi K, Jabbour E, Montalban-Bravo G, Yilmaz M, Pierce S, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kadia TM. Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Across Therapy Subtypes. Blood. e-Pub 2020.
112. Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, Keating MJ, O’Brien S, Wierda WG, Ferrajoli A, Burger JA. Ibrutinib induces durable remissions in treatment-naïve CLL patients with 17p deletion/TP53 mutations: Five year follow-up from a phase 2 study. Blood. e-Pub 2020.
113. Tabe Y, Saitoh K, Yamatani K, Yang H, Jacamo R, Ma H, Ruvolo V, Zhang Q, Kuruvilla V, Baran N, Imoto J, Ikeo K, Moriya K, Murakami-Tonami Y, Suzuki K, Miida T, Andreeff M, Vellano CP, Marszalek JR, Konopleva M. The direct interactions with bone marrow microenvironment confer resistance to the inhibition of Oxidative Phosphorylation in AML. Blood. e-Pub 2020.
114. Muftuoglu M, Andreeff M. High Dimensional Analytic Approaches Identify Stressor Specific Response Patterns in AML. SOHO 2020. e-Pub 2020.
115. Muftuoglu M, Alaniz Z, Mak D, Lin AJ, Burks J, Carter BZ, Andreeff M. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Patients with Relapsed/Refractory AML. SOHO 2020. e-Pub 2020.
116. Carter BZ, Mak PY, Tao W, Ruvolo V, Zhang X, Nishida Y, Kornblau SM, Hughes PE, Chen X, Morrow PK, Andreeff M. Co-targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-resistant and TP53 mutated AML. Blood. e-Pub 2020.
117. Bose P, Pemmaraju N, Masarova L, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Cortes JE, Jain N, Borthakur G, Alvarado Y, Huynh-Le J, Henriquez M, Richie MA, Dobbins M, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept (ACE-011) for anemia of myelofibrosis: a phase 2 study. Blood. e-Pub 2020.
118. Zhang W, Chang KH, Basyal M, Jia Y, Ostermann L, Fogler WE, Magnani JL, Zal MA, Zal T, Andreeff M. Combined Blockage of E-selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models. Blood. e-Pub 2020.
119. Ruvolo PP, Ma H, Ruvolo VR, Zhang X, Post S, Andreeff M. LGALS1 acts as a pro-survival molecule in AML. SOHO 2020. e-Pub 2020.
120. Yilmaz M, Kantarjian H, Muftuoglu M, Kadia TM, Konopleva M, Borthakur G, DiNardo CD, Pemmaraju N, Short NJ, Alvarado Y, Montalban Bravo G, Jurisprudencia C, Pike AM, Ohanian M, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver NG. Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. Blood. e-Pub 2020.
121. Muftuoglu M, Alaniz Z, Mak D, Lin AJ, Burks J, Carter BZ, Andreeff M. High-Dimensional Single-Cell Proteomics Analysis Reveals Therapeutic Vulnerabilities and Informs Potential Mechanisms of Resistance in Patients with Relapsed and Refractory AML. Single Cell Omics Symposium abstract 2020. e-Pub 2020.
122. Nishida Y, Montoya RH, Ostermann LB, Zhang W, Meric-Bernstam F, Kunos CA, Andreeff M. THERAPEUTIC TARGETING OF DNA-PKCS WITH M3814 IN COMBINATION WITH CPX-351 (VYXEOS) ACHIEVES PROFOUND LEUKEMIA REDUCTION IN TP53WT AND TP53MUT ACUTE MYELOID LEUKEMIA. EHA Abstract 2020. e-Pub 2020.
123. Mohanty V, Shen Y, Issa GC, Benton CB, Alaniz Z, Wang F, Futreal AP, Wang W, Jorgensen JL, Navin N, Konopleva M, Andreeff M, Chen K. Elucidating transcriptomic signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk AMLs. AACR Abstract 2020. e-Pub 2020.
124. Zhang W, Chang KH, Basyal M, Jia Y, Ostermann L, Fogler WE, Magnani JL, Andreeff M. Combined Targeting of E-selectin/CXCR4 and FLT3 by GMI-1359 and Sorafenib Effectively Reduces Leukemia Cell Burden and Protects Normal Hematopoiesis in a Patient-derived AML Xenograft Model. AACR Abstract, 2020. e-Pub 2020.
125. Jaggupilli A, Ly S, Borkar R, Nguyen K, Yuan B, Putluri N, Andreeff M, Battula VL. Oxidative stress induces glutamine-dependent GD2+ triple negative breast cancer stem cells phenotype and function in triple negative breast cancer. AACR Abstract 2020. e-Pub 2020.
126. Alotaibi AA, Yilmaz M, Kadia T, DiNardo C, Borthakur G, Guerra V, Andreeff M, Konopleva M, Pemmaraju N, Jabbour E, Short N, Garcia-Manero G, Patel K, Ravandi-Kashani F, Kantarjian H, Daver N. Sequential FLT3 and NGS based mutational analysis in relapsed FLT-3 positive AML post FLT3- inhibitors based therapy. EHA Abstract 2020. e-Pub 2020.
127. Tyagi A, Yuan B, Ly S, El-Dana F, Kuruvilla V, Zhang Q, Zhou X, deCrombrugghe B, Konopleva M, Andreeff M, Battula VL. Osteoprogenitor cells, but not mature osteoblasts/osteocytes that support AML growth in the bone marrow microenvironment. SOHO Abstract 2020. e-Pub 2020.
128. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, MD, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Afujo HO, Goswamy GV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce S, Wierda W, Kornblau S, Ravandi F, Cortes JE. Impact of Stem-Cell Transplantation on Healthcare Utilization in Acute Myeloid Leukemia. EHA Abstract 2020. e-Pub 2020.
129. Maiti A, DiNardo CD, Kadia TM, Rausch CR, Pemmaraju N, Daver NG, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, MD, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Maduike RE, Guerrero JA, Bivins CA, Wade A, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Ravandi F, MD, Garcia-Manero G, Welch JS, Kantarjian HM, Konopleva MY. Ten-day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (HR MDS). ASCO 2020 Abstract. e-Pub 2020.
130. El Dana F, Yuan B, Ly S, Yan Y, Ruvolo V, Shpall EJ, Konopleva M, Andreeff M, Battula VL. Bone marrow stromal cells induce chemotherapy resistance in AML cells through TGF-β-p38-ALDH2 pathway. SOHO 2020. e-Pub 2020.
131. Rytelewski M, Harutyunyan K, Mallampati S, Zal AM, Baran N, Cavazos A, Butler JM, Konplev S, Marszalek J, Andreeff M, Vinogradov S, Zal T, Konopleva M. Inhibition of oxidative phosphorylation reverses bone marrow hypoxia in an imageable syngeneic B-ALL mouse model. MDA Annual Symposia on Cancer Research, 2019. e-Pub 2019.
132. Ohanian M, Zhang H, Pemmaraju N, Rice W, Howell S, Tang G, Bueso-Ramos C, Borthakur G, Andreeff M. Early evidence of MYC Downregulation in AML by APTO-253. Blood. e-Pub 2019.
133. Abbas HA, Alfayez M, Wang F, Garcia-Manero G, Ravandi F, Kadia T, DiNardo C, Matthews J, Flores W, Andreeff M, Kornblau S, Borthakur G, Konopleva M, Cortes J, Neelapu S, Kantarjian H, Davis RE, and Daver N. RNA based immune signatures may Predict Responses to PD-1 Inhibition and Azacitidine Treatment in Acute Myeloid Leukemia (AML): A subset analysis of a Phase 2 Study. ASCO Abstract 2019. e-Pub 2019.
134. Mu H, Ostermann L, Muftuoglu M, Schober WD, Patel N, Vaidya A, Bonifant C, Gottschalk S, Velasquez MP, Andreeff M. IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia. Blood. e-Pub 2019.
135. Zal T, Zal MA, Andreeff M. MD Anderson Advanced Microscopy Core Facility. GCC Translational Imaging Symposium - Houston, 2019. e-Pub 2019.
136. Ruvolo PP, Zhang X, Singh K, Kornblau SM, H-G W, Andreeff M. EIF4A inhibitor CR31B suppresses MYC and induces apoptosis in AML cells especially those harboring a FLT3 ITD mutation. Blood. e-Pub 2019.
137. Ly S, Yuan B, Grimm S, Andreeff M, Buhring HJ, Battula VL. B7-H3 an immune checkpoint protein is overexpressed in AML and the blocking monoclonal antibodies enhance NK cell mediated apoptosis in AML cells. AACR Abstract 2019. e-Pub 2019.
138. Aitken MJL, Ma H, Zhang X, Yasuhiro T, Tanaka K, Kozaki R, Yoshizawa T, Ruvolo VR, Muftuoglu M, Andreeff M, Khoury JD, Post SM, and Ruvolo PP. AXL/MERTK inhibitor ONO-7475 promotes differentiation and induces cell death of acute megakaryoblastic leukemia using in vitro and in vivo models. Blood. e-Pub 2019.
139. Perez JR, Kadia T, Montalban-Bravo G, Benton CB, Faderl S, Sasaki K, Naqvi K, Cortes J, Daver N, DiNardo C, Jabbour E, Borthakur G, Al Azzawi H, Pemmaraju N, Konopleva M, Pierce S, Garcia-Manero G, Andreeff M, Kantarjian H, Ravandi F, Alvarado Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood. e-Pub 2019.
140. Pourebrahim R, Luong A, Ostermann L, Montoya RH, Alaniz Z, Ruvolo P, Kornblau S, Khouri J, Bueso-Ramos CE, Andreeff M. p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development. MDACC Symposium Cancer Research 2019. e-Pub 2019.
141. Skwarska A, Panis P, Zhang Q, Herbrich S, Kurvilla VM, Baran N, Halilovic E, Ruvolo P, Ruvolo V, Morris E, Wei A, Moujalled D, Andreeff M, Konopleva M. Synergistic activity of the MCL-1 inhibitor S63845 with midostaurin in preclinical human models of FLT3-ITD mutated acute myeloid leukemia (AML). SOHO 2019. e-Pub 2019.
142. Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi P, Mak D, Ruvolo V, Wang X, Tan L, Cidado J, Drew L, Andreeff M. Mcl-1 Inhibition Exerts Anti-leukemia Activity and Overcomes Venetoclax Resistance in vitro and in vivo in AML through Modulation of Cell Death, Leukemia-stromal Interactions and Metabolic Functions. CSH Apoptosis Meeting, 2019. e-Pub 2019.
143. Piya S, Yang Y, Bhattacharya S, Mu H, Ruvolo V, Baran N, Davis RE, Qian Y, You MJ, Konopleva M, Kantarjian H, Andreeff M, Borthakur G. Targeting NOTCH1-MYC-CD44 axis to eliminate Leukemia Initiating Cells (LIC) in T-ALL. SOHO 2019. e-Pub 2019.
144. Nishida Y, Ishizawa J, Ruvolo VR, Kojima K, Daver N, Lesegretain A, Shacham S, Andreeff M. Dual Inhibition of MDM2 and XPO1 Induces Synergistic Apoptosis in Wild-type p53 Acute Myeloid Leukemia through Nuclear Accumulation of p53 and Suppression of c-Myc. SOHO 2019. e-Pub 2019.
145. Thompson P, Ferrajoli A, Keating M, Banerjee P, Andreeff M, Rezvani K, Wierdaiw W. High-dose blinatumomab is active in Richter’s Syndrome. iwCLL2019. e-Pub 2019.
146. Daver N, Zhang W, Graydon R, Dawra V, Xie J, Kumar P, Andreeff M. A phase 1 study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia (AML). ASCO 2019, 2019. e-Pub 2019.
147. Morita K, Wang F, Jahn K, Yan Y, Durruthy-Durruthy R, Parikh A, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel K, Bueso-Ramos C, DiNardo C, Ravandi F, Jabbour E, Andreeff M, Cortes JE, Konopleva M, Garcia-Manero G, Kantarjian H, Eastburn D, Futreal PA, Beerenwinkel N, Takahashi K. Single-cell atlas of driver mutations in AML. EHA Abstract 2019. e-Pub 2019.
148. Jappupilli A, Nguyen K, Ly S, Andreeff M, Chlikani P, Battula VL. Characterization of small molecule inhibitor for GD3 synthase (ST8S1A1), a novel target in breast cancer stem-like cells. AACR Abstract 2019. e-Pub 2019.
149. Maiti A, Kantarjian HM, Popat V, Blanco C, Velasquez M, Garcia-Manero G, Konopleva MY, Verstovsek S, Andreeff M, Borthakur G, Kadia TM, Daver NG, Pemmaraju N, DiNardo CD, Pierce S, Wierda W, Kornblau S, Ravandi F, Cortes JE. Clinical Value of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML). ASCO Abstract 2019. e-Pub 2019.
150. Abbas H, Alfayez M, Garcia-Manero G, Ravandi F, Kadia TM, Dinardo CD, Mathews J, Flores W, Andreeff M, Kornblau SM, Konopleva M, Cortes JE, Neelapu SS, Kantarjian HM, Davis RE, Daver NG. IL2-STAT5 Immune Signatures Predict Responses to PD-1 Inhibition and Azacitidine Treatment in Acute Myeloid Leukemia (AML): A subset analysis of a Phase 2 Study. ASCO Abstract 2019. e-Pub 2019.
151. Daver N, Alfayez M, Garcia-Manero G, Abbas H, Basu S, Konopleva M, Jabbour E, Cortes JE, Ravandi F, Kadia TM, DiNardo C, Assi R, Pierce S, Andreeff M, Estrov ZE, Pemmaraju N, Takahashi K, Ning J, Gonzalez NG, Kornblau SM, Matthews J, Flores WR, Allison JP, Sharma P, Kantarjian H. SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY. EHA 2019, 2019. e-Pub 2019.
152. Alfayez M, Kantarjian H, Ravandi F, Konopleva M, Jabbour E, Garcia-Manero G, Kadia T, Borthakur G, DiNardo C, Estrov Z, Pemmaraju N, Pierce S, Yilmaz M, Short N, Takahashi K, Assi R, Andreeff M, Cortes JE, Daver N. . Exploratory analysis of Co-Mutations and Outcomes with sequential FLT3-inhibitor (FLT3i) based therapies in relapsed FLT3-mutated AML patients (pts). EHA 2019, 2019. e-Pub 2019.
153. Shoukier M, Konopleva M, DiNardo CD, Ravandi F, Andreeff M, Garcia-Manero G, Jabbour E, Daver NG, Borthakur G, Pemmaraju N, Montalban-Bravo G, Benton CB, Short NJ, Bhalla KN, Cortes, JE, Kantarjian HM, Kadia TM. Activity of Venetoclax-based Therapy in TP53-mutated Acute Myeloid Leukemia. ASCO 2019, 2019. e-Pub 2019.
154. Dumbrava EEI, Pinchasik D, Damodar S, Hess K, Pairawan SS, Moore J Hong DS, Janku F, Rodon J, Piha-Paul SA, Murthy R, Tapia C, Litton J, Luna K, Stuckett AS, Ferari D, Andreeff M, Tripathy D, Aivado M, Meric-Bernstam F. A Phase 1b Study of ALRN-6924 in Combination with Paclitaxel in Wild-type (WT) TP53 Metastatic Solid Tumors including Estrogen-Receptor Positive Breast Cancer. ASCO 2019, 2019. e-Pub 2019.
155. Yuan B, Ly S, Veletic I, Malsonado K, Zhou X, deCrombrugghe B, Andreeff M, Battula VL. Acute myeloid leukemia cells induce new bone formation by expanding osteoprogenitor niche in the bone marrow. AACR 2019, 2019. e-Pub 2019.
156. Chien KS, Benton CB, Class CA, Kadia TM, Dinardo CD, Konopleva M, Andreeff M, Sasaki K, Naqvi K, Gomez IG, Wei Y, Yang H, Pierce SA, Patel KP, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Patterns of Leukemic Transformation in Patients with TP53-Mutant Myelodysplastic Syndromes. ASCO 2019, 2019. e-Pub 2019.
157. Bhattacharya S, Piya S, McQueen T, Konopleva M, Andreeff M, Borthakur G. Inhibition of Autophagy Kinase ULK1 Combined with Chemotherapy Results in Modulation of Reactive Oxygen Species and DNA Damage Response to Induce Synergistic Cell Death in Acute Myeloid Leukemia. 8th Annual Postdoctoral Symposium (APSS) at MD Anderson. e-Pub 2018.
158. Andreeff M, Seki T, Zhang W, Isoyama T, Iwanaga K, Togashi N, Kumar P, Zernovak O, Daver N. Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan Results in Greater Pre-Clinical Anti-Leukemic Activity in FLT3-ITD Mutant/P53 Wild-Type Acute Myeloid Leukemia Models. EHA 2018, 2018. e-Pub 2018.
159. Hsu J, Wang F, Yan Y, Mathew J, Gumbs C, Little L, Tippen S, Song X, Zhang J, Kornblau S, Kadia T, Pemmaraju N, Daver N, DiNardo C, Konopleva M, Andreeff M, Kantarjian H, Bhalla K, Garcia-Manero G, Donehower L, Futreal A, Goodell M, Takahashi K. Prevalence and Clinical Implications of PPM1D Truncating Mutations in Therapy-Related Myeloid Neoplasms. EHA 2018, 2018. e-Pub 2018.
160. Wang W, Mak PY, Ma W, Su X, Mu H, Tao W, Andreeff M, Carter BZ. Targeting Wnt/β-catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML via Rac1-mediated MCL-1 inhibition. Blood, 2018. e-Pub 2018.
161. Borthakur G, Tallman MS, Ofran Y, Foran J, Uy G, DiPersio J, Nagler A, Rowe J, Showel MM, Altman JK, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, Lustig TM, Brawer S, Bohana-Kashtan O, Cortes JE, Andreeff M. The CXCR4 Inhibitor BL8040 in Combination with Cytarabine Results in a Significantly Extended Overall Survival of Relapsed/Refractory AML Patients. EHA 2018, 2018. e-Pub 2018.
162. Benton CB, Al Rawi A, Wang F, Zhang J, Jorgensen J, Mu H, Schober W, Alaniz Z, Gumbs C, Futreal A, Garcia-Manero G, Kantarjian H, Navin, N, Konopleva M, Andreeff, M. Minimal residual disease from high-risk AML patients has distinct gene expression. ASH 2018, 2018. e-Pub 2018.
163. Garcia-Manero G, Bose P, Alvarado Y, Borthakur G, Daver N, Ravandi F, Jabbour E, Takahashi K, Andreeff M, Kadia T, DiNardo C, Cortes J, Kornblau S, Naqvi K, Benton CB, Ohanian M, Konopleva M, Estrov Z, Montalban-Bravo G, Pierce S, Bodden K, Kantarjian H. A Phase II Clinical Trial of Guadecitabine (SGI-110) for Patients with Previously Untreated Myelodysplastic Syndrome. EHA 2018, 2018. e-Pub 2018.
164. Olson A, Marini F, Westin S, Coleman R, Thall P, Al Jahdami V, Al-Atrash G, Anderlini P, Andersson BS, Alousi A, Ahmed S, Bashir Q, Ciurea S, Hosing C, Im J, Jenq R, Jones R, Kebriaei P, Khouri I, Marin D, Mehta R, Nieto Y, Oran B, Parmar S, Popat U, Qazilbash M, Rezvani K, Timmons M, Champlin RE, Shpall E, Andreeff M. A Phase I Trial of Mesenchymal Stem Cells Transfected with a Plasmid Secreting Interferon Beta in Advanced Ovarian Cancer (Oral Presentation). ISCT 2018, 2018. e-Pub 2018.
165. Andreeff M, Marini FC, Westin S, Coleman R, Thall P, Al Jahdami V, Qazilbash M, Rezvani K, Timmons M, Heese L, Wang RY, Champlin RE, Shpall E, Olson A. A Phase I Trial of Mesenchymal Stem Cells Transfected with a Plasmid Secreting Interferon Beta in Advanced Ovarian Cancer. AACR 2018, 2018. e-Pub 2018.
166. Olson A, Marini FC, Westin S, Coleman R, Thall P, JahdamiV A, Qazilbash M, Rezvani K, Timmons M, Heese L, Wang RY, Champlin RE, Shpall E, Andreeff M. A Phase I Trial of Mesenchymal Stem Cells Transfected with a Plasmid Secreting Interferon Beta in Advanced Ovarian Cancer (Poster Presentation). BMT Tandem Meeting, 2018. e-Pub 2018.
167. Morita K, Wang F, Patel K, Bueso-Ramos CE, Zahr AA, Gumbs C, Zhang J, Song X, Mendoza M, Wu CJ, Kornblau S, DiNardo CD, Ravandi F, Garcia-Manero G, Jabbour E, Andreeff M, Kantarjian HM, Konopleva M, Futreal A, Takahashi K. Genomic landscape of adult mixed phenotype acute leukemia (MPAL). ASCO Abstract 2017. e-Pub 2017.
168. Takahashi K, Wang F, Patel K, Bueso-Ramos CE, Issa GC, Song X, Zhang J, Tippen S, Little L, Gumbs C, Ravandi F, Kadia TM, Daver NG, DiNardo CD, Konopleva M, Andreeff M, Cortes JE, Jabbour E, Futreal A, Kantarjian HM. Distinct patterns of somatic mutation clearance and association. ASCO Abstract 2017. e-Pub 2017.
169. Benton CB, Assi R, Wang F, Pierce S, Patel K, Kornblau SM, AlRawi A, Zhang J, Hamilton BK, Takahashi K, DiNardo CD, Futreal A, Garcia-Manero G, Kadia TM, Kantarjian HM, Andreeff M, Verstovsek S. Frequency and type of JAK3 variants in adult patients with leukemia. ASCO Abstract 2017. e-Pub 2017.
170. Borthakur G, Tallman MS, Ofran Y, Foran J, Uy GL, DiPersio JF, Nagler A, Rowe JM, Showel MM, Altman JK, Al-Rawi A, Wang RW, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, Lustig T, Aharon A, Bueso-Ramos C, Cortes JE, Andreeff M. The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, is Mediated by Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies From a Ph2a Trial in Acute Myeloid Leukemia. Blood. e-Pub 2017.
171. Tabe Y, Sekihara K, Saitoh K, Ruvolo V, Ishizawa J, Miida T, Andreeff M, Spagnuolo PA, Konopleva M. Novel fatty acid oxidation inhibitor avocatinB induces AMPK-dependent apoptosis of AML cells co-cultured with BM-adipocytes. Blood. e-Pub 2017.
172. Battula VL, Yan Y, Nguyen K, K-A D, Andreeff M. ST8SIA1 is up-regulated in triple negative breast cancer and positively correlated with TP53 mutations and a cancer stem cell gene signature. AACR 2017, 2017. e-Pub 2017.
173. Nguyen K, Yan Y, Bartholomeusz C, Ueno N, K-A D, Andreeff M, Battula VL. Knockout of ST8SIA1 inhibits tumorigenesis in triple negative breast cancer by inducing PTEN and ganglioside GM1 mediated tumor growth arrest. AACR 2017, 2017. e-Pub 2017.
174. Chamoun K, Benton CB, AlRawi A, Jacamo R, Williams P, Wang F, Zhang J, Daver NG, Garcia-Manero G, Kantarjian HM, Futreal A, Andreeff M. Immune-related gene expression deficit of leukemia stem cells (LSC) in AML. ASCO Abstract 2017. e-Pub 2017.
175. OConnor K, Russell K, Tucker A, BunnellB, Lacey M, Andreeff M. Differential Expression of Neuron-Glial Antigen 2 (NG2) and Melanoma Cell Adhesion Molecule (CD146) in Mesenchymal Stem Cells. 2017 AlChE Annual Meeting (Food, Pharmaceutical & Bioengineering Division). e-Pub 2017.
176. Montalban-Bravo G, Bose P, Alvarado Y, Daver NG, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbor E, Kadia TM, Kornblau S, Ohanian M, Huang X, Nogueras-Gonzalez GM, Bodden K, Pierce S, Kantarjian HM, Garcia-Manero G. Updated results from Phase 2 study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia. ASCO Abstract 2017. e-Pub 2017.
177. Daver NG, Garcia-Manero G, Basu S, Ravandi F, Kadia TM, Borthakur G, Jabbour E, DiNardo CD, Pemmaraju N, Brandt M, Pierce S, Hussin N, Kornblau SM, Andreeff M, Konopleva M, Ning J, Allison JP, Sharma P, Kantarjian HM. Phase IB/II Study of lirilumab with azacytidine (AZA) in replaspsed AML. ASCO Abstract 2017. e-Pub 2017.
178. Konopleva M, DiNardo CD, Pan R, Han L, Zhang Q, Daver N, Kantarjian H, Andreeff M. Target Agents in AML (ABT199). Acute Leukemias XVI - Biology and Treatment Strategies, 2017. e-Pub 2017.
179. Carter BZ, Mak PY, Wang X, Mu H, Ruvolo V, Andreeff M. Novel ARC/IL1B/PGE2/B-catenin circuit regulates leukemia and leukemia microenvironment. ESH 2nd Scientific Workshop on Tumour Environment in Haematological Malignancies, 2017. e-Pub 2017.
180. Battula VL, Le PM, Sun JC, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Kukkillaya ARU, Al-Altrash G, Konopleva M, Davis RE, Harrington MA, Palisch CW, Bueso-Ramos C, Andreeff M. Acute myeloid leukemia cells induce osteogenic differentiation in the bone marrow microenvironment to gain growth advantage through BMP- and CTGF-mediated signaling. ESH 2nd Scientific Workshop on Tumour Environment in Haematological Malignancies, 2017. e-Pub 2017.
181. Yan Y, Nguyen K, K-A D, Ueno N, Andreeff M, Battula VL. ST8SIA1 is Over-expressed in Triple Negative Breast Cancer and Associated with p53 Mutations. SABCS 2016, 2017. e-Pub 2017.
182. Yan Y, Nguyen K, K-A D, Ueno N, Andreeff M, Battula VL. ST8SIA1 Regulates Tumorigenesis in Triple Negative Breast Cancer. SABCS 2016, 2017. e-Pub 2017.
183. Nguyen K, Sun J, Dasgupta A, Bartholomeusz C, Andreeff M, Battula VL. GD2-mediated FAK Signaling Regulates Breast Cancer Stem Cell Function in Triple Negative Breast Cancer. SABCS 2016, 2017. e-Pub 2017.
184. Battula VL, Piyarathna B, Nguyen K, Sun J, Jin F, Coarfa C, Nagireddy P, Andreeff M. Metabolic Stress Induces GD2 Expression and Cancer Stem Cell Phenotype in Triple Negative Breast Cancer. SABCS 2016, 2017. e-Pub 2017.
185. Williams P, Basu S, Garcia-Manero G, Cortes J, Ravandi F, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo-Lopez J, Kornblau S, Andreeff M, Flores W, Bueso-Ramos C, Somani N, Blando J, Al-Atrash G, Allison J, Kantarjian H, Sharma P, Daver N. Checkpoint Expression by Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity. Blood 130, Suppl 1, 2017. e-Pub 2017.
186. Wang X, Mak PY, Mu H, Tao W, Pachter J, Weaver D, Xu B, Andreeff M, Carter BZ. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML. Blood 130, Suppl 1, 2017. e-Pub 2017.
187. Tao W, Mak PY, Andreeff M, Z Carter AB. Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells. Blood 130, Suppl 1, 2017. e-Pub 2017.
188. Tabe Y, Sekihara K, Yang H, Saito K, Ruvolo V, Taka H, Kaga N, Miida T, Andreeff M, Spagnuolo PA, Konopleva M. Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. Blood 130, Suppl 1, 2017. e-Pub 2017.
189. Swaminathan M, Kantarjian H, Daver N, Borthakur G, Ohanian M, Kadia T, DiNardo C, Jain N, Estrov Z, Ferrajoli A, Garcia-Manero G, Konopleva M, Andreeff M, Pemmaraju N, Jabbour E, Alvarado Y, Wierda W, Pinsoy MR, Ravandi F, Cortes JE. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood 130, Suppl 1, 2017. e-Pub 2017.
190. Ruvolo PP, Hu C, Qiu YH, Ruvolo VR, Coombes KR, Qutub AA, Andreeff M, and Kornblau SM. Galectin 3 protein network analysis by Reverse Protein Arrays demonstrates Regulation of MCL-1, PKC delta and CD74 Associated with Poor Survival in Patients with AML. Blood 130, Suppl 1, 2017. e-Pub 2017.
191. Padua RA, Chiquet M, Zhang Q, Kappel C, Krief P, Setterblad N, Omidvar N, Leboeuf C, Janin A, Noguera ME, Konopleva M, Andreeff M, Pla M, Ades L, Fenaux P, Chomienne C. BCL-2 inhibition with ABT-199 shows efficacy in AML cell lines with synergistic effects upon addition of the MEK inhibitor GDC-0973 and prolongs survival in an NRAS/BCL2-mediated mouse model of AML post-MDS. Blood, 2017. e-Pub 2017.
192. Benton CB, Khan M, Nogueras González GM, Nazha A, Piao J, Ning J, Aung F, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Komrokji RS, Steensma D, DeZern A, l Roboz G, Sekeres M, Andreeff M, Kantarjian H, Garcia-Manero G. Sequential Stratification Prognostic Score for Patients with Intermediate-Risk Myelodysplastic Syndrome. Blood 130, Suppl 1, 2017. e-Pub 2017.
193. Benton CB, Boddu PC, DiNardo C, Bose P, Wang F, Pemmaraju N, Devendra KC, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia T, Cortes J, Kantarjian H, Andreeff M, and Verstovsek S. JAK2 Variants Associated with Secondary-AML from MPN. Blood 130, Suppl 1, 2017. e-Pub 2017.
194. Yamatani K, Tabe Y, Sekihara K, Yang H, Saitoh K, Zhang W, Kinjo S, Ikeo K, Mogushi K, Hosoya M, Hayashizaki Y, Yamanaka Y, Harada H, Miida T, Konopleva M, Andreeff M. XPO1 inhibition targets transcriptional vulnerability of FLT3-ITD+835D double mutant AML through p53 accumulation and inhibition of oncogenic transcription factors: lesson learned from CAGE sequencing of primary AML cells. Blood 130, Suppl 1, 2017. e-Pub 2017.
195. Piya S, Mu H, Bhattacharya S, McQueen T, Davis RE, Ruvolo V, Baran N, Qian Y, Raina K, Crews CM, You MJ, Zweider-McKay P, Konopleva M, Kantarjian H, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825 targets both NOTCH1-MYC regulatory circuit and leukemia-microenvironment in T-ALL. Blood 130, Suppl 1, 2017. e-Pub 2017.
196. Li L, Muftuoglu M, Chen H, Mak D, Burks J, Mehta R, Xi Y, Lv J, Hu B, Jimenez J, Kaplan M, Shaim H, Imahashi N, Banerjee P, Kerbauy LN, Mendt MC, FLLW I, Daher M, Basar R, Andreeff M, Wang J, Marin D, Champlin R, Shpall EJ, Rezvani K. NK cell diversity influences outcomes after cord blood transplantation. Blood 130, Suppl 1, 2017. e-Pub 2017.
197. Daver N, Pollyea DA, Yee K, Fenaux P, Brandwein J, Vey N, Martinelli G, Kelly K, Roboz GJ, Garcia JS, Pigneux A, Kshirsagar S, Dail M, Wang J, Mobasher M, Chen LC, Hong WJ, Konopleva M, Andreeff M. Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML. Blood 130, Suppl 1, 2017. e-Pub 2017.
198. Burger JA, Sivina M, Ferrajoli A, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Ohanian M, Andreeff M, Thomas M, Alexander-Williams L, Kantarjian H, O’Brien S, Wierda WG, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL). Blood 130, Suppl 1, 2017. e-Pub 2017.
199. Chamoun K, Benton CB, AlRawi A, Jacamo R, Williams P, Wang F, Zhang J, Daver N, Kantarjian K, Konopleva M, Futreal A, Andreeff M. Immune-related gene expression deficit of leukemia stem cells (LSC) in AML. ASCO 2017, 2017. e-Pub 2017.
200. Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia TM, Dinardo CD, Konopleva M, Allison JP, Kantarjian HM, Sharma P. Phase IB/II Study of Nivolumab with Azacytidine (AZA) in Patients (pts) with Relapsed AML. ASCO, 2017, 2017. e-Pub 2017.
201. Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Mendt MC, Imahashi N, Kerbauy LN, FLLW I, Li L, Muftuoglu M, Champlin R, Ruvolo P, Andreeff M, Kantarjian H, Garcia-Manero G, Shpall EJ, Rezvani K. The TGF-β/SMAD signaling pathway as a mediator of NK cell dysfunction and immune evasion in Myelodysplastic Syndrome. Blood 130, Suppl 1, 2017. e-Pub 2017.
202. Yu G, Zhang W, Ly C, Zhang H, Rice WG, and Andreeff M. CG’806, a Novel Pan-FLT3/BTK Multi-kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status. Blood 130, Suppl 1, 2017. e-Pub 2017.
203. Yang H, Tabe Y, Sekihara K, Saitoh K, Ma H, Ruvolo V, Imoto J, Ikeo K, Mogushi K, Hosoya M, Hayashizaki Y, Yamanaka Y, Miida T, Andreeff M, Marszalek JR, Konopleva M. Novel Oxidative phosphorylation inhibitor IACS-010759 induces AMPK-dependent apoptosis of AML cells. Blood, 2017. e-Pub 2017.
204. Nii T, Ishizawa J, Prabhu V, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Kojima K, Garnett MJ, McDermott U, Benes CH, l Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Andreeff M. The novel imipridone ONC212 induces pronounced anti-leukemia effects in vitro and in vivo and is highly synergistic with the BCL-2 inhibitor ABT-199. Blood 130, Suppl 1, 2017. e-Pub 2017.
205. Muftuoglu M, Li L, Mak DH, Burks JK, Xi Y, Hu B, Shaim H, Imahashi N, Bdaiwi MH, Jimenez JE, Banerjee PP, FLLW I, Kerbauy LN, Kaplan M, DePombo AM, Mendt MC, Basar R, Daher M, Marin D, Andreeff M, Wang J, Wierda WG, Thompson PA, Jain N, Keating MJ, Armstrong-James D, Champlin RE, Shpall EJ, Rezvani K. Evaluation of T cell Compartment by Mass Cytometry Reveals Distinct Patterns of Expression of Exhaustion Markers in Chronic Lymphocytic Leukemia. Blood 130, Suppl 1, 2017. e-Pub 2017.
206. Mu H, MD, PhD, Konopleva M, MD, PhD, Jacamo R, PhD, Carter BZ, PhD, McQueen T, MS, Andreeff M, MD, PhD. Comparison of Induction Chemotherapy in NSG and NOD-Rag1nullIL2rgnull Mouse Models of FLT3 Mutant AML. Blood 130, Suppl 1, 2017. e-Pub 2017.
207. Maiti A, Kantarjian HM, Popat V, Garcia-Manero G, Konopleva, M, Verstovsek S, Andreeff M, Borthakur G, Kadia T, Daver N, Pemmaraju N, DiNardo C, Pierce S, Wierda W, Kornblau S, Ravandi F, Cortes JE. The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right?. Blood 130, Suppl 1, 2017. e-Pub 2017.
208. Ly C, Zhang W, Yu G, Mu H, Zhang H, Rice WG, and Andreeff M. The Pan-FLT3/BTK Multi-kinase Inhibitor CG’806 Induces AML Killing in FLT-mutant and Wild Type Cells, and Exerts Synergistic Pro-apoptotic Effects with Concomitant Targeting of Anti-apoptotic Bcl-2 and/or Mcl-1. Blood 130, Suppl 1, 2017. e-Pub 2017.
209. Li L, Muftuoglu M, Liu E, Ang S, Lv J, Wan X, Cai R, Chen H, Hu B, Jimenez J, Mak D, Burks J, Bdaiwi M, Banerjee P, Imahashi N, Kerbauy LN, Lu J, FLLW I, Mendt MC, l DePombo A, Daher M, Basar R, Neelapu S, Orlowski R, Andreeff M, Marin D, Champlin R, Shpall E, Rezvani K. CS1-specific chimeric antigen receptor drives cord blood NK cell maturation and expansion in vivo. Blood 130, Suppl 1, 2017. e-Pub 2017.
210. Kerbauy LN, MD, Ang S, PhD, Liu E, MD, Banerjee P, PhD, Wu Y, MS, Shaim H, MD, Inng Lim FW, MD, Basar R, MD, Li L, MD, Muftuoglu M, MD, Daher M, MD, Imahashi N, MD, PhD, Mendt MC, PhD, Kaplan M, MS, Mukherjee M, PhD, Lee J, Jordan Orange MD, PhD, Konopleva MY, MD, PhD, Andreeff M, MD, PhD, Champlin R, MD, Shpall EJ, MD, Rezvani K, MD, PhD. Cord blood NK cells engineered to express a humanized CD123-targeted chimeric antigen receptor (CAR) and IL-15 as off-the-shelf therapy for acute myeloid leukemia. Blood 130, Suppl 1, 2017. e-Pub 2017.
211. Jacamo R, Hoang NM, Al Rawi A, Ly C, Parihar R, McQueen T, Ruvolo P, Williams P, Al-Atrash G, Konopleva M, and Andreeff M. Up-regulation of iNOS in AML Blasts Creates an Immunosuppressive Microenvironment, Inhibits T-cell Proliferation and Transforms T-cells Towards a Tumor-tolerating Phenotype. Blood 130, Suppl 1, 2017. e-Pub 2017.
212. Ishizawa J, Zhao R, Heese L, Jaeger A, Nishida Y, Jacamo RO, Kojima K, John Ma MC, Ruvolo V, Chachad D, Devine W, Lindquist S, Davis R, Porco JA, Jr, Whitesell L, Andreeff AM. Inhibition of Translation Initiation and Heat Shock Factor 1 (HSF1): a novel strategy targeting FLT3 double mutant and non-FLT3 mutant AML progenitor/stem cells. Blood 130, Suppl 1, 2017. e-Pub 2017.
213. Herbrich S, Ruvolo P, Ruvolo V, Baggerly K, Al-Atrash G, Andreeff M, Konopleva M. Robust Bioinformatics Approach for Identifying Novel AML LSC Targets: putative role of Galectin-1 in the Immune-Microenvironment. Blood 130, Suppl 1, 2017. e-Pub 2017.
214. Daver N, Garcia-Manero G, Basu S, Cortes J, Ravandi F, Jabbour E, Assi R, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia T, Flores W, Matthews J, Dinardo C, Konopleva M, Allison J, Sharma P, Kantarjian H. Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) and Frontline Elderly AML. Blood 130, Suppl 1, 2017. e-Pub 2017.
215. Daver N, Assi R, Garcia-Manero G, Ravandi, Borthakur G, Jabbour E, DiNardo CD, Kadia TM, Ning J, Nogueras-Gonzalez G, Pierce S, Kelly M, Zhang W, Gombos DS, Kornblau S, Konopleva M, Cortes J, Kantarjian H, Andreeff M. A Phase I/II study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 mutated Acute Myeloid Leukemia (AML). Blood 130, Suppl 1, 2017. e-Pub 2017.
216. Carter BZ, Mak PY, Wang X, Mu H, Tao W, Ruvolo V, Andreeff M. Novel ARC/IL1/PGE2/-catenin/ARC Circuit Regulates Leukemia and Leukemia Microenvironment and Drug Resistance in AML. Blood 130, Suppl 1, 2017. e-Pub 2017.
217. Carter BZ, Mak PY, Mu H, Mak DH, Dettman EJ, Cardone M, Wang X, Schober W, Tao W, Seki T, Andreeff M. Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML. Blood 130, Suppl 1, 2017. e-Pub 2017.
218. Boddu P, Swaminathan M, Ravandi F, Garcia-Manero G, Borthakur G, Jabbour E, DiNardo C, Daver N, Jain N, Pemmaraju N, Jorgensen J, Wang S, Andreeff M, Cortes JE, Kantarjian H, Kadia T. Prognostic implications of minimal residual disease detection in acute myeloid leukemia (AML) with cytarabine based therapy of differing dose intensities. Blood 130, Suppl 1, 2017. e-Pub 2017.
219. Short NJ, Garcia-Manero G, Naqvi K, Kornblau S, Takahashi K, Montalban-Bravo G, Khouri R, Andreeff M, Konopleva M, DiNardo CD, Alvarado Y, Ghosn M, Estrov Z, Bose P, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial. Blood 130, Suppl 1, 2017. e-Pub 2017.
220. Morita K, Wang F, Patel K, Bueso-Ramos C, IssaGC, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Ravandi F, Kadia T, Daver N, Konopleva M, Andreeff M, Cortes JE, Garcia-Manero G, Jabbour EJ, Futreal A, Kantarjian HM, Takahashi. Persistent Somatic Mutation at Remission Is Associated with Poor Survival and Higher Risk of Relapse in Patients with Acute Myeloid Leukemia. Blood 130, Suppl 1, 2017. e-Pub 2017.
221. Assi, R, Benton CB, Al Rawi A, Chamoun K, Wang F, Pierce S, Patel KP, Hamilton BK, DiNardo CD, Garcia-Manero G, Kantarjian HM, Kadia T. JAK3 Variants in Adults with Myeloid Malignancies and Potential for Response to JAK3 Inhibition. Blood 130, Suppl 1, 2017. e-Pub 2017.
222. Khoury JD, Xagoraris I, Tsesmetzis N, Myrberg IH, Olsen TK, Ng BS, Chng WJ, Yan B, Ng CH, Andreeff M, Medeiros LJ, Kantarjian HM, Nikloas H, Grander D, Rassidakis G. MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia 130, Suppl 1, 2017. e-Pub 2017.
223. Bhattacharya S, PhD, Piya S, PhD, McQueen T, MS, Konopleva M, MD, PhD, Andreeff M, MD, PhD, Borthakur G, MD. Inhibition of Unc51 like Autophagy Activating Kinase 1 (ULK1) Is Highly Synergistic with Chemotherapy and Bcl2 Inhibition in Acute Myeloid Leukemia (AML). Blood 130, Suppl 1, 2017. e-Pub 2017.
224. Takahashi K, Wang F, Morita K, Yan Y, Patel K, Bueso-Ramos CE, Gumbs C, Zhang J, Kornblau S, DiNardo CD, Ravandi F, Garcia-Manero G, Jabbour EJ, Andreeff M, Kantarjian HM, Konopleva M, Futreal A. Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia (MPAL). Blood 130, Suppl 1, 2017. e-Pub 2017.
225. Cavazos A, Ma H, Han L, Cai T, Zhang Q, Harutyunyan K, Baran N, Zhang W, Daver N, Andreeff M, Ashoorzadeth A, Anderson R, Patterson A, Smaill JB, Konopleva. Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML. Blood 130, Suppl 1, 2017. e-Pub 2017.
226. Han L, Cavazos A, Baran N, Zhang Q, Kuruvilla VM, Gay JP, Feng N, Battula VL, Andreeff M, Kantarjian HM, Daver N, Marzalek JR, Konopleva M. Targeting Residual Chemotherapy-Resistant Acute Myeloid Leukemia Cells By a Novel Oxphos Inhibitor IACS010759. Blood 130, Suppl 1, 2017. e-Pub 2017.
227. Andreeff M, Jacamo R, Hoang NM, Zeng Z, Piya S, Burks J, Al-Rawi A, Borthakur G, Battula L, Zhang W, Han L, Mak PY, Mu H, Nguyen K, Ruvolo V, Wang X, Baran N, Mak D, Ruvolo P, Bueso-Ramos C, Benton CB, Konoplev S, Kornblau S, Carter B, Zal T, Konopleva M. BRD4, ARC and CXCR4 as Targets in the AML Microenvironment. ESH 2nd Scientific Workshop on Tumour Environment in Haematological Malignancies, 2017. e-Pub 2017.
228. Zhou X, Yuan B, Yan Y, Nguyen K, Ruvolo V, Mu H, Mc Queen T, Shpall EJ, Do KA, Konopleva M, Andreeff M, Battula VL. Bone marrow stromal cells induce ALDH+ stem cell phenotype and chemotherapy resistance in AML cells through TGF-β1 mediated signaling: reversal by TGFβ inhibitor Galunisertib. Blood 130, Suppl 1, 2017. e-Pub 2017.
229. Zhang Q, Han L, Cai T, Kuruvilla VM, Cavazos A, Ma H, Battula V, Baran N, Harutyunyan K, Andreeff M, Tabe Y, Marszalek and JR, Konopleva M. BCL-2 antagonist ABT-199 combined with complex I inhibitor IACS-010759 blocks mitochondrial respiration and facilitates anti-leukemia effect in pre-clinical AML models. Blood 130, Suppl 1, 2017. e-Pub 2017.
230. Zeng Z, Lu H, Wang RY, Liu W, Chen J, Benton CB, Baggerly KA, Shpall E, Champlin R, Konopleva M, Andreeff M. Proteomic profiling identifies c-KIT and 53BP1 as resistance factors of AML relapse post allgeneic stem cell transplantation with G-CSF/Plerixafor/Busulfan-Fludarabine conditioning. Blood, 2017. e-Pub 2017.
231. Montalban-Bravo G, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau SM, Ohanian M, Pierola AA, Huang X, Nogueras-Gonzalez GM, Bodden K, Littles K, Pierce S, Bueso-Ramos CE, Kantarjian H, Garcia-Manero G. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 128(22), 2016. e-Pub 2016.
232. Pemmaraju N, Carter BZ, Kantarjian H, Bose P, Kadia T, Jabbour E, DiNardo C, Daver N, Estrov Z, Cortes J, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle C, Piere S, Popat U, Verstovsek S. Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood 128:3105, 2016. e-Pub 2016.
233. Wang X, Mak PY, Mu H, Jiang X, Mak D, Pachter JA, Weaver DT, Xu B, Andreeff M, Carter BZ. Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML. Blood 128:1574, 2016. e-Pub 2016.
234. Zeng Z, Ly C, Mak D, Shah NP, Konopleva M, Andreeff M. AMG925, a Dual FLT3-CDK4/6 Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML Progenitor/Stem Cells. Blood 128(22), 2016. e-Pub 2016.
235. DiNardo CD, Rosenthal J, Andreeff M, Zernovak O, Kumar P, Gajee R, Chen S, Rosen M, Song S, Kochan J, Limsakun T, Olin R. Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies – Preliminary Results. Blood 128(22), 2016. e-Pub 2016.
236. Ruvolo P, Ma H, Ruvolo V, Mu H, Shober W, Yasuhiro T, Yoshizawa T, Gallardo M, Zhang X, Khoury JD, Cortex JE, Andreeff M, Post SM. AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells. Blood 128(22), 2016. e-Pub 2016.
237. Jiang X, Mak PY, Mu H, Mak D, Zhang Q, Konopleva M, Andreeff M, Carter BZ. Disruption of Wnt/β-Catenin Signaling Exerts Antileukemia Activity and Sensitizes with Tyrosine Kinase Inhibitors in FLT3 Mutated AML In Vivo. Blood 128:2828, 2016. e-Pub 2016.
238. Gleixner KV, Schneeweiss M, Herrmann H, Blatt K, Berger D, Eisenwort G, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl, R, Deininger M, Lion T, Andreeff M, Valent P. Simultaneous inhibition of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Ludwig Boltzmann Healthy Science Meeting, Vienna, 2016. e-Pub 2016.
239. Lee HJ, Andreeff M, Benes C, Allen JE, Schalop L, Oster W, Wang M. First-in-class Small Molecules ONC201 in B-cell Malignancies. ASCO Abstract 2016. e-Pub 2016.
240. Collins R, Kantarjian HM, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Daver NG, Pemmaraju N, Jabbour E, Estrov Z, Ramachandran A, Paradela J, Pond B, Ravandi F, Vusirikala M, Patel PA, Levis MJ, Perl AE, Andreeff M, Cortes JE. Crenolanib besylate, a type I pan-FLT3 inhibitor, demonstrates clinical activity in multiply relapsed FLT3-ITD and D835 AML. ASCO Abstract 2016. e-Pub 2016.
241. Ohanian M, Rozovski U, Kantarjian HM, Loghavi S, Zuang Z, Abruzzo L, Huh YO, Garcia-Manero G, Ravandi F, Andreeff M, Kornblau S, Borthakur G, Nguyen M, Hu P, Medeiros J, Nogueras-Gonzalez GM, Huang X, Estrov Z, Bueso-Ramos CE, Cortes JE. MYC Protein Expression is Prognostic in Acute Myeloid Leukemia. ASCO Abstract 2016. e-Pub 2016.
242. Dettman EJ, Doykan C, Cardone MH, Hills R, White P, Burnett AK, Andreeff M. Mitochondrial Profiling as a Predictive BIomarker for Response to Cytarabine-based Treatment of Acute Myelogenous Leukemia. ASCO Abstract 2016. e-Pub 2016.
243. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Pierce S, Vaughan K, Ning J, Gonzalez G, Pemmarjau N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes JE, Craig A, Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (PTS) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). EHA Abstract 2016. e-Pub 2016.
244. Borthakur G, Tallman MS, Ofran Y, Foran J, Uy GL, DiPersion JF, Nagler A, Rowe JM, Showel MM, Altman JK, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, Aharon A, Bueso-Ramos C, Cortes JC, Andreeff M. Clinical Response in Relapsed/Refractory AML Patients Correlates with Leukemic Blast Mobilization and Differentiation Induced by BL-8040, A Potent CXCR4 Antagonist; Results of a Phase IIA Study. EHA 2016. e-Pub 2016.
245. Zhang W, Mu H, Zhang Q, Patel NB, Fogler WE, Magnani JL, Andreeff M. The E-selectin/CXCR4 Inhibitor GMI-1359 Effrectively Mobilizes Bone Marrow Leukemia Cells and Enhances FLT3 Inhibitor Efficacy in a Murine AML Model. AACR Abstract 2016. e-Pub 2016.
246. Borthakur G, Tallman MS, Ofran Y, Foran J, Uy GL, DiPersio JF, Nagler A, Rowe JM, Showel MM, Altman JK, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, Lustig T, Aharon A, Bueso-Ramos C, Cortes JE, Andreeff M. Final Phase IIa study results evaluating the CXCR4 antagonist BL-8040 in combination with cytarabine (Ara-C) for the treatment of relapsed/refractory AML patients. SOHO Abstract 2016. e-Pub 2016.
247. Daver N, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Jabbour EJ, Pierce S, Ning J, Konopleva M, Andreeff, M, Kornblau SM, Borthakur G, Pemmaraju N, Bueso-Ramos CE, Lopez JE, Blando J, Allison J, Kantarjian HM, Padmanee S. Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood 128(22), 2016. e-Pub 2016.
248. Jabbour EJ, O'Brien SM, Thomas DA, Ravandi F, Garcia-Manero G, Cortes JE, Short NJ, Verstovsek S, Yilmaz M, Wierda WG, Borthakur G, Kadia TM, Konopleva M, Khouri MR, Ferrajoli A, Daver NG, Pemmaraju N, DiNardo CD, Jain N, Benton CB, Takahashi K, Naqvi K, Bose P, Kornblau SM, Andreeff M, Keathing MJ, Freireich EJ, Kantarjian H. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood 128(22), 2016. e-Pub 2016.
249. Benton CB, Takahashi K, Bose P, Wang F, H-C C, Zheng X, Zhang J, Wang X, Su X, Montalban-Bravo G, Issa GC, Daver N, Jabbour EJ, DiNardo CD, Bueso-Ramos CE, Patel K, Kornblau SM, Konopleva M, Borthakur G, Kadia TM, Cortes JE, Ravandi F, Andreeff M, Garcia-Manero G, Futreal A, Kantarjian H. Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. Blood 128(22), 2016. e-Pub 2016.
250. Borthakur G, Tallman MS, Ofran Y, Foran JM, Uy GL, DiPersio JF, Nagler A, Rowe JM, Showel MM, Altman JK, Al-Rawi A, Wang RY, Peled A, Abraham M, Pereg Y, Vainstein A, Oberkovitz G, Lustig T, Aharon A, Bueso-Ramos CE, Cortes JE, Andreeff M. The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia. Blood 128(22), 2016. e-Pub 2016.
251. Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour EJ, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Kornblau SM, Pemmaraju N, Bueso-Ramos CE, Blando J, Lopez JE, Allison J, Kantarjian HM, Sharma P. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood 128(22), 2016. e-Pub 2016.
252. Gleixner KV, Schneeweiss MA, Herrmann H, Blatt K, Berger D, Eisenwort G, Geriner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Gunning PT, Maeda H, Moriggl R, Deininger MW, Lion T, Andreeff M, Valent P. Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml. Blood 128(22), 2016. e-Pub 2016.
253. Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia TM, Cortes JE, Daver N, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Konopleva M, Pierce S, Patel KP, Kornblau SM, Kantarjian HM, Young KH, Garcia-Manero G, Andreeff M. Pure Erythroid Leukemia Is Characterized By TP53 mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. Blood 128(22), 2016. e-Pub 2016.
254. Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, Xiao L, Lopez J, Kornblau SM, Konopleva M, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, Allison J, Kantarjian HM, Sharma P. Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). Blood 128(22), 2016. e-Pub 2016.
255. Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, DiNardo CD, Pierce S, patel KP, Tse A, Davis RE, Rao A, Andreeff M. Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b. Blood 2016 128(22), 2016. e-Pub 2016.
256. Short NJ, Garcia-Manero G, Naqvi K, Kornblau SM, Abhishek M, Konopleva M, DiNardo CD, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islan R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood 128(22), 2016. e-Pub 2016.
257. Han L, Zhang Q, Shi C, Cavazos A, Ruvolo V, Leverson J, Dail M, Phillips CD, Chen J, Jin SS, Jacamo RO, Daver N, Jabbour EJ, Kantarjian HM, Andreeff M Sampath D, Konopleva M. Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models. Blood 128(22), 2016. e-Pub 2016.
258. Zhang Q, Han L, Shi C, Pan R, John MC, Ryan J, Kurtz SE, Mu H, Ruvolo V, Ma H, Andreeff M, Mi Y, Tyner JW, Leverson J, Letai A, Davis RE, Konopleva M. Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML. Blood 128(22), 2016. e-Pub 2016.
259. Baran N, Molina J, Cavazos A, Harutyunyan K, Feng N, Gay J, Piya S, Velandy SS, Jabbour EJ, Andreeff M, Tiziani S, Ferrando AA, Zweidler-McKay P, DiFrancesco ME, Marzalek JR, Konopleva M. Mitochondrial Complex I Inhibition with Iacs-010759 in T-ALL Preclinical Models. Blood 128(22), 2016. e-Pub 2016.
260. Tabe Y, Sekihara K, Saitoh K, Monma N, Ikeo K, Kaczkowski B, Zhang W, Yamanaka Y, Takashi M, Shah NP, Harada H, Hayashizaki Y, Konopleva M, Andreeff M. Cap Analysis of Gene Expression (CAGE) Sequencing Reveals Alterations of the Transcriptional Signatures of FLT3-ITD with Secondary D835 TKD Mutations in Acute Myeloid Leukemia. Blood 128(22), 2016. e-Pub 2016.
261. Nii T, Ishizawa J, Zhao R, Zeng J, Chachad D, Kojima K, Konopleva M, Davis RE, Allen JE, Stogniew M, Andreeff M. ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies. Blood 128(22), 2016. e-Pub 2016.
262. Borthakur G, Ishizawa J, DiNardo CD, Kadia TM, Weise K, Allen JE, Oster W, Cortes JE, Kantarjian HM, Andreeff M. A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias. Blood 128(22), 2016. e-Pub 2016.
263. Zeng J, Soragni A, Ishizawa J, Ruvolo V, Benton CB, McQueen T, Ruvolo P, Qi Y, Su X, Burks J, Eisenberg DS, Andreeff M. Targeting Aggregation of Wilde-Type p53 and Mutant p53 with ReACp53 As a Novel Therapeutic Concept for AML. Blood 128(22), 2016. e-Pub 2016.
264. Piya S, Bhattacharya S, Mu H, Lorenzi PL, McQueen T, Davis RE, Ruvolog V, Baran N, Qian Y, Crews C, Kantarjian HM, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects. Blood 128(22), 2016. e-Pub 2016.
265. Zhang W, Ly C, Zhang Q, Mu H, Battula VL, Patel N, Schober W, Han X, Fogler WE, Magnani JL, Andreeff M. Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograft Murine Model. Blood 128(22), 2016. e-Pub 2016.
266. Wang X, Mak PY, Mu H, Jian X, Mak D, Pachter JA, Weaver DT, XU B, Andreeff M, Carter BZ. Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML. Blood 128(22), 2016. e-Pub 2016.
267. Tabe Y, Sekihara K, Saitoh K, Ruvolo V, Miida T, Andreeff M, Spagnuolo PA, Konopleva M. Novel Fatty Acid Oxidation Inhibitor Avocatinb Induces AMPK-Dependent Apoptosis of AML Cells Co-Cultured with BM-Adipocytes. Blood 128(22), 2016. e-Pub 2016.
268. Jiang X, Mak PY, Mu H, Mak D, Zhang Q, Konopleva M, Andreeff M, Carter BZ. Disruption of Wnt/β-Catenin Signaling Exerts Antileukemia Activity and Sensitizes with Tyrosine Kinase Inhibitors in FLT3 Mutated AML In Vivo. Blood 128(22), 2016. e-Pub 2016.
269. Chachad D, Ishizawa J, Danter WR, Mills G, Andreeff M, Kojima K. The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism. Blood 128(22), 2016. e-Pub 2016.
270. Ly C, Zhang W, Ruvolo V, Shah NP, Andreeff M. Mechanism-Based Combinatorial Strategy for Overcoming FLT3-Inhibitor Resistance in Dual FLT3 ITD and TKD Point Mutations. Blood 128(22), 2016. e-Pub 2016.
271. Jacamo RO, Zhang Q, McQueen T, Davis RE, Konopleva M, Andreeff M. Silencing TG2 in Acute Myeloid Leukemia. Possible Role of TG2 in Microenvironment-Mediated Chemoresistance. Blood 128(22), 2016. e-Pub 2016.
272. Han L, Zhang Q, Shi C, Leverson JD, Dail M, Phillips DC, Chen J, Jin SS, Jacamo RO, Daver N, Jabbour EJ, Kantarjian HM, Andreeff M, Sampath D, Konopleva M. Concomitantly Targeting BCL2 with Venetoclax (ABT199/GDC0199) and MAPK Signaling with Cobimetinib (GDC0973) in Acute Myeloid Leukemia Models. Blood 126(23), 2015. e-Pub 2015.
273. Ishizawa J, Jacamo RO, Kojima K, Chachad D, Ruvolo V, Ruvolo P, Zhang W, Tabe Y, Konopleva M, Devine W, Lindquist S, Porco, Jr JA, Whitesell L, and Andreeff M. Inactivating Heat Shock Factor 1 (HSF1) in Acute Myeloid Leukemia by Pharmacological Inhibition of eIF4a: A Promising Therapeutic Approach. Blood 126(23), 2015. e-Pub 2015.
274. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski RZ, Sarbassov DD, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ONC201 Induces p53-independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies by Induction of ATF4 Through Integrated Stress Response. Blood 126(23), 2015. e-Pub 2015.
275. Carter BZ, Kornblau S, Mak PY, Yang H, Qiu Y, Jiang X, Coombes K, Zhang N, Garcia-Manero G, and Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. Blood 126(23), 2015. e-Pub 2015.
276. Ravandi F, Cortes JE, Garcia-Manero G, Estey E, Borthakur G, Jabbour EJ, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, Kornblau SM, Kadia T, Daver N, DiNardo C, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, Kantarjian HM. Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. Blood 126(23), 2015. e-Pub 2015.
277. Tabe Y, Konopleva M, Monma K, Mogushi K, Yamanaka Y, Matsushita H, Miida T, Hayashizaki Y, Andreeff M. Cap analysis of gene expression (CAGE) sequencing reveals alterations of the transcript signatures in acute monocytic leukemia cells by fatty acid oxidation inhibition. Blood 126(23), 2015. e-Pub 2015.
278. Tabe Y, Hatanaka Y, Nakashiro M, Sekihara K, Yamamoto S, Matsushita H, Kazuno S, Sasai K, Iwabuchi K, Andreeff M, Konopleva M, Miida T. LDIR modulates expression of GPAM in immortalized EBV infected B cells through miRNA network. Blood 126(23), 2015. e-Pub 2015.
279. Battula VL, Le PM, Sun J, Hu H, Mc Queen T, Shpall EJ, Konopleva M, Bueso-Ramos CE, Harrington M, Palisch CW, Andreeff M. Acute Myeloid Leukemia (AML) Cells Alter the Bone Marrow Microenvironment by Inducing Osteogenic and Suppressing Adipogenic Differentiation of MSCs Through BMP-RUNX2-CTGF Mediated Mechanisms. Blood 126(23), 2015. e-Pub 2015.
280. Ravandi F, Jeffrey JL, Jabbour EJ, Borthakur G, Kadia T, Faderl S, Pierce S, Brandt M, Wang SA, Konoplev S, Daver N, Pemmaraju N, Garcia-Manero G, Andreeff M, Konopleva M, Cortes JE, and Kantarjian HM. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia. Blood 126(23), 2015. e-Pub 2015.
281. Vélez JL, Zacharias N, Rakheja D, Bhagat TD, Lee J, Dutta P, Gonzalez D, Andreeff M, Bhattacharya PK, Verma A, Konopleva M. Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML. Blood 126(23), 2015. e-Pub 2015.
282. Zhang Q, Pan R, Han L, Shi C, Kurtz S, Mu H, Ma H, Andreeff M, Leverson J, Mi Y, Tyner JW, Konopleva M. Mechanisms of acquired resistance to venetoclax in preclinical AML models. Blood 126(23), 2015. e-Pub 2015.
283. Zhang W, Patel NB, Fogler WE, Magnani JL, Andreeff M. The dual E-selectin/CXCR4 inhibitor, GMI-1359, enhances efficacy of anti-leukemia chemotherapy in FLT3-ITD mutated acute myeloid leukemia. Blood 126(23), 2015. e-Pub 2015.
284. Piya S, McQueen T, Mak D, Konopleva M, Zweidler-McKay P, Lu J, Qian Y, Andreeff M, Borthakur G. BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Leukemias and Overcomes Stroma Mediated Resistance by Modulating Surface Expression of CXCR4. Blood 126(23), 2015. e-Pub 2015.
285. Pan R, Ruvolo V, Mu H, Zheng Z, Leverson J, Kojima K, Konopleva M, Nichols G Andreeff M. BCL-2 Inhibition by ABT-199 (Venetoclax/GDC-0199) and p53 Activation by RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms. Blood 126(23), 2015. e-Pub 2015.
286. Ohanian M, Kantarjian HM, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Lim M, Pierce S, O'Brien S, Quintas-Cardama A, Somer BG, Tari A, Verstovsek S, Wierda WG, and Cortes JE. Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood 126(23), 2015. e-Pub 2015.
287. Kornblau SM, Ruvolo P, Wang RY, Ruvolo V, Qui YH, Battula VL, Zeng Z, McQueen T, Yoo SY, Konopleva M, and Andreeff M. Acute Myelogenous Leukemia (AML) Mesenchymal Stromal Cell (MSC) Have Distinct Protein Expression Patterns Compared to Normal MSC. Blood 126(23), 2015. e-Pub 2015.
288. Jiang X, Mak PY, Mu H, Zhang W, Mak DH, Ruvolo P, McQueen T, Zhou H, Cortes JE, Andreeff M, and Carter BZ. Concurrent Inhibition of β-catenin/CBP and FLT3 Strongly Suppresses c-Myc and Synergistically Induces Apoptosis in FLT3 Mutant AML Cells. Blood 126(23), 2015. e-Pub 2015.
289. Jacamo RO, Mu H, Zhang Q, Chachad D, Wang Z, Ma W, Zhang M, Mak PY, Mak D, Ruvolo P, McQueen T, Lowe S, Zuber J, Eulberg D, Kruschinski A, Konopleva M, Davis RE, Andreeff M. Effects of CCL2/CCR2 Blockade In Acute Myeloid Leukemia. Blood 126(23), 2015. e-Pub 2015.
290. Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Amdreeff M, Carter BZ. Synergistic Effects of Combined Targeting of β-catenin/CBP and Bcr-Abl in CML Blast Crisis Stem/Progenitor Cells In Vitro and In Vivo as Analyzed by Single Cell Mass Cytometry (CyTOF). Blood 126(23), 2015. e-Pub 2015.
291. Kadia T, Cortes JE, Ravandi F, Garcia-Manero G, Andreeff M, Takahashi K, Borthakur G, Jabbour E, Bhalla K, Konopleva M, Daver N, Dinardo C, Bose P, Pierce S, Kantarjian H. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood 126(23), 2015. e-Pub 2015.
292. Birendra KC, Kantarjian H, Borthakur G, Garcia-Manero G, Daver N, Konopleva M, Andreeff M, Chihara D, Kadia T, Bose P, Estrov Z, Pemmaraju N, Ravandi F, Cortes J. Prognostic significance of somatic mutations in treatment of AML in salvage setting: a retrospective analysis. Blood 126(23), 2015. e-Pub 2015.
293. Borthakur G, Ofran Y, Nagler A, Rowe J, Foran J, Uy GL, DiPersio JF, Altman JK, Frankfurt O, Tallman MS, Peled A, Pereg Y, Vainstein A, Aharon A, AlRawi A, McQueen T, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors by Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia. Blood 126(23), 2015. e-Pub 2015.
294. Zhang W, Ishizawa J, Mu H, Daver N, Ruvolo V, and Andreeff M. Combinatorial Targeting of XPO1 and FLT3-ITD Exerts Synergistic Anti-Tumor Effects in FLT3-Mutated Acute Myeloid Leukemias. Blood 126(23), 2015. e-Pub 2015.
295. Ruvolo P, Qiu Y, Ruvolo V, Wang RY, Zeng Z, Burks J, Pan R, Hail Jr N, McQueen T, Yoo SY, Kornblau SM, and Andreeff M. Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment. Blood 126(23), 2015. e-Pub 2015.
296. Borthakur G, Foran J, Wang E, Rakkar A, Minderman H, Burns J, Andreeff M, Tibes R. A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome who are Naïve, Refractory or Have Relapsed to 5-Azacitadine. Blood 126(23), 2015. e-Pub 2015.
297. Zeng Z, Liu W, Tsao T, Qiu Y, Samudio I, Baggerly K, Kornblau SM, Kantarjian HM, Andreeff M, Konopleva A, M. Mapping Microenvironment-Mediated Signaling Dependency of Targeted Inhibitors: A Mechanism-Based Approach of Selecting Effective Therapy Targeting Drug Resistant AML. Blood 126(23), 2015. e-Pub 2015.
298. Mu H, Konopleva M, Shi C, Battula V, Carter BZ, Sweidler-McKay P, Andreeff M. NSG-S Mouse is Superior to NSG Mouse in Acute Leukemia Patient-derived Xenograft Murine Models. Regenerative Medicine at TMC 2015, 2015. e-Pub 2015.
299. Ruvolo P, Wang RY, Ruvolo V, Zeng Z, Qui YH, Pierce SA, McQueen T, Kornblau SM, Andreeff M. Proteomic Profiling Identifies Distinct Bone Marrow Niche Mesenchymal Stem Cell Populations In AML Patients. SOHO 2015, 2015. e-Pub 2015.
300. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Wencai M, Lee HC, Orlowski R, Sarbassov DD, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis, RE, Andreeff M. First-in-class anti-tumor agent ONC201 induces apoptosis in hematological malignancies with wild type and mutant p53. SOHO 2015, 2015. e-Pub 2015.
301. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined Targeting of Bcl-2 and Bcr-Abl Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem/Progenitor Cells. SOHO 2015, 2015. e-Pub 2015.
302. Battula VL, Le PM, Sun J, Mu H, Mc Queen T, Shpall EJ, Konopleva M, Harrington M, Palisch CW, Bueso-Ramos CE, Andreeff M. Acute Myeloid Leukemia (AML) Cells Functionally Alter Bone Marrow Microenvironment (BME) to Gain Growth Advantage. SOHO 2015, 2015. e-Pub 2015.
303. Zhang W, Ishizawa J, Mu H, Daver N, Ruvolo V, Andreeff M. Targeting CRM1 and FLT3 is an effective combinatorial strategy for overcoming FLT3 inhibitor resistance in acute myeloid leukemias. SOHO 2015, 2015. e-Pub 2015.
304. Abraham M, Al-Rawi A, Pereg Y, Klein S, Wald H, Eizenberg O, Bulvik B, Russovsky L, Vainstein A, Aharon A, McQueen T, Pemmaraju N, Cortes J, Peled A, Borthakur G, Andreeff M. BL-8040, A novel CXCR4 inhibitor, affects AML blasts survival and induces their terminal differentiation. SOHO 2015, 2015. e-Pub 2015.
305. Ruvolo P, Ruvolo V, Hail N, Schober W, Andreeff M. Targeting Galectin As A Strategy To Improve BH3 Mimetic Efficacy For The Therapy Of Acute Myeloid Leukemia. SOHO 2015, 2015. e-Pub 2015.
306. Batula VL, Sun J, Nguyen K, Hortobagyi GN, Andreeff. GD2+ Breast Cancer Stem Cell Growth is Dependent on NFkB Signaling and Suppressed by the IKK Inhibitor BMS345541 in Vitro and in Vivo. AACR Annual Meeting 2015, 2015. e-Pub 2015.
307. Sun J, Hortobagyi GN, Andreeff M, Battula VL. The Spontaneous Generation of GD2+ Breast Cancer Stem-like Cells is Directly Proportional to Tumor Progression and Mediated by Epithelial to Mesenchymal Transition and NFkB Activation. AACR Annual Meeting 2015, 2015. e-Pub 2015.
308. Tabe Y, Mogushi K, Kazuno S, Fujimura T, Miida T, Samudio I, Konopleva M, Hayashizaki Y, Andreeff M. Bone Marrow Adipocyte-Derived Free Fatty Acids Induce Gene Signatures Linking Transcription with Metabolic Changes that Contribute to Survival of Acute Monocytic Leuekmia Cells. GAP, MDACC, 2015. e-Pub 2015.
309. Battula VL, Le P, Sun J, Benton C, McQueen T, Shpall E, Bueso-Ramos C, Konopleva M, Andreeff M. Acute Myeloid Leukemia Cells Induce Osteogenic Differentiation in Mesenchymal Stem Cells Through Bone Morphogenetic Protein- and RUNX-2- mediated Signaling. AACR Annual Meeting 2015, 2015. e-Pub 2015.
310. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Matre PR, Allen JE, Sarbassov DD, Neelapu SS, McDonnellT, Miranda R, Wang M, Kwak LW, Kantarjian H, Konopleva M, Davis RE, Andreeff M. A Novel ER Stress Inducer ONC201 Exerts p53-independent Apoptosis in Hematological Malignancies and Leukemic Stem/Progenitor Cells by Targeting ER Stress Response, mTOR and MCL1. GAP, MDACC, 2015. e-Pub 2015.
311. Sekihara K, Yamamoto S, Kikkawa M, Taka H, Kaga N, Matsushita H, Hayashi H, Tanaka M, Miida T, Andreeff M, Konopleva M, Tabe Y. The mTOR kinase inhibitor AZD-2014 enhances the antitumor effects of XPO1 antagonist KPT-185 in mantle cell lymphoma. ESMO, Asia 2015. e-Pub 2015.
312. Chen C, Garzon R, Gutierrez M, Jacoby M, Brown P, Flinn I, Stone R, Savoie L, Baz R, Gabrail N, Wang M, Martin P, Seigel D, Mau-Sorensen M, Andreeff M, Marshall T, Saint-Martin JR, Carlson R, Shacham S, Kauffman M, Kuruvilla J. Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330). Blood 126(23), 2015. e-Pub 2015.
313. Zhou H, Mak, PY, Mu H, Mak DH, Kouji H, Cortes J, Konopleva M, Andreeff M, Carter BZ. Combination of Tyrosine Kinase Inhibitor with β-catenin/CBP modulator C-82 Reverses TKI Resistance, Eradicates Quiescent CML Stem/Progenitors Cells, and Overcomes MSC-associated Microenvironmental Protection. Blood, 2014. e-Pub 2014.
314. Thomas DA, OBrien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, Estrov Z, Garcia-Manero G, Burger JA, Wierda W, Konopleva M, Andreeff M, Kornblau SM, Verstovsek S, Borthakur G, Kadia T, Garris R, Pemmaraju N, Daver N, Jain N, Cortes J, Kantarjian HM. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood, 2014. e-Pub 2014.
315. Zeng Z, R-Y W, Shi Y, Qiu YH, Mak DH, Coombes K, Yoo SY, Jessen K, Liu Y, Rommel C, Kantarjian HM, Kornblau SM, Fruman D, Andreeff M, Konopleva M. MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML. Blood, 2014. e-Pub 2014.
316. Ishizawa J, Kojima K, Chachad D, Ruvolo PP, Ruvolo V, Jacamo RO, Dilip A, Mu H, Zeng Z, Matre PR, Allen JE, Neelapu SS, McDonnell T, Miranda M, Kwak LW, Kantarjian H, Konopleva M, Davis RE, Andreeff M. ONC201 induces p53-independent apoptosis and cell cycle arrest in hematological malignancies and leukemic stem/progenitor cells by inducing ER stress and mTOR inhibition. Blood, 2014. e-Pub 2014.
317. Gallardo M, Lee HJ, Zhang X, Pageon LR, Multani A, Reschke M, Clohessy JG, Quintas-Cardama A, Andreeff M, Kornblau SM, Pandolfi PP, Post SM. hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression. Blood, 2014. e-Pub 2014.
318. Allen JE, Ishizawa J, El-Deiry WS, Andreeff M. ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies. Blood, 2014. e-Pub 2014.
319. Tabe Y, Harada M, Miyamae Y, Matsushita H, Kojima K, Fujimura T, Kazuno S, Ueno T, Miida T, Konopleva M, Andreeff M. The mTOR kinase inhibitior AZD-2014 effectively reverses XPO1/CRM1 antagonist KPT-185–induced glycolysis / gluconeogenesis, enhancing antitumor effects in mantle cell lymphoma. Blood, 2014. e-Pub 2014.
320. Tabe Y, Harada M, Miyamae Y, Kazuno S, Fujimura T, Ueno T, Miida T, Konopleva M, Andreeff M. Selective inhibitor of nuclear export selinexor (KPT-330) and BCL2 inhibitor ABT-199 enhance the anti-lymphoma effect of BTK inhibitor ibrutinib in mantle cell lymphoma. Blood, 2014. e-Pub 2014.
321. Tabe Y, Hatanaka Y, Ruvolo P, Miida T, Kornblau S, Andreeff M, Konopleva M. Pro-survival effects of TGF-β1 are associated with molecular signaling changes of ERK, FLI-1, and CD44 in AML cells. Blood, 2014. e-Pub 2014.
322. Tabe Y, Harada M, Miyamae Y, Fujimura T, Ueno T, Miida T, Andreeff M, Konopleva M. Metabolic re-programming in Notch-activated T-ALL by mTOR inhibitor AZD2014 combined with L-Asparaginase. Blood, 2014. e-Pub 2014.
323. TabeY, Harada M, Miyamae Y, Mogushi K, Kazuno S, Fujimura T, Matsushita H, Ueno T, Yokomizo T, Miida T, Samudio I, Andreeff M, Konopleva M. Bone marrow adipocyte-derived free fatty acids induce gene signature linking transcription with metabolic changes that contribute to survival of acute monocytic leukemia cells. Blood, 2014. e-Pub 2014.
324. Ruvolo PP, Battula VL, Qui YH, Ruvolo V, Jacamo R, Zeng Z, WangR-Y McQueen T, Rao A, YooS-Y, Le PM, Hail, Jr N, Carter B Kornblau SM, Andreeff M. Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling. Blood, 2014. e-Pub 2014.
325. Piya S, Ruvolo V, Ruvolo P, Davis RE, Wang Z, McQueen T, Schober W, Andreeff M, Borthakur G. Ablation of autophagy-related E1 Ligase Atg7 Primes Acute Myelogenous Leukemia Cells to Apoptosis, Sensitizes to Chemotherapy and Overcomes Stroma Mediated Protection. Blood, 2014. e-Pub 2014.
326. Pinnamaneni P, Kantarjian H, Jorgensen JL, Jabbour E, Pierce S, Brandt M, Wang S, Konopleva M, Kornblau S, Kadia T, DiNardo C, Pemmaraju N, Andreeff M, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Persistence of Minimal Residual Disease Assessed by Multi-parameter Flow Cytometry (MFC) at 30 and 90 days After Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. Blood, 2014. e-Pub 2014.
327. Badar T, Kantarjian H, Borthakur G, Garcia-Manero G, Andreeff M, Konopleva M, Kadia T, Daver N, Wierda W, Ravandi F, Cortes J. Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade. Blood, 2014. e-Pub 2014.
328. Battula VL, Le PM, Sun J, McQueen T, Somanchi A, R-Y W, Strunk D, Shpall EJ, Ruvolo PP, Kantarjian HM, Konopleva M, Andreeff M. Acute Myeloid Leukemia Cells Acquire Chemo-Resistance By Inducing Osteoblast Differentiation in Mesenchymal Stem Cells through up-Regulation of RUNX2. Blood, 2014. e-Pub 2014.
329. Borthakur G, Foran J, Wang ES, Rakkar A, Hager S, Frey N, Andreeff M, Garcia-Manero G, Kadia T, Carter BZ, Minderman H, Russell L, Tibes R. A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome who are Naïve to, Refractory to or Have Relapsed on 5-Azacitadine: A Preliminary Analysis. Blood, 2014. e-Pub 2014.
330. Pan R, Kojima K, Zheng Z, Ruvolo V, Nichols G, Leverson J Dangl M, Konopleva M, Andreeff M. Activation of p53 by Novel MDM2 Antagonist RG7388 Overcomes AML Inherent and Acquired Resistance to Bcl-2 Inhibitor ABT-199 (GDC-0199). Blood, 2014. e-Pub 2014.
331. Nishida Y, Kojima K, Maeda A, Chachad D, Kitamura H, Ishizawa J, Andreeff M, Kornblau S, Kimura S. Prognostic impact and targeting of BMI-1 in acute myeloid leukemia. Blood, 2014. e-Pub 2014.
332. Borthakur G, Nagler A, Ofran Y, Rowe J, Altman JK, Frankfurt O, Tallman MS, Avivi I, Peled A, Pereg Y, Foley-Comer A, Russovsky L, Aharon A, McQueen T, Pemmaraju N, Bueso-Ramos C, Cortes J, Andreeff M. BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. Blood, 2014. e-Pub 2014.
333. Han L, Rowinsky E, Brooks C, Zal T, Zal MA, Burks J, Zhou J, Ciurea SO, Alatrash G, Cortes J, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M. Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate in acute myeloid leukemia. Blood, 2014. e-Pub 2014.
334. Borthakur G, Kantarjian H, O’Brien S, Garcia-Manero G, Jabbour E, Daver N, Kadia T, Gborogen R, Konopleva M, Andreeff M, Ravandi F, Cortes J. The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood, 2014. e-Pub 2014.
335. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Konopleva M, Cortes J, Andreeff M. Cooperative targeting of Bcl-2 family proteins by ABT-199 (GDC-0199) and tyrosine kinase inhibitors to eradicate blast crisis CML and CML stem/progenitor cells. Blood, 2014. e-Pub 2014.
336. B-S C, Zeng Z, Mu H, Wang Z, McQueen T, Protopopova M, Cortes J, Marszalek J, S-B P, Davis RE, Thornton DE, Andreeff M, Konopleva M. Pronounced anti-leukemia activity in vivo of the novel peptidic CXCR4 antagonist LY2510924 as a single agent and in combination with chemotherapy. Blood, 2014. e-Pub 2014.
337. Davis RE, Ruvolo V, Z-Q W, Ma W, Schober W, James Rolke J, Tidmarsh G, Andreeff M, Ruvolo PP. GCS-100 Induces Apoptosis of Acute Myeloid Leukemia Cells by Disrupting Galectin-Mediated Survival Signaling. Blood, 2014. e-Pub 2014.
338. Eckstein O, Wang L, Punia J, Kornblau SM, Andreeff M, Wheeler D, Goodell M. Mixed Phenotype Acute Leukemia (MPAL) Has a High Frequency of Mutations in Epigenetic Regulatory Genes: Results from Whole Exome Sequencing. Blood, 2014. e-Pub 2014.
339. Matre P, Protopopova M, Feng N, Gay J, Greer J, Velez J, Mu H, Lodi A, Tadi S Sweeney SR, Andreeff M, Tiziani S, Di Francesco ME, Marszalek JR, Konopleva M. Novel nanomolar potency mitochondrial complex I inhibitor IACS-1131 selectively kills OXPHOS-dependent AML cells. Blood, 2014. e-Pub 2014.
340. Matre P, Shariati M, Velez J, Qi Y, Konoplev S, Su X, DiNardo C, Daver N, Majeti R Andreeff M, Chan S Konopleva M. Efficacy of novel glutaminase inhibitor CB-839 in acute myeloid leukemia. Blood, 2014. e-Pub 2014.
341. Mak PY, Kornblau SM, Qiu Y, Wei W, Kouji H, Coombes K, Cortes J, Andreeff M, Carter BZ. Disrupting Wnt/-catenin signaling by a -catenin/CBP modulator C-82 suppresses cell growth and induces apoptosis in AML blasts and CD34+38- AML progenitor cells. Blood, 2014. e-Pub 2014.
342. Jacamo R, Ling X, WangX, Ma W, Zhang M, Ruvolo P, Ruvolo V, Lowe S, Zuber J, Konopleva M, Davis RE, Andreeff M. AML Genotype-specific and Non-specific Regulation of Mesenchymal Stem Cell Transcriptome in the Bone Marrow Microenvironment. Blood, 2014. e-Pub 2014.
343. Ok CY, Salim AA, Loghavi S, Rajyalakshmi L, Routbort MJ, Singh RR, Zuo Z, Pierce S, Garcia-Manero G, Kantarjian HM, Cortes JE, Ravandi F, Andreeff M, Medeiros LJ, Patel KP. DNMT3A Mutation as a Molecular Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia. USCAP, 2014. e-Pub 2014.
344. Battula VL, Le PM, Sun J, McQueen T, Somanchi, A, Wang RY, Strunk D, Shpall EJ, Ruvolo P, Kantarjian H, Konopleva M, Andreeff M. Mesenchymal Stem Cells Differentiate into Osteoblasts in the Presence of AML Cells through Up-regulation of RUNX2 and Induce Chemo Resistance. SOHO 2014, 2014. e-Pub 2014.
345. Carter BZ, Mak PY, Mak DH, Schober W, McQueen T, Konopleva M, Cortes J, Andreeff M. p53 Activation via MDM2 Blockade with Nutlin3a Sensitizes Primary Blast Crisis Chronic Myeloid Leukemia Cells and Stem/Progenitor Cells to ABT-737- and Nilotinib-induced Apoptosis. 16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2014. e-Pub 2014.
346. Glexiner K, Herrmann H, Blatt K, Berger D, Stefanzl G, Konopleva M, Maeda H, Andreeff M, Valent P. Targeting of STAT3 and STAT5 by a novel drug-combinationemploying Ponatinib and bardoxolone-methyl leads to synergistic effects in BCR/ABL-T315l+ CML cells. 16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2014. e-Pub 2014.
347. Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Zeng Z, Qiu Y, Yoo SY, Pan R, Hail N, Konopleva M, Calin S, Kornblau SM, Andreeff M. Tumor Suppressor Role for B55 alpha PP2A Isoform in AML. SOHO 2014, 2014. e-Pub 2014.
348. Bz C, Mak PY, Mak DH, Kojima K, Dilip A, Ruvolo V, Jacamo R, Andreeff. Tumor Suppressor p53 is Antagonized by ARC (apoptosis repressor with caspase recruitment domain) in AML. 16th International p53 Workshop, 2014. e-Pub 2014.
349. Tabe Y, Kojima K, Jin L, Iwanami H, Matsushita H, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M. Molecular mechanisms of inhibition of ribosomal biogenesis and translational flux by the Selective Inhibitor of Nuclear Export (SINE) XPO1/CRM1 antagonist KPT-185 in mantle cell lymphoma. GAP Conference, 2014. e-Pub 2014.
350. Ciuffreda L, Falcone I, Benfante A, Matteoni S, Eramo A, Sette G, Sacconi A, Malusa F, De Luca T, Cesta Incani U, Del Curatolo A, Konopleva M, Andreeff M, Del Bufalo D, Cognetti F, De Maria R, Todaro M, Stassi G, and Milella M. Synergistic growth inhibitory activity of combined MEK/mTOR pathway blockade in PTEN-null cancers. ESMO 2014 Meeting, 2014. e-Pub 2014.
351. Somanchi A, Andreeff M. Role of MicroRNA 424 in modulating the Activity of Transcription Factors YY1 and CEBPα due to SDF1/CXCR4 Signaling Axis in the Bone Marrow Microenvironment. Experimental Therapeutics Academic Program 4th Annual Retreat 2014, 2014. e-Pub 2014.
352. Ishizawa J, Kojima K, Duvvuri SR, McQueen T, Ruvolo VR, Nogueras-Gonzalez GM, Huang X, Pierceall W, Cordone M, Lena R, Doykan C, Shacham S, Kauffman M, Konopleva M, Andreeff M. Mitochondrial Priming of New Targeted Agents in Acute Myeloid Leukemia. AACR 2014, 2014. e-Pub 2014.
353. Matre P, Samudio I, Jacamo R, Wang Y, Wang J, Davis RE, Su X, s S, Cook F, Newman R, Hu J, Haferlach T, Andreeff M, Flores ER, Gounarides J, Schimmer A, Konopleva M. Bone marrow microenvironment supports glutamine addiction in leukemias. Keystone Conference on Hypoxia, 2014. e-Pub 2014.
354. Yoshimura M, Ishizawa J, Dilip A, Shacham S, Kauffman M, Tabe Y, Kimura S, Andreeff M, Kojima K. Induction of p53 transcription and apoptosis by CRM1 inhibition in mantle cell lymphoma. The Japanese Association for Molecular Target Therapy of Cancer, 2014. e-Pub 2014.
355. Cortes JE, Carter BZ, Quintas-Cardama A, Inada T, Morita K, Fujimori M, Kouji H, Mak PY, Ruvolo V, Borthakur G, Andreeff M, Konopleva M, Ravandi F, Kantarjian H. A Phase I Dose-Escalation Study OF PRI-724, A CBP/B-Catenin Modulator In Patients With Advanced Acute Myeloid Leukemia (AML). EHA Conference, Milano Italy, 2014. e-Pub 2014.
356. Gleixner KV, Herrmann H, Blatt K, Berger D, Stefanzl G, Konopleva M, Maeda H, Andreeff M, Valent P. Targeting of STAT3 and STAT5 by a novel drug- combination employing ponatinib and bardoxolone methyl (CDDO-Me) leads to synergistic effects in BCR/ABL-T315I-mutated cells in Ph+ CML. EHA Conference, Milano Italy, 2014. e-Pub 2014.
357. Daver N, Kantarjian H, DeBose K, Jabbour E, Borthakur G, Pemmaraju N, Garcia-Manero G, Kornlbau S, Wierda W, Burger J, DiNardo C, Ravandi F, Cortes J, Andreeff M, Konopleva M. BKM-120, PI3K Inhibitor, Demonstrates Acceptable Tolerability And Prelimary Activity In A Phase I/II Trial Of Patients With Advanced Leukemia's. EHA Conference, Milano Italy, 2014. e-Pub 2014.
358. Takahashi K, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Konopleva M, Andreeff M, Cortes J. Propensity score matched comparison of intermediate intensity chemotherapy induction versus intensive chemotherapy induction in elderly patients (ages 60 years or older) with AML. EHA Conference, Milano Italy, 2014. e-Pub 2014.
359. Andreeff M, Borthakur G, Zeng Z, Kelly MA, R-Y W, McQueen TJ, Y-H Q, Mak D, Burger JA, Daver NG, Pemmaraju N, Kadia TM, Jabbour E, Pierce S, Ravandi F, Garcia-Manero G, O'Brien SM, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. ASCO, 2014. e-Pub 2014.
360. Takahashi K, Kantarjian HM, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, Dinardo CD, Jabbour E, Konopleva M, Andreeff M, Cortes JE. Propensity score matched comparison of intermediate intensity chemotherapy induction versus intensive chemotherapy induction in elderly patients (age ≥ 60) with acute myeloid leukemia (AML). ASCO, 2014. e-Pub 2014.
361. OConnor K, Russell K, Tucker A, Bunnell B, Andreeff M, Schober W, Lacey M. Differential Expression of Neuron-Glial Antigen 2 (NG2) Selects for Cell Survival during High-Throughput Enrichment of Marrow-Derived Mesenchymal Stem Cells. AIChE, 2013. e-Pub 2013.
362. Konoplev S, Lin P, Yin CC, Lin E, Nogueras Gonzalez GM, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. .CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patients With Acute Myeloid Leukemia. CLML 13(6):686-692, 2013. e-Pub 2013.
363. Mak PY, Mak DH, Kojima K, Dilip A, Ruvolo V, Jacamo R, Andreeff M, Carter BZ. ARC suppresses cell death by antagonizing p53 function and suppressing TRAIL in AML cells. Blood 122, 2013. e-Pub 2013.
364. Quintas-Cardama A, Post SM, Kojima K, Qiu YH, Andreeff M, Bueso-Ramos CE, Kornblau SM. High p53 Protein Expression LEVEL Independent Of Mutational Status Is An Adverse Prognostic Factor For Survival In ACUTE Myeloid Leukemia. Blood 122, 2013. e-Pub 2013.
365. Zhang W, Borthakur G, Gao C, Chen Y, Lan YS, Ruvolo VR, Nomoto K, Zhao N, Konopleva M, Andreeff M. Study Of Activity Of E6201, a Dual FLT3 and MEK Inhibitor, In Acute Myelogenous Leukemia With FLT3 Or RAS Mutation. Blood 122, 2013. e-Pub 2013.
366. Jacamo R, Zeng Z, Chen Y, Shi Y, McQueen T, Kruschinski A, Konopleva M, Ruvolo PP, Andreeff M. SDF-1 Inhibition Using Spiegelmer® Nox-A12 As a Novel Strategy For Targeting AML Cells Within Their BM Microenvironment. Blood 122, 2013. e-Pub 2013.
367. Shah SS, Kantarjian HM, Ravandi F, O'Brien S, Garcia-Manero G, Andreeff M, Konopleva M, Jabbour E, Pierce SR, Borthakur G, Cortes JE. Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy. Blood 122, 2013. e-Pub 2013.
368. Benton CB, Gu L, Kantarjian HM, Qiu P, Ravandi F, MGarcia-Manero G, Pierce S, Brandt M, Konopleva M, Cortes JE, Andreeff M, Quintas-Cardama A. Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status. Blood 122, 2013. e-Pub 2013.
369. Tabe Y, Jin L, Iwanami H, Matsushita H, Kazuno S, Fujimura T, Ueno T, Miida T, Andreeff M, Konopleva M, Kimura S. Metabolic Shift In Hypoxia-Adapted CML Cells and Mechanisms Of Acquired Dasatinib Resistance Uncovered By Proteomic iTRAQ Profiling. Blood 122, 2013. e-Pub 2013.
370. Ohanian M, Kantarjian HM, Ravandi F, Borthakur G, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, O'Brien S, Quintas-Cardama A, Somer BG, Tari A, Verstovsek S, Wierda WG, Cortes JE. Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood 122, 2013. e-Pub 2013.
371. Shetty A, Kantarjian HM, Champlin RE, Borthakur G, Badar T, Garcia-Manero G, Andersson BS, Oran B, Ciurea SO, Konopleva M, Andreeff, M, Kornblau SM, Wierda WG, Pierce S, Ravandi F, Cortes JE. Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood 122, 2013. e-Pub 2013.
372. Nazha A, Kantarjian HM, Ravandi F, Xuelin H, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brand M, Faderl SH. Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 122, 2013. e-Pub 2013.
373. Pan R, Debose L, Benito JM, Golfman LS, Zweidler-McKay PA, Han L, Harutyunyan KG, Mu H, Ruvolo VR, Park E, Muschen M, Leverson J, Borthakur G, Kantarjian HM, Ruvolo PP, Andreeff M, Konopleva M. BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia. Blood 122, 2013. e-Pub 2013.
374. Ruvolo PP, R-Y W, Ruvolo VR, Jacamo R, McQueen T, Borthakur G, Qiu YH, Kevin R Coombes KR, Zhang N, Shpall EJ, Champlin RE, Garzon R, Marcucci G, Croce CM, Konopleva M, Andreeff M, Kornblau SM. Phosphorylation Of GSK3β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. Blood 122, 2013. e-Pub 2013.
375. Ahmed S, Di Stasi A, Shpall EJ, Khouri IF, Alousi AM, Ciurea SO, Bashir Q, Qazilbash M, Jones RB, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing CM, Oran B, Andreeff M, Anderlini P, Andersson BS, Champlin RE, Popat U. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 122, 2013. e-Pub 2013.
376. Konopleva M, Handisides DR, Benito JM, Borthakur G, Jabbour E, Faderl S, Cortes JE, Kroll S, Andreeff M, Kantarjian HM, Thomas DA. A Phase 1 Study of TH-302, a Hypoxia-targeted Drug, in Patients with Advanced Leukemias. Blood 122, 2013. e-Pub 2013.
377. Matre P, Samudio I, Jacamo R, Wang Y, Wang J, Davis RE, Su X, Schindela S, Newman R, Hu J, Haferlach T, Andreeff M, Flores ER, Schimmer A, Konopleva M. Unraveling The Molecular and Metabolic Basis for Glutamine Addiction In Leukemias. Blood 122, 2013. e-Pub 2013.
378. Tabe Y, Jin Y, Kazuno S, Fujimura T, Matsushita H, Ueno T, Miida T, Andreeff M, Konopleva M. Molecular mechanisms of adipocyte-leukemia interactions revealed by the quantitative proteomics technology: pro-survival function of adipocyte-derived free fatty acids on acute monoblastic leukemia mitochondrial biogenesis. Blood 122, 2013. e-Pub 2013.
379. Tabe Y, Kojima K, Jin L, Iwanami H, Matsushita H, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M. Molecular mechanisms of inhibition of ribosomal biogenesis and translational flux by the Selective Inhibitor of Nuclear Export (SINE) XPO1/CRM1 antagonist KPT-185 in mantle cell lymphoma. Blood 122, 2013. e-Pub 2013.
380. Tabe T, Jin L, Hatanaka Y, Matsushita H, Kazuno S, Fujimura T, Ueno T, Sasa K, Iwabuchi K, Andreeff M, Konopleva M, Miida T. Integrative genomic and proteomic analysis of low-dose ionizing irradiation effects on bone marrow stromal microenvironment and on survival of pre-leukemic cells. Blood 122, 2013. e-Pub 2013.
381. Tabe Y, Jin L, Iwanami H, Matsushita H, Kazuno S, Fujimura T, Ueno T, Miida T, Weinstock D, Thomas DA, Andreeff M, Konopleva M. Efficacy and mechanisms of the mTOR inhibitor AZD2014 combined with L-Asparaginase or JAK2 inhibitor TG101348 in ALL. Blood 122, 2013. e-Pub 2013.
382. Konopleva M, Benito JM, Harutyunyan KG, Marzo I, Debose L, Gonzalo O, Zhou P, Jacamo J, Park E, Muschen M, Mulloy JC, Bendall LJ, Zweidler-McKay PA, Coombes KR, Qiu YH, Zhang N, Leverson J, Thomas DA, O'Brien S, Kantarjian HM, Kornblau SM, Andreeff M. Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199. Blood 122, 2013. e-Pub 2013.
383. Yoshimura M, Ishizawa J, Dilip A, Shacham S, Kauffman M, Tabe Y, Kimura S, Andreeff M, Kojima K. Induction of p53 transcription and apoptosis by XPO1 inhibition in mantle cell lymphoma. Blood 122, 2013. e-Pub 2013.
384. Ishizawa J, Kojima K, Dilip A, Ruvolo V, Carter BZ, Allen JE, Neelapu SS, McDonnell T, Talekar M, El-Deiry WS, Kwak LW, Andreeff M. ONC201 exerts p53-independent cytotoxicity through TRAIL and DR5 induction in mantle cell lymphomas. Blood 122, 2013. e-Pub 2013.
385. Ishizawa J, Sugihara E, Hashimoto N, Kuninaka S, Kojima K, Andreeff M, Okamoto S, Saya H. Loss of function of the cell cycle regulator Cdh1 causes cell fragility due to aberrant G2/M checkpoint and develops resistant disease in a B-ALL/LBL mouse model. Blood 122, 2013. e-Pub 2013.
386. Han L, Zeng Z, Qiu P, Jorgensen JL, Mak DH, Burks JK, McQueen TJ, Ravandi F, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-cell mass cytometry reveals phenotypic and functional heterogeneity in acute myeloid leukemia at diagnosis and in remission. Blood 122, 2013. e-Pub 2013.
387. Han L, Jorgensen JL, Wang SA, Huang X, Nogueras González GM, Brooks C, Rowinsky E, Levis M, Zhou J, Ciurea SO, AI-Atrash G, Cortes J, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M. Leukemia stem cell marker CD123 (IL-3R alpha) predicts minimal residual disease and relapse, providing a valid target for SL-101 in acute myeloid leukemia with FLT3-ITD mutations. Blood 122, 2013. e-Pub 2013.
388. Carter BZ, Mak PY, Chen Y, Jacamo R, Ruvolo V, Andreeff M. ARC supports leukemia-stromal interactions by regulating multiple receptor-chemokine axes in AML. Blood 122, 2013. e-Pub 2013.
389. Carter BZ, Mak PY, Mak DH, Konopleva M, Cortes J, Andreeff M. Activation of p53 by MDM2-inhibition sensitizes quiescent blast crisis CML stem/progenitor cells to Bcl-2 inhibitor- and tyrosine kinase inhibitor-induced cell death. Blood 122, 2013. e-Pub 2013.
390. Battula VL, Benito J, Somanchi AG, Duvvuri S, Hodgson L, Chen Y, Ma W, Davis RE, McNiece I, Shpall EJ, Konopleva M, Andreeff M. Bone Marrow Microenvironment Induces Stem Cell-like Phenotype in Acute Myeloid Leukemia. Blood 122, 2013. e-Pub 2013.
391. Andreeff M, R-Y W, Davis E, Jacamo R, Ruvolo P, McQueen T, Huang X, Battula VL, Chen Y, Majumdar S, Benito JM, Zeng Z, Benton C, Carter B, Mu H, Ma W, Ruvolo V, Hodgson L, Konoplev S, Pan R, Somanchi A, Strunck D, Zhang Q, Kornblau SM, Kantarjian H, Marcucci G, Garzon R, Zuber J, Lowe S, Croce C, Konopleva M. Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo. Blood 122, 2013. e-Pub 2013.
392. Weltzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM. Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. CLML 13(4):430-434, 2013. e-Pub 2013.
393. Gorombei P, Omidvar N, Beurlet S, Krief P, Le Pogam C, Guereene L, Patel S, Sarda-mantel L, Leboeuf C, de la Grange P, M-E N, Janin A, Pla M, Konopleva M, Andreeff M West R, Fenaux P, Chomienne C, Padua R A. Abt-737 Prolongs Survival In An Nrasd12/Bcl2-Mediated Mouse Model Of Myelodysplastic Syndrome (Mds) By Targeting Leukemia Initiating Cells (Lic), Primitive Lin-/Sca1+/Kit+ (Lsk) And Progenitors. 18th Congress of the European Hematology Association, 2013. e-Pub 2013.
394. Battula VL, Chen Y, Yang F, Konopleva M, Andreeff M. Bone marrow Microenvironment contributes to Stem Cell Phenotype in Acute Myeloid Leukemia. AACR 2013, 2013. e-Pub 2013.
395. Richard DJ, Carlson N, Pierceall W, Lena R, Bannister T, Hodder P, Spicer T, Andreeff M, Opferman J, Koss B, Kung A, Cardone M. Characterization and development of on-target Mcl-1 inhibitors; BH3 profiling provides a valuable drug discovery tool. AACR 2013, 2013. e-Pub 2013.
396. Fang Z, Pan R, Ruvolo P, Andreeff M. Activity of WP1130, a Deubiquitinase Inhibitor, against Acute Myelogenous Leukemia. CPRIT Fellowship, 2013. e-Pub 2013.
397. Pierceall WE, Carlson N, Richard D, Huang X, Elaschoff M, Konopleva M, Kornblau SM, Cardone M, Andreeff M. BH3 Profiling is a Predictive Biomarker for Response to Cytarabine-based Treatment of Acute Myelogenous Leukemia. ASCO 2013, 2013. e-Pub 2013.
398. Pan R, Ruvolo V, Pellecchia M, Konopleva M, Reed JC, Ruvolo PP, Andreeff M. Broad Spectrum BH3 Mimetic -BI97D6 Effectively Induces Apoptosis of Acute Myeloid Leukemia Cells. Cancer Biology Program Retreat, 2013. e-Pub 2013.
399. Tabe Y, Jin Y, Iwanami H, Matsushita H, Kazuno S, Fujimura T, Ueno T, Miida T, Andreeff M, Konopleva M, Kimura S. Metabolic shift in hypoxia-adapted CML cells and mechanisms of acquired dasatinib resistance uncovered by proteomic iTRAQ profiling. Blood 122, 2012. e-Pub 2012.
400. R-Y W, Qui YH, Yoo SY, McQueen T, Chen Y, Zeng Z, Coombes KR, Schober W, Konopleva M, Kornblau SM, Andreeff M. Proteomic Profiling of AML Bone Marrow-Derived Mesenchymal Stem Cells (MSC) Reveals Marked Differences from Normal MSC. Blood 120(21), 2012. e-Pub 2012.
401. Tabe Y, Jin L, Hatanaka Y, Miida T, Kornblau SM, Andreeff M, Konopleva M. TGF-β1 supports leukemia cell survival via negative regulation of FLI-1 transcription factor, ERK inactivation and MMP-1 secretion. Blood 120(21), 2012. e-Pub 2012.
402. Tabe Y, Jin L, Kazuno S, Fujimura T, Matsushit H, Ueno T, Miida T, Andreeff M, Gutterman JU, Konopleva M. A plant triterpenoid Avicin D stimulates adipocytic differentiation of bone marrow stromal cells and promotes their pro-survival effects on acute monoblastic leukemia cells. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
403. Gao C, Zhang W, Chen Y, Jacamo RO, Ramachandran A, Small JD, Konopleva M, Cortes J, Andreeff M. Combination of Crenolanib with Sorafenib Produces Synergistic Pro-apoptotic Effects in FLT3-ITD-Inhibitor-Resistant Acute Myelogenous Leukemias with FLT3 Mutations. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
404. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce CM, Andreeff M. The Hsa-Let-7a miRNA Enhances Ara-C Induced Apoptosis in Human Acute Myeloid Leukemia Cells. Blood 120(21), 2012. e-Pub 2012.
405. Carter BZ, Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau S, Andreeff M. Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
406. Carter BZ, Mak PY, Chen Y, Jacamo R, Ruvolo V, Mak DH, McQueen T, Konopleva M, Kornblau SM, Andreeff M. Apoptosis Repressor with Caspase Recruitment Domain (ARC) Increases AML Cell Migration and Adhesion in vitro and in vivo by Regulating Leukemia-Stroma Interactions. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
407. Benton C, Qiu P, Ravandi F, Kantarjian H, Garcia-Manero G, Pierce S, Borthakur A, Konopleva M, Cortes J, Andreeff M, Quintas-Cardama A. Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
408. Benton C, Konopleva M, Saliba R, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Zeng Z, Chen J, Rondon G, McMullin B, R-Y W, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Qiao W, Thall P, Andreeff M, Champlin R. Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
409. Benito JM, Volgin A, Chen Y, Lu H, Shi Y, McQueen TJ, Zweidler-McKay P, Handisides D, Hart CP, Andreeff M, Konopleva M. Leukemia microenvironment and pathologic hypoxia: sensitivity to hypoxia-activated cytotoxinTH-302. Blood 120(21), 2012. e-Pub 2012.
410. Benito J, Hongbo L, Wilson WR, Melink TJ, Feliu J, Konoplev S, Estey E, Kantarjian H, Gutheil JC, Andreeff M, Konopleva M. Targeting hypoxia and AKR1C3 with PR-104 in patients with acute leukemia. Blood 120(21), 2012. e-Pub 2012.
411. Andreeff M, Zeng Z, Kelly MA, R-Y W, McQueen T, Duvvuri S, Nowshad G, Borthakur G, Burger J, Kadia T, Jabbour E, Cortes J, Kantarjian H, Konopleva M. Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib : Results from a Phase I Trial in Relapsed/Refractory AML Patients. Blood 120(21), 2012. e-Pub 2012.
412. Tabe Y, Jin L, Iwanami H, Kazuno S, Fujimura T, Matsushita H, Ueno T, Miida T, Andreeff M, Konopleva M, Kimura S. Analysis of Dasatinib-induced molecular mechanisms of apoptosis in hypoxia-adopted CML cells utilizing quantitative iTRAC proteomics technology. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
413. Tabe Y, Kojima K, Jin L, Milda T, Shacham S, Kauffman M, Andreeff M. Molecular mechanisms of antitumor activity of the Selective Inhibitor of Nuclear Export (SINE) CRM1 antagonist KPT-185 in mantle cell lymphoma. Blood 120(21), 2012. e-Pub 2012.
414. Ruvolo PP, Jacamo R, Ruvolo VR, Burks JK, Battula VL, McQueen T, Konopleva M, Kornblau SM, Garzon R, Croce C, Andreeff M. Exosomes mediate communication between the microenvironment and leukemic cells in Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
415. Ruvolo PP, Jacamo R, McQueen T, Pan R, Samudio I, Konopleva M, Kornblau SM, Garzon R, Croce C, Andreeff M. Suppression of miR-93 May Regulate Anti-Oxidant Metabolism in Mesenchymal Stromal Cells Derived from Acute Myeloid Leukemia Patients. Blood 120(21), 2012. e-Pub 2012.
416. Mak PY, Mak DH, Shi Y, Ruvolo V, Jacamo R, Andreeff M, Carter BZ. ARC Is Regulated by MAPK and PI3K and Confers Drug Resistance and Survival Advantage to AML in vitro and in vivo. Blood (ASH Annual Meeting Abstracts) 120(21), 2012. e-Pub 2012.
417. Ling X, Chen Y, Ruvolo P, Ruvolo V, Wang Z, Shi Y, Konopleva M, Davis RE, Andreeff M. Unique Effects of p53-/- Leukemic Cells On Mesenchymal Stromal Cell Gene Expression Profile in Vitro. Blood 120(21), 2012. e-Pub 2012.
418. Kornblau SM, Qutub A, Yao H, York H, Qiu Y, Graber D, Andreeff M, Zhang N, Coombes KR. Protein Expression in Acute Myelogenous Leukemia CD34+CD38- Stem Cells is Markedly Different from CD34+ and Bulk Leukemic Cells. Blood 120(21), 2012. e-Pub 2012.
419. Kojima K, Kornblau SM, Ruvolo V, Duvvuri S, Davis ER, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu Y, Burks JK, Ruvolo P, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 120(21), 2012. e-Pub 2012.
420. Jin L, Konopleva M, Shikami M, Ikegami T, Kojima K, Andreeff M, Miida T, Tabe Y. Molecular mechanisms of pro-survival and differentiating function of bone marrow-derived adipocytes on acute monoblastic leukemia cells. Blood 120(21), 2012. e-Pub 2012.
421. Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Battula V, Schobber WD, Davis RE, Konopleva M, Andreeff M. NF-κB Activation in Mesenchymal Stromal Cells Mediates Leukemia Cell Chemoresistance. Blood 120(21), 2012. e-Pub 2012.
422. Kojima K, Kornblau SM, Ruvolo V, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Ruvolo P, Shacham S, Kauffman M, Andreeff M. Prognostic Impact and Targeting of CRM1 in Acute Myeloid Leukemia. Hematologic Malignancies 2012, 2012. e-Pub 2012.
423. Jam B, Lu H, Shi Y, Jacamo RO, McQueen TJ, Konoplev S, Bueso-Ramos C, Zweidler-McKay P, Handisides D, Hart CP, Andreeff M, Konopleva M. Hypoxia Activated Pro-drug TH-302 Induces Hypoxia-dependent anti-leukemia Activity in vitro and in vivo. Hematologic Malignancies 2012, 2012. e-Pub 2012.
424. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, S-CJ Y. A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia. CLML 122:355-362, 2012. e-Pub 2012.
425. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Kornblau S, McQueen T, Weng D, Burns J, Andreeff M. Antagonizing IAPs by SMAC Mimetic Birinapant Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy in vitro and in vivo. Hematologic Malignancies 2012, 2012. e-Pub 2012.
426. Mak PY, Mak DH, Shi Y, Ruvolo V, Jacamo R, Andreeff M, Carter BZ. ARC Is Regulated by MAPK and PI3K and Confers Drug Resistance and Survival Advantage to AML in vitro and in vivo. Hematologic Malignancies 2012, 2012. e-Pub 2012.
427. Milella M, Konopleva M, Ciuffreda L, Ricciardi R, Incani UC, Falcone I, Bergamo P, Del Curatol A, Iacovelli S, Eramo A, De Maria R, Cognetti F, Tafuri A, Andreeff M. Beyond single pathway inhibition: MEK inhibition-based vertical and lateral combination strategies. Global Academic Programs 2012 Conference, 2012. e-Pub 2012.
428. Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity against AML Stem/Progenitor Cells in vitro and in a Murine Model of AML. Texas Screening Alliance for Cancer Therapeutics, 2012. e-Pub 2012.
429. Carter BZ, Mak DH, Qiu Y, Kornblau S, Mak PY, Weng D, McKinlay MA, Andreeff M. Antagonizing IAP' by SMAC Mimetic TL32711 Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy. Texas Screening Alliance for Cancer Therapeutics, 2012. e-Pub 2012.
430. Battula VL, Shi Y, Evans KW, R-Y W, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Mani SA, Andreeff M. Ganglioside GD2 Identifies Cancer Stem Cells and Inhibition of GD2 Biosynthesis by Targeting GD3 Synthase Exerts Anti-tumor Effects. Texas Screening Alliance for Cancer Therapeutics, 2012. e-Pub 2012.
431. Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Battula VL, Schober WD, Davis RE, Konopleva M, Andreeff M. NFkB activation in Mesenchymal Stromal Cells induced by Leukemia-Stroma interaction plays a central role in stroma-mediated chemo-resistance of leukemic cells. Texas Screening Alliance for Cancer Therapeutics, 2012. e-Pub 2012.
432. Tabe Y, Kojima K, Andreeff. p53 as a biomarker for cancer cell susceptibility to HDM2 inhibition. Japan Association of Molecular Target Therapy Conference, 2012. e-Pub 2012.
433. Andreeff M, Zeng Z, Kelly MA, R-Y W, McQueen TJ, Duvvuri S, Nowshad G, Borthakur G, Burger JA, Kadia TM, Jabbour E, Cortes JE, Kantarjian G, Konopleva M. Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib. J Clin Oncol 30, 2012. e-Pub 2012.
434. Borthakur G, Duvvuri S, Tsao T, Zhang W, Ruvolo V, Lu H, Kojima K, Konopleva M, Andreeff M. Insulin-like growth factor 1 receptor (IGF1R) inhibitor BMS754807 is active against FLT3-ITD mutated acute myelogenous leukemia and activity is p53 dependent. AACR, 2012. e-Pub 2012.
435. Benito JM, Lu H Shi Y, Jacamo RO, McQueen TJ, Konoplev S, Bueso-Ramos C, Zweidler-McKay P, Handisides D, Hart CP, Andreeff M, Konopleva M. FLT3/ITD acute myeloid leukemia (AML) cells show C-MYC- and PIM-1- mediated CDC25A overexpression despite the presence of intrinsic DNA damage. AACR, 2012. e-Pub 2012.
436. Andreeff M, Chen Y, Battula VL, Hofmann NA, Reinisch A, Shi Y, R-Y W, Konoplev S, Strunk D, Konopleva M. Human extramedullary bone and bone marrow in mice: Firest in vivo model of a genetically controlled hematopoietic environment-Role of CTGF and HIF1-a. AACR, 2012. e-Pub 2012.
437. Pan R, Ruvolo PP, Pellecchia M, Wei J, Shi Y, Konopleva M, Reed JC, Andreeff M. Broad spectrum BH3 mimetic BI-97D6 induces apoptosis of acute myeloid leukemia cells even when co-cultured with supporting stromal cells. AACR, 2012. e-Pub 2012.
438. Battula VL, Shi Y, Evans K, R-Y W, Spaeth EL, Jacamo R, Guerra R, Sahin A, Marini F, Mani S, Andreeff M. Ganglioside GD2 identifies cancer stem cells and inhibition of GD2 biosynthesis by targeting GD3 synthase exerts antitumor effects. AACR, 2012. e-Pub 2012.
439. Jacamo RO, Chen Y, Wang Z, Ma W, Zhang M, Venkata BL, Schober WD, Davis RE, Konopleva M, Andreeff. NFkB activation in mesenchymal stromal cells induced by leukemia-stroma interaction plays a central role in stroma-mediated chemo-resistance of leukemic cells. AACR, 2012. e-Pub 2012.
440. Ruvolo PP, Zeng Z, Ruvolo VR, Borthakur G, Kornblau SM, Andreeff M, Konopleva M. The AKT inhibitor MK-2206 promotes apoptosis in acute myeloid leukemia cells. AACR 2013, 2012. e-Pub 2012.
441. Benito J, Lu H, Shi Y, Jacamo R, McQueen T, Konoplev S, Bueso-Ramos C, Zweidler-McKay P, Handisides C, Hart M, Andreeff M, Konopleva M. Hypoxia activated pro-drug TH-302 induces hypoxia-dependent anti-leukemia activity in vitro and in vivo. AARC, 2012. e-Pub 2012.
442. Konopleva M, Handisides D, Lorente GA, Benito JM, Richie MA, Borthakur G, Jabbour E, Faderl S, Cortes JE, Kroll S, Andreeff M, Kantarjian H, Thomas DA. Phase 1 study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias. J Clin Oncol 30, 2012. e-Pub 2012.
443. Benton CB, Ravandi F, Andreeff M, Kantarjian H, Konopleva M. AML patients with IDH1 or IDH2 mutations treated with hypomethylating agents: A case series. J Clin Oncol 30, 2012. e-Pub 2012.
444. Chen Y, Jacamo RO, Hofmann NA, Y-X S, R-Y W, Konoplev S, Strunk K, Konopleva M, Andreeff M. Human Extramedullary Bone and Bone Marrow in Mice: First In Vivo Model of a Genetically Controlled Hematopoietic Environment. Blood 118(21):584, 2011. e-Pub 2011.
445. Hofmann NA, Ortner A, Jacamo RO, Reinisch A, Schallmoser K, Fruewirth M, Diwoky C, Rohban R, Beham-Schmid C, Andreeff M, Strunk D. Neo-Vasculogenesis In Vivo Is Facilitated by Oxygen Sensing Mesenchymal Stem and Pogenitor Cells. Blood 118(21):319, 2011. e-Pub 2011.
446. Ruvolo PP, Ruvolo V, Zeng Z, Qui Y, Zhou L, Gallagher KE, Konopleva M, Kornblau SM, Andreeff M. The PP2A Subunit B55α Suppresses Survival Signaling in Acute Myeloid Leukemia Cells. Blood 118(21):182, 2011. e-Pub 2011.
447. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau SM, Andreeff M, Garris R, Cortes JE, O'Brien S. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab). Blood 118(21):661-62, 2011. e-Pub 2011.
448. Nazha A, Ravandi F, Kantarjian HM, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Du M, Brant M, Faderl S. Clofarabine, Idarubicin, and Cytarabin (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 118(21):674, 2011. e-Pub 2011.
449. Borthakur G, Andreeff M, Coombes KR, Qiu Y, Duvvuri S, Zhang N, Ruvolo V, Konopleva M, Garcia-Manero G, Ruvolo PP, Cortes JE, Kantarjian HM, Kornblau SM. High expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukema- Time to Target Autophagy to Improve Therapy Outcomes?. Blood 118(21):1076-77, 2011. e-Pub 2011.
450. Andersson BS, de Lima MJ, Saliba RM, Shpall EJ, Popat U, Jones R, Nieto Y, Hosing CM, Kebriaei P, Alousi AM, Worth LL, Madden T, Gulbis A, Chen JJ, Rondon G, McAdams P, McMullin B, Andreeff M, Champlin R. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS ; Results of a Randomized Phase III Study. Blood 118(21):407-08, 2011. e-Pub 2011.
451. Tabe Y, Shi Y, Zeng Z, Jin L, Zhou Y, Miida T, Andreeff M, Konopleva M. TGF-β Neutralizing Antibody 1D11 Inhibits LIF-JAK-Stat3 Signaling and Enhances Cytarabine Induced Apoptosis in AML Cells in Bone Marrow Microenvironment. Blood 118(21):421-22, 2011. e-Pub 2011.
452. Tabe Y, Jin L, Miida T, Andreeff M, Konopleva M. Growth-Inhibitory Effects of a Class I PI3K Inhibitor GDC-0941 Are Modulated by Hypoxia-Induced mTOR Pathway Activation in Mantle Cell Lymphoma. Blood 118(21):619, 2011. e-Pub 2011.
453. Alvarado Y, Kantarjian HM, Ravandi F, Luthra R, Borthakur G, Garcia Manero G, Faderl S, Konopleva M, Estrov Z, Andreeff M, Cortes JE. FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations. Blood 118(21):648, 2011. e-Pub 2011.
454. Jin L, Tabe Y, Konopleva M, Andreeff M, Ohsaka A, Miida T. Bone Marrow-Derived Adipocytes Promote Differentiation, Proliferation and Survival of Acute Monoblastic Leukemia Cells. Blood 118(21):651, 2011. e-Pub 2011.
455. Andreeff M, Kojima K, Ruvolo V, Younes A, Wei W, Konopleva M, Duvvuri S, Huang Z, Wu L, Jukofsky L, Vassilev L, Zhi J, Geho D, Nichols G. Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Blood 118(21):671, 2011. e-Pub 2011.
456. Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity Against AML Stem/Progenitor Cells in Vitro and in a Murine Model of AML. Blood 118(21):672, 2011. e-Pub 2011.
457. Battula VL, Chen Y, Konopleva M, Andreeff M. Connective Tissue Growth Factor (CTGF) Regulates Mesenchymal Stromal Cell De-Differentiation Into Adipocyte Progenitors and Facilitates Leukemic Cell Homing to Extra-Medullary Bone Marrow. Blood 118(21):1029, 2011. e-Pub 2011.
458. Sugihara E, Shimizu T, Kojima K, Ishizawa J, Andreeff M, Saya H. Arf and Ink4a Are Critical Factors Determining the Cell of Origin and Therapeutic Sensitivity in Myc-Induced Mouse Lymphoid Tumor. Blood 118(21):1051-52, 2011. e-Pub 2011.
459. Jin L, Tabe Y, Kojima K, Ruvolo V, Miida T, Andreeff M, Konopleva M, Kimura S. The Anti-Proliferative Effects of Hsp90 Inhibitor Tricyclic Coumarin GUT-70 and Geldanamycin Analog 17-DMAG in AML Cells in Hypoxia. Blood 118(21):1062-63, 2011. e-Pub 2011.
460. Lu H, Battula VL, Shi Y, Lock RB, Spong S, Andreeff M, Konopleva M. Role of Connective Tissue Growth Factor (CTGF) in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia. Blood 118(21):1113, 2011. e-Pub 2011.
461. Zhang W, Konopleva M, Jacamo RO, Borthakur G, Chen W, Cortes JE, Ravandi F, Andreeff M. Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML. Blood 118(21):1495, 2011. e-Pub 2011.
462. Takahashi K, Kantarjian HM, Pemmaraju N, Borthakur G, Faderl S, Garcia-Manero G, Andreeff M, Pierce S, Ravandi S, Cortes JE. FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations. Blood 118(21):1547-48, 2011. e-Pub 2011.
463. Carter BZ, Mak DH, Qiu Y, Kornblau SM, Mak PY, Weng D, McKinlay MA, Andreeff. Antagonizing IAPs by SMAC Mimetic TL32711 Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy. Blood 118(21):32, 2011. e-Pub 2011.
464. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes JE, Kantarjian HM, Andreeff M, Kornblau SM. Survivin Is Highly Expressed in AML Stem Cells and Predicts Poor Clinical Outcome. Blood 118(21):108-9, 2011. e-Pub 2011.
465. Gleixner KV, Herrmann H, Blatt K, Pickl WF, Konopleva M, Bharate GY, Andreeff M, Maeda H, Valent P. The Heat Shock Protein 32 (Hsp32)/HO-1- Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effercts on TKI-Resistant Leukemic Cells in Ph+CML. Blood 118, 2011. e-Pub 2011.
466. Kojima K, Ruvolo V, Wei W, Huang Z, Duvvuri S, Vassilev L, Nichols G, Rueger R, Borthakur G, Konopleva M, Samaniego F, Younes A, O'Brien S, Andreeff M. Non-genotoxic p53 Activation by HDM2 Inhibition as Novel Therapeutic Concept for CLL/SLL. NCI Translational Science Meeting, 2011. e-Pub 2011.
467. Andreeff, M. New Mobilization Agents. EBMT, Paris, France, 2011. e-Pub 2011.
468. Hu S, Ruvolo V, Lu H, Kantarjian HM, Wheeler D, Muzny DM, Medeiros LJ, Bueso-Ramos C, Konopleva M, Andreeff M, Konoplev S. HIF1a Expression is Associated With NPM1 Mutation, But Not IDH1 Or IDH2 Mutations In Acute Myeloid Leukemia With Normal Karyotype. USCAP, 2011. e-Pub 2011.
469. Abel EL, McIvor E, Bubel JD, Simper MS, Powell L, Fields T, Andreeff M, MacLeod MC, DiGiovanni J. Inducers of the gluthathione detoxification pathway protect against the alkylating agent, 2-chloroethyl ethyl sulfide (CEES), 2011. e-Pub 2011.
470. Beryozkina A, Zhi J, Nichols G, Reckner M, Vassilev RL, Ruediger, Andreeff M, Padmanabhan S, Strair R, Kirschbaum M, Maslak P, Hillmen P, Gore L, Patnaik A, Sarapa N. Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemia and solid tumor. ASCO 2011, 2011. e-Pub 2011.
471. Konoplev S, Cameron C, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, Lu G, Zuo Z, Luthra R, Medeiros LJ, Bueso-Ramos CE. NPM1 mutation occurs in a subset of Ph+ AML suggesting that this entity is distinct from CML in myeloid blast phase. Association for Molecular Pathology's 2011 Annual Meeting, 2011. e-Pub 2011.
472. Andreeff M, Konopleva M, Carter B, Zhang W, Samudio I, Ruvolo P, Reed JC, Garzon R, Croce C, Champlin R, Andersson B, de Lima M, Murphy W, Plunkett W, Cortes J, Borthkaur G, Estey E, O'Brien S, Kornblau S, Berry D, Kantarjian H. Strategies for Overcoming Apoptosis and Microenvironment-Mediated Resistance in Acute Myelogenous Leukemia. NCI Translational Res Conference, 2011. e-Pub 2011.
473. Andreeff M, Borthakur G, Duvvuri S, Konopleva M, Kojima K. P53 Activation as Novel Therapeutic Strategy for AML. NCI- Translational Res Conference, 2011. e-Pub 2011.
474. Ling X, Marini F, Shi Y, Wang RY, Schober W, Yuan X, Andreeff M. Stat3 inhibition by IFN-b produced in situ by marrow derived mesenchymal stromal cell (MSC) as therapy for primary and metastatic breast cancer. 61st MD Anderson Annual Symposium on Cancer Research, "Systems Biology of Cancer", 2011. e-Pub 2011.
475. Andreeff M, Zhang W, Konopleva M, Kojima K. Synergistic induction of Apoptosis in acute myelogenous leukemias (AML) by concomitant MAP or Aurora kinase and Mdm2 inhibition of Mdm2, MAP and Aurora Kinases. 14th International P53 Workshop:27-31, 2011. e-Pub 2011.
476. Andreeff M, Kojima K, Padmanabhan S, Strair R, Kirschbaum M, Maslak P, Hillmen P, O'Brien S, Samaniego F, Borthakur G, Konopleva M, Vassilev L, Nichols G. A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112: A First in Class p53-MDM2 Antagonist, in Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocitic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL). Blood 116(21), 2010. e-Pub 2010.
477. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Kornblau SM, Zweidler-McKay P, Wilson W, Campana D, Borthakur G, Bueso-Ramos CE, Kantarjian HM, Shpall EJ, Thomas DA, Jordan CT, Lock RB, Andreeff M, Konopleva M. Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104. Blood 116(21), 2010. e-Pub 2010.
478. Chen Y, Zeng Z, Shi Y, Jacamo R, Ludin C, Dembowsky K, Frenette PS, Konopleva M, Andreeff M. Targeting CXCR4, SDF1 and Beta-Adrenergic Receptors In the AML Microenvironment by Novel Antagonist POL6326, G-CSF and Isoproterenol. Blood 116(21):899-900, 2010. e-Pub 2010.
479. Carter B, Mak DH, Schober WD, Konopleva M, Cortes JE, Kantarjian HM, Koller E, Huang Z, Reed JC, Andreeff M. Targeting XIAP and ARC (apoptosis repressor with caspase recruitment domain) Overcomes Imatinib Resitance In Blast Crisis CML Cells. Blood 116(21):1399, 2010. e-Pub 2010.
480. Mak DH, Manton C, Andreeff M, Carter BZ. SMAC-Mimetic BV-6 Sensitizes Therapeutic Agents-Induced Apoptosis In AML Cells. Blood 116(21):899, 2010. e-Pub 2010.
481. Thomas DA, O'Brien S, Jorgensen J, Wang SA, Faderl S, Wierda WG, Garris R, Andreeff M, Cortes JE, Kantarjian H. Significance of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) In Adults with De Novo Acute Lymphoblastic Leukemia (ALL) After Therapy with the Modified Hyper-CVAD Regimen. Blood 116(21):886, 2010. e-Pub 2010.
482. Zeng Z, Shi Y, Tsao T, Qiu Y, Kornblau SM, Baggerly K, Liu W, Liu Y, Rommel C, Fruman DA, Andreeff, Konopleva M. Targeting mTOR1/2 by a mTOR Kinase Inhibitor (PP242) induces Apoptosis In AML Cells Under Conditions Mimicking Bone Marrow Microenvironment. Blood 116(21):341-42, 2010. e-Pub 2010.
483. Jin L, Tabe Y, Zhou Y, Milda T, Andreeff M, Konopleva M. Efficacy and Mechanisms of Apoptosis Induction by Simultaneous Inhibition of PI3K with GDC-0941 and Blockade of Bcl-2 (ABT-737) or FLT3 (Sorafenib) In AML Cells In the Hypoxic bone Marrow Microenvironment. Blood 116(21):341, 2010. e-Pub 2010.
484. Frolova O, Frankel AE, Korchin B, Cortes J, Kantarjian HM, Andreeff M, Konopleva M. IL3R Directed Agents, SL-401 and SL-501, Inhibit the Growth of Leukemia Stem Cells In CML. Blood 116(21):1393, 2010. e-Pub 2010.
485. Tabe Y, Jin L, Yixin Z, Ichikawa N, Iwabuchi K, Milda T, Cortes J, Andreeff M, Konopleva K. Role of Stromal Microenvironment In Non-Pharmacological Resistance of CML to Tyrosine Kinase Inhibitors through Lyn/CXCR4 Interactions In Lipid Rafts. Blood 116(21):1388, 2010. e-Pub 2010.
486. Shi Y, Tsao T, Lu H, Konoplev S, Schober WD, Andreeff M, Konopleva M. The Synergistic effect of DNA Methylation Inhibitor 5-Azacytidine and Bcl-2 Signaling Blockade ABT-737 Combination Treatment Induce Apoptosis In AML. Blood 116(21):1356-27, 2010. e-Pub 2010.
487. Padua RA, Beurlet S, Krief P, Omidvar N, Pogam CL, Auboeuf D, le la Grange P, Soulie A, Janin A, M-E N, Merlet P, Sarda-Mantel L, Fenaux P, Konopleva M, Andreeff M, Tu A, Yang P, Fan AC, Kogan SC, Weissman IL, Felsher DW, Pla M, West R, Chomienne C. ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival. Blood 116(21):1355-56, 2010. e-Pub 2010.
488. Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Liu JS, Kornblau SM, Grable M, I-R H, Borthakur G, Mankin A, Bivins C, Garcia-Manero G, Kadia T, Harris D, Ravandi F, Andreeff M, Cortes JE, Niecestro R, Bergstein I, Kantarjian HM, Frankel AE. Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targetign Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood 116(21):1351, 2010. e-Pub 2010.
489. Lu H, Battula VL, Korchin B, Spong S, Canizales M, Lock RB, Andreeff M, Konopleva M. Targeting Connective Tissue Growth Factor (CTGF) In Acute Lymphoblastic Leukemia Pre-Clinical Models: Anti-CTGF Monoclonal Antibody Attenuates Tumor Growth In Mouse Models of ALL. Blood 116(21):1335-36, 2010. e-Pub 2010.
490. Zhou Y, Tabe Y, Jin L, Milda T, Zeng Z, Andreeff M, Konopleva M. Inhibition of TGF-β and CXCR4 Signaling Promotes Cell Cycle Arrest and Apoptosis In Leukemic Cells Co-Cultured with Stromal Cells. Blood 116(21):758, 2010. e-Pub 2010.
491. Ruvolo PP, Qui Y, Coombes KR, Zhang N, Ruvolo V, Konopleva M, Andreeff, Kornblau SM. Role for PP2A Regulatory Subunit B44α as a Regulator of AKT and Other Signaling Pathways In AML. Blood 116(21):699-700, 2010. e-Pub 2010.
492. Jin L, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Milda T, Konopleva M, Andreeff M, Tabe Y. The Anti-Proliferative Effects of Tricyclic Coumarin GUT-70 as An Hsp90 Inhibitor In Mantle Cell Lymphoma. Blood 116(21):1622, 2010. e-Pub 2010.
493. Al-Ameri A, Kantarjian H, Malik A, Badoux X, Andreeff M, Quintas-Cardama A, Borthakur G. Decitabine and Gemtuzumab Ozogamicin In Patients with Advanced Myelofibrosis. Blood 116(21), 2010. e-Pub 2010.
494. Jacamo R, Benito J, Frolova O, Chen Y, Lu H, Konopleva M, Andreeff M. Role of Hypoxia and Hypoxia-Inducible-Factor 1α (HIF1A) In the BM Microenvironment-Mediated Protection of Leukemic Cells. Blood 116(21):1070, 2010. e-Pub 2010.
495. Ma W, Davis RE, Jacamo R, Konopleva M, Garzon R, Croce CM, Andreeff M. Mesenchymal Stromal Cells From AML Bone Marrow Are Abnormal by Gene Expression Profiling. Blood 116(21):463, 2010. e-Pub 2010.
496. Konopleva M, Zeng Z, R-Y W, Thall PF, McCormic G, Lu H, Chen JJ, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat U, Anderlini P, Nieto Y, Parmar S, McMullin B, Rondon G, Schober WD, Gulbis A, Cool R, Lin E, Andreeff M, Champlin R. A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation. Blood 116(21):975, 2010. e-Pub 2010.
497. Kojima K, McQueen T, Shpall EJ, R-Y W, Andreeff M. p53 Activation of Mesenchymal Stromal Cells (MSC) Partially Abrogates Microenvironment-Mediated Resistance to FLT3 Inhibition In FLT3/ITD AML. Blood 116(21):888-89, 2010. e-Pub 2010.
498. Duvvuri S, v R, Mak DH, Kojima K, Konopleva M, Andreeff M, Borthakur G. MDM2 Inhibitor Nutlin-3a Triggers Augophagic Cell Death In Addition to Apoptosis In Leukemia Cell Lines with Wild-Type p53. Blood 116(21):1352, 2010. e-Pub 2010.
499. Fidler JM, An J, Musser JH, Mak DH, Carter B, Andreeff. Preclinical Development of Triptolide Derivative MRx102 as a Therapeutic Agent for Acute Myeloid Leukemia. Blood 116(21):1340-41, 2010. e-Pub 2010.
500. Battula VL, MdG C, Wang Z, Ma W, Benito J, Ruvolo PP, Davis RE, Konopleva M, Andreeff M. Connective Tissue Growth Factor (CTGF) Is Essential for Self Renewal and Proliferation of Mesenchymal Stromal cells (MSCs) and Affects Leukemia-Stromal Interactions. Blood 116(21):1573-74, 2010. e-Pub 2010.
501. Andreeff M, Ling X, Shi YX, Spaeth E, Watson K, Battula VL, Lang F, Hortobagyi G, Marini F. Stroma and Stroma-Tumor Interactions as Therapeutic Targets in Breast Cancer. NCI, 2010. e-Pub 2010.
502. Andreeff M, Zeng Z, Frolova O, Konoplev S, Fiegl M, Samudio I, Benito J, Shi Y, Jacamo R, Lu H, Bueso-Ramos C, Thomas D, Kantarjian H, Konopleva M. Targeting Hypoxic Microenvironment in Acute Myelogenous Leukemia (AML). Blood, 2010. e-Pub 2010.
503. Ricciardi MR, Tsao T, Abrams SL, Bergamo P, Steelman LS, Decandia S, Felicioni L, Ciuffreda L, Di Sanza C, Marchetti A, Cognetti F, McCubrey J, Konopleva M, Andreeff M, Tafuri A, Milella M. Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition. Blood 114(22):246-47, 2009. e-Pub 2009.
504. Jin L, Konopleva M, Zhou Y, Osaka A, Andreeff M, Miida T, Tabe Y. Pro-Apoptotic and Proliferative Effects of Bone Marrow Adipocytes on Myeloid Leukemia Cells. Blood 114(22), 2009. e-Pub 2009.
505. Jin L, Kimura S, Zhou Y, Kuroda J, Asou H, Inaba T, Andreeff M, Miida T, Tabe Y. The Tricyclic Coumarin GUT-70 Induces Apoptosis and Cell Cycle Arrest Preferentially in Mantle Cell Lymphomas with Mutant p53. Blood 114(22):672, 2009. e-Pub 2009.
506. Garzon R, Heaphy CEA, Stauffer N, Havelange V, Volinia S, Andreeff M, Croce CM. Discovery and Functional Implications of a Novel Mir-29b/Mir-29a Polymorphism in Acute Myeloid Leukemia. Blood 114(22):781-82, 2009. e-Pub 2009.
507. Frolova O, R-Y W, Korchin B, Watt JC, Cortes J, Frankel AE, Kantarjian HM, Andreeff M, Konopleva M. Targeting IL3 Receptor in Chronic Myeloid Leukemia. Blood 114(22):854-55, 2009. e-Pub 2009.
508. Borthakur G, Duvvuri S, Samudio IJ, Kojima K, Konopleva M, Andreeff M. Synergistic Activation of p53 Family of Proteins by the Combination of Nutlin 3a and SAHA in Acute Myelogenous Leukemia. Blood 114(22):691, 2009. e-Pub 2009.
509. Bernstein SH, Lin B, Hilchey S, Villaluna N, Chen L, Madura K, Morse K, Metcalf H, Andreeff M, Brookes PS, Suzuki CK. The Triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid and its Derivatives Inhibit Mitochondrial Lon Protease Activity: A Potential Novel Pathway for the Induction of Lymphoma Cell Death. Blood 114(22):172, 2009. e-Pub 2009.
510. Ayoubi M, Thomas DA, Kantarjian H, O'Brien S, Ravandi F, Garcia-Manero G, Verstovsek S, Rytting M, Borthakur G, Kadia T, Kornblau SM, Andreeff M, Feliu J, Faderl S. Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase. Blood 114(22):802, 2009. e-Pub 2009.
511. Al-Kali A, Jones D, Cortes J, Faderl S, Ao X, Garcia-Manero G, Borthakur G, Konopleva M, Brandt M, Andreeff M, Kantarjian H, Ravandi F. Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML). Blood 114(22):820-21, 2009. e-Pub 2009.
512. Andreeff M, Fiegl M, Konopleva M, Korchin B, Kaluarachchi K, Bornmann WG, Guthrie PH, Harmancey R, Taegtmeyer H, Samudio IJ. Pharmacological Inhibition of Fatty Acid Oxidation as a Novel Therapeutic Concept for Acute Myeloid Leukemia. Blood 114(22):1453-54, 2009. e-Pub 2009.
513. Havelange V, Volinia S, Andreeff M, Marcucci G, Corce CM, Garzon R. Functional Implications of miRNAs in Acute Myeloid Leukemia (AML) by miRNA-mRNA Expression Profiling. Blood 114(22):653, 2009. e-Pub 2009.
514. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, e J, Ravandi F, Kadia T, Garcia-Manero G, Kornblau SM, Andreeff M, Garris R, Keating MJ, O'Brien S. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 114(22):344-45, 2009. e-Pub 2009.
515. Carter BZ, Zhang N, Coombes KR, Mak DH, Qiu Y, Thomas DA, Ravandi F, Kantarjian H, Andreeff M, Kornblau SM. Expression of Apoptosis Repressor with Caspase Recruitment Domain (ACR), An Antiapoptotic Protein, Is Strongly Prognostic in Acute Myeloid Leukemia (AML). Blood 114(22):166, 2009. e-Pub 2009.
516. Wetzler M, Wang ES, Shepard R, Thomas DA, Andreeff M, O'Brien S, Kantarjian HM. Phase I Trial of Nanomolecular Liposomal Annamycin in Adult Patients with Refractory Acute Lymphoblastic Leukemia. Blood 114(22), 2009. e-Pub 2009.
517. R-Y W, Y-X S, Zeng Z, Schober WD, McQueen TJ, Hopwood VL, Korchin B, Konopleva M, Andreeff M. Mesenchymal Stem Cells from Patients with Acute Myeloid Leukemia (AML) can Differentiate into B-Cells in NOD/SCID/IL-2Rγ-/- Mice. Blood 114(22), 2009. e-Pub 2009.
518. Tabe Y, Jin L, Zhou Y, Ichikawa N, Iwabuchi K, Miida T, Cortes J, Andreeff M, Konopleva M. Role of Stromal Microenvironment in Non-Pharmacological Resistance of CML to Imatinib through Lyn/CXCR4 Interactions. Blood 114(22), 2009. e-Pub 2009.
519. Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H. Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3-Via Mcl-1/Noxa Axis. Blood 114(22):1019, 2009. e-Pub 2009.
520. Mak DH, Schober WD, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Inhibition of Bcl-2/Bcl-XL Promotes Apoptosis in Blast Crisis CML Including Quiescent Primitive Progenitor Cells Regardless of Cellular Responses to Tyrosine Kinase Inhibitors. Blood 114(22):268, 2009. e-Pub 2009.
521. Konopleva M, Milella M, Watts JC, Ricciardi MR, Korchin B, Tsao T, Bergamo P, Mak DH, Decandia S, McCubrey J, Tafuri A, Andreeff M. Simultaneous Targeting of Bcl-2-XL and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both In Vitro and In Vivo. Blood 114(22):1078, 2009. e-Pub 2009.
522. Konopleva M, Benito J, Y-X S, Konoplev S, Kornblau SM, Frolova O, Zweidler-McKay, PA, Qiu YH, Wilson WR, Campana D, Jacamo R, Lu H, Fang W, Borthakur G, Bueso-Ramos CE, Kantarjian HM, Thomas DA, Andreeff M. Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia. Blood 114(22):805-06, 2009. e-Pub 2009.
523. Pemmaraju N, Kantarjian HM, Ravandi F, Garcia-Manero G, Borthakur G, Parikh SA, Konopleva M, Kornblau SM, Andreeff M, O'Brien S, Cortes J. FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact on Survival According to FLT3 Status. Blood 114(22):424-25, 2009. e-Pub 2009.
524. Lu H, Zeng Z, Shi Y, Konoplev S, Wong D, Konopleva M, Andreeff M. Disruption of leukemia/stroma cell interactions by CXCR4 antagonist CTCE-9908 enhances chemotherapy-induced apoptosis in AML. Blood 112(11):841, 2008. e-Pub 2008.
525. Samudio I, Fiegl M, Konopleva M, Kaluarachchi K, McMurray JS, Korchin B, Clise-Dwyer K, Harmancey R, Guthrie P, Taegtmeyer H, Andreeff M. Targeting Anaplerotic Pathways That Support Fatty Acid Metabolism as a Therapeutic Strategy for Hematological Malignancies: The Achilles’ heel of the Warburg Effect. Blood 112(11):576, 2008. e-Pub 2008.
526. Zhou L, Konopleva M, Andreeff M. HDAC inhibition by SX-275 restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. 61st Annual Symposium on Cancer Research, "Systems Biology of Cancer", 2008. e-Pub 2008.
527. Andreeff M, McQueen T, Williams C, Gu J, Hopwood VL, Appleberry T, Rich C, Dallaire S, Kornblau S, R-Y W. Clonal abnormalities in MSC derived from AML bone marrows. Blood 112(11):845-846, 2008. e-Pub 2008.
528. Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 112(11):677-678, 2008. e-Pub 2008.
529. Carter BZ, Mak DH, Morris S, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian HM, Andreeff M. Pharmacodynamic study of Phase 1/2 trial of the XIAP antisense oligonucleotide (AEG35156) in combination with chemotherapy in patients with relapsed/refractory AML. Blood 112(11):678, 2008. e-Pub 2008.
530. Frolova O, Samudio IJ, Mnjoyan ZH, Lu H, Konople S, Thomas DA, Kantarjian HM, Shpall EJ, Andreeff M. Targeting the hypoxic microenvironment by mTOR inhibitors sensitizes ALL cells to chemotherapy. Blood 112(11):13, 2008. e-Pub 2008.
531. Konoplev S, Lu H, Fiegl MA, Zeng Z, Chen W, Andreeff M, Konopleva M. Expression and function of the CXCR7 chemokine receptor in leukemias. Blood 112(11):844, 2008. e-Pub 2008.
532. Kornblau SM, Qiu YH, Chen W, Chou P, Blau L, Nashino H, Ravandi F, Andreeff M, Kantarjian H, Neeley S, Ju Z, Zhang N, Coombes KR. Proteomic profiling of 150 proteins in 511 acute myelogenous leukemia (AML) patient samples using reverse phase proteins arrays (RPPA) reveals recurrent proteins expression signatures with prognostic implications. Blood 112(11):281, 2008. e-Pub 2008.
533. Kornblau SM, Qiu YH, Graber G, Chen W, Melendez J, Konopleva M, Faderl S, Andreeff M, Borthakur G, Yao H, Coombes KR. Protein expression in acute myelogenous leukemia stem cells compared to bulk AML cells using reverse phase proteins arrays (RPPA). Blood 112(11):881, 2008. e-Pub 2008.
534. Omidvar N, Berulet S, Le Pogam C, Janin A, Leboeuf C, Soulie A, Setterblad N, Andreeff M, Chomienne C, Padua RA. ABT-737 targets intrinsic apoptosis during cooperation of bcl-2 and oncogenic NRAs in an in vivo progression model of myelodysplasia/acute myeloid leukemia. Blood 112(11):315, 2008. e-Pub 2008.
535. Patel A, R-Y W, Hixson P, Li J, Milosavljevic A, Kantarjian HM, Cheung S, Andreeff M. Clinical evaluation of a custom genome wide 44k oligoarray for copy number changes in cute myeloid leukemia. Blood 112, 2008. e-Pub 2008.
536. Ravandi F, Cortes J, Faderl S, Garcia-Manero G, O'Brien S, Borthakur G, Pierce S, Brandt M, Lang M, Zhang W, Luthra R, Jones D, Levis M, Konopleva M, Andreeff M, Kantarjian H. Combination of sorafenib, idarubicin, and cytarabine has a high response rate in patients with newly diagnosed acute myeloid leukemia younger than 65 years. Blood 112, 2008. e-Pub 2008.
537. Tabe Y, Jin L, Ichikawa N, Konopleva M, Andreeff M, Miida T. Bcr-abl inhibition by imatinib restores Lyn trafficking to lipid rafts and promotes CXCR4 surface expression of CML cells in BM microenvironment. Blood 112(11):1094, 2008. e-Pub 2008.
538. Zhang W, Konopleva M, Shi Y, Ling X, Andreeff M. Combination of sorafenib and arsenic trioxide exerts synergistic anti-leukemia effects in sorafenib-resistant FLT3-ITD-harboring AML cells. Blood 112(11):285, 2008. e-Pub 2008.
539. Zhou L, Konopleva M, Andreeff M. HDAC inhibition by SX-275 restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Blood 112(11):121, 2008. e-Pub 2008.
540. Schimmer AD, Eh E, Borthakur G, Carter B, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Jacob C, Morris S, Jolvet J, Andreeff M. Phase 1/2 trial of the XIAP antisense oligonucleotide (AEG35156) in combination with Idarubicin and Cytarabine in patients with Relapsed/Refractory AML. Blood 112(11):283, 2008. e-Pub 2008.
541. Fiegl M, Samudio IJ, Clise-Dwyer K, Burks J, Fritsche H, Mnjoyan ZH, Andreeff M. CXCR4 Expression and Biological activity is dependent on oxygen partial pressure in acute myeloid leukemia. Blood 112(11):346, 2008. e-Pub 2008.
542. Konopleva M, Tsao T, Ling X, Kojima K, Watt J, Mak DH, Verhaegen M, Bornmann W, Soengas M, Andreeff M. Activation of p53 signaling is Synergistically enhanced by Bcl-2 inhibition through induction of Noxa and Bak/Bax Heterodimers resulting in apoptosis of AML stem cells. Blood 112(11):1011, 2008. e-Pub 2008.
543. Foster A, Okur F, Dott G, Shafer J, Lu A, Biagi E, Yvon E, Bollard CM, Savoldo B, Andreeff M, Goodell MA, Rooney CM, Brenner MK. Selective loss of a putative precursor population of B-Chronic Lymphocytic leukemia Cells following Immunization with hCD401/IL-2 expressing autologous tumor cells. Blood 112(11):1088, 2008. e-Pub 2008.
544. Milella M, Ricciardi MR, Bergamo P, Scerpa MC, Gervasoni J, Petrucci MT, Chiaretti S, Tavolaro S, Ciuffreda L, Decandia S, Libotte F, Abrams SL, Steelman LS, Konopleva M, Cognetti C, Foa R, Andreeff M, McCubrey J, Tafuri A. Development of Mek inhibition (MEK-I)-based therapeutic strategies in acute myeloid leukemia (AML). Blood 112, 2008. e-Pub 2008.
545. Ricciardi MR, Decandia S, Santinelli S, Gregorj C, De Cave F, Scerpa MC, Bergamo P, Libotte F, De Benedictis C, Vitale A, Petrucci MT, Konopleva M, Andreeff M, Milella M, Foa R, Tafuri A. Multiple strategies based on MEK, mTOR and BCL-2 signal transduction inhibition in acute lymphoblastic leukemia (ALL). Blood, 2008. e-Pub 2008.
546. Andreeff M, Zhang W, Konopleva M, Kojima K. Synergistic induction of Apoptosis in acute myelogenous leukemias (AML) by. Fudan University Oncology Hospital, 2008. e-Pub 2008.
547. Andreeff M, Zhang W, Konopleva M, Kojima M. Microenvironment as target for cancer and leukemia therapy. Fudan University Oncology Hospital, 2008. e-Pub 2008.
548. w Z, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Strov Z, Quintas-Cardama A, Samll D, Cortes J, Andreeff. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Linst 6(100(3)):184-98, 2008. e-Pub 2008. PMID: 18230792.
549. Battula V, Samudio I, Konopleva M, Andreeff M. Identification and characterization of drug resistant leukemic stem/progenitor cells using aldehyde dehhydrogenase (ALDH) activity in acute myeloid leukemia patients. Leukemia 2008, 2008. e-Pub 2008.
550. Zeng Z, Carter BZ, Samudio IJ, Agarwal NK, Sarbassov DD, Andreeff M, Konopleva M. Activation of AKT suppresses apoptosis triggered via blockade of MDM2-p53 interactions but is reversible upon simultaneous inhibition of rictor/mTOR complex. Blood 12(11), 2008. e-Pub 2008.
551. Zhou L, Konopleva M, Andreeff M. HDAC inhibition by SX-275 restores expression of silenced leukemia-associated transcription factors Nur77 and NOR1 key pro-apoptotic proteins in AML. Leukemia 2008, 2008. e-Pub 2008.
552. Samudio I, Fiegl M, Konopleva M, Dwyer K, Harmancey R, Guthrie P, Taegtmeyer H, Andreeff M. Targeting fatty acid metabolism as anovel therapeutic strategy for hematological malignancies: The achilles heel of the warburg effect. Leukemia 2008, 2008. e-Pub 2008.
553. Konoplev S, Kornblau SM, Schlette E, Lu H, Thomas DA, Zhang N, Qiu YH, Coombes K, Neeley S, Kantarjian HM, Medeiros LJ, Andreeff M, Konopleva M. Overexpression of HIF1 alpha predicts worse overall and event-free survival in patients with Philadelphia chromosome-negative precursor B-lymphoblastic leukemia. Blood 112(11):870, 2008. e-Pub 2008.
554. Cabreira-Hansen, MD, Frolova O, Wang RY, Schober WD, Konopleva M, Andreeff M. Uncovering Functional Binding Sites on Hematopoietic System by Phage Display Biopanning: Discovering Connective Tissue Growth Factor Activities on the Stem Cell Niche. ISSCR 2007, 2007. e-Pub 2007.
555. Faderl S, Thomas SA, Ravandi F, Garcia-Manero G, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau SM, O’Brien S, Vu K, Kwari M, Bretz J, Kantarjian HM. Intensification of hyper-CVAD with L-asparaginase, vincristine, and dexamethasone(“augmented hyper-CVAD”) has activity in adult patients with relapsed/refactory acute lymphoblastic leukemia (ALL). Blood 110(11):149b, 2007. e-Pub 2007.
556. Andreeff M, Dietrich M, Corn P, Konoplev S, Konopleva M, Samudio I. The hypoxic microenvironment in acute myelogenous leukemia: critical role of CXCR4 in the induction of HIF-1-alpha. Blood 110(11):539a, 2007. e-Pub 2007.
557. Mak DH, Schober WD, Chen W, Cortes JE, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to Imatinib in blast crisis CML cells and sensitizes Imatinib. Blood 110(11):481a, 2007. e-Pub 2007.
558. Tabe Y, Jin L, Konoplev S, Hongbo L, Kimura S, M-B R, Kantarjian HM, Andreeff M, Konopleva M. Upregulation of CXCR4 is essential for the migration and survival of quiescent CML progenitor cells in the bone marrow microenvironment after Imatinib treatment. Blood 110(11):304a, 2007. e-Pub 2007.
559. Tabe Y, Xu Y, McQueen T, Andreeff M, Konopleva M. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in leukemic cells co-cultured with stromal cells. Blood 110(11):837a, 2007. e-Pub 2007.
560. Wang R, Samudio IJ, McQueen T, Schober WD, Ruvolo VR, Kornblau SM, Konopleva M, Andreeff. Apoptosis inducing factor acts as a suvival factor in acute myelogenous leukemia through mitochondrial complex 1. Blood 110(11):537a, 2007. e-Pub 2007.
561. Kornblau SM, Barnett J, Qiu Y, Chen W, Faderl S, Coombes KR, Andreeff M. P53 protein expression levels are prognostic in AML and predict for mutational status. Blood 110(11):708a, 2007. e-Pub 2007.
562. Zeng Z, Samudio I, Andreeff M, Konopleva M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and mTOR/Akt pathways in acute myeloid leukemia. Blood 110(11):474a, 2007. e-Pub 2007.
563. Zhang W, Konopleva M, Schober WD, McQueen T, Andreeff M. MEK inhibitor AZD6244 induces cell growth arrest and synergizes with Nutlin-3a-mediated cell death by upregulating p53 and PUMA levels in AML. Blood 110(11):201a, 2007. e-Pub 2007.
564. Abrams SL, Evangelisi C, Chiarini F, Misaghian N, Basecke J, Millela M, Tafuri A, Libra M, Stivala F, Konopleva M, Andreeff M, Steelman LS, Troppmair J, Martelli AM, McCubrey JA. Roles of Raf/MEK/ERK and PI3K/Akt/mTOR pathways in prevention of apoptosis and induction of drug resistance in myeloid hematopoietic cells. Blood 110(11):197a, 2007. e-Pub 2007.
565. Garzon R, Pichiorri F, Marcucci G, Kornblau S, Andreeff M, Croce C. MiRNA-29b targets MCL-1 and is down-regulated in chemotherapy-resistant acute myeloid leukemia (AML). Blood 110(11):220a, 2007. e-Pub 2007.
566. Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Strasser A, Taniwaki M, Maekawa T. ABT-737 is a useful component of combinatory chemotherapies for chonic myelogenous leukemias with diverse drug resistance mechanisms. Blood 110(11):248a, 2007. e-Pub 2007.
567. Jr DJ, Kantarjian HM, Andreeff M, Faderl S, Wright JJ, Zhang W, Konopleva M, Verstovsek S, Borthakur G, Ravandi F, Cortes J. Update of a Phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 110(11):272a, 2007. e-Pub 2007.
568. Andreeff M, Dembinski J, Studeny M, Ling X, McQueen T, Klopp A, Marini F. Mesenchymal stem cells selectively engraft into tumor stroma and produce potent antitumor proteins in situ. J Clin Oncol 25(18S):3025, 2007. e-Pub 2007.
569. Quintas-Cardama A, Kantarjian H, Andreeff M, Faderi S, Wright J, Zhang W, Konopleva M, Verstovsek S, Borthakur G, Cortes J. Phase I trial of intermittent administration of sorafenib (Bay 43-9006) for patients with refractory/relapsed acute myelogenous leukemia. J Clin Oncol 25(18S):7018, 2007. e-Pub 2007.
570. Vu KD, Lavis VR, Strom S, Faderl SH, Konopleva M, Thomas DA, Gruschkus S, Andreeff M, Kantarjian H. Hyperglycemia and obesity in patients (pts) with acute lymphoblastic leukemia (ALL): Association with prevalence, response, and survival. J Clin Oncol 25(18S):7074, 2007. e-Pub 2007.
571. Dezube BJ, Kurzrock R, Eder JP, Supko JG, Meyer CJ, Camacho LH, Andreeff M, Konopleva M, Lescale-Matys L, Hong D. Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies. J Clin Oncol 25(18S):14101, 2007. e-Pub 2007.
572. R-Y W, Ruvolo V, McQueen T, Schober WD, Kornablau SM, Konopleva M, Andreeff M. Overexpression of apoptosis-inducing factor (AIF) and pro-survival function in AML. Blood 108(11):4395, 2006. e-Pub 2006.
573. Watt JC, Konopleva M, Contractor R, Samudio I, Harris D, Estrov Z, Viallet J, Andreeff M. Inhibition of Bcl-2 signaling by small molecule BH3 inhibitor GX15-070 as a novel therapeutic strategy in AML. Blood 108(11):2584, 2006. e-Pub 2006.
574. McQueen T, Tabe Y, Konopleva M, Andreeff M. Inhibition of PI3K or integrin-linked kinase (ILK) target primary AML cells within the bone marrow microenvironment in the in vitro co-culture system. Blood 108(11):1903, 2006. e-Pub 2006.
575. Foster AE, Dotti G, Lu A, Andreeff M, Goodell M, Rooney CM, Brenner MK. Immune responses are induced against side-population B-CLL “Stem Cells” by patient vaccination with hCD40L/IL2 gene modified tumor cells. Blood 108(11):2552, 2006. e-Pub 2006.
576. Frolova O, Buglio D, Samudio I, McQueen T, Kantarjian H, Weiser MA, Andreeff M, Konopleva M. Relationship between m-TOR-mediated upregulation of glycolysis and chemosensitivity of ALL blasts. Blood 208(11):1833, 2006. e-Pub 2006.
577. Garzon R, Volinia S, Liu CG, Pichiorri F, Palumbo T, Fabbri M, Cimmino A, Alder H, Flomenberg N, Coombes KR, Calin GA, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and outcome in acute myeloid leukemia. Blood 108(11):151, 2006. e-Pub 2006.
578. Yazbeck VY, Georgakis GV, Li Y, McConkey D, Andreeff M, Younes A. Inhibition of the Pan-Bcl-2 family by the small molecule GX15-070 induces apoptosis in Mantle cell lymphoma (MCL) cells and enhances the activity of two proteasome inhibitors (NPI-0052 and bortezomib), and doxorubicin chemotherapy. Blood 108(11):2532, 2006. e-Pub 2006.
579. Zeng, Z, Sarbassov DD, Giles FJ, Samudio I, Yee KWL, Jackson CE, Sabatini DM, Andreeff M, Konopleva M. Rapamycin analogs reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 108(11):156, 2006. e-Pub 2006.
580. Zhang W, Konopleva M, Y-X S, Harris D, Small D, Ling X, Estrov Z, Cortes J, Andreeff M. Sorafenib (BAY 43-9006) directly targets FLT3-ITD in acute myelogenous leukemia. Blood 108(11):255, 2006. e-Pub 2006.
581. Giles F, Bergstrom DA, Garcia-Manero G, Kornblau S, Andreeff M, Kantarjian H, Jones D, Freedman SJ, Verstovsek S. MK-0457 is a novel aurora kinase and janus kinase 2 (JAK2) inhibitor with activity in transformed JAK2-positive myeloproliferative disease (MPD). Blood 108(11):4893, 2006. e-Pub 2006.
582. Konoplev S, Rassidakis GZ, Estey EH, Kantarjian HM, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 in acute myeloid leukemia predicts adverse overall and progression-free survival independently of FLT3 gene mutation. Blood 108(11):1890, 2006. e-Pub 2006.
583. Kornblau SM, Qui Y, Tibes R, Chen W, Lemker E, Andreeff M, Coombes KR, Mills GB. High throughout proteomic analysis of 559 acute myelogenous leukemia (AML) patient samples on a single slide using reverse phase proteins arrays (RPPA): analysis of signal transduction pathway (STP) and apoptosis regulating proteins. Blood 108(11):107, 2006. e-Pub 2006.
584. Kress CL, Konopleva M, Krajewska M, Martinez-Garcia V, Lefebvre S, Hyer ML, McQueen T, Andreeff M, Reed JC, Zapata J. Triterpenoids display single agent activity in a mouse model of CLL/SBL. Blood 108(11):2530, 2006. e-Pub 2006.
585. Kuroda J, Kimura S, Strasser A, Andreeff M, Ashihara E, Tabe Y, Taniwaki M, Maekawa T. BH3 mimetic augments the induction of apoptosis by INNO-406, a novel Bcr-Abl/Lyn inhibitor, in Bcr-Abl+ leukemic cells. Blood 108(11):2178, 2006. e-Pub 2006.
586. McCubrey JA, Abrams SL, Steelman LS, Wong E, Chappell WH, Basecke J, Stivala F, Libra M, Milella M, Tafuri A, Troppmair J, Konopleva M, Andreeff M, Evangelisti C, Martelli AM. Dominant role of Raf/MEK/ERK signaling in hematopoietic cell cycle progression, prevention of apoptosis and drug resistance. Blood 108(11):1116, 2006. e-Pub 2006.
587. Andreeff M, Konoplev S, R-Y W, Zeng Z, McQueen T, Y-X S, Medeiros J, Estey E, McCarty JM, Elkins S, Champlin R, Calandra G, Bridger G, Konopleva M. Massive mobilization of AML, cells into circulation by disruption of leukemia/stroma cell interactions using CXCR4 antagonist AMD3100: First evidence in patients and potential for abolishing bone marrow microenvironment-mediated resistance. Blood 108(11):568, 2006. e-Pub 2006.
588. Wierda WG, O’Brien S, Faderl S, Ferrajoli A, Ravandi-Kashani F, Cortes J, Giles F, Andreeff M, Koller CA, Lerner S, Kantarjian HM, Keating MJ. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108(11):31, 2006. e-Pub 2006.
589. Andreeff M, Dembinski J, Hall BM, Studeny M, Ling X, Marini FC. Mesenchymal stem cells selectively engraft into tumor stroma and produce potent antitumor proteins in situ. Blood 108(11):352, 2006. e-Pub 2006.
590. Andreeff M, Konopleva M, Watt JC, Samudio IJ, Satterthwait AC, Kitada S, Zhang X, Reed JC. A novel peptide containing a nine acid sequences from Nur77 induces Bcl-2 dependent apoptosis in AML. Blood 108(11):2607, 2006. e-Pub 2006.
591. Thomas DA, Kantarjian HM, Cortes J, Faderl S, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Andreeff M, Letvak LA, Jones D, Champlin R, O’Brien S. Outcome with the hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 108(11):284, 2006. e-Pub 2006.
592. Contractor R, Konopleva M, Samudio I, Kantarjian H, Andreeff M. Inhibition of Bcl-2 signaling by small molecule BH3 inhibitor GX15-070 as a novel therapeutic strategy in AML. Blood 106:942a, 2006. e-Pub 2006.
593. Andreeff M, Dembinski J, Studeny M, Ling X, Cabreira-Hansen M, Zompetta C, McQueen T, Fueyo J, Champlin R, Marini F. Mesenchymal stem cells: Precursors for tumor stroma and targeted delivery vehicles for anticancer agents. Proc Amer Assoc Cancer Res 47:1008, 2006. e-Pub 2006.
594. Andreeff M, Konopleva M, Samudio I, McQueen T, Tsao T, Zeng Z, Kojima K. Mdm2 inhibitor nutlin-3a induces p53-dependent apoptosis via transcription-dependent and –independent pathways and overcomes fludarabine-resistance in CLL. Proc Amer Assoc Cancer Res 47:4977, 2006. e-Pub 2006.
595. Ling X, Andreeff M. Therapeutic effect of ds siRNA of STAT3 in vivo on mouse breast tumor. Proc Amer Assoc Cancer Res 47:2724, 2006. e-Pub 2006.
596. Konopleva M, Contractor R, Ruvolo P, Deng X, Samudio I, Shi Y, McQueen T, Wang R, Schober W, Ling X, Marini F, Harris D, Estrov Z, McCubrey J, May W, Andreeff M. Mechanism of apoptosis induction by inhibitors of bcl-2 in acute leukemia cells. Proc Amer Assoc Cancer Res 47:4864, 2006. e-Pub 2006.
597. Samudio I, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann W, Ying Y, Evans R, Andreeff M. A novel mechanism of action methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me): Direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Proc Amer Assoc Cancer Res 47:4693, 2006. e-Pub 2006.
598. Wang D, Kong G, Wu J, Ruvolo P, Andreeff M, Konopleva M, Maurer B. Synthetic triterpenoid CDDO and its derivatives increase ceramides and are cytotoxic to pediatric acute lymphoblastic leukemia cell lines. Proc Amer Assoc Cancer Res 47:4643, 2006. e-Pub 2006.
599. Carter B, Mak D, Schober W, Koller E, Dean N, Marcusson E, Monia B, Andreeff M. Inhibiting Mcl-1 with an antisense oligonucleotide induces cell death in acute myeloid leukemia cells. Proc Amer Assoc Cancer Res 47:4075, 2006. e-Pub 2006.
600. Sun X, Wang E, Jones D, Shen H, Johnson M, Issa J, Amin H, Ginsberg C, Kantarjian H, Andreeff M, Kornblau S, Glassman A, Arlinghaus R. SOX4 gene expression in human leukemia and benign hematopoietic cells. Proc Amer Assoc Cancer Res 47:3035, 2006. e-Pub 2006.
601. Elsawa SF, Novak AJ, Konopleva M, Andreeff M, Witzig TE, Ansell SM. Preferential inhibition of malignant cell growth by CDDO in Waldenstrom macroglobulinemia. Blood 108(11):2528, 2006. e-Pub 2006.
602. Drakos E, Thomaides A, Li J, Konopleva M, Medeiros LJ, Andreeff M, Rassidakis GZ. Nutlin-3A, an MDM2 antagonist, induces p53-dependent cell cycle arrest and apoptosis in Hodgkin lymphoma (HL). Blood 108(11):2506, 2006. e-Pub 2006.
603. Carter BZ, Kim TK, Mak DH, Hu W, Pinilla C, Reed JC, Andreeff M. AML progenitor/stem cells overexpress XIAP are sensitive to the small molecular XIAP inhibitor 1396-11. Blood 108(11):2586, 2006. e-Pub 2006.
604. Carter BZ, Mak DH, Schober WD, Dietrich M, Pinilla C, Reed JC, Andreeff M. Triptolide sensitizes leukemic cells to TRAIL induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 108(11):528, 2006. e-Pub 2006.
605. Mak DH, Schober WD, Chen W, Heller J, Andreeff M, Carter BZ. Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of cdc2 and survivin. Leuk Lymphoma 108(11):4366, 2006. e-Pub 2006.
606. Andreeff M, Ruvolo V, Gadgil S, Chen W, Coombes K, Zeng C, Baron A, Drabkin H. HOX expression patterns identify major cytogenetic groups and are of prognostic importance in adult AML. Blood 108(11):2243, 2006. e-Pub 2006.
607. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Cortes J, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Koller CA, Beran M, Kornblau SM, Andreeff M, Jones D, O’Brien S. Outcome after detection of minimal residual disease during treatment with the modified hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). Blood 108(11):1861, 2006. e-Pub 2006.
608. Tibes R, Giles F, McQueen T, Bergstrom DA, Freedman SJ, Andreeff M. Translational in vivo and in vitro studies in patient (pts) with acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and myeloproliferative disease (MPD) treated with MK-0457 (MK), a novel Aurora kinase, Flt3, JAK2, and Bcr-Abl inhibitor. Blood 108(11):1362, 2006. e-Pub 2006.
609. Tabe Y, Jin L, McQueen T, Andreeff M, Zweidler-McKay P, Konopleva M. Notch1 signaling promotes survival of leukemic cells in close contact with bone marrow-derived stromal cells by activating AKT and Stat-3 pathways. Blood 108(11):1398, 2006. e-Pub 2006.
610. Tabe Y, Jin L, Leysath CE, Kimura S, Kantarjian H, Andreeff M, Konopleva M. CXCR4 up-regulation by imatinib mesylate induces CML cell migration to bone marrow stroma and promotes survival of chemoresisitance quiescent CML cells. Blood 108(11):2123, 2006. e-Pub 2006.
611. Tabe Y, Xu Y, Jin L, Andreeff M, Konopleva M. Bone marrow stroma-produced TGF-beta 1 confers chemoresistance of leukemia cells. Blood 108(11):4248, 2006. e-Pub 2006.
612. Soriano AO, Yang H, Tong W, Faderl S, Wierda W, Andreeff M, Estrov Z, Ouzounian S, Clavell J, Kantarjian H, J-P I, Garcia-Manero G. Significant clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic (ATRA) acid in leukemia: results of a phase I/II study. Blood 108(11):160, 2006. e-Pub 2006.
613. Milella M, Ricciardi MR, Gregorj C, De Cave F, Abrams SL, Steelman LS, Chiaretti S, Konopleva M, Petrucci MT, Cognetti F, Foa R, Andreeff M, McCubrey J, Tafuri A. Molecular and functional effects of the novel MEK inhibitor PD0325901 in preclinical models of human leukemias. Blood 108(11):254, 2006. e-Pub 2006.
614. Jin L, Tabe Y, Tanaka N, Xu Y, Kato A, Kantarjian H, Andreeff M, Konopleva M. Bone marrow stromal cells modulate sensitivity of CXCR4-deficient CML cells to pharmacological inhibitors of PI3K/AKT signaling. Blood 106:4888, 2005. e-Pub 2005.
615. Pelicano H, Carew JS, McQueen TJ, Andreeff M, Keating MJ, Huang P. 17-AAG potentiates the apoptotic action of the antileukemic drug arsenic trioxide. Clin Cancer Res 11S:260, 2005. e-Pub 2005.
616. Ferguson D, Ling X, Meyer CJ, Marty J, Wick M, McQueen T, Frolova O, Konopleva M, Andreeff M. CDDO-Me (RTA 402) is effective as single agent and in combination therapy in the 4T1 in vivo model of breast cancer. Clin Cancer Res 11S:253, 2005. e-Pub 2005.
617. Samudio I, Ruvolo P, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann WG, Y-M Y, Evans R, Younes A, Andreeff M. Methyl-2-cyano-3,12 dioxooleana-1,9 diene-28-oate (CDDO-Me) directly permeabilizes the inner mitochondrial membrane to inhibit electron transport and induce apoptosis: A paradigm for the facilitation of death receptor signaling. Clin Cancer Res 11S:252, 2005. e-Pub 2005.
618. Cheng X, Manshouri T, Huang P, Golemovic M, Zingaro R, Freireich E, Andreeff M, Gale RP, Kantarjian H, Verstovsek S. Mechanisms of increased reactive oxygen species (ROS) generation induced by organic arsenic-lipid (glycerol) derivatives Z10-102. Clin Cancer Res 11S:252, 2005. e-Pub 2005.
619. Konopleva M, Zhang W, Ling X, Samudio I, Y-Xi S, McQueen T, Tsao T, Meyer C, Munsell MF, Yu D, Safe SH, M-C H, Andreeff M. Synthetic triterpenoids CDDO (RTA 401) and CDDO-Me (RTA 402) inhibit HER2-driven growth of breast cancer in vivo. Clin Cancer Res 11S:251, 2005. e-Pub 2005.
620. Samudio I, Konopleva M, Hail N, Y-X S, McQueen T, Hsu T, Evans R, Meyer C, Honda T, Gribble GW, Sporn M, Gilbert HF, Safe S, Andreeff M. 2-cyano-3,12 dioxooleana-1,9 diene-28-imidazolide (CDDO-Im) and 2-cyano-3,12 dioxooleana-1,9, diene-28-methyl ester (CDDO-Me) induce caspase-independent cell death in pancreatic cancer in vitro and prevent the growth of pancreatic cancer xenografts in vivo. Clin Cancer Res 11S:251, 2005. e-Pub 2005.
621. Murphy WJ, Konopleva M, Andreeff M, Meyer C, Ma W, Wilkins D, Welniak LA, Sun K. Immunomodulatory effects of the triterpenoid CDDO after allogeneic bone marrow transplantation in mice: Reduction of acute graft-versus-host disease lethality. Clin Cancer Res 11S:205, 2005. e-Pub 2005.
622. Carter BZ, Mak D, Shi Y, Schober WD, Wang R, McQueen T, Konopleva M, Koller E, Dean NM, Andreeff M. Regulation and targeting of Eg5 in blast crisis CML: overcoming Imatinib resistance. Blood 106:806a, 2005. e-Pub 2005.
623. Buglio D, Konopleva M, McQueen T, Samudio I, Broglio KR, Ruvolo V, Contractor R, Chen W, Kantarjian H, Andreeff M, Weiser MA. Relationship between m-TOR-mediated upregulation of glycolysis, chemoresistance, and prognosis in patients with ALL. Blood 106:8a, 2005. e-Pub 2005.
624. Andreeff M, Contractor R, Ruvolo PP, Deng X, Samudio IJ, Shi Y, McQueen T, R-Y W, Schober WD, Ling X, Marini FC, Harris D, Estrov Z, McCubrey J, May WS, Konopleva M. Mechanisms of apoptosis induction by BH3 inhibitor ABT-737 in AML. Blood 106:74a-75a, 2005. e-Pub 2005.
625. Andreeff M, Dembinski J, Studeny M, Ling X, Cabreira-Hansen M, Zompetta C, McQueen T, Fueyo J, Champlin RE, Marini FC. Mesenchymal progenitor cells as gene delivery systems for cancer and leukemia therapy: Tropism and efficacy. Proc Am Assoc Cancer Res 46:1254, 2005. e-Pub 2005.
626. Carter BZ, Mak D, Schober W, Koller E, Dean NM, Andreeff M. Simultaneous inhibition of Mcl-1 and XIAP to induce apoptosis in AML cells. Blood 106:437a, 2005. e-Pub 2005.
627. Cheng X, Taghi M, Huang P, Golemovic M, Zingaro R, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. Mechanisms of increased reactive oxygene species (ROS) generation induced by organic arsenic derivative S-dimethylarsino-glutathione (SGLU; ZIO-101). Blood 106:4445, 2005. e-Pub 2005.
628. Cortes J, Talpaz M, O’Brien S, Ravandi F, Verstovsek S, Garcia-Manero G, Koller C, Andreeff M, Estrov Z, Kantarjian H. A randomized trial of high-dose (HD) imatinib mesylate (IM) with or without Peg-interferon (PEG-IFN) and GM-CSF as frontline therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP). Blood 106:316a, 2005. e-Pub 2005.
629. Drabkin H, Ruvolo V, Gadgil S, Chen W, Zeng C, Baron AE, Kornblau S, Estey E, Coombes K, Andreeff M. Comprehensive HOX gene expression profiles are associated with major cytogenetic prognostic categories in AML. Blood 106:838a, 2005. e-Pub 2005.
630. Faderl S, Thomas DA, Garcia-Manero G, Ravandi F, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, Vu K, Jarmon R, Kantarjian HM. Augmented hyper-CVAD in acute lymphoblastic leukemia (ALL): The MDACC experience with intensified L-asparaginase and vincristine in adult ALL salvage. Blood 106:523a, 2005. e-Pub 2005.
631. Garcia-Manero G, Yang H, Sanchez-Gonzalez B, Verstovsek S, Ferrajoli A, Keating M, Andreeff M, O’Brien S, Cortes J, Wierda W, Faderl S, Koller C, Davis J, Morris G, J-P I, Frankel SR, Richon V, Fine B, Kantarjian H. Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome. Blood 106:785a, 2005. e-Pub 2005.
632. Kojima K, Konopleva M, Samudio IJ, McQueen T, Tsao T, Zeng Z, Plunkett WK, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-dependent apoptosis via transcription-dependent and –independent pathways and overcomes fludarabine-resistance in CLL. Blood 106:134a-135a, 2005. e-Pub 2005.
633. Konopleva M, Samudio I, Tsao T, Kornblau SM, Shi Y, McQueen T, Contractor R, Sporn MB, Meyer C, Huff W, Safe SH, Kantarjian H, Andreeff M. Mechanisms and activity of PPARgamma-active triterpenoids CDDO and CDDO-Me in leukemias. Blood 106:692a, 2005. e-Pub 2005.
634. Kornblau SM, Banker DE, Lemker E, Estrov Z, Faderl S, Verstovsek S, Cortes J, Garcia-Manero G, Koller CA, Ravandi-KBlood:ani F, Andreeff M, Jackson CE, Chen W, Petersdorf S, Estey E, Appelbaum FR. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of Pravastatin to idarubicin + high dose ara-C: a phase 1 study. Blood 106:122a, 2005. e-Pub 2005.
635. Manshouri T, Kala SV, Ashoori F, Zingaro R, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. Comparison of uptake and intracellular induced structural changes of arsenic trioxide, an inorganic compound and organic arsenic derivative S-dimethylarsino-glutathione (SGLU; ZIO-101) in NB4 acute promyelocytic leukemia (APL) cells. Blood 106:4446, 2005. e-Pub 2005.
636. McQueen T, Konopleva M, Andreeff M. Activity of targeted molecular therapeutics against primary AML cells: putative role of the bone marrow microenvironment. Blood 106:648a-649a, 2005. e-Pub 2005.
637. Murphy WJ, Frolova O, Konopleva M, Andreeff M, Ma W, Wilkins D, Welniak LA, Sun K. Immunomodulatory effects of the triterpenoid CDDO after allogeneic bone marrow transplantation in mice: reduction of acute graft-versus-host disease lethality. Blood 106:382a, 2005. e-Pub 2005.
638. Ricciardi MR, Scerpa MC, Ciuffreda L, Chiaretti S, Tavolaro S, Gervasoni J, De Cave F, Gregorj C, Petrucci MT, Del Bufalo D, Cognetti F, Andreeff M, Zupi G, Foa R, Tafuri A, Milella M. Effective targeting of MEK/ERK signaling at nanomolar concentrations by the novel small molecule inhibitor, PD0325901, in hematopoietic and solid tumors. Blood 106:942a, 2005. e-Pub 2005.
639. Samudio I, Konopleva M, Safe S, Andreeff M. Guggulsterones induce apoptosis and differentiation in AML: identification of isomer-specific antileukemic activities of the pregnanedienedione structure. Blood 106:4466, 2005. e-Pub 2005.
640. Samudio I, Konopleva M, Pelicano H, Huang P, Frolova O, Bornmann W, Y-M Y, Evans R, Andreeff M. A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me): direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Blood 106:4462, 2005. e-Pub 2005.
641. Tabe Y, Contractor R, Radke S, Andreeff M, Konopleva M. Novel role of HDAC inhibitors in bone marrow microenvironment: activation of leukemia cell phagocytosis through Annexin A1. Blood 106:626a, 2005. e-Pub 2005.
642. Tabe Y, Jin L, Tanaka N, Andreeff M, Konopleva M. Stroma-activated integrin-linked kinase (ILK) supports survival of leukemic cells via stimulation of Notch-Hes signaling: new therapeutic opportunities. Blood 106:693a, 2005. e-Pub 2005.
643. Thomas DA, Faderl S, Cortes J, O’Brien S, Giles F, Garcia-Manero G, Kornblau S, Andreeff M, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Kantarjian H. Outcome with the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 106:520a-521a, 2005. e-Pub 2005.
644. Thomas DA, Cortes J, O’Brien S, Faderl S, Ravandi F, Garcia-Manero G, Giles F, Beran M, Koller C, Wierda W, Verstovsek S, Ferrajoli A, Kornblau S, Keating M, Andreeff M, Kantarjian H. Update of the modified hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 106:521a, 2005. e-Pub 2005.
645. R-Y W, Fuller GN, McQueen T, Y-X S, Champlin RE, Andreeff M. Distribution and differentiation of donor-derived bone marrow stem cells in various areas of the human brain. Blood 106:481a, 2005. e-Pub 2005.
646. R-Y W, Carter BZ, Tsao T, Schober W, McQueen T, Konopleva M, Andreeff M. The role of apoptotic inducing factor (AIF) in acute myeloid leukemia (AML). Blood 106:666a-667a, 2005. e-Pub 2005.
647. Wierda WG, O’Brien S, Ferrajoli A, Faderl S, Koller C, Giles F, Cortes J, Thomas D, Ravandi F, Garcia-Manero G, Andreeff M, Lerner S, Kantarjian H, Keating M. Salvage therapy with combined cyclophosphamide ( C ), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL. Blood 106:213a, 2005. e-Pub 2005.
648. Zeng Z, Konopleva M, Nowak B, Plunkett W, Borthakur G, Estey E, Champlin R, Bridger G, Andreeff M. Disruption of leukemia/stroma cell interactions by CXCR4 antagonist AMD3465 enhances chemotherapy-induced apoptosis in AML. Blood 106:142a, 2005. e-Pub 2005.
649. Zeng Z, Estrov Z, Harris D, Giles F, Andreeff M, Konopleva M. Intra-pathway inhibition of upstream (PI3K) and downstream (mTOR) kinases synergistically induces apoptosis in AML. Blood 106:696a, 2005. e-Pub 2005.
650. Zhang W, Konopleva M, McQueen T, Cortes J, McCubrey J, Andreeff M. Raf inhibitor BAY 43-9006 induces Bim desphosphorylation and activates the intracellular apoptotic pathway in AML. Blood 106:941a, 2005. e-Pub 2005.
651. Y-X S, Konopleva M, Munsell M, Marini FC, Steelman LS, McCubrey JA, Andreeff M. Inhibition of ERK signaling suppresses leukemia derived from Raf-1 transformed hematopoietic cells. Proc Am Assoc Cancer Res 46:1508, 2005. e-Pub 2005.
652. Tsao T, Andreeff M, Konopleva M. DRIP205 co-activator overexpression enhances PPARgamma-mediated differentiation of leukemia cells by CDDO. Proc Am Assoc Cancer Res 46:1855, 2005. e-Pub 2005.
653. Kurinna SM, Samudio IJ, Contractor R, Ruvolo PP, Andreeff M, Konopleva M. The novel triterpenoid CDDO-Me promotes apoptosis in Gleevec-resistant chronic myeloid leukemia cells by caspase-independent mechanism. Proc Am Assoc Cancer Res 46:2240, 2005. e-Pub 2005.
654. Samudio I, Contractor R, Konopleva M, Andreeff M. The novel triterpenoid CDDOme potently synergizes with inhibition of bcl-2 function to induce apoptosis in AML via disruption of intracellular redox domeostasis. Proc Am Assoc Cancer Res 46:4955, 2005. e-Pub 2005.
655. Zapata JM, Kress CL, Konopleva M, Krajewska M, Hyer ML, McQueen T, Andreeff M, Reed JC. Triterpenoids show activity against leukemic cells in a transgenic mouse model of CLL. Proc Am Assoc Cancer Res 46:5179, 2005. e-Pub 2005.
656. Andreeff M, Dembinski J, Studeny M, Ling X, Hansen M, Xompetta C, McQueen T, Fueyo J, Champlin R, Marini F. Mesenchymal progenitor cells as gene delivery systems for cancer therapy: Tropism and efficacy. Proc Am Assoc Cancer Res 46:5302, 2005. e-Pub 2005.
657. Samudio I, Konopleva M, Jr HN, Y-X S, McQueen T, Hsu T, Evans R, Andreeff M. 2-cyano-3,12 dioxoolean-1,9 diene-28-imidazolide induces apoptosis in pancreatic cancer via redox-dependent cytoplasmic stress. Proc Am Assoc Cancer Res 46:5899, 2005. e-Pub 2005.
658. Zapata JM, Kress CL, Konopleva M, Krajewska M, Hyer M, McQueen T, Andreeff M, Reed JC. CDDO and CDDO-Im reduce tumor burden in a transgenic mouse model of CLL. Blood 104:948a, 2004. e-Pub 2004.
659. Konopleva M, Ruvolo P, Contractor R, Kurinna S, Shi Y, McQueen T, Milella M, Andreeff M. Triterpenoid methyl-CDDO is a potent inducer of apoptosis in CD34+ AML progenitor cells via activation of SAPK pathways and inhibition of MAPK cascades. Blood 104:694a, 2004. e-Pub 2004.
660. Zeng Z, Konopleva M, Estrov Z, Hu W, Carlson-Bremer D, Harris D, Carter BZ, Milella M, Lu Y, Mills GB, Andreeff M. Inhibition of AKT signaling by a small molecule KP372-1 induces apoptosis in AML. Proc Am Assoc Cancer Res 45:919, 2004. e-Pub 2004.
661. Kojima K, Konopleva M, Shikami M, Cabreira-Hansen M, Jackson CE, Shpall EJ, Kornblau SM, Vassilev LT, Andreeff M. Inhibition of p53-MDM2 interaction by small-molecule antagonist of MDM2 effectively induces apoptosis in leukemias. Blood 104:695a, 2004. e-Pub 2004.
662. Zeng Z, Evans RL, Huang Z, Andreeff M, Konopleva M. CXCR4 inhibition as a therapeutic strategy in leukemia. Blood 104:133a, 2004. e-Pub 2004.
663. Jiffar TW, Kurinna S, Suck G, Carlson-Bremer D, Ricciardi MR, Konopleva M, Andreeff M, Ruvolo PP. PKCa promotes chemoresistance in acute lymphoblastic leukemia derived REH cells by a Bcl2-dependent, MAPK-independent mechanism. Proc Am Assoc Cancer Res 45:779, 2004. e-Pub 2004.
664. Zhang W, Y-X S, McQueen T, M-C H, Madden T, Sporn MB, Andreeff M, Konopleva M. Synthetic triterpenoid CDDO as effective therapy for HER2-expressing resistant breast cancer. Proc Am Assoc Cancer Res 45:876-877, 2004. e-Pub 2004.
665. Andreeff M, Studeny M, Dembinski J, Cabreira-Hansen M, Zompetta C, McQueen T, Fueyo J, Champlin RE, Lang F, Marini FC. Mesenchymal progenitor cells as gene delivery systems for cancer and leukemia therapy. EJC 2(8):131, 2004. e-Pub 2004.
666. Andreeff M, Studeny M, Dembinski J, Konopleva M, Wang R, Yang H, Fueyo J, Champlin RE, Lang F, Marini FC. Mesenchymal stem cells as delivery systems for cancer and leukemia gene therapy. Proc Am Soc Clin Oncol 23:242, 2004. e-Pub 2004.
667. Georgakis GV, Li Y, Robin H, Andreeff M, Susan O, Albert V, Younes A. Selective agnostic monoclonal antibodies to the TRAIL receptors R1 and R2 induce cell death and potentiate the effect of chemotherapy and bortezomib in primary and cultured lymphoma cells. Proc Am Soc Clin Oncol 23:579, 2004. e-Pub 2004.
668. Andreeff M, Studeny M, Dembinski J, Cabreira-Hansen M, Zompetta C, H-Y Y, McQueen T, Fueyo J, Champlin RE, Pasqualini R, Lang Jr F, Marini III FC. Mesenchymal progenitor cells as gene delivery systems for cancer and leukemia therapy. Proc Am Assoc Cancer Res 45:1304, 2004. e-Pub 2004.
669. Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, O’Brien S, Plunkett W, Garcia-Manero G, Kantarjian H, Andreeff M. 2 chlorodeoxyadenosine (2-CdA) and cytarabine (Ara-C) combination is effective and safe in idiopathic hypereosinophilic syndrome (HES). Blood 104:274b, 2004. e-Pub 2004.
670. Contractor R, Samudio I, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva M. A novel ring-substituted diindolylmethane 1,1-bis[3’(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane abrogates ERK activation and induces apoptosis in acute myeloid leukemia (AML). Blood 104:927a, 2004. e-Pub 2004.
671. Contractor R, Konopleva M, Deng X, Harris D, Ruvolo P, Estrov Z, May WS, Rosenberg SH, Andreeff M. Inhibition of Bcl-2 signaling at nanomolar concentrations by small molecule BH3 inhibitor, ABT-737 as a novel therapeutic strategy in acute myeloid leukemia (AML). Blood 104:217a, 2004. e-Pub 2004.
672. Zhang W, Konopleva M, McQueen T, Schober W, Andreeff M. Induction of cell cycle arrest and apoptosis by dephosphorylation of ERK, Akt and Bcl-2 and phosphorylation of JNK by LY293111 in human anaplastic large cell lymphoma (ALCL). Blood 104:927a, 2004. e-Pub 2004.
673. Cheng X, Golemovic M, Giles F, Arlinghaus R, M-Z G, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. Organic arsenic lipid derivatives are more potent and less toxic than inorganic arsenic trioxide in preclinical testing. Blood 104:499a, 2004. e-Pub 2004.
674. Carter BZ, Schober WD, McQueen T, Evans RL, Andreeff M. Triptolide-induced apoptosis is dependent on caspase activation and NFkB signaling and mediated by XIAP and survivin downregulation through the mitochondrial pathway in leukemic cells. Blood 104:926a, 2004. e-Pub 2004.
675. Buglio D, Schober W, Contractor R, McQueen T, Zeng Z, Kantarjian H, Weiser MA, Andreeff M, Konopleva M. High glucose activates AKT signaling and induces upregulation of genes encoding glycolytic enzymes glut-1 and HK-2 in acute lymphocytic leukemia. Blood 104:565a, 2004. e-Pub 2004.
676. Biagi E, Popat U, Raphael R, Eric Y, Giampietro D, Lawrence R, Andreeff M, Brenner M. Immunotherapy of chronic lymphocytic leukemia using CD40L and IL2 expressing autologous tumor cells. Blood 104:220a, 2004. e-Pub 2004.
677. Thomas DA, Faderl S, Cortes J, O’Brien S, Giles F, Garcia G, Kornblau S, Andreeff M, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Kantarjian H. Updated of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 104:748a, 2004. e-Pub 2004.
678. Tsimberidou AM, Tirado-Gomez M, Andreeff M, O’Brien S, Kantarjian HM, Keating MJ, Lopez-Berestein G, Estey E. Single agent liposomal-encapsulated (lipo) all-trans retinoic acid (ATRA) can cure patients with untreated acute promyelocytic leukemia (APL): An update and comparison with an ATRA+idarubicin induction regimen. Proc Am Soc Clin Oncol 23:559, 2004. e-Pub 2004.
679. R-Y W, Fuller GN, Champlin RE, Andreeff M. Low frequency of donor-derived neuronal, glia, and endothelial cells in the cerebellum of patients undergoing sex-mismatched bone marrow transplantation. Blood 104:980a, 2004. e-Pub 2004.
680. Tabe Y, Jin L, Mills GB, Tsutsumi-Ishii Y, Andreeff M, Konopleva M. Mesenchymal stem cells promote survival of leukemic cells via integrin-linked kinase (ILK)-dependent Akt and STAT3 activation: Implications for leukemia therapy. Blood 104:922a, 2004. e-Pub 2004.
681. Tabe Y, Contractor R, Radke S, Andreeff M, Konopleva M. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis through histone acetylation and upregulation of Annexin A1 in AML1-ETO expressing Kasumi-1 cells. Blood 104:170b, 2004. e-Pub 2004.
682. Shikami M, Konopleva M, Samudio I, Hoshino K, Garcia-Manero G, Kojima K, Tsao T, McQueen T, Andreeff M. ARTS, a pro-apoptotic mitochondrial septin-like protein that binds to XIAP, is silenced in acute lymphoblastic and primitive acute myeloblastic leukemia cells. Blood 104:922a, 2004. e-Pub 2004.
683. Schimmer AD, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, Schober WD, Nefzi A, Houghten R, Brandwein J, Minden MD, Schuh A, Wells RA, Messner H, Reed JC, Carter BZ. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of leukemia cell lines and patient samples. Blood 104:217a, 2004. e-Pub 2004.
684. Ricciardi MR, Konopleva M, Ruvolo PP, McQueen T, Milella M, Andreeff M. Pro-apoptotic synergistic interactions between ERK1/2 and Bcl-2 inhibitors in acute myeloid leukemia cells. Blood 104:928a, 2004. e-Pub 2004.
685. Wierda W, Faderl S, O’Brien S, Cortes J, Ferrajoli A, Giles F, Andreeff M, Koller C, Kantarjian H, Keating M. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL. Blood 104:101a, 2004. e-Pub 2004.
686. Yee KWL, Garcia-Manero G, Thomas D, Ravandi-Kashani F, Verstovsek S, Andreeff M, Dancey JE, Giles FJ. A phase II study of temsirolimus (CCI-779) in patients with advanced leukemias. Blood 104:214b, 2004. e-Pub 2004.
687. Milella M, Konopleva M, Tabe Y, Precupanu C, Gregorj C, Ricciardi MR, Petrucci MT, Cognetti F, Tafuri A, Andreef M. MEK blockade converts AML differentiating response to retinoic acid (RA) into extensive apoptosis: Involvement of Bcl-2 modulation and ROS accumulation. EJC 2(8):107, 2004. e-Pub 2004.
688. Kornblau SM, Womble M, Jackson E, Chen WJ, Estey E, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia (AML). Blood 104:818a, 2004. e-Pub 2004.
689. Sampath D, Cortes J, Du M, Terry N, Shi Z, Andreeff M. Action of 7hydroxystaurosporine (UCN-01) in combination with ara-C on S phase checkpoint activation and survival pathways during therapy of AML. Proc Am Assoc Cancer Res 44:679, 2003. e-Pub 2003.
690. R-Y W, Fuller GN, Sahin AA, Luna MA, de Lima MJ, Champlin RE, Andreeff M. Transdifferentiation of bone-marrow derived stem cells is infrequent in organs and absent in tumor metastases. Blood 102:337a, 2003. e-Pub 2003.
691. Konopleva M, Hu W, Carlson-Bremer D, Zeng Z, Carter BZ, Milella M, Lu Y, Mills GB, Andreeff M. Inhibition of AKT signaling by a small molecule KP372-1 induces apoptosis in AML. Blood 102:258b, 2003. e-Pub 2003.
692. Konopleva M, Shi Y, Steelman LS, Shelton JG, Contractor R, McCubrey JA, Andreeff M. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf and Bcl-2 transformed hematopoietic cells. Blood 102:625a, 2003. e-Pub 2003.
693. Konopleva M, Ruvolo P, Contractor R, Kurinna S, Xie Z, Milella M, Andreeff M. Suppression of ERK activation is required for triterpenoid methyl-CDDO-induced apoptosis in AML. Blood 102:387a, 2003. e-Pub 2003.
694. Konopleva MY, Hu WX, Lu Y, Carter BZ, Mills GB, Andreeff M. Inhibition of AKT signaling induces apoptosis in myeloid leukemia. Proc Am Assoc Cancer Res 44:1271, 2003. e-Pub 2003.
695. Konopleva M, Lapillonne H, Y-X S, McQueen T, Tsao T, Gold DL, Johansen MJ, Madden TL, Andreeff M. Synthetic triterpenoid CDDO as a novel therapy for resistant breast cancer. Proc Am Assoc Cancer Res 44:623, 2003. e-Pub 2003.
696. Wierda W, O’Brien S, Ferrajoli A, Faderl S, Kornblau SM, Andreeff M, Koller C, Garcia-Manero G, Thomas D, Kantarjian H, Keating M. Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL. Blood 102:360b, 2003. e-Pub 2003.
697. Milella M, Konopleva M, Tabe Y, Precupanu C, Gregorj C, Carter BZ, Kornblau SM, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoic acid (RA) into extensive apoptosis. Blood 102:595a, 2003. e-Pub 2003.
698. Thomas DA, Cortes J, Giles F, O’Brien S, Faderl S, Garcia-Manero G, Beran M, Koller C, Andreeff M, Kornblau S, Keating M, Kantarjian H. Update of the modified hyper-CVAD regimen in newly diagnosed adule acute lymphocytic leukemia (ALL). . Blood 102:880a, 2003. e-Pub 2003.
699. Johansen MJ, Scholz C, Newman RA, Thapar NC, Andreeff M, Konopleva M, Madden T. Pharmacology and preclinical pharmacokinetics of the triterpenoid CDDO methyl ester. Proc Am Assoc Cancer Res 44:392, 2003. e-Pub 2003.
700. Ricciardi MR, Konopleva M, Mills GB, Andreeff M. AKT inhibitor KP372-1 induces growth arrest, apoptosis and downregulation of phospho-ERK1/2 in primary AML cells. Blood 102:625a, 2003. e-Pub 2003.
701. Thomas DA, Faderl S, Cortes J, O’Brien S, Giles FJ, Garcia-Manero G, Keating M, Kornblau S, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Kantarjian H. Update of the hyper-CVAD and Imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 102:225a, 2003. e-Pub 2003.
702. Thomas DA, Garcia-Manero G, Cortes J, O’Brien S, Jeha S, Andreeff M, Kornblau SM, Letvak L, Talpaz M, Kantarjian HM. Results of intensive chemotherapy with hyper-CVAD and Imatinib mesylate in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Proc Am Soc Clin Oncol 102:225a, 2003. e-Pub 2003.
703. Ricciardi MR, Konopleva M, Ruvolo P, McQueen T, Milella M, Sneed T, Andreeff M. Simultaneous inhibition of MAPK and Bcl-2 signaling by novel small-molecule inhibitors synergistically induces apoptosis in AML cells at nanomolar concentrations. Blood 102:624a, 2003. e-Pub 2003.
704. Ricciardi MR, McQueen T, Milella M, Edwards K, Kaldjian E, Sebolt-Leopold J, Konopleva M, Andreeff M. Constitutive MAPK phosphorylation and pharmacodynamic inhibitio of MEK/MAPK in relapsed/refractory primary acute myelogenous leukemia (AML) cells. Blood 102:389a, 2003. e-Pub 2003.
705. Gregorj C, Petrucci MT, De Cave F, Scerpa MC, Vitale A, Ricciardi MR, Precupanu C, Cimino G, Mancini M, Vignetti M, Milella M, Andreeff M, Mandelli F, Foa R, Tafuri A. Expression and role of extracellular signal-regulated kinase-1/2 (ERK) and p21CIP-1/WAF1 in primary adult acute lymphoblastic leukemia cells. 102 102:382a, 2003. e-Pub 2003.
706. M-C G, Qiu J, Kornblau SM, Andreeff M, Margolin JF. Identification of low- and high-risk marks in acute lymphoblastic leukemia. Blood 102:557a, 2003. e-Pub 2003.
707. J-J B, R-Y W, Brey E, Andreeff M, Patrick CW, Atkinson EN, Yu Y, Bast RC. Reexpression of the ARHI gene suppresses motility of ovarian cancer. Proc Am Assoc Cancer Res 44:1003, 2003. e-Pub 2003.
708. Giles F, Kantarjian H, Cortes J, Tsimberidou A, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Weirda W, Ferrajoli A, Kornblau S, Andreeff M, O’Brien S, Beran M, Estey E. Adaptive randomized study of idarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS). Bllod 102:253b, 2003. e-Pub 2003.
709. Georgakis GV, Li Y, Humphreys R, Johnson R, Andreeff M, Fiscella M, Pukac L, O’Brien S, Albert V, Younes A. Activity of selective agonistic monoclonal antibodies to TRAIL death receptors R1 and R2 in primary and cultured tumor cells of hematological origin. Blood 102:228a, 2003. e-Pub 2003.
710. Tabe Y, Contractor R, Konopleva M, Igari J, Andreeff M. Combination of histone deacetylase inhibitor depsipeptide (KF228) and ATRA enhances differentiation in ATRA-sensitive and –resistant APL cells. . Blood 102:258b, 2003. e-Pub 2003.
711. Andreeff M, Studeny M, Dembinski J, Cabreira-Hansen M, Zompetta C, Champlin RE, Chada S, JrFF L, Marini III FC. Mesenchymal progenitor cells as gene delivery systems for cancer and leukemia therapy. Blood 102:60a, 2003. e-Pub 2003.
712. Frolova O, Konopleva M, Ricciardi M, Andreeff M, Kornblau S. Development of an in vivo murine model to evaluate the efficacy of small molecule inhibitors for the treatment of leukemic cells with activated MAPK/ERK signaling. Blood 102:195b, 2003. e-Pub 2003.
713. Andreeff M, Studeny M, Dembinski JL, Zompetta C, Cabreira-Hansen M, Champlin RE, Marini III FC. Targeted delivery of biological agents by mesenchymal stem cells: A new paradigm for cancer therapy. Proc Am Assoc Cancer Res 44:1485, 2003. e-Pub 2003.
714. Tabe Y, Konopleva M, Contractor R, Igari J, Andreeff M. Upregulation of MDR1 and induction of doxorubicin resistance by synergistic use of histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 102:860a, 2003. e-Pub 2003.
715. Suck G, Jiffar T, Konopleva M, Andreeff M, Ruvolo P. Dysregulation of PP2A activity by a mechanism involving suppressed PP2A a expression may result in chemoresistance in AML. Blood 102:214b, 2003. e-Pub 2003.
716. Contractor R, Konopleva M, Samudio I, Safe S, Andreeff M. Mechanisms of apoptosis inhibition by a novel ring-substituted diindolylmethane (1,1-bis[3'-(5-methoxy indolyl)]-1-[p-t-butylphenyl]methane) (BMIPTM) in leukemic cells. Blood 102:261b, 2003. e-Pub 2003.
717. Sneed TB, Konopleva M, Ruvolo P, Rosenberg S, Andreeff M. Cell permeable small molecule inhibitors of BH3 induce apoptosis in myeloid cell lines. Blood 102:627a, 2003. e-Pub 2003.
718. Navolanic PM, Steelman LS, Leslie NR, Coffer PJ, Konopleva M, Hu W, Andreeff M, Blagosklonny MV, McMahon M, McCubrey JA. Induction of in vitro chemotherapeutic drug resistance by activation of Raf/MEK/ERK or PI3K/PDK/AKT signal transduction pathways in MCF-7 breast cancer cells. Proc Am Assoc Cancer Res 44:465, 2003. e-Pub 2003.
719. Scholz C, Johansen MJ, Newman R, Andreeff M, Konopleva M, Madden T. Sensitive and specific method for the determination of CDDO methyl ester in mouse, rate, dog, monkey and human plasma by LC-tandem mass spectrometry. Proc Am Assoc Cancer Res 44:1448, 2003. e-Pub 2003.
720. Carter BZ, Schober WD, McQueen T, Andreeff M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: Survivin as a therapeutic target in STI571 resistant CML cells. Blood 102:651a, 2003. e-Pub 2003.
721. Carter BZ, Milella M, R-Y W, Schober WD, Chism D, Andreeff M. Targeting survivin expression induces G2/M block and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Proc Am Assoc Cancer Res 44:23, 2003. e-Pub 2003.
722. Ling X, Marini F, Andreeff M, X-F L, Bast R, Arlinghaus RB. An efficient and stable lentivirus-mediated gene transduction system designed for enhanced gene expression in hematopoietic cells. Blood 102:497b, 2003. e-Pub 2003.
723. Bolontrade MF, Worth LL, Zhou Z, Andreeff M, Kleinerman ES. Bone marrow-derived stem cells contribute to vascular growth in Ewing’s sarcoma tumors. Proc Am Assoc Cancer Res 44:466, 2003. e-Pub 2003.
724. Andreeff, M, Tsao T, Lapillonne H, Sudarikov A, McQueen T, Hu W, Monaco G, R-Y W, Belmont J, Sporn M, Konopleva M. PPARgamma nuclear receptor as a novel modecular target in leukemias:149, 2002. e-Pub 2002.
725. Andreeff, M, Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ. Bone marrow-derived mesenchymal stem cells are precursors for stromal fibroblasts in tumors: Impleciations for cancer therapy. Proc Am Assoc Can Res 43:594, 2002. e-Pub 2002.
726. Andreeff, M, Milella M, Konopleva M. Induction of apoptosis in AML by HA14-1, a small molecule Bcl-2 antagonist is independent of caspases-8 and –9. Blood 100:543a, 2002. e-Pub 2002.
727. Apostolidou, E, Garcia-Manero G, Cortes J, Thomas D, Andreeff M, Keating M, Tallman M, Kantarjian H, Giles F. Phase I study of OSI-211, a novel liposomal topoisomerase 1 (Topo 1) inhibitor, in patients with refractory leukemia. Blood 100:262b, 2002. e-Pub 2002.
728. Ater, J, Okcu MF, Wang RY, Schober W, Weidner D, Andrassy J, Blakely M, Bueso-Ramos C, Andreeff M, Chan KW. Flow cytometry (FCM) and fluorescence in situ hybridization (FISH) to detect residual neuroblastoma (NB) cells in bone marrow (BM). Proc Am Soc Clin Oncol 21:400a, 2002. e-Pub 2002.
729. Bao, J-J, X-F L, R-Y W, Andreeff M, Yu Y, Bast RC. ARHI induces apoptosis through a caspase-in ependent pathway. Proc Am Assoc Can Res 43:620, 2002. e-Pub 2002.
730. Biagi, E, Rousseau RF, Yvon E, Takahashi S, Rill D, Marini F, Andreeff M, Popat U, Brenner MK. CD40-activated, IL-2 transduced chronic lymphocytic leukemia B-cells (B-CLL) express high levels of CD40L, B7-1: Feasability for immunotherapy of CLL. Proc Am Assoc Can Res 43:557, 2002. e-Pub 2002.
731. Bolontrade, MF, Worth LL, Marini FC, Andreeff M, Kleinerman ES. Bone marrow-derived cells participate in the formation of tumor vasculature in Ewing’s carcinoma. Blood 100:159b, 2002. e-Pub 2002.
732. Carter, BZ, Milella M, Schober WD, Chism D, Andreeff M. Targeting survivin expression induces G2/M block and subsequent cell death in myeloid leukemic cells. Blood 100:270b, 2002. e-Pub 2002.
733. Cortes, J, Talpaz M, O’Brien S, Giles F, Kornblau SM, Andreeff M, Rios MB, Kantarjian HM. Significance of lack of early cytogenetic (CG) response after therapy with imatinib mesylate in relation to later achievement of major or complete CG response in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML). Blood 100:787a, 2002. e-Pub 2002.
734. Fujii, S, Yuan J, Luo RZ, Hu W, Andreeff M, Kadota M, Oshimura M, J-P I, Bast, JrRC, Yu Y. Transcriptional reactivation of the imprinted tumor suppressor gene ARHI in human breast cancer by inhibition of histone deacetylase. Proc Am Assoc Can Res 43:1116, 2002. e-Pub 2002.
735. Garcia-Manero, G, Faderl S, Giles F, Verstovsek S, Beran M, Andreeff M, Cortes J, Thomas D, Koller C, Pierce S, Ouzonian S, Kantarjian H, Estey E. Double induction (DI) chemotherapy for patients (pts) with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). Blood 100:342a, 2002. e-Pub 2002.
736. Hu, G, Khodadoust M, Konopleva M, Huang Z, Andreeff M. Induction of apoptosis in lymphoid cell lines and primary CLL by HA14-1, a cell permeable organic small molecule that binds to the BH1 to BH3 surface pocket of Bcl-2 protein. Proc Am Assoc Can Res 43:873, 2002. e-Pub 2002.
737. Hu, W, Konopleva M, Lu Y, Carter BZ, Mills GB, Andreeff M. New AKT inhibitor KP-302 induces apoptosis in myeloid leukemia. Blood 100:269b, 2002. e-Pub 2002.
738. Konopleva, M, Lapillonne H, Clay CE, McQueen T, Studeny M, Madden T, Sporn M, Andreeff M. Activation of nuclear transcription factor PPAR-gamma by the novel triterpenoid CDDO as targeted therapy in breast cancer:158, 2002. e-Pub 2002.
739. Konopleva, MY, Tsao T, Lapillonne HF, Sudarikov A, McQueen T, Hu WX, Monaco G, R-Y W, Belmont J, Sporn MB, Andreeff M. PPAR-gamma nuclear receptor as a novel molecular target in leukemia therapy. . Proc Am Assoc Can Res 43:955, 2002. e-Pub 2002.
740. Konopleva, M, Lapillonne H, Lee R, R-Y W, Tsao T, McQueen T, Andreeff M. PPARgamma ligand CDDO induces apoptosis in leukemias via multiple apoptosis pathways. Blood 100:562a, 2002. e-Pub 2002.
741. Kornblau, SM, Womble MF, Qiu YH, Cade JS, Thomas D, Cortes J, Garcia-Manero G, Jackson CE, Andreeff M. A prospective study of apoptosis related proteins BCL2, Bax, PKCa, ERK2 & pERK in AML. Blood 100:329a, 2002. e-Pub 2002.
742. Kornblau, SM, Qiu YH, Womble M, Cade JS, Jackson CE, Andreeff M. Patterns of expression of apoptosis regulating proteins in survivor cells from AML patients may predict response to therapy. Blood 100:329a, 2002. e-Pub 2002.
743. Kornblau, SM, Qiu YH, Womble WF, Cade JS, Jackson CE, Milella M, Konopleva M, Andreeff M. Effect of MEK inhibition with PD184352 + Ara-c on patterns of expression of apoptosis regulating proteins in acute myelogenous leukemia (AML) surivivor cells. Blood 100:732a, 2002. e-Pub 2002.
744. Lapillonne, H, Hu W, Schober WD, Weidner DA, Andreeff M. ABC transporters and cell cycle regulators in SP+/lin- cells in AML: Comparison to normal SP+/lin- cells. Blood 100:181b, 2002. e-Pub 2002.
745. Ricciardi, MR, McQueen T, Chism DD, Milella M, Edwards K, Andreeff M. Flow cytometric monitoring of constitutive MAPK phosphorylation and of pharmacodynamic MEK/MAPK inhibition in primary AML samples. Blood 100:270b, 2002. e-Pub 2002.
746. Tabe, Y, Konopleva M, Tsao T, Lapillonne H, Jackson CE, Andreeff M. Chromatin-mediated transcriptional activation with novel peroxisome proliferator-activated receptor gamma(PPARgamma) ligand 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) in acute promyelocytic leukemia cells. Blood 100:557a, 2002. e-Pub 2002.
747. Tabe, Y, Konopleva M, Kondo Y, J-P I, Andreeff M. Effects of histone deacetylase inhibitor suberoylanikide hydroxamic acid (SAHA) and DNA methylation inhibitor 5-Aza-2’deoxycytidine (DAC) on the transcriptional activation of RAR-beta and p21WAF in acute promyelocytic leukemia cells. Blood 100:765a, 2002. e-Pub 2002.
748. Thomas, DA, Cortes J, Garcia-Manero G, Faderl S, O’Brien S, Pierce S, Verstovsek S, Giles FJ, Andreeff M, Kornblau SM, Letvak L, Kantarjian HM. Minimal residual disease (MRD) after hyper-CVAD and Imatinib mesylate (STI571) for Philadelphia (PH) positive adult acute lymphoblastic leukemia (ALL). Blood 100:764a, 2002. e-Pub 2002.
749. Yuan, J, Luo RZ, Fujii S, Hu W, Andreeff M, Kadota M, Oshimura M, J-P I, Bast, JrRC, Yu Y. Aberrant methylation inhibits expression of the imprinted tumor suppressor gene ARHI in human breast cancer. Proc Am Assoc Can Res 43:1114, 2002. e-Pub 2002.
750. Garcia-Manero G, Kwari M, Cortes J, Faderl S, Giles F, O’Brien S, Koller C, Quackenbush R, Andreeff M, Beran M, Kantarjian H, Berd D, Estey E. Immunotherapy with an autologous cell vaccine in patients with acute myelogenous leukemia (AML) in second remission. Blood 98:212b, 2001. e-Pub 2001.
751. Tsimberidou AM, O’Brien S, Cortes J, Faderl S, Andreeff M, Kantarjian H, Keating M, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) treatment of patients with Richter’s syndrome (RS), refractory prolymphocytic leukemia (PLL) or refractory non-Hodgkin’s lymphoma (NHL). Blood 98:250b, 2001. e-Pub 2001.
752. Kantarjian HM, Cortes J, O’Brien S, Faderl S, Thomas D, Giles F, Garcia-Manero G, Albitar M, Andreeff M, Kornblau SM, Rios MB, Shan J, Beran M, Koller CA, Resta D, Capdeville R, Estey EH, Keating MJ, Freireich EJ, Talpaz M. Results of imatinib mesylate (STI571) in Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (Ph+ CML-CP) post interferon alpha (IFN) failure. Blood 98:260b, 2001. e-Pub 2001.
753. Zhao S, Calvert L, Chang S, Arlinghaus RB, Guo JQ, Siciliano M, Riley R, Kantarjian H, Andreeff M. Detection of BCR-ABL fusion mRNA, protein and Ph’ chromosome in CML patients in complete hematological remission: Comparison of real-time Taqman PCR, RT-PCR, Western blot, FISH and cytogenetics. Blood 98:269b, 2001. e-Pub 2001.
754. Khodadoust M, Konopleva M, Leysath C, Frankel SR, Giles FJ, Andreeff M. Bcl-2 antisense oligodeoxynucleotide (Genasense) enhanced gemtuzumab ozogamicin (Mylotarg)-induced cytotoxicity in acute myeloid leukemia. Blood 98:102a, 2001. e-Pub 2001.
755. Hu W, Konopleva M, McCubrey J, Milella M, McQueen T, Zhao S, Andreeff M. PI3K/Akt as a potential therapeutic target in AML. Blood 98:103a, 2001. e-Pub 2001.
756. W-S S, Shinichi K, Kim Y, Andreeff M, Sporn M, Suh N, Reed JC. Triterpenoids CDDO and CDDO-Me down-regulate FLIP expression and sensitize AML cells to TRAIL-induced apoptosis. Blood 98:118a, 2001. e-Pub 2001.
757. Konopleva M, McQueen T, Tsao T, Monaco G, Lapillonne H, R-Y W, Younes A, Belmont J, Sporn MB, Andreeff M. PPAR ligands are potent inducers of apoptosis in leukemias and lymphomas. Blood 98:119a, 2001. e-Pub 2001.
758. Lapillonne H, Hu W, Weidner DA, Champlin RE, Andreeff M. Cyclin E expression is low in early CD34+CD38- progenitor cells in acute myelogenous leukemia (AML). Blood 98:324a, 2001. e-Pub 2001.
759. Konopleva M, Cortes J, S-C C, Hayes K, Giles F, O’Brien S, Kantarjian H, Andreeff M, Estey E. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed AML, RAEB-t, or RAEB. Blood 98:328a, 2001. e-Pub 2001.
760. Tsao T, Konopleva M, Sporn MB, Andreeff M. Targeted induction of apoptosis in leukemias by PPAR ligation. Blood 98:568a, 2001. e-Pub 2001.
761. Thomas DA, Cortes J, Giles FJ, O’Brien S, Faderl S, Koller C, Beran M, J-P I, Garcia-Manero G, Estey E, Pierce S, Andreeff M, Kornblau S, Keating M, Kantarjian H. The modified hyper-CVAD regimen in newly diagnosed adult acute lymphoblastic leukemia (ALL). Blood 98:590a, 2001. e-Pub 2001.
762. Giles FJ, Faderl S, Thomas DA, Cortes J, Jeha SS, Garcia-Manero G, Douer D, Levine AM, Estey EH, Beran M, O’Brien S, Koller C, Andreeff M, H: K. Troxatyl plus topotecan, Ara-C, or idarubicin in patients (pts) with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or blastic-phase chronic myeloid leukemia (CML-BP): A randomized phase I/II study. Blood 98:594a, 2001. e-Pub 2001.
763. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Andreeff M, Cabanillas F, Carbone A, Aggarwal B, Younes A. Differential activity of TRAIL/apo-2L in Hodgkin disease (HD) and CD30+ lymphoid cell lines is independent of CD30 activation. Blood 98:599a, 2001. e-Pub 2001.
764. Guo JQ, Lin H, Kantarjian H, Talpaz M, Glassman A, Andreeff M, Champlin R, Arlinghaus RB. Large scale comparison of real-time and competitive quantitative RT-PCR in chronic myelogenous (CML) patients. Blood 98:614a, 2001. e-Pub 2001.
765. Studeny M, Marini FC, Zompetta C, Champlin RE, Fidler IJ, Andreeff M. Bone marrow derived mesenchymal stem cells serve as precursors for stromal fibroblasts in malignant tumors and show potential for cancer therapy. Blood 98:696a, 2001. e-Pub 2001.
766. Abbott BL, A-M C, Barnes Y, Marini F, Andreeff M, Sorrentino B. ABCG2 expression is an infrequent cause of drug resistance in adult AML. Blood 98:716a, 2001. e-Pub 2001.
767. Andreeff M, Konopleva M, Leysath C, Khodadoust M, Huang Z. Induction of apoptosis in primary human leukemia cells by HA14-1, a cell-permeable organic compound identified by protein structure-based computer screening that binds the BH1 to BH3 surface pocket of Bcl-2. AACR-NCI-EORTC International Conference 7:3722s, 2001. e-Pub 2001.
768. Schoffski P, Tacke F, Trautwein C, Andreeff M, Marini III FC, Manns MP, Ganser A. Thrombopoietin serum levels are not decreased in liver transplant candidates, but elevated in patients with chronic hepatitis B/C infection. Blood 98:37a, 2001. e-Pub 2001.
769. Tsimberidou A, Thomas DA, O’Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian HM, Giles FJ. Recombinant human soluble tumor necrosis factor receptor (P75) fusion protein (TNFR: Fc) (Enbrel) in patients with refractory hematological malignancies. Blood 98:280b, 2001. e-Pub 2001.
770. Kornblau SM, Milella M, Ball G, Qiu YH, Ruvolo P, Estrov Z, Beran M, Kantarjian H, May WS, Andreeff M. ERK2 and phospho-ERK2 are prognostic for survival in AML and complement the prognostic impact of Bax and Bcl-2. Blood 98:716a, 2001. e-Pub 2001.
771. Konopleva M, McQueen T, Tsao T, Monaco G, Wang R, Belmont J, Sporn M, Andreeff M. PPAR nuclear receptor as a novel therapeutic target in leukemia. AACR-NCI-EORTC International Conference 7:3722s, 2001. e-Pub 2001.
772. Carter BZ, Milella M, Kornblau SM, Schober WD, Tsao T, Contreras P, Reed JC, Andreeff M. Expression and regulation of XIAP in acute myeloid leukemia by MAPK and PI3K signaling. Blood 98:761a, 2001. e-Pub 2001.
773. Tabe Y, Konopleva M, Marini FC, Zompetta C, McQueen T, Munsell MF, Pierce S, Jackson CE, Estey E, Andreeff M. Expression of PML-RAR in APL cells is associated with induction of leptin receptor (OB-R): Putative role of mesenchymal stem cell derived-adipocytes in survival of APL cells. Blood 98:764a, 2001. e-Pub 2001.
774. Wierda W, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Kantarjian H, Keating M. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 98:771a, 2001. e-Pub 2001.
775. Andreeff M, Leysath C, Konopleva M, Huang Z. Induction of apoptosis in primary human leukemia cells by HA14-1, a cell-permeable organic compound identified by protein structure-based computer screening that binds the BH1 to BH3 surface pocket of Bcl-2. AACR 42:28, 2001. e-Pub 2001.
776. Marini F, Zoltick P, Zompetta C, Wang RY, Wilson JM, Andreeff M. Novel CML therapy using mesenchymal stem cells (MSC) to deliver localized regulated interferon-2B (IFN-). AACR 42:455, 2001. e-Pub 2001.
777. Pan Y, Luo RZ, Peng H, Bao J, Hu W, Andreeff M, Issa JP, Bast RC, Yu Y. Aberrant methylation of an imprinted tumor suppressor gene ARHI in human breast cancer cells. AACR 42:475, 2001. e-Pub 2001.
778. Bolontrade MF, Zhou RR, Andreeff M, Weidner DA, Kleinerman ES. Role of bone marrow derived cells in the development of Ewing’s sarcoma. AACR 42:566, 2001. e-Pub 2001.
779. Pahler JC, Niemer I, Clavert LR, Andreeff M, Keating M, McConkey DJ. Proteasome inhibitor-induced apoptosis is associated with immediate disruption of mitochondrial function. AACR 42:636, 2001. e-Pub 2001.
780. Konopleva MY, Elstner E, McQueen T, Tsao T, Estrov Z, Koeffler HP, Sporn M, Andreeff M. PPARg nuclear receptor as a novel therapeutic target in AML. AACR 42:830, 2001. e-Pub 2001.
781. Andreeff M, Giles F, Kornblau S, Konopleva M, Leysath C, Jackson CE, Edwards K, Ross B, Faldas M, Williams A, Estey E, Kantarjian H. Phase I study of Annamycin, A novel liposomal anthracycline, in patients with relapsed/refractory acute myeloid and lymphoid leukemias. ASCO 20:303, 2001. e-Pub 2001.
782. Kayl AE, Seabrooke LF, Forman AD, Andreeff M. Dementia associated with idiopathic hypereosinophilic syndrome: A case Report. Archives of Clin Neuropsychology 8, 2001. e-Pub 2001.
783. Johansen MJ, Newman RA, Andreeff M, Konopleva M, Madden T. Preclinical toxicology of single and multiple doses of CDDO, a novel triterpenoid antitumor agent. AACR-NCI-EORTC International Conference 7:3707s, 2001. e-Pub 2001.
784. O’Brien S, Giles F, Rai K, Andreeff M, Cunningham C, Frankel S, Keating M. Bcl-2 antisense (Genasense) as monotherapy for refractory chronic lymphocytic leukemia. Blood 98:772a, 2001. e-Pub 2001.
785. R-Y W, Fuller GN, Luna MA, De Lima M, Champlin RE, Andreeff M. Bone marrow origin of epithelial cells of multiple organs in human sex-mismatched bone marrow transplant recipients. Blood 98:791a, 2001. e-Pub 2001.
786. Milella M, Estrov Z, Kornblau SM, Konopleva M, Tari AM, Carter BZ, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 98:840a, 2001. e-Pub 2001.
787. Hu G, Khodadoust M, Konopleva M, Huang Z, Andreeff M. Induction of apoptosis in lymphoid cell lines and primary CLL by HA14-1, a cell permeable organic small molecule that binds to the BH1 to BH3 surface pocket of Bcl-2 protein. Blood 98:840a, 2001. e-Pub 2001.
788. R-Y W, Hayes K, Andreeff M. Unexpected t(18;21)(q21;q22) with translocation of the AML1 gene to chromosome 18q21 in HL60 cells transduced with Bcl-2. Blood 98:156b, 2001. e-Pub 2001.
789. Andreeff M, McQueen T, Edwards K, Cortes J, Giles F, Estey E, Konopleva M, Kornblau SM. Caspase independent cell death in AML: An in vivo study in patients undergoing chemotherapy. Blood 98:208b, 2001. e-Pub 2001.
790. Keating MJ, O’Brien S, Lerner S, Giles F, Andreeff M, Cortes J, Albitar M, Kantarjian H. Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL). Blood 96(11):514a, 2000. e-Pub 2000.
791. Marini F, Zompetta C, Wang RY, Studeny M, Zoltick P, Wilson J, Andreeff M. Mesenchymal stem cells (MSC) from patients with chronic myelogenous leukemia (CML) patients can be transduced with common gene transfer vectors at high efficiency, and are genotypically normal. Blood 96(11):740a, 2000. e-Pub 2000.
792. Marini F, Zoltick P, Zompetta C, Wilson J, Andreeff M. Novel CML therapy using mesenchymal stem cells (MSC) to deliver localized regulated interferon-alpha 2B (INF). Blood 96(11):738a, 2000. e-Pub 2000.
793. Milella M, Estrov Z, Carter BZ, Harris D, Sebolt-Leopold J, Andreeff M. The MEK/ERK kinase module: A potential new targer for AML therapy. Blood 96(11), 2000. e-Pub 2000.
794. Wang RY, Weidner D, McQueen T, Andreeff M. Quantitative determination of Bcl-2 in FACS-sorted single cells by laser scanning cytometry (LSC): Comparison with flow cytometric and Western blot analysis. Blood 96(11):717a, 2000. e-Pub 2000.
795. Zhao S, Konopleva M, Xie Z, Hu W, Estrov Z, Milella M, Mills G, Andreeff M. Inhibition of PI3K by LY294002 promotes apoptosis and dephosphorylates BAD in myeloid leukemias. Blood 96(11), 2000. e-Pub 2000.
796. Veiga JP, Nunes R, Konopleva M, Sallan SE, Sporn MB, Nadler LM, Andreeff M, Cardoso AA. The synthetic triterpenoid CDDO-me is an effective inhibitor of the leukemia-associated de novo angiogenesis. Blood 96(11), 2000. e-Pub 2000.
797. Suh WS, Eksioglu-Demiralp E, Kitada S, Andreeff M, Champlin RE, Reed JC. Defect in caspase activation pathway in AML and blast crisis AML. Blood 96(11), 2000. e-Pub 2000.
798. Monaco G, Konopleva M, Zhao S, Leysath C, Estey E, Belmont JW, Andreeff M. Engraftment potential of AML progenitors into NOD/scid mice: Correlation with baseline CXCR4 expression. Blood 96(11), 2000. e-Pub 2000.
799. Marini F, Zompetta C, von Seggern D, Nemerow G, Wickham T, Kovesdi I, Andreeff M. Biodistribution of 2 modified Ad5 adenovirus vectors (Adv) in mice, the enhanced infection AdpK7, and the fiber deleted Ad5.F: Ablation of both the fiber/CAR and integrin/penton interactions is necessary to block infection. Gene Therapy of Cancer Conference, 2000. e-Pub 2000.
800. Marini F, Zoltick P, Zompetta C, Wilson JM, Andreeff M. Mesenchymal stem cells (MSC) to deliver localized regulated interferon-alpha 2B (INF): A novel CML therapy. Gene Therapy of Cancer Conference, 2000. e-Pub 2000.
801. Grant S, Cragg L, Feldman E, Andreeff M, Roberts J, Tombes MB, Winning M. Phase I trial of high-dose 1-B-D-arabinofuranosylcytosine (HiDAC) and bryostatin 1 (NSC 339555) in patients with refractory acute myelogenous or lymphoblastic leukemia and CML-myeloid blast crisis (CML-MBC). Blood 96(11):323a, 2000. e-Pub 2000.
802. Pahler JC, Niemer I, Calvert L, Andreeff M, Keating M, McConkey DJ. Proteasome inhibitor-induced apoptosis in CLL is associated with immediate disruption of mitochondrial function. Blood 11(513a), 2000. e-Pub 2000.
803. Konopleva M, Calvert L, Leysath C, McQueen T, Edwards K, Talpaz M, Kantarjian H, Andreeff M. CML bone marrow progenitors are CXCR4-deficient: Restored expression after interferon alpha treatment in vivo. Blood 96(11):738a, 2000. e-Pub 2000.
804. Konopleva MY, Hayes KJ, Pierce SA, Zhao L, Andreeff M, Glassman AB, Freireich EJ, Estey EH. Day 21 cytogenetics (CG) to stratify patients with AML and -5/-7 into chemosensitive and resistant groups. Blood 96(11):707a, 2000. e-Pub 2000.
805. Konopleva M, Stiouf I, Estrov Z, Tsao T, Harris D, Munsell M, Leysath C, Zhao S, Jackson CE, Chang S, Sporn M, Andreeff M. Novel synthetic triterpenoid CDDO-me: Potent antiproliferative, proapoptotic and differentiating agent in AML. Blood 96(11), 2000. e-Pub 2000.
806. Konopleva M, Estrov Z, Monaco G, Tsao T, Sporn MB, Andreeff M. PPAR- nuclear receptor as a novel therapeutic target in AML. Blood 96(11):460a, 2000. e-Pub 2000.
807. Carter BZ, Milella M, Tsao TY, Wathen JK, Altieri DC, Andreeff M. Expression and regulation of survivin ini acute myeloid leukemia (AML): Through MEK/ERK and PI3K pathways. Blood 96(11):461a, 2000. e-Pub 2000.
808. Andreeff M, Leysath C, Konopleva M, Huang Z. Induction of apoptosis in AML by HA14-1, A cell-permeable organic compound identified by protein structure-based computer screening that binds the BH1 to BH3 surface pocket of Bcl-2. Blood 96(11):502a, 2000. e-Pub 2000.
809. Marini F, Zoltick P, Zompetta C, Wilson JM, Andreeff M. Mesenchymal stem cells (MSC) delivering localized regulated interferon-alpha 2B (INF) into the bone marrow as targeted therapy for CML. 53rd Annual Symposium on Fundamental Cancer Research: Genetic Mechanisms in Cancer Conference, 2000. e-Pub 2000.
810. Carter BZ, Milella M, Tsao TY, Wathen JK, Altieri DC, Andreeff M. Expression and regulation of survivin in acute myeloid leukemia (AML): Through MEK/ERK and PI3K pathways. 53rd Annual Symposium on Fundamental Cancer Research: Genetic Mechanisms in CancerConference, 2000. e-Pub 2000.
811. Konopleva M, Estrov Z, Monaco G, Tsao T, Sporn M, Andreeff M. PPAR- nuclear receptor as a novel therapeutic target in AML. 53rd Annual Symposium on Fundamental Cancer Research: Genetic Mechanisms in Cancer Conference, 2000. e-Pub 2000.
812. Milella M, Estrov Z, Carter BZ, Harris D, El-Tounsi I, Konopleva M, Zhao S, Sebolt-Leopold J, Andreeff M. Preclinical rationale for developing MEK inhibition as a therapeutic strategy in acute myelogenous leukemia. 53rd Annual Symposium on Fundamental Cancer Research: Genetic Mechanisms in Cancer Conference, 2000. e-Pub 2000.
813. Konopleva M, Estrov Z, Monaco G, Tsao T, Sporn M, Andreeff M. PPAR nuclear receptor as a novel therapeutic target in AML. Leukemia 2000, Houston, TX, 2000. e-Pub 2000.
814. Milella M, Estrov Z, Carter BZ, Harris D, Sebolt-Leopold J, Andreeff M. The MEK/ERK kinase module: A potential new target for AML therapy. Leukemia 2000, Houston, TX, 2000. e-Pub 2000.
815. Engel H, Wang RY, Weidner R, Kleine HD, Jiang S, Andreeff M. The CD34+/CD38- but not the CD34+/HLA-DR- progenitor cell compartment harbours highly proliferative leukemic cells in acute myeloid leukemia and myelodysplastic syndromes in complete remission. Gemeinsame Jahrestagung der Deutschen und Oesterreichischen Gesellschaften fuer Haematologie und Onkologie, 2000. e-Pub 2000.
816. Guo JQ, Lin H, Lin F, Champlin R, Talpaz M, Kantarjian HM, Andreeff M, Zhao S, Glassman A, Arlinghaus RB. Detection and quantitation of Bcr-Abl transcripts using a comprehensive quantitative RT-PCR analysis system for minimal residual disease in CML patients. Acta Haematologica 103:31, 2000. e-Pub 2000.
817. Monaco G, Konopleva M, Zhao S, Leysath C, Estey E, Belmont JW, Andreeff M. Correlation of the engraftment potential of AML progenitors into NOD/scid mice with baseline CXCR4 expression. Acta Haematologica 103:1, 2000. e-Pub 2000.
818. Konopleva M, Estrov Z, Monaco G, Tsao T, Cardoso A, Leysath C, Xie Z, Zhao S, Belmont J, Sporn M, Andreeff M. Peroxisome proliferator-activated receptor nuclear receptor as a novel therapeutic target in acute myelogenous leukemia. Acta Haematologica 103:37, 2000. e-Pub 2000.
819. Andreeff M, Wulf G, Weidner DA, Wang RY, Zhao S, Kuenle I, Marini F, Estey E, Kantarjian H, Brenner MK, Goodell MA. CD34- lin- “SP” progenitor cells in acute and chronic myeloid leukemias. Acta Haematologica 103:4, 2000. e-Pub 2000.
820. Andreeff M, Weidner DA, Wang RY, Zhao S, Kuenle I, Kantarjian H, Brenner MK, Goodell MA. Absence of detectable Ph+ cells in CD34- lin- “SP” bone marrow progenitor cells from patients with chronic myeloid leukemia (CML). 8th Ann Intl Symp Recent Advances in Hematopoietic Stem Cell Transplantation, Heidelberg, Germany, 2000. e-Pub 2000.
821. Pahler JC, Niemar I, Andreeff M, Keating MJ, McConkey DJ. PKC and AKT dependent cell survival pathways in CLL. Am Assoc Can Res 41:756, 2000. e-Pub 2000.
822. Andreeff M, Carter B, Konopleva M, Zhao S, Tsao T, Weidner D, Estey E, Lopez-Berestein G, Estrov Z, Altieri D, Kornblau SM, Reed JC. Inhibitor-of-Apoptosis (IAP) proteins XIAP and survivin in primary acute myelogenous leukemias (AML): Regulation and therapeutic targets. Am Assoc Can Res 41:739, 2000. e-Pub 2000.
823. Zhang L, Zhao SR, Andreeff M, Claxton DF. Expression of CBFB-MYH11 fusion gene blocks differentiation of human leukemia cells. Am Assoc Can Res 41:393, 2000. e-Pub 2000.
824. Giles FJ, Cortes JE, Bivins C, Andreeff M, Talpaz M, Jolivet J, Kantarjian HM. Troxatyl (troxacitabine) has activity in blastic phase chronic myeloid leukemia (CMLBP). Blood 96(11):254b, 2000. e-Pub 2000.
825. Guo JQ, Lin H, Lin F, Champlin R, Talpaz M, Kantarjian HM, Andreeff M, Zhao S, Glassman A, Arlinghaus R. Detection and quantitation of Bcr-abl transcripts using a comprehensive quantitative RT-PCR analysis system for minimal residual disease in CML patients. Blood 96(11):255b, 2000. e-Pub 2000.
826. Snell V, Li Y, Mukhopadhyay A, Younes M, Andreeff M, Cabanillas F, Carbone A, Aggarwal BB, Younes A. Resistance of Hodgkin’s disease cell lines to TRAIL is independent of its receptor expression, cFLIP, and NF-kB. Blood 96(11):727a, 2000. e-Pub 2000.
827. Pahler JC, Niemer I, Andreeff M, Keating MJ, McConkey DJ. PKC- and AKT-dependent cell survival pathways in CLL. Blood 94:703a, 1999. e-Pub 1999.
828. O’Brien SM, Thomas DA, Freireich EJ, Andreeff M, Giles FJ, Keating MJ. Rituxan has significant activity in patients with CLL. Blood 603a, 1999. e-Pub 1999.
829. Chandra J, Pahler J, Niemer I, Andreeff M, Keating M, McConkey DJ. Inhibition of NFkb induces apoptosis in CLL lymphocytes. Blood 94:279a, 1999. e-Pub 1999.
830. Kitada S, Zapata JM, Andreeff M, Reed JC. Kinetic studies of protein kinase C inhibitor 70H-staurosporine (UCN-01) and CDK-family kinase inhibitor flavopiridol: Correlations between expression of survival genes and induction of apoptosis in B-cell chronic lymphocytic leukemia (B-CLL). Blood 94:127a, 1999. e-Pub 1999.
831. Tamm I, Kornblau SM, Segall H, Kitada S, Scudiero DA, Tudor G, QuiYH, Monks A, Sausville E, Andreeff M, Reed JC. Expression and prognostic significance of IAP-family genes in human cancers and leukemias. Blood 94:69a, 1999. e-Pub 1999.
832. Lin CW, Manshouri T, Neuberg D, Patel K, Gidel C, Kantarjian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in leukemias and myelodysplasia as measured by PCNA levels and caspase-e activity. Blood 94:69a, 1999. e-Pub 1999.
833. Kornblau SM, Andreeff M, Qui YH, Patel S, Thomas D, Giles F, Beran M, Estrov Z. Expression and prognostic impact of XIAP expression in acute myelogenous leukemia (AML). Blood 94:207b, 1999. e-Pub 1999.
834. Konopleva M, Marini F, Leysath C, Champlin R, Andreeff M, Korbling M. G-SCF induces CXCR4 expression on CD34+38- peripheral blood progenitor cells in vivo. Blood 94:322b, 1999. e-Pub 1999.
835. Konopleva M, Calvert L, Leysath C, McQueen T, Snell V, Talpaz M, Kantarjian H, Andreeff M. CML progenitors are CXCR4-deficient: Restored expression after interferon alpha or tyrosine-kinase inhibitor treatment in vivo. Blood 94:275b, 1999. e-Pub 1999.
836. Kantarjian HM, Talpaz M, Cortes J, Rios MB, Giles FJ, Thomas D, Andreeff M, Mallard S, Lim J, Murgo A, Cheson B, Keating M, O’Brien S. Triple combination therapy with interferon-alpha (INFa) low-dose cytarabine (Ldara-C) and homoharringtonine (HHT) in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) in early chornic phase. Blood 94:275b, 1999. e-Pub 1999.
837. Andreeff M, Weidner DA, Wang RY, Kuenle I, Kantarjian H, Brenner MK, Goodell MA. Abscence of detectable Philadelphia chromosome (Ph+) and Bcr/Abl positive cells in lin- SP bone marrow progenitor cells from patients with CML. Blood 94:271b, 1999. e-Pub 1999.
838. Andreeff M, Giles R, Sanchez-Williams G, Zhao S, Konopleva M, Priebe W, Freireich EJ, Cortes J, Koller C, Thomas D, Kantarjian H, Estey E. Phase I study of annamycin: A novel MDR-1 independent anthracycline in relapsed/refractory AML. Blood 94:225b, 1999. e-Pub 1999.
839. Kornblau SM, Estrov Z, Qui YH, Patel S, Kantarjian H, Beran M, Koller CA, Andreeff M. Expression and prognostic impact of caspase 8 in acute myelogenous leukemia (AML). Blood 94:206b, 1999. e-Pub 1999.
840. Konopleva M, Monaco G, Zhao S, Leysath C, Estey E, Belmont JW, Andreeff M. Engraftment potential of AML progenitors into NOD/SCID mice is dependent on basline CXCR4 expression. Blood 94:166b, 1999. e-Pub 1999.
841. Konopleva M, Monaco G, Wang RY, Weidner D, Studeny M, Itoh K, Belmont JW, Andreeff M. Transplantation of gene-marked MS-5 stromal cells into NOD/SCID model: Lack of support for CML engraftment. Blood 94:165b, 1999. e-Pub 1999.
842. Okcu MF, Zhou J, Benedict WF, Andreeff M. Cyclins D1 and D3 are dysregulated in childhood acute lymphoblastic leukemia which may be partially due to lack of function of p16. Blood 94:159b, 1999. e-Pub 1999.
843. McQueen T, Tacke F, Zhao S, Marini III FC, Xie Z, Konopleva M, Hu SX, Xu HJ, Andreeff M. Compensatory upregulation of antiapoptotic proteins in response to overexpression of Bcl-XS prevents apoptosis and chemosensitization in AML cell lines. Blood 94:158b, 1999. e-Pub 1999.
844. Carter BZ, Tsao T, Contreras P, Andreeff M. The apoptosis inhibiting protein, XIAP is highly expressed in myeloid leukemic cells, regulated by ATRA and cytokines, and cleaved by caspases. Blood 94:154b, 1999. e-Pub 1999.
845. Shimoni A, Anderlini P, Andersson B, Andreeff M, Braunschweig I, Claxton D, Cohen A, Donato M, Estey E, Gajewski J, Khouri I, Korbling M, Kornblau S, Molldrem J, Ueno N, Champlin R, Giralt S. Allogeneic transplantation for leukemia in patients older than 60 years: Age should not exclude treatment with non-myeloablative regimens. Blood 94:710a, 1999. e-Pub 1999.
846. Giralt S, Khouri I, Braunschweig I, Ippolitti C, Claxton D, Donato M, Cohen A, Davis M, Andersson B, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno N, Molldrem J, Champlin R. Melphalan and purine analog containing preparative regimens. Less intensive conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation (PCT). Blood 94:564a, 1999. e-Pub 1999.
847. Cortes JE, Wright J, Giles FJ, Thomas D, Andreeff M, O’Brien S, Estey E, Kantarjian HM. Phase I study of dolastatin-10 in refractory or relapsed acute leukemia. Blood 94:508a, 1999. e-Pub 1999.
848. Zhao S, Konopleva M, Chang S, Xie Z, Andreeff M. PI3K inhibition blocks Bad protein phosphorylation and induces apoptosis in cytokine-treated myeloid leukemic cells: Synergism with retinoic acid. Blood 94:483a, 1999. e-Pub 1999.
849. Carter BZ, Altieri DC, Andreeff M. Expression of survivin, a member of the inhibitor of apoptosis (IAP) family of caspase inhibitors is expressed in AML and regulated by cytokines and ATRA. Blood 94:479a, 1999. e-Pub 1999.
850. Konopleva M, Estrov Z, Stiouf I, Chang S, Zhao S, Harris D, Leysath C, Xie Z, Jackson E, Hong WK, Honda T, Gribble G, Place A, Suh N, Sporn M, Andreeff M. Novel synthetic triterpenoid, CDDO, and its methyl ester: Potent antiproliferative, proapoptotic and differentiating agents in AML. Blood 94:479a, 1999. e-Pub 1999.
851. Stiouf I, Konopleva M, Van N, Andreeff M, Kornblau SM. Culture of leukemia cell lines on stromal cell line KM102 does not affect proliferation, chemosensitivity or apoptosis inducibility. Blood 94:282a, 1999. e-Pub 1999.
852. Ruvolo P, Konopleva M, Leysath C, Deng X, Grant S, Tang L, Sporn M, Andreeff M. 471.Ruvolo P, Konopleva M, Leysath C, Deng X, Grant S, Tang L, Sporn M, Andreeff M: The novel triterpenoid methyl-CDDO inhibits Bcl-2 phosphorylation and potently kills U937 cells. Blood 280a, 1999. e-Pub 1999.
853. Arena C, Graham SE, Braunschweig I, Claxton D, Dimatulac A, White K, Andreeff M. The use of oral transmucosal fentanyl citrate (OTFC) as preprocedure analgesia and sedation for bone marrow aspiration and biopsy in adult cancer patients. Blood 94:187a, 1999. e-Pub 1999.
854. Wang RY, Zhao S, Lin HY, Guo W, Weidner D, Nagarajan L, Lemischka IR, Andreeff M. The early hematopoietic gene HDD-2 localizes to 18Q12.1-12.2 and is not expressed in myeloid neoplasms. Blood 94:74A, 1999. e-Pub 1999.
855. Kornblau SM, Ruvolo P, Qui YH Patel S, Thomas D, Giles F, Beran M, Estrov Z, May WS, Andreeff M. Expression and prognostic impact of ERK2, Bcl-XL and PP2A in acute myelogenous leukemia. Blood 94:68a, 1999. e-Pub 1999.
856. Faderl S, Thall PF, Kantarjian HM, Talpaz M, Estey E, Thomas D, Andreeff M, Kornblau S, Harris D, Van Q, Estrov Z. Dissimilar effects of caspase 3 and caspase 3 levels in adults with de novo ALL and AML. Blood 94:68a, 1999. e-Pub 1999.
857. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA. Leukemia involvement of the CD34 negative bone marrow side population (SP) in patients with AML. Blood 66a, 1999. e-Pub 1999.
858. Xie Z, Konopleva M, Zhao S, Cortes J, Andreeff M. Dolastatin 10 affects CD95/fas, XIAP and Bcl-2 family proteins and is dependent on baseline MDR-1 levels in primary AML: Correlative study in a phase I trial. Blood 94:66a, 1999. e-Pub 1999.
859. Grant S, Cragg L, Roberts J, Andreeff M, Feldman E, Winning M, Tombes M. Phase I trial of the PKC activator/downregulator bryostatin 1 (NSC 339555) and high-dose Ara-C (HIDAC) in patients with refractory acute leukemia. Blood 94:509a, 1999. e-Pub 1999.
860. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao RP, Andreeff M, Price J, Paul RW, Anklesaria P, Yu DH, Hung MC. Combined E1A gene therapy and taxol in HER-2/neu-overexpressing ovarian cancer: E1A chemosensitization through apoptosis involving caspase-3 pathway. ASGT:171a, 1999. e-Pub 1999.
861. Zhang L, Zhao S, Andreeff M, Claxton DF. Emodin promotes apoptosis of CBFB-MYH11 expressing human leukemia cells through downregulation of Bcl-2 and Bcl-XL and activation of caspase. Am Assoc Can Res 40:550, 1999. e-Pub 1999.
862. Andreeff M, Konopleva M, Zhao S, Tari A, Lopez-Berestein G, Priebe W, Kornblau S, Kantarjian H, Cortes J, Estey. Perspectives of the role of anthracyclines. Ann Hematol, 1999. e-Pub 1999.
863. Andreeff M, Konopleva M, Zhao S, Tari A, Lopez-Berestein G, Priebe W, Kornblau S, Kantarjian H, Cortes J, Estey. Perspectives of the role of anthracyclines. Ann Hematol, 1999. e-Pub 1999.
864. Konopleva M, Tari A, Estrov Z, Harris D, Lopez-Berestein G, Andreeff M. Inhibition of bcl-2 with liposomal p-ethoxy antisense oligonucleotides induces apoptosis in the presence of high level of bcl-xl and is critically depending on baseline bcl-2 levels in AML. Blood 92, 1998. e-Pub 1998.
865. Konopleva M, Zhao S, Jiang S, Snell V, Zhang X, Reed JC, Andreeff M. Overexpression of antiapoptotic bcl-xl and bcl-2 contributes to chemoresistance of quiescent leukemic progenitors and can be selectively reversed by ATRA. Blood 92, 1998. e-Pub 1998.
866. Zhao S, Xu H, Xie Z, Chang S, Konopleva M, Kavka K, Calvert L, Guo JQ, Arlinghaus R, Siciliano M, Andreeff M. Preliminary comparison of real time QPCR with cytogenetic karyotype, hypermetaphase FISH and western blot analysis in CML patients in clinical remission. Blood 92:294, 1998. e-Pub 1998.
867. Xie Z, Zhao S, Chang S, McQueen T, Andreeff M. Differential gene expression patterns in human myeloblastic leukemia HL-60 and multidrug resistant HL-60/DOX cells analyzed by human cDNA expression array. Blood 92, 1998. e-Pub 1998.
868. Won JH, Garcia-Sanchez F, Nanakorn T, Krause D, Pizzorno G, Wang WL, Liang J, Andreeff M, Zelterman D, Lin D, Srimatkandada S, Carbone R, Brown R, Deisseroth A. Serum free (SF) conditions for the vector mediated separation and modification of hematopoietic stem cells which preserve their short and long term reconstituting capability for use in transplantation. Blood 92, 1998. e-Pub 1998.
869. Varella-Garcia M, Murata-Collins J, Berger R, Andreeff M, Ai H, Richkind K, McGavran L, Paskulin G, Erickson P, Drabkin H. Detection of minimal residual disease in t(8;21) acute myelogenous leukemia (AML) using a D-FISH AML1/ETO probe. Blood 92, 1998. e-Pub 1998.
870. A-H S, Medeiros LJ, Herling M, Khorana S, Kliche KO, Mesina O, Hagemeister FB, Romaguera J, McLaughlin P, Preti HA, Rodriguez MA, Andreeff M, Cabanillas F. The expression of the EBV-coded latent membrane protein-1 (LMP-1) in Reed-Sternberg cells of Hodgkin’s Disease (HD) is associated with higher serum IL-10 levels and inferior failure-free survival (FFS). Blood 92, 1998. e-Pub 1998.
871. Xie Z, Zhao S, Chang S, McQueen T, Andreeff M. Effect of bcr/abl transfection of the gene expression profile of human hematopoietic MO7e cells: analysis by c-DNA expression array. Blood 92, 1998. e-Pub 1998.
872. Kitada S, Zapata JM, Andreeff M, Reed JC. Comparison of CD40L and bryostatin effects on apoptosis, chemoresponses, and expression of immunomodulatory antigens and cell survival genes in B-cell chronic lymphocytic leukemia (B-CLL). Blood 92, 1998. e-Pub 1998.
873. Kitada S, Tamm I, Andreeff M, Reed JC. Protein kinase C inhibitor 7OH-staurosporine (UCN-01) and CDK-family kinase inhibitor flavoperidol down-regulate expression of survival gens and induce apoptosis in B-cell chronic lymphocytic leukemia (B-CLL). Blood 92, 1998. e-Pub 1998.
874. O’Brien S, Freireich E, Andreeff M, Lerner S, Keating M. Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL). Blood 92, 1998. e-Pub 1998.
875. Segall H, Zhao S, Xie Z, Kavka K, Konopleva M, Sanchez-Williams G, Kantarjian H, Champlin R, Andreeff M. Expression of the inhibitor of apoptosis protein (IAP) family in acute and chronic leukemia blasts. Blood 92, 1998. e-Pub 1998.
876. Zhang L, Johnson B, Zhao S, Xie Z, Andreeff M, Claxton DF. Expression of CBFB-MYH11, the human leukemia inv(16) fusion protein results in apoptosis and altered gene expression. Blood 92, 1998. e-Pub 1998.
877. Sarris AH, Viviani S, Bonfante V, Kliche KO, Notti P, Peethambaram P, Tucker S, Preti A, Mesina O, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Andreeff M, Witzig T, Bonadonna J, Cabanillas F. A prognostic model for Hodgkin’s disease (HD) based on IL-10. Blood 92, 1998. e-Pub 1998.
878. Kantarjian H, O’Brien S, Keating MJ, Cortes J, Giles FJ, Beran M, Koller C, Andreeff M, Kornblau S, Pierce S, Murphy S, Freireich EJ. Update of the hyper-CVAD dose-intensive regimen in adult acute lymphocytic leukemia (ALL). Blood 92, 1998. e-Pub 1998.
879. Clodi K, Asgary Z, Zhao S, Younes M, Wimmer D, Cabanillas F, Andreeff M, Younes A. 452.Clodi K, Asgary Z, Zhao S, Younes M, Wimmer D, Cabanillas F, Andreeff M, Younes A: B cells of Hodgkin’s disease (HD) may contribute to Reed-Sternberg (RS) cells survival by providing CD40 ligand (CD40L) survival signals in vivo. Blood 92, 1998. e-Pub 1998.
880. Marini FC, Yu Q, Wickham TJ, Kovesdi I, Andreeff M. High-efficiency gene transfer into human CD34+ progenitor cells using the genetically retargeted adenoviral vector Ad pK7. Blood 92, 1998. e-Pub 1998.
881. Kliche KO, Colome M, Younes M, Zhao S, Andreeff M, Champlin R, Younes A. Potential involvement of Fas ligand (FASL) in the pathogenesis of human graft-vs-host disease (GVHD). Blood 92, 1998. e-Pub 1998.
882. O’Brien S, Kantarjian H, Koller C, Andreeff M, Feldman E, Keating M, Beran M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine (HHT) and interferon (IFN-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML). Blood 92, 1998. e-Pub 1998.
883. Kornblau SM, Vu H, Ruvolo P, Cortes J, O’Brien S, Kantarjian H, Estrov Z, Andreeff M, May WS. Bax and PKCa modulate the prognostic impact of Bcl2 expression in acute myelogenous leukemia (AML). Blood 92, 1998. e-Pub 1998.
884. Okcu MF, Andreeff M. Cyclins D1 and D3 are dysregulated in childhood acute lymphoblastic leukemia. Blood, 1998. e-Pub 1998.
885. Wang XJ, Yang J, Huang Y, Andreeff M, Becker FF, Gascoyne PRC. Changes in membrane dielectric properties of HL-60 cells during genistein-induced apoptosis-significance in discrimination of apoptotic, necrotic and normal cells. Blood 92, 1998. e-Pub 1998.
886. Andreeff M, Zhao S, Xie Z, Konopleva M, Estey E, Munsell M, Sanchez-Williams G, Kornblau S, Reed J. Control of apoptosis in AML by bcl-2 and Bcl-XL: Critical impact of cytogenetics. Blood 92, 1998. e-Pub 1998.
887. Konopleva M, Hayes K, Pierce S, Zhao L, Andreeff M, Glasman E, Freireich E, Estey E. Cytogenetic (CG) and fluorescent in situ hybridization (FISH) analysis on course 1 (CO 1) day 21 of chemotherapy (CT) for newly diagnosed AML/MDS. Blood 92, 1998. e-Pub 1998.
888. Konopleva M, Konoplev S, Zaritskey A, Afanasiev B, Andreeff M. Stromal cells prevent apoptotic cell death of AML by upregulation of bcl-2 in CD34+ cells. Blood 92, 1998. e-Pub 1998.
889. Reed JC, Andreeff M, Kitada. Investigations of apoptosis dysregulation and chemoresponses in chronic lymphocytic leukemia. American Society of Hematology, 1998. e-Pub 1998.
890. Gengenbacher DM, Brandes J, Keyhani A, Jiang S, Sanchez-Williams G, Andreeff M. Relation between asynchronous differentiation, expression of bcl-2 and karyotypic abnormalities for monitoring minimal residual disease during hematologic remission (CR) of acute myeloid leukemia (AML). Sixth Euroconference on Apoptosis or Programmed Cell Death, Saltjo-Boo, Sweden, 1998. e-Pub 1998.
891. Sarris AH, Viviani S, Bonfante V, Kliche KO, Notti P, Peethambaram P, Tucker S, Preti A, Mesina O, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Andreeff M, Witzig T, Bonadonna G, Cabanillas F. A prognostic model for Hodgkin's disease (HD) based on IL-10, 1998. e-Pub 1998.
892. Sarris AH, K-O K, Peethambaram PP, Preti A, Jackow C, Mesina O, Hagemeister F, McLaughlin P, M-A R, Romaguera J, Fritsche H, Duvic M, Witzig T, Andreeff M, Cabanillas F. Serum interleukin-10 (IL-10) and failure-free survival (FFS) of adult Hodgkin’s disease (HD). The Fourth Intl Symp on Hodgkin’s Lymphoma, Koln, Germany, Leukemia & Lymphoma 29:32, 1998. e-Pub 1998.
893. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu SQ, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Dayn A, Holzmayer T, Hamer J, Bachier C, Ostrove J, Przepiorka D, Burtners B, Cote R, Bast R, Hortobagyi G, Deisseroth A. 12 cycles of paclitaxel (T) immediately following high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) can induce complete remissions (CR) in patients (Pt) with advanced breast and ovarian carcinoma (ABOC). Am Soc Clin Oncol:75a, 1998. e-Pub 1998.
894. Zhao S, Clodi K, Kliche O, Asgari Z, Cabanillas F, Andreeff M, Younes A. Fas ligand and TRAIL expression in Hodgkin’s Disease lymphocytes. HD Meeting, Kolon, Germany, 1998. e-Pub 1998.
895. Kantarjian H, O’Brien S, Rios MB, Cortes J, Giles FJ, Andreeff M, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome (Ph)-positive early chronic phase (CP) chronic myelogenous leukemia (CML) with daily doses of interferon alpha (IFN- ) and low dose cytosine arabinoside (ARA-C). Blood 92, 1998. e-Pub 1998.
896. Snell V, Jackson E, Buck D, Andreeff M. Expression of the AC133 antigen in leukemic and normal progenitors. Blood 92, 1998. e-Pub 1998.
897. Konopleva M, Zhao S, Xie Z, Sanchez-Williams G, Kavka K, Andreeff M. Absence of BH1- BH2 Bcl-2 domains mutation in AML. Blood 92, 1998. e-Pub 1998.
898. Beran M, Kantarjian H, Keating M, O’Brien S, Pierce S, Koller C, Cortes J, Andreeff M, Kornblau S, Estey E. Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside (ara-C) in previously untreated patients with high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Blood 90:583a, 1997. e-Pub 1997.
899. Cortes J, Kantarjian H, O’Brien S, Andreeff M, Estey E, Keating M. Methotrexate, vincristine, PEG-asparaginase and prednisone (MOAP) for patients (pts) with refractory or relapsed acute lymphoblastic leukemia (ALL). Blood 90:239b, 1997. e-Pub 1997.
900. Cortes J, Kantarjian H, Beran M, O’Brien S, Koller C, Kornblau S, Andreeff M, Keating M, Freireich EJ, Estey E. Cyclophosphamide (CTX), ara-C and topotecan (TOP)(CAT) in patients (pts) with refractory or relapsed acute leukemias and transformed chronic myelogenous leukemia (CML). Blood 90:505a, 1997. e-Pub 1997.
901. Chandra J, Neimer I, Gilbreath J, Kliche KO, Andreeff M, Keating M, McConkey DJ. Inhibition of the proteasome and subsequent downregulation of NFKB induces apoptosis in glucocorticoid resistant chronic lymphocytic leukemic lymphocytes in vitro. Blood 90:306b, 1997. e-Pub 1997.
902. Chandra J, Kliche KO, Andreeff M, McConkey DJ. Inhibitors of the nuclear scaffold protease block apoptosis of myeloid leukemic lymphocytes in vitro. Blood 90:227b, 1997. e-Pub 1997.
903. Kliche KO, Andreeff M, Sarris H. The IP-10-dependent inhibition of MO7e cell growth is not mediated by apoptosis. Blood 90:168b, 1997. e-Pub 1997.
904. Kliche KO, Andreeff M. Fas (CD95) expression in normal progenitor cells, myelodysplastic syndromes (MDS) and secondary AML (sAML). Blood 90:288b, 1997. e-Pub 1997.
905. Kliche KO, Sarris AH, Estey E, Snell V, Andreeff M. Interleukin-10 plasma levels are frequently elevated in MDS and acute and chronic myeloid leukemias. Blood 90:288b, 1997. e-Pub 1997.
906. Kliche KO, Andreeff M. High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal progenitors: comparison with primary AML (pAML). Blood 90:202a, 1997. e-Pub 1997.
907. Weinkauff R, Starostik P, Hayes K, Huh YO, Hirsch-Ginsberg C, Bueso-Ramos C, Andreeff M, Keating M, Kantarjian H, Freireich E, Estey E, Albitar M. Use of peripheral blood blasts versus bone marrow blasts for diagnosis of acute leukemia. Blood 90:224b, 1997. e-Pub 1997.
908. Sarris AH, Luthra R, Kliche KO, McBride A, Andreeff M, Cabanillas F. The t(2;5)(p23;q35) is not detectable in normal donor peripheral blood mononuclear cells by polymerase chain reaction amplification (PCR) of genomic DNA. Blood 90:335a, 1997. e-Pub 1997.
909. Sarris AH, Kliche KO, Peethambaram PP, Witzig T, Andreeff M, Cabanillas F. 414.Sarris AH, Kliche KO, Peethambaram PP, Witzig T, Andreeff M, Cabanillas F: Interleukin-10 as a prognostic factor for Hodgkin’s disease (HD) treated with ABVD: Results from MD Anderson (MDA) and Mayo Clinic (MC). Blood 90:335a, 1997. e-Pub 1997.
910. Sarris AH, Romaguera J, Kliche KO, Luthra R, Santiago M, Pugh W, McBride A, Andreeff M, Cabanillas F. Anaplastic large cell lymphoma (ALCL): Presentation, failure-free survival (FFS), and prognostic factors with doxorubicin-based regimens. Blood 90:335a, 1997. e-Pub 1997.
911. Sarris AH, Romaguera J, Kliche KO, Luthra R, Santiago M, Pugh W, McBride A, Andreeff M, Cabanillas F. Anaplastic large cell lymphoma (ALCL): Presentation, failure-free survival (FFS), and prognostic factors with doxorubicin-based regimens. Blood 90:335a, 1997. e-Pub 1997.
912. Kantarjian H, Manshouri T, Talpaz M, O’Brien S, Keating M, Cortes J, Pierce S, Andreeff M, Kornblau S, Albitar M. Multidrug resistance (MDR) expression in chronic myelogenous leukemia (CML). Blood 90:502a, 1997. e-Pub 1997.
913. Albitar M, Kantarjian H, Manshouri T, O’Brien S, Andreeff M, Kornblau S, Beran M, Keating M, Talpaz M. Expression of bcl-2 and fas in chronic myelogenous leukemia. Blood 90(275b), 1997. e-Pub 1997.
914. Clodi K, Snell V, Zhao S, Thomas E, Cabanillas F, Andreeff M, Younes A. Imbalanced fas and CD40 expression of Mantle cell lymphoma cells may be responsible for their survival advantage. Blood 90:75a, 1997. e-Pub 1997.
915. Clodi K, McDuff B, Zhao S, Kliche KO, Palmer JL, Cabanillas F, Andreeff M, Younes A. Elevated soluble CD40 ligand (sCD40L) levels in the serum of patients with B cell lymphoma. Blood 90:75a, 1997. e-Pub 1997.
916. Kornblau SM, Le XF, Estey E, Andreeff M, Groner Y, Chang KS. Expression of AML-2 protein is highly prognostic in acute myelogenous leukemia (AML) FAB-M2. Blood 90:71a, 1997. e-Pub 1997.
917. Kornblau SM, Thall P, Walterscheid M, Estrov Z, Keating M, Patel S, Kantarjian H, Estey E, Andreeff M. Acute myelogenous leukemia (AML) patients with lower levels of bcl-2 expression and unfavorable cytogenetics have a very poor prognosis. Blood 90:216b, 1997. e-Pub 1997.
918. Kornblau SM, Thall P, Estrov Z, Kantarjian H, Estey E, Andreeff M. Proliferation and apoptosis regulating proteins and cytogenetics predict prognosis in acute myelogenous leukemia (AML). Blood 90:71a, 1997. e-Pub 1997.
919. Garderet L, Snell V, Przepiorka D, Lu JG, Andreeff M, Champlin R. Effective removal of alloreactive lymphocytes from peripheral blood mononuclear cell preparations by immunomagnetic CD25 depletion. Blood 90:214a, 1997. e-Pub 1997.
920. Xie Z, Zhao S, McQueen T, Aime-Sempe C, Reed JC, Andreeff M. Bax over-expression sensitizes pre-B lymphoid cells to multiple chemotherapeutic agents. Blood 90:495a, 1997. e-Pub 1997.
921. Xie Z, Zhao S, Konopleva M, Ke S, McQueen T, Reed JC, Andreeff M. Melarsoprol and arsenic trioxide increase cell death on doxorubicin-resistant human leukemia and myeloma cells by regulating expression of bcl-2 apoptosis regulatory family. Blood 90:495a, 1997. e-Pub 1997.
922. Zhao S, Xie Z, Konopleva M, Reed JC, Andreeff M. Differential expression of bcl-2 family proteins in doxorubicin-resistant and parental HL-60 cells. Blood 90:467a, 1997. e-Pub 1997.
923. Zhao S, Xie Z, Konopleva M, Zhang X, Kitada S, Jung J, Kornblau S, Reed JC, Andreeff M. Pro-apoptotic protein BAD: Expression and phosphorylation in leukemia. Blood 90:497a, 1997. e-Pub 1997.
924. Pachmann K, Zhao S, Kantarjian H, Andreeff M. In situ amplification of bcr/abl sequences for analysis of mRNA expression at the single cell level in chronic myeloid leukemia (CML). Blood 90:280b, 1997. e-Pub 1997.
925. Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau S, Jung J, Kliche KO, Jiang S, Przepiorka D, Snodgrass HR, Estey E, Andreeff M. A functional leptin receptor in AML: Correlation of expression with blast count and FAB M1. Blood 90:68a, 1997. e-Pub 1997.
926. Konopleva M, Zhao S, Jiang S, Snell V, Zhang X, Reed JC, Andreeff M. The antiapoptotic genes bcl-XL and bcl-2 are overexpressed in quiescent leukemic progenitor cells. Blood 90:558a, 1997. e-Pub 1997.
927. Konopleva M, Tari A, Lopez-Berestin G, Andreeff M. Inhibition of bcl-2 with liposomal-delivered antisense oligonucleotides (AS-ODN) induces apoptosis and increases the sensitivity of primary acute myeloid leukemia (AML) cells and cell lines to cytosine arabinoside and doxorubicin. Blood 90:494a, 1997. e-Pub 1997.
928. Konopleva M, Konoplev SN, Zaritskey AY, Andreeff M. Mouse stromal cell line MS-5 inhibits proliferation and prevents apoptotic cell death of leukemic cell line HL-60. Blood 90:172b, 1997. e-Pub 1997.
929. Andreeff M, Zhao S, Konopleva M, Xie Z, Zhang X, Snell V, McQueen T, Jiang S, K-O K, Schenk T, Weidner D, Estey E, Thall P, Sanchez-Williams G, Kornblau SM, Reed JC. The role of bcl-2 apoptosis regulating genes in acute myeloid leukemia (AML). Blood 90:66a, 1997. e-Pub 1997.
930. Sarris AH, Kliche KO, Smith T, Mesina O, Preti A, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Pugh W, Fuller L, Ha C, Cox J, Andreeff M, Cabanillas F. Hodgkin’s disease: Prognostic factors, including IL-10: A model for pathogenesis and a guide to therapy. Intl J Oncol 11:913, 1997. e-Pub 1997.
931. Konopleva M, Zhao S, Jiang S, Snell V, Zhang X, Reed J, Andreeff M. The antiapoptotic genes BCL-X and BCL-2 are overexpressed in quiescent leukemic progenitor cells. Acta Haematol Suppl 1:86, 1997. e-Pub 1997.
932. Kleine HD, Zech I, Andreeff M, Freund M. Continuous Gating: A Scanning Technique of flow cytometric listmode-data used for analysis of proliferation patterns of CD34-positive cells in normal and CML bone marrow. Acta Haematol Suppl 1:67, 1997. e-Pub 1997.
933. Pachmann K, Zhao S, Goodacre A, Andreeff M. Expression of bcr/abl mRNA as determined by in situ amplification in individual cells of CML patients. Acta Haematol Suppl 1:67, 1997. e-Pub 1997.
934. Andreeff M, Zhao S, Konopleva M, Kliche KO, Lisovsky M, Snell V, Zhong X, Hu G, Sanchez-Williams G, Zhang X, Reed J, Estey E. Regulation of apoptosis in normal hematopoiesis and in myeloid leukemias. Acta Haematol Suppl 1:13, 1997. e-Pub 1997.
935. McConkey D, Chandra J, K-O K, Andreeff M. Protease activation in drug-induced apoptosis in CLL. Acta Haematol Suppl 1:13, 1997. e-Pub 1997.
936. Sarris AH, K-O K, Preti A, Jackow C, Smith T, Mesina O, Hagemeister F, McLaughlin P, M-A R, Romaguera J, Pugh W, Fritsche H, Duvic M, Andreeff M, Cabanillas F. Pretreated serum interleukin-10 is a prognostic factor for failure-free survival of adults with Hodgkin’s disease: implications for therapy. The Pan-Pacific Lymphoma Conferenc, 1997. e-Pub 1997.
937. Bachier C, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Haley T, Andreeff M, Cabanillas F, Champlin R, Berenson R, Heimfeld S, Deisseroth AB. Stem cell (SC) transplant and retroviral (RV) transduction of hematopoietic cells (HC) in patients (pts) with follicular non-Hodgkin’s lymphoma (FNHL). ASCO 16:93a, 1997. e-Pub 1997.
938. Hu G, Liu W, Mendelsohn J, Ellis L, Radinsky R, Andreeff M, Deisseroth AB. Epidermal growth factor receptor: a potential target for uterine cervical carcinoma therapy. ASCO 16:553a, 1997. e-Pub 1997.
939. Rahman Z, Kavanagh J, Giles R, Hanania E, Holmes F, Booser D, Fu SQ, Zu Z, Ellerson D, Calvert L, Claxton D, Bachier C, Berenson R, Heimfield S, Hortobagyi G, Bast R, Andreeff M, Champlin R, Deisseroth A. Toxicity/Response analysis of 12 cycles of post-transplant chemotherapy for breast and ovarian cancer shows safety and efficacy. ASCO 16:187a, 1997. e-Pub 1997.
940. Rahman Z, Kavanagh J, Giles R, Hanania E, Holmes F, Booser D, Fu SQ, Zu Z, Ellerson D, Calvert L, Claxton D, Bachier C, Berenson R, Holzmayer T, Dayn A, Heimfield S, Hortobagyi G, Bast R, Andreeff M, Champlin R, Deisseroth A. Paclitaxel immediately following autologous bone marrow transplantation further reduces residual disease in patients with metastatic breast cancer (MBC). AACR, 1997. e-Pub 1997.
941. Clodi K, Armitage R, Kliche O, Cabanillas F, Andreeff M, Younes A. Elevated soluble CD40 ligand (sCD40L) in the serum from patients with B cell lymphomas. Intl Soc Haematol, 1997. e-Pub 1997.
942. Sarris AH, Kliche O, Preti A, Jackow C, Smith T, Mesina O, Hagemeister F, McLaughlin P, Rodriguez MA, Romaguera J, Pugh W, Fritsche H, Duvic M, Andreeff M, Cabanillas F. Elevated serum IL-10 is an adverse prognostic factor for failure-free survival of adults with Hodgkin’s disease. Intl Soc Haematol, 1997. e-Pub 1997.
943. Hoque A, Strom SS, Annegers JF, Spitz MR, Cooper SP, Ford C, Andreeff M. Epidemiology of secondary leukemia: Chromosomal abnormalities and family history of cancer. Amer Soc Preventive Oncol, 1997. e-Pub 1997.
944. Mendelsohn J, Ellis L, Radinsky R, Andreeff M, Deisseroth A. Proliferation of cervical cancer cell lines in vitro is dependent on epidermal growth factor receptor levels which can be down-regulated by decreases in the expression of the E6/E7 transforming proteins of the integrated human papilloma virus. Biomedicine, 1997. e-Pub 1997.
945. Rahman Z, Kavanagh J, Giles R, Hanania E, Holmes F, Booser D, Fu SQ, Zu Z, Ellerson D, Calvert L, Claxton D, Bachier C, Berenson R, Holzmayer T, Dayn A, Heimfield S, Hortobagyi G, Bast R, Andreeff M, Champlin R, Deisseroth A. Post-autologous transplant taxol chemotherapy results in response above and beyond that achievable with pre-transplantation intensive therapy. Biomedicine, 1997. e-Pub 1997.
946. Sarris AH, Kliche O, Preti A, Mesina O, Pugh W, Andreeff M, Cabanillas F. Elevated serum IL-10 is an adverse prognostic factor for failure-free survival (FFS) among adults with advanced Hodgkin’s disease (HD). AACR/ASCO Joint Conference, Basic & Clinical Aspects of Lymphoma, 1997. e-Pub 1997.
947. Bachier C, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Haley T, Andreeff M. Retroviral gene marking to identify the origin of relapse following autologous CD34 positive bone marrow (BM) and peripheral blood (PB) transplantation in follicular non-Hodgkin’s lymphoma (FNHL). Blood 88(10):430a, 1996. e-Pub 1996.
948. Kliche KO, Andreeff M. Hyperapoptosis as pathophysiologic basis of myelodysplastic syndromes (MDS). Blood 88(10):639a, 1996. e-Pub 1996.
949. Konopleva M, Estrov Z, Andreeff M, Metha K. Cell surface antigen CD38 induces a cell growth signal in leukemic cells. Blood 88(10):87a, 1996. e-Pub 1996.
950. Konopleva M, Zhao S, Jiang S, Snell V, Andreeff M. Differential expression of apoptosis-related genes in quiescent normal and leukemic progenitor cells. Blood 88(10):117b, 1996. e-Pub 1996.
951. Bseiso AW, Jiang S, Kantarjian HM, Champlin R, Talpaz M, Andreeff M. Decreased expression of CD45RO on primitive hemtopoietic progenitor cells (HPC) in chronic myelogenous leukemia (CML). Blood 88(10):234a, 1996. e-Pub 1996.
952. Choudhury A, Gajewski J, Liang JC, Claxton D, Popat U, Andreeff M, Champlin R. Generation of Philadelphia chromosome-positive dendritic cells from leukemic progenitors and their utilization for ex vivo expansion of anti-leukemic, cytotoxic t-cells in chronic myelogenous leukemia. Blood 88(10):675a, 1996. e-Pub 1996.
953. Clodi K, Younes A, Goodacre A, Roberts M, Palmer J, Younes A, Cabanillas F, Andreeff M. p53 gene deletions in non-Hodgkin’s lymphoma determined by dual color fluorescence in situ hybridization. Blood 88(10):182a, 1996. e-Pub 1996.
954. Marini FC, Zhang X, Trapnell B, Andreeff M. Inefficient infection of primitive hematopoietic precursors cells (CD34+) using CMV driven adenoviral. Blood 88(10):292b, 1996. e-Pub 1996.
955. Marini FC, Zhang X, Trapnell B, Andreeff M. Bone marrow purin of residual breast cancer by adenoviral transfer of the HSV-TK gene. Blood 88(10):272a, 1996. e-Pub 1996.
956. Melnyk A, Theriault R, Andreeff M, Sansores-Garcia L, Philips MD. Factor V leiden (GG1691A) and the risk of thrombosis in patients with solid tumors: a prospective case control study. Blood 88(10):176a, 1996. e-Pub 1996.
957. Sarris AH, Kliche KO, Smith T, Preti A, Messina O, Hess M, Pugh W, Andreeff M, Cabanillas F. Elevated serum IL-10: An adverse prognostic factor for failure-free survival (FFS) in adults with advanced Hodgkin’s disease (HD). Blood 88(10):226a, 1996. e-Pub 1996.
958. Schenk TM, Keyhani A, Kliche KO, Kantarjian H, Andreeff M. Multilineage involvement in acute lymphoblastic leukemia (ALL) - New evidence for “stem cell ALL” by interphase FISH. Blood 88(10):75a, 1996. e-Pub 1996.
959. Seong D, Estey E, Claxton D, Xu J, Swatkowski J, Zhao Y, O’Brien S, Keating M, Freireich EJ, Andreeff M, Kantarjian H, Champlin R, Siciliano M. Detection of clinically relevant minimal residual disease in acute myelogenous leukemia by hypermetaphase-fluorescence in situ hybridization. Blood 88(10):161b, 1996. e-Pub 1996.
960. Cortes J, Kantarjian H, O’Brien S, Beran M, Estey E, Koller C, Andreeff M, Kornblau S, Keating M, Freireich EJ, Talpaz M. Suppression of clonal evolution in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on interferon alfa therapy (IFN-A) therapy. Blood 88(10):232a, 1996. e-Pub 1996.
961. Snell V, Clodi K, Goodwin R, Kadin M, Cabanillas F, Andreeff M, Younes A. Biologic activity of the TNF-related apoptosis-inducing ligand (TRAIL) against human lymphoid malignancies and cell lines. Blood 88(10):384a, 1996. e-Pub 1996.
962. Zhao S, Kliche KO, Clodi K, Andreeff M, Cabanillas F. T-lymphocytes of Hodgkin’s disease have low expression of fas ligand and CD30 ligand which can be unregulated by interferon-a and anti CD3. Blood 88(10):670a, 1996. e-Pub 1996.
963. Zhao S, Ling YH, Snell V, Zhang X, Reed JC, Perez-Soler R, Andreeff M. Sensitization to the cytotoxic effect of topoisomerase-1 inhibitors in BAX transfection of lymphoblastic leukemia. Blood 88(10):70a, 1996. e-Pub 1996.
964. Gengenbacher D, Keyhani A, Engel H, Sanchez-Williams G, Champlin R, Andreeff M. Detection of residual leukemic cells and mixed chimerism after allogenic bone marrow transplantation by dual color fluorescence in situ hybridization (FISH). BMT Conference, Edinburgh, UK, 1996. e-Pub 1996.
965. Melnyk A, Zhao S, Andreeff M. The RTPCR of K-19 mRNA for the evaluation of minimal residual disease (MRD) of breast cancer in bone marrow (BM) samples lacks specificity with 50 or more total PCR cycles. Second Meeting of the European Haematology Association, Paris, France, 1996. e-Pub 1996.
966. W-JM W, Consoli U, Lane C, Durett A, Lauppe M, Heimfeld S, Berenson R, Champlin R, Andreeff M, Deisseroth A. Integrin VCAM apoptosis rescue pathway is operative in the early CD34 selected but not the mature infractionated nuclear cell populations of human marrow and peripheral blood mononuclear cells. ASCO, 1996. e-Pub 1996.
967. Estey E, Beran M, Hayes K, Lovshe D, Kornblau S, Pierce S, Koller C, O’Brien S, Kantarjian H, Andreeff M. Cytogenetic (CG) and fluorescent in situ hybridization (FISH) analysis on course 1 day 21 of chemotherapy (CT) for newly diagnosed AML/MDS. Blood 88(10), 1996. e-Pub 1996.
968. Fayad L, Kantarjian H, O’Brien S, Beran M, Koller C, Kornblau S, Andreeff M, Estey E, Keating M, Freireich E. Significance of day 7 (D7) persistence of peripheral blasts (Pbb) >0, and day 14 (D14) persistence of bone marrow blasts (Bmb) >55 in adult acute lymphocytic leukemia (ALL) according to treatment intensity. Blood 88(10):564a, 1996. e-Pub 1996.
969. Fleming R, Estey E, Kantarjian H, O’Brien S, Keating M, Kornblau S, Freireich E, Andreeff M, Cortez J, Vassilaki M, Turan A, Risser J, Luna M, Anaissie E. Invasive aspergillosis during induction therapy for acute leukemia predisposing and prognostic factors. Blood 88(10), 1996. e-Pub 1996.
970. Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth A. Bcl-2 and Bcl-xl are expressed in higher levels in poor prognosis (monosomy 5 and monosomy 7) acute myeloid leukemia AML) cells than in good prognosis [inversion 16 and t(8;21)] AML cells. AACR 37:22, 1996. e-Pub 1996.
971. Goodacre AM, Luthra R, Clodi K, Grace C, Younes A, Cabanillas F, Pugh W, Andreeff M. Partial trisomy of 3Q21Qter is a consistent abnormality in mantel cell lymphoma identified by comparative genomic hybridization (CGH). Blood 88(10):383a, 1996. e-Pub 1996.
972. W-JM W, Consoli U, Berenson R, Heimfeld S, Andreeff M, Deisseroth A. Role of VLA-4 and VCAM-1 in regulation of apoptosis of immature (CD34 selected) versus mature (C34 unselected) human hematopoietic precursor cells by adhesion to bone marrow stromal cells. AACR 37:22, 1996. e-Pub 1996.
973. Mehta K, McQueen T, Neamati N, Collins S, Andreeff M. Differential regulation of differentiation and cell death by retinoids receptors RAR and RXR in HL-60 cells. AACR 37:223, 1996. e-Pub 1996.
974. Goodacre AM, Clodi K, Grace C, Younes A, Cabanillas F, Andreeff M. Comparative genomic hybridization (cgh) redefines deletion 6q in lymphoid malignancies. Blood 88(10):142b, 1996. e-Pub 1996.
975. Hanania E, Giles R, Fu SQ, Zu Z, Cote R, Dayn A, Wang T, Ellerson D, Berenson R, Heimfeld S, Rahman Z, Andreeff M, Champlin R, Deisseroth AB. MDR-1 vector marking shows that CFUMS do not contribute to engraftment in patients following intensive systemic combination chemotherapy. Blood 88(10):595a, 1996. e-Pub 1996.
976. Melnyk A, Albitar M, Bartram C, Oliff A, Andreeff M. In-vitro effects of the farnesyltransferase inhibitor ‘749 on leukemic cell lines with Ras mutations and myelodysplastic syndrome (MDS) patients’ samples with and without Ras mutations. AACR 37:421, 1996. e-Pub 1996.
977. Goodacre A, Grace C, Ford R, Andreeff M. New loci in lymphomagenesis identified by comparative genomic hybridization (CGH). AACR 37:557, 1996. e-Pub 1996.
978. Dohi DE, H-Y L, Han GR, Walsh GL, Nesbitt JC, Andreeff M, Hong WK, Kurie JM. Characterization of retinoic acid-induced growth inhibition of normal bronchial epithelial cells. AACR 37:500, 1996. e-Pub 1996.
979. Jiang S, Konopleva M, Bseiso A, Zhao S, Andreeff M. Isotype conversion of CD45R to CD45RO as an early event in ara-C induced apoptosis of acute lymphoblastic leukemia (ALL) cells. Blood 88(10):67a, 1996. e-Pub 1996.
980. Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth A. Bcl-X long expression is higher in poor prognosis (monosomy 5 and monosomy 7) acute myelogenous leukemia (AML) cells than in good prognosis [inversion 16 and t(8;21)] AML cells. ASCO, 1996. e-Pub 1996.
981. Jurecic R Nachtman R, Chen AJ, Jiang S, Snell V, Van NT, Andreeff M, Belmont JW. High-throughput readout of diffferential gene expression in murine and human hematopoietic stem cells and progenitors using long-distance dd-pcr and cDNA sequencing. Blood 88(10):595a, 1996. e-Pub 1996.
982. Andreeff M, Zhao S, Kliche KO, Jian S, Consoli U, Lisovsky M, Snell V, Zhang X, Sanchez-Williams G, Reed J, Estey E. Regulation of apoptosis in normal hematopoiesis and in myeloid leukemias. Blood 88(10):81a, 1996. e-Pub 1996.
983. Kantarjian H, O’Brien S, Beran M, Giralt S, Estey E, Koller C, Kornblau S, Andreeff M. Results with decitabine, a hypomethylating agent in the treatment of chronic myelogenous leukemia (CML) in accelerated or blastic phases. Blood 88(10):199b, 1996. e-Pub 1996.
984. Kavanagh J, Hanania E, Giles R, Berenson SQ, Heimfeld S, Cote R, Holzmayer T, Mechetner E, Dayn A, Andreeff M, Champlin R, Deisseroth AB. Enetic modification of cells used for transplant following intensive therapy for ovarian cancer and breast cancer. Blood 88(10):272a, 1996. e-Pub 1996.
985. Hu G, Liu W, Hanania EG, Consoli U, Fu S, Wang T, Andreeff M, Deisseroth AB. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 mRNA for the transforming proteins of the HPV 18 and the sense mRNA for retinoblastoma (RB) gene in cervical carcinoma cells. ASCO 14:545, 1995. e-Pub 1995.
986. Ham L, Sadeghi S, Farquhar D, Andreeff M, Andersson B, Murray D. 4-Hydroperoxycyclophosphamide (4HC) resistance in human CML line B5-180. 19th ICC, 1995. e-Pub 1995.
987. Yousuf H, Whimbey E, Couch R, Andreeff M, Lewis V, Koller C, Englund J, Tarrand J, Bodey G. Influenza virus infection among hospitalized adult immunocompromised patients with Leukemia. Infectious Diseases Society of America, 1995. e-Pub 1995.
988. Andreeff M, Jiang S, Consoli U, Brandes J, Sanchez-Williams G, Deisseroth A, Estey E. In vivo regulation of bcl-2 in AML progenitors by granulocyte-colony stimulating factor (G-CSF) and direct evidence for selection of bcl-2 ++ cells by induction chemotherapy of AML. Blood 86(10):511a, 1995. e-Pub 1995.
989. Consoli U, Snell V, Zhao S, Sanchez-Williams G, Estey E, Andreeff M. P-glycoprotein expression can be induced in AML blasts in vivo following short term exposure to chemotherapy. Blood 86(10):754a, 1995. e-Pub 1995.
990. El-Tounsi I, Consoli U, Younes A, Zhao S, Snell V, Thomas E, Lynch D, Andreeff M. Upregulation of Fas expression in B- chronic lymphocytic leukemia (CLL) cells by IL-2 and IL-7 is associated with enhancement of Fas ligand (FasL) mediated apoptosis. Blood 86(10):346a, 1995. e-Pub 1995.
991. El-Tounsi I, Zhao S, Younes A, Consoli U, Thomas E, Lynch D, Andreeff M. Bcl-2, Bcl-XL may confer resistance to Fas/Fas ligand mediated apoptosis in chronic lymphocytic leukemia (CLL) cells. Blood 86(10):346a, 1995. e-Pub 1995.
992. Engel H, Goodacre A, Keyhani A, Jiang S, Van N, Kimmel M, Sanchez-Williams G, Andreeff M. Detection of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in clinical remission by molecular cytogenetic. Blood 86(10):268a, 1995. e-Pub 1995.
993. Ford R, Goodacre A, Siciliano M, Claypool K, H-L S, Chan J, Andreeff M. Unique non-Hodgkin’s lymphoma, showing immature lymphoid phenotype, lack of lineage commitment, and N-MYC oncogene amplification. Blood 86(10):812a, 1995. e-Pub 1995.
994. Gisslinger H, Jiang S, Andreeff M, Kurzrock R, Talpaz M. FAS/APO-1, Another interferon inducible gene. Blood 86(10):541a, 1995. e-Pub 1995.
995. Fraizer G, Patmasiriwat P, Zhang X, Zhao S, Andreeff M, Saunders G. The tumor suppressor gene, WT1, is expressed in both human and mouse hematopoietic tissues. Blood 86(10):146a, 1995. e-Pub 1995.
996. Jiang S, Munker R, Andreeff M. Expression of bcl-2 in human natural killer cells and its induction by interleukin-2. Blood 86(10):717a, 1995. e-Pub 1995.
997. Kantarjian H, O’Brien S, Beran M, Keating M, Koller C, Robertson L, Andreeff M, Murphy S, Freireich E. Update of the hyper-CVAD program in newly-diagnosed adult acute lymphocytic leukemia (ALL). Blood 86(10):173a, 1995. e-Pub 1995.
998. Kantarjian H, O’Brien S, Beran M, Koller C, Andreeff M, M-B R, Keating M, Freireich E, Talpaz M. Interferon Alpha (IFN-A) and low dose cytosine arabinoside (ARA-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood 86(10):529a, 1995. e-Pub 1995.
999. Kobayashi T, Consoli U, Andreeff M, Shiku H, Reed J, Owen-Schaub L, Deisseroth A, Zhang W. Expression of FAS/APO-1 as an early and BAX as a late event in irradiation-induced apoptosis of wild-type P53-containing leukemia cells. Blood 86(10):325a, 1995. e-Pub 1995.
1000. Kornblau S, Estey E, Consoli U, Zhao S, Snell V, Newman R, Andreeff M. A phase I study of mitoxantrone + VP-16 with multidrug blockage by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. Blood 86(10):514a, 1995. e-Pub 1995.
1001. Kornblau S, Andreeff M, Koller C, Kantarjian H, Beran M, Keating M, O’Brien S, Estey E. Double anthracycline (mitoxantrone + idarubicin) therapy with cyclosporin a (CSA) to block multidrug resistance (MDR) as salvage therapy for relapsed or refractory acute myelogenous leukemia (R-AML). Blood 86(10):514a, 1995. e-Pub 1995.
1002. Kornblau S, Andreeff M, Beran M, Estey E, Keating M, Koller C, O’Brien S, Kantarjian H. CECA-Cyclophosphamide (CTX) etiposide (VP) carboplating (CBP) and cytosine arabinoside (araC)- A new salvage regimen for relapsed or refractory acute myelogenous leukemia (R-AML). Blood 86(10):514a, 1995. e-Pub 1995.
1003. Lisovsky M, Estrov Z, Consoli U, Munker R, Andreeff M. FLT3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia blasts. Blood 86(10):22a, 1995. e-Pub 1995.
1004. Liu Y, Drach J, Drach D, Zhao S, Andreeff M. Cytokine mRNA expression of FACS sorted normal CD34 positive bone marrow cells by reverse transcription polymerase chain reaction RT-PCR). Blood 86(10):672a, 1995. e-Pub 1995.
1005. Liu Y, H-D K, Engel H, Van N, Zhao S, Andreeff M. T cell activation in chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS): cytokine expression in FACS sorted T cells. Blood 86(10):718a, 1995. e-Pub 1995.
1006. Melnyk A, Estey E, Andreeff M. CD33 and CD34 antigen expression at presentation and relapse in acute promyelocytic leukemia (APL). Blood 86(10):770a, 1995. e-Pub 1995.
1007. Munker R, Zhao S, Thomas E, Andreeff M. Induction of DC95 (Fas/APO-1) HLA-DR and CD54 on blasts of acute myelogenous leukemias by TNA- and IFN- and resistance to Fas-mediated apoptosis. Blood 86(10):772a, 1995. e-Pub 1995.
1008. Snell V, Consoli U, Hude K, Mills G, Andreeff M. Rapamycin enhances ARA-C and Idarubicin inducted apoptosis in AML in vitro. Blood 86(10):513a, 1995. e-Pub 1995.
1009. Ueno N, Zhao S, Robertson L, Consoli U, Andreeff M. 2- Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Blood 86(10):803a, 1995. e-Pub 1995.
1010. Vadhan-Raj S, Broxmeyer HE, Jeha S, Estey E, Andreeff M, Thompson P, Trahan-Rieger P, Garrison L. Effects of PIXY 321 (GM-CSF/IL-3 fusion protein) in Patients with myelodysplastic syndromes. Blood 86(10):337a, 1995. e-Pub 1995.
1011. Younes A, Consoli U, Snell V, Kliche K, Thomas E, Armitage R, Cabanillas F, Andreeff M. Regulation of CD30 ligand expression on peripheral blood B-lymphocytes of Hodgkin’s disease patients. Blood 86(10):827a, 1995. e-Pub 1995.
1012. Zhang X, Jin X, Consoli U, Zhao S, Jiang S, Roth J, Andreeff M. Adenovirus delivered p16/CDKN2 gene decreases cell proliferation and induces erythroid differentiation in K562 cells. Blood 86(10):148a, 1995. e-Pub 1995.
1013. Zhao S, El-Tounsi I, Lin Y, Andreeff M. Increased expression of BCL-2 family genes in HL-60 doxorubicin resitant cell line and acute myeloid leukemia (AML) cells treated with chemotherapy. Blood 86(10):519a, 1995. e-Pub 1995.
1014. Goodacre A, Andreeff M, Ford R. New loci in lymphromagenesis identified by comparative genomic hybridization. MDAH Symposium, Genetic Mechanisms in Cancer, 1995. e-Pub 1995.
1015. Oeschlagel U, Nowak R, Zengler H, Hoffmann R, Naumann R, Ehninger G, Andreeff M. Detection of minimal residual disease in acute lymphoblastic leukemia with flow cytometric DNA quantification in immunophenotyped cells. Blood 86(10):774a, 1995. e-Pub 1995.
1016. Jurecic R, Andreeff M, Belmont JW. Identification and isolation of genes preferentially expressed in murine and human hematopoietic stem cells and progenitors. Blood 86(10):669a, 1995. e-Pub 1995.
1017. Engel H, Klein HD, Jiang S, El-Tounsi I, Andreeff M. Detection of normal cells in an early stem cell compartment in AML and MDS by molecular cytogenetics. Onkologie:138, 1995. e-Pub 1995.
1018. Kleine HD, Zech I, Andreeff M, Freund M. Continuous gating: A new scaning technique of flow cytometric list mode-date used for analysis of proliferation pattersn of normal and CML bone marrow progenitor cells. Onkologie:146, 1995. e-Pub 1995.
1019. Engel H, Drach J, Keyhani A, Jiang S, Goodacre A, Andreeff M. Quantitation of minimal residual disease in AML and MDS in complete remission by moldecular cytogenetics of progenitor cells. Onkologie:11, 1995. e-Pub 1995.
1020. Andreeff, M, Jin X, Consoli U, Zhao S, Jiang S, Roth J, Zhang X. Adenovirus delivered p16/CDKN2 gene decreases cell proliferation and induces hemoglobin synthesis in K562 cells. Keystone Symposia, 1995. e-Pub 1995.
1021. Younes A, Jiang S, Zhao S, Gruss H, Andreeff M. Decreased expression of the CD30 ligand (CD30L) on peripheral blood lymphocytes (PBL) isolated from patients with Hodgkin’s disease (HD) and Ki-1+ Non-Hodgkin’s lymphoma (NHL). ASCO 14:388, 1995. e-Pub 1995.
1022. O’Brien S, Kantarjian H, Feldman E, Andreeff M, Keating M, Koller C, Hester J, Rios MB, Talpaz M. Sequential homoharringtonine (HHT) and Interferon (IFN-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML). ASCO 14:336, 1995. e-Pub 1995.
1023. Kornblau S, Andreeff M, Beran M, Escudier S, Kantarjian H, Koller C, O, Brien S, Robertson LE, Estey E. 2-CDA + ARA-C is ineffective therapy for relapsed or refractory AML in adults. ASCO 14:336, 1995. e-Pub 1995.
1024. Fu SQ, Consoli U, Hanania EG, Zu Z, Claxton D, Andreeff M, Deisseroth AB. Transduction with a PML/RAR retrovirus rescues TF-1 cells from growth factor withdrawal-induced apoptosis. ASCO 14:78, 1995. e-Pub 1995.
1025. H-D K, Scheinischen D, El-Tounsi I, Andreeff M. Proliferation of B-CLL-cells cultured in a supplemented IMDM medium is increased by interleukin-2. Blood 84(10):459a, 1994. e-Pub 1994.
1026. Neamati N, Perez-Soler R, Andreeff M, Priebe W. Apoptosis induced by 2'-Bromo 4'-Epi daunorubicin (WP401), a novel non-cross restrantant anthracycline antibiotic. AACR, 1994. e-Pub 1994.
1027. Neamati N, Perez-Soler R, Andreeff M, Priebe W. Synthesis and Cellular pharmacology of 2'-Bromo-4' -epi-Daunorubicin (WP401), a novel non-cross-resistant anthracycline antibiotic. AACR, 1994. e-Pub 1994.
1028. Estey E, Cabinillas F, Rosenblum M, Kurzrock R, Bole J, Andreeff M, Keating M, Kantarjian H, Lopez-Berestein G. Phase I and pharmacology study of liposomal (L)-ALL transretinoic acit (ATRA). Blood 84(10):380a, 1994. e-Pub 1994.
1029. Gross HJ, Verwer B, Champlin R, Andreeff M. Detection of very low levels of metastatic breast cancer cells by 7-parametric flow cytometry in bone marrows of patients after chemotherapy. Blood 84(10):351a, 1994. e-Pub 1994.
1030. Zhao S, Consoli U, Arceci R, Andreeff M. New semi-automated method (QPCRTM) for quantitating multi-drug resistance (MDR1) in drug resistant cell lines and acute myeloid leukemia. Blood 84(10):53a, 1994. e-Pub 1994.
1031. Consoli U, Kleine HD, Brown W, DiRaimondo F, Andreeff M. Fludarabine monophosphate (FAMP) induced apoptosis of leukemic B and normal T-cells in chronic lymphocytic leukemia. Blood 84(10):458a, 1994. e-Pub 1994.
1032. Consoli U, Kantarjian H, Kleine HD, Estey E, Sanchez-Williams G, Robinson J, Andreeff M. Failure to detect high numbers of circulating apoptotic cells in leukemia patients undergoing cytoreductive therapy. Blood 84(10):617a, 1994. e-Pub 1994.
1033. Zhao S, Engel H, Mahedevia R, Bole J, Estey E, Andreeff M. Increased expression of CD38 in HL-60, NB4 cell lines cultured with ATRA and leukemia, lymphoma samples treated with liposomal ATRA in vivo. Blood 84(10):54a, 1994. e-Pub 1994.
1034. Engel H, Kleine H, Jiang S, Sanchez-Williams G, Andreeff M. Detection of normal cells in an early stem cell compartment in myeloid leukemia by molecular cytogenetics. Blood 84(10):300a, 1994. e-Pub 1994.
1035. Engel H, Drach J, Keyhani A, Jiang S, Sanchez-Williams G, Andreeff M. Detection of high proliferative minimal residual disease in ALL patients with AML and MDS in complete remission with monosomy 7 by FACS/FISH. Blood 84(10):421a, 1994. e-Pub 1994.
1036. Kline HD, Scheinichen D, El-Tounsi I, Andreeff M. Proliferation of B-CLL-cells cultured in a supplemented IMDM medium is increased by interleukin-2. Blood 84(10):459a, 1994. e-Pub 1994.
1037. Kleine H, Griffin M, Champlin R, Andreeff M. Proliferation patterns of human bone marrow progenitor cells analyzed by a new scanning technique of activation markers: comparison of chronic myeloid leukemia (CML) and normal hematopoiesis. Blood 84:10 Suppl 1, #2260, 569a, 1994. Blood 84(10):569a, 1994. e-Pub 1994.
1038. Wetzler M, Talpaz M, Yee G, Stass AS, Van Etten RA, Andreeff M, Goodacre A, Kleine H, Mahadevia R, Kurzrock R. Cell cycle-related shifts in subcellular localization of BCR: Association with mitotic chromosomes and with heterochromatin. Blood 84(10):139a, 1994. e-Pub 1994.
1039. Goodacre A, Consoli U, Andreeff M. Simultaneous detection of apoptosis with multi-drug resistance associated p-glycoprotein and genetic markers by FISH. Blood 84(10):143a, 1994. e-Pub 1994.
1040. Goodacre A, Ford R, Andreeff M. Comparative genomic hybridization resolves karyotypic heterogeneity and complexity in high grade non-Hodgkin lymphoma. Blood 84(10):143a, 1994. e-Pub 1994.
1041. Younes A, Zhao S, Andreeff M. Expression of the multi-drug resistance associated protein (MRP) in patients with non-Hodgkin's lymphoma (NHL). Blood 84(10):616a, 1994. e-Pub 1994.
1042. Younes A, Jiang S, Gruss H, Andreeff M. Expression of the CD30 ligand (CD30L) on human peripheral blood lymphocytes from normal donors and patients with lymphoid malignancies. Blood 84(10):161a, 1994. e-Pub 1994.
1043. Rondon G, Khouri I, Giralt S, Huh Y, Andreeff M, Champlin R. Chimerism following sex-mismatched allogeneic BMT in chronic lymphocytic leukemia (CLL). Blood 84(10):208a, 1994. e-Pub 1994.
1044. Körbling M, Przepiorka S, Engel H, van Besien K, Giralt S, Andersson B, Huh Y, Deisseroth A, Andreeff M, Champlin R. Allogeneic blood stem cell transplantation (allo-PBSCT) in 9 patients with refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 84(10):396a, 1994. e-Pub 1994.
1045. Fu S, Consoli U, Hanania EG, Zu S, Claxton D, Andreeff M, Deisseroth AB. RML/RARA, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells. Blood 84(10):19a, 1994. e-Pub 1994.
1046. Estey E, Cabanillas F, Rosenblum M, Kurzrock R, Bole J, Andreeff M, Keating M, Kantarjian H, Lopez-Berestein G. Phase I and pharmacology study of liposomal (L)-all trans retinoic acid (ATRA). Blood 84(10):380a, 1994. e-Pub 1994.
1047. Escudier S, Engel E, Pierce S, Keating M, Andreeff M. Trisomy 12 in chronic lymphocytic leukemia. Blood 84(10):453a, 1994. e-Pub 1994.
1048. Escudier S, Albitar M, Robertson LE, Andreeff M, Kantarjian H. Adult acute lymphoblastic leukemia following preleukemic syndromes. Blood 84(10):148a, 1994. e-Pub 1994.
1049. Engel H, Körbling M, Palmer J, Mehra R, Walker J, Andreeff M, Champlin R. Randomized trial of G-CSF alone vs sequential interleukin-3 (IL-3) and G-CSF treatment to peripheralize progenitor cells for apheresis and blood stem cell autotransplantation in patients with advanced stage breast cancer. Blood 84(10):108a, 1994. e-Pub 1994.
1050. Beran M, Kantarjian H, O'Brien S, Estey E, Andreeff M, Pierce S, Robinson J, Koller C, Keating M. Topotecan, a new topoisomerase I (Topo I) inhibitor, has significant activity in patients with chronic myelomonocytic leukemia (CMML). Blood 84(10):151a, 1994. e-Pub 1994.
1051. Anderlini P, Kantarjian H, Andreeff M, Kornblau S, O'Brien S, Pierce S, Benjamin R, Estey E. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia (AML) and myelodysplasia (MDS). Blood 84(10):305a, 1994. e-Pub 1994.
1052. Anderlini P, Kantarjian, Andreeff M, Kornblau S, O'Brien S, Pierce S, Keating M, Estey E. Causes of initial remission induction failure in acute myeloid leukemia (AML) and myelodysplasia (MDS). Blood 84(10):147a, 1994. e-Pub 1994.
1053. Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Andreeff M, Deisseroth AB. Gene-therapy animal model to evaluate the long term effect and the efficiency of using the multiple drug resistance gene retroviral vectors in conferring the chemo resistance phenotype upon early progenitor cells. AACR:210, 1994. e-Pub 1994.
1054. Neamati N, Perez-Soler R, Andreeff M, Priebe W. Cytotoxicity and cellular pharmacology of 2'bromo-4'-epi-daunorubicin (WP 401), a novel non cross-resistant anthracycline analog. AACR(423), 1994. e-Pub 1994.
1055. Neamati N, Perez-Soler R, Andreeff M, Priebe W. Design and cellular pharmacology of 2'-Bromo-4'-epi-daunorubicin (401), a novel non cross-resistant anthracycline antibiotics. BioInternational 94 Conference and Exhibiton, Houston, 1994. e-Pub 1994.
1056. O'Brien S, Kantarjian H, Keating M, Koller C, Andreeff M, Feldman E, Beran M, Escudier S, Hester J, Robertson L, Talpaz M. Homoharringtonine (HHT) produces high response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML). 9th Mediterranean Congress of Chemotherapy, Milano, Italy, 1994. e-Pub 1994.
1057. Jendiroba DB, Younes A, Katz R, Hill D, Rodriguez MA, Cabanillas F, Andreeff M. Fluorescence in situ hybridization detects high incidence of chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. AACR 10, 1994. e-Pub 1994.
1058. Goodacre A, Engel H, Andreeff M. Loss of 17p during clonal evolution in CML: A new consistent pattern of whole arm translocations evaluable by interphase FISH. 25FISH - Clinical Applications in Cancer & Genetics, 1994. e-Pub 1994.
1059. Goodacre A, Ford R, Stilgenbauer S, Cabanillas F, Grace C, Andreeff M. Comparative genomic hybridization (CGH) of non-Hodgkin lymphoma (NHL). CFISH - Clinical Applications in Cancer & Genetics, 1994. e-Pub 1994.
1060. Goodacre A, Ford R, Stilgenbauer S, Cabanillas F, Grace C, Andreeff M. Comparative genomic hybridization (CGH) of non-Hodgkin lymphoma (NHL). FISH - Clinical Applications in Cancer & Genetics, 1994. e-Pub 1994.
1061. Stilgenbauer S, Goodacre A, Grace C, Andreeff M. Comparative genomic hybridization (CGH) in the genetic analysis of hematologic malignancies. FISH - Clinical Applications in Cancer & Genetics, 1994. e-Pub 1994.
1062. Younes A, Jendiroba D, Goodacre A, Andreeff M. Fluorescent in situ hybridization applications in lymphoma, studies of chromosomes 12, 17, 18 and X abnormalities. FISH - Clinical Applications in Cancer & Genetics, 1994. e-Pub 1994.
1063. Escudier SM, Engel H, Pierce S, Andreeff M. Fluorescent in situ hybridization (FISH) studies of trisomy 12 in chronic lymphocytic leukemia. FISH - Clinical Applications in Cancer & Genetics, 1994. e-Pub 1994.
1064. Andreeff M, Escudier A, Goodacre A, Stilgenbauer S, Engel H, Walker S, Gahn B, Keyhani A, Shi G, Drach J, Zhao S, Liu Y, Rondon G, Jendiroba D, Cabanillas F, Siciliano M, Champlin R, Younes. FISH in the study of hematopoietic malignancies. FISH - Clinical Applications in Cancer & Genetics, 1994. e-Pub 1994.
1065. Younes A, Jendiroba D, Goodacre A, Andreeff M. Fluorescence in situ hybridization applications in lymphoma. ASCO, 1994. e-Pub 1994.
1066. del Giglio A, Drach J, Novaes M, Khetan R, Sawaya N, Lacer PD, Chamone DF, Andreeff M, Hester J, Deisseroth A. Proliferation cell nuclear antigen (PCNA) expression by peripheral blasts correlates with remission induction in patients with acute myelogenous leukemia (AML). ASCO:114, 1994. e-Pub 1994.
1067. Hanania E, Fu S, Roninson I, Mechetner E, Holzmeyer T, Hegewisch-Becker S, Zu Z, Hill L, Andreeff M, Berenson R, Heimfeld S, Gottesman M, Deisseroth A. Retroviral mediated introduction of the multidrug (MDR-1) cDNA confers Taxol resistance on long-term culture initiating cells (LTCIC) in human marrow transplantation model. ASCO:406, 1994. e-Pub 1994.
1068. Andreeff M, Drach J, Sanchez-Williams G, Zhao S, Liu S, Kornblau S, Escudier S, Kantarjian H, Deisseroth A, Estey E. Treatment with G-CSF, Fludarabine and ARA-C (FLAG) of poor prognosis AML and MDS: Response, biological effects and monitoring of minimal disease. ASCO 12:309, 1993. e-Pub 1993.
1069. Drach J, Zhao S, Goodacre A, Pereira-Leahy J, Drach D, Escudier S, Seong D, Liu Y, Siciliano M, Deisseroth A, Andreeff M. Molecular cytogenetics and gene regulation of normal and leukemia hematopoiesis. Cytometry Suppl 6:8A, 1993. e-Pub 1993.
1070. Escudier S, Drach JW, Andreeff M. Minimal Residual Disease (MRD) in chronic lymphocytic leukemia (CLL) detected by fluorescent in situ hybridization (FISH) on FACS-sorted cells. Cytometry Suppl 6:11A, 1993. e-Pub 1993.
1071. Andreeff M, Drach J, Sanchez-Williams G, Zhao S, Liu Y, Kornblau S, Escudier S, Tafuri A, Kantarjian H, Deisseroth A, Estey E. Treatment with Cytokine/ Chemotherapy combinations of poor prognosis and relapsed AML and MDS: Response, biological effects and monitoring of minimal disease. Leukemia - the next questions, 1993. e-Pub 1993.
1072. Drach J, Leahy J, Goodacre A, Drach D, Sanchez-Williams G, Weier HU, Pinkel D, Andreeff M. Fluorescence in situ hybridization of FACS-sorted cells detects residual disease in acute myelogenous leukemia and predicts clinical relapse. 12th Meeting International Society of Haematology:45, 1993. e-Pub 1993.
1073. Drach J, McQueen T, Zhao S, Robertson KA, Collins SJ, Malvasi F, Andreeff M, Mehta K. All-trans retinoic acid (ATRA) induces CD38 expression on myeloid leukemia cells and normal CD34+ bone marrow cells. 12th Meeting International Society of Haematology:113, 1993. e-Pub 1993.
1074. Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. G-CSF, GM-CSF, SCF, PIXY-321, IL-3, and IL-7: Receptor binding and effects on clonogenic growth in acute lymphoblastic leukemia (ALL). 12th Meeting International Society of Haematology(27), 1993. e-Pub 1993.
1075. Przepiorka D, Giralt S, Andreeff M, Huh YO, Luna M, Reading C, Thomas M, Champlin RE. Engraftment and graft-vs-host disease after sequential autologous allogeneic bone marrow transplantation in patients with lymphoma. J. Cell Biochem Suppl 16A:186, 1992. e-Pub 1992.
1076. Keating M, Estey E, Kantarjian H, O'Brien S, Koller C, Andreeff M. Idarubicin and high-dose arabinoside is a highly effective remission induction regimen in acuet myelogenous leukemia (AML). Brit. Journal of Haematology, 1992. e-Pub 1992.
1077. Tafuri A, De Felice L, Meloni G, De Gregoris C, Fenu S, Goodacre A, Cedrone M, Guglielmi G, Burgio VL, Petrucci MT, Valentini T, Amadori S, Andreeff M, Mandelli F. Interleukin-3/chemotherapy treatment of acut emyeloid leukemia: in vivo and in vitro studies. Amer. Assoc. Cancer Res 33:1385, 1992. e-Pub 1992.
1078. Zhang W, Drach J, Andreeff M, Deisseroth A. Cis and trans defects in the regulation of the retinoblastoma (RB) gene in acute myelogenous leukemia (AML). Amer. Assoc. Cancer Res 33:2261, 1992. e-Pub 1992.
1079. Andreeff M, Estey E, Tafuri A, Reading C, Estrov Z, Drach J, Escudier S, Goodacre A, Zhao S, Zhang W, Plunkett W, Mandelli F, Deisseroth A. Interleukin-3/chemotherapy combinations in acute myeloblastic leukemia (AML). Amer. Soc. Clin. Oncol 11:273, 1992. e-Pub 1992.
1080. Escudier SM, Pereira-Leahy JM, Drach JW, Weier HU, Keating MJ, Andreeff M. Detection of minimal residual disease in chronic lymphocytic leukemia (CLL) using fluorescence in situ hybridization (FISH) studies of trisomy 12. Amer. Soc. Clin. Oncol 11:103, 1992. e-Pub 1992.
1081. Jakubowski AA, Gordon M, Moore MAS, Tafuri A, Andreeff M, Shieh JH, Brown S, Vincent M, Gabrilove JL. In vivo and in vitro studies of RHG-CSF in acute nonlymphocytic leukemia. Annals of Hematol:A114, 1991. e-Pub 1991.
1082. Andreeff M, Tafuri A, Goodacre A, Escudier S, Leahy M, El-Naggar A, Van N, Collins C, Estey E. Cytokine effects in acute leukemia analysis of cytokine receptors cell cycle kinetics and clonality in normal and leukemic target cells. Ann. Hematol A95, 1991. e-Pub 1991.
1083. Tafuri A, Collins D, Lukas R, Mandelli F, Andreeff M. Cytokine receptor determination by flow cytometry in normal and malignant hematopoietic cells. ASCO 10, 1991. e-Pub 1991.
1084. Frankel SR, Scheinberg DA, Miller, Jr, WH, Dmitrovsky E, Jakubowski A, Gabrilove J, Tafuri A, Andreeff M, Jhanvar S, Gordon M, Warrell Jr D. Differentiation therapy of acute promyelocytic leukemia (APL) with ALL-trans-retinoic acid. ASCO 10, 1991. e-Pub 1991.
1085. Goodacre AM, Tafuri A, Pereira M, Estrov Z, Reading C, Deisseroth A, Andreeff M. Selectivity of recombinant human growth factors on proliferation of normal vs leukemic cells in myeloid leukemia in vitro and in vivo assayed by BUdR and chromosome-specific fluorescence in situ hybridization (FISH). Fluorescence in situ hybridization: Molecular probes in tumor diagnosis:36, 1991. e-Pub 1991.
1086. Schwartz MA, Lovett DR, Redner A, Divgi CR, Graham MC, Finn R, Gee TS, Andreeff M, Oettgen HF, Larson SM, Old LJ, Scheinberg DA. Leukemia cytoreduction and marrow ablation after therapy with 131-I labeled monoclonal antibody M 195 for acute myelogeneous leukemia (AML). ASCO 10, 1991. e-Pub 1991.
1087. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Ch S, Haas O, Vieder L, Schulz G, Speiser W, Geissler K, Kier P, Hinterberger W, Lechner K. GM-CSF in combination with cytotoxic chemotherapy in AML patients. Ann. Hematol 62:A8, 1991. e-Pub 1991.
1088. Homge-Offenberg M, Pereira-Leahy M, Keman N, O'Reilly R, Andreeff M. FISH in sex-mismatched bone marrow transplantation. Fluorescence in situ hybridization: Molecular probes in tumor diagnosis:34, 1991. e-Pub 1991.
1089. Andreeff M, Homge-Offenberg M, Goodacre A, Pereira-Leahy M, Tafuri A, Drach J. Lineage involvement in myeloid leukemias as assayed by FISH. Fluorescence in situ hybridization: Molecular probes in tumor diagnosis:35, 1991. e-Pub 1991.
1090. Andreeff M, Tafuri A, Bettelheim P, Valent P, Estey E, Lemoli R, Homge M, Collins D, Goodacre A, Clarkson B, Mandelli F, Deisseroth A. Cytokinetic resistance in acute leukemia. Ann. Hematol 62:A6, 1991. e-Pub 1991.
1091. Andreeff M, Stone R, Young C, Tong W, Ervin T, Tafuri A, Kolitz J, Rifkind R, Kufe D, Marks P. Hexamethylene bisacetamide (HMBA) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). International Workshop: Therapy of Myelodysplastic Syndromes: Advances and Perspectives: Innsbruck, Austria, 1990. e-Pub 1990.
1092. Andreeff M, Hegewisch-Becker S, Rehermann B, Godfrey L, Maslak P. Flow cytometric determination of p-glycoprotein in acute leukemia. AACR 31:1134, 1990. e-Pub 1990.
1093. Homge M, Pinkel D, van Dekken H, Brochstein J, Kernan NA, O'Reilly RI, Segraves R, Gray J, Andreeff M. Detection of residual host cells after bone transplantation using fluorescence in situ hybridization (FISH). ASHG, 1990. e-Pub 1990.
1094. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Survanaravan K, Homge M, Render A, Gray J, Pinkel D. Detection of BCR-ABL fusion in chronic myelogenous leukemia by two-color fluorescence in situ hybridization. Amer. Soc. Human Genetics, 1990. e-Pub 1990.
1095. Redner A, Hegewisch-Becker S, Smith M, Squires J, Andreeff M. BCR/ABL transcripts detected by polymerase chain reaction and prognosis in chronic myelogenous leukemia. AACR 31:1857, 1990. e-Pub 1990.
1096. Homge M, Pinkel D, van Dekken H, Brochstein J, Kernan NA, O'Reilly RJ, Gray J, Andreeff M. Detection of residual host cells after sex-mismatched bone marrow transplantation (BMT) using fluorescence in situ hybridization. ASCO 9:785, 1990. e-Pub 1990.
1097. Godfrey L, Espiritu E, Maslak P, Tafuri A, Andreeff M. Ki67 expression and acridine orange (AO) cell cycle analysis in leukemia. Cytometry Suppl 4:97, 1990. e-Pub 1990.
1098. Maslak P, Espiritu E, Godfrey L, Andreeff M. Clinical application of DNA/RNA flow cytometry in adult leukemia. Cytometry Suppl 4:97, 1990. e-Pub 1990.
1099. Homge M, Haimi J, Pinkel D, Gray J, Chaganti R, O'Reilly R, Kernan N, Andreeff M. Detection of host cells after sex-mismatched bone marrow transplantation (BMT) by FISH using chromosome-specific DNA probes. Cytometry Suppl 4:58, 1990. e-Pub 1990.
1100. Pinkel D, Tkachuk E, Segraves R, Finger E, Gray J, Waldman F, Andreeff M, Homge M. Detection of structural abnormalities in tumors by in situ hybridization. Cytometry Suppl 4:57-58, 1990. e-Pub 1990.
1101. Tafuri A, Andreeff M. Kinetic effects of cytokines in acute myeloid leukemia (AML) and its application in recruitment therapy. Cytometry Suppl 4:29, 1990. e-Pub 1990.
1102. Redner A, Smith M, Hegewisch-Becker S, Andreeff M. Polymerase chain reaction (pcr) in the detection of minimal residual leukemia. Cytometry Suppl 4:23, 1990. e-Pub 1990.
1103. Steinherz P, Haimi J, Redner A, Meyers P, Andreeff M. Therapy for acute lymphoblastic leukemia The MSK NY II protocol, with quantitative monitoring of cytoreduction for the selection of optimal therapy. International Society of Paediatric Oncology SIOP XXI Meeting, Prague, Czechoslovakia, 1989. e-Pub 1989.
1104. Maslak P, McKenzie S, Scheinberg D, Andreeff M, Clarkson B. Immunophenotypic, cytogenetic and morphologic characteristics of terminal deoxynucleotidyl transferase (TdT) positive acute nonlymphocytic leukemia (ANLL). 80th Annual Meeting AACR 30:226, 1989. e-Pub 1989.
1105. Berman E, Raymond V, Gee TS, Kempin SJ, Andreeff M, Gabrilove J, Young CW, Clarkson, BD, Wiernik PH, Case DE, Arlin ZA, Vogler WR, Velez Garcia E, Omura G, Raney M. Idarubicin in acute leukemia: Results in U.S. Trials. Bone Marrow Transplantation, 1989. e-Pub 1989.
1106. Tafuri A, Uckun F, Andreeff M. Cytokines increase cytotoxicity of chemotherapeutic agents in acute leukemia. 80th Annual Meeting AACR 30:283, 1989. e-Pub 1989.
1107. Haimi J, Pinkel D, Gray J, Rehermann B, Kernan N, Chaganti R, O'Reilly R, Andreeff M. Determination of residual host cells in sex mismatched bone marrow transplantation (BMT) by fluorescence in situ hybridization (FISH) using chromosome specific DNA probes. 80th Annual Meeting AACR 30:39, 1989. e-Pub 1989.
1108. Crown J, Rigas J, McKenzie S, Lee R, Dietz K, Berman E, Andreeff M, Kolitz J, Reich L, Clarkson B, Gee T. Mitoxantrone and etoposide (MVP16) in failed acute leukemia (AL) and blastic chronic myeloid leukemia (CML). ASCO 8:208, 1989. e-Pub 1989.
1109. Hegewisch Becker S, Smith M, Redner A, Wisniewski D, Clarkson B, Andreeff M. RNA isolation for PCR of bcr abl rearrangements from CML samples with minimal cell numbers. UCLA Symposium on DNA Polymerase Chain Reaction, 1989. e-Pub 1989.
1110. Albino AP, Nanus DM, Andreeff M. Activation of ras oncogenes in malignant melanoma. Relationship to differentiation state. 80th Annual Meeting AACR 30:430, 1989. e-Pub 1989.
1111. Andreeff M, Hegewisch Becker S, Haimi J, Rehermann B, Berman E, Bertino J. Multidrug resistance, expression of P glycoprotein, anthracycline uptake and ARA C resistance in acute leukemia: Assessment by flow cytometry and correlation with response to therapy. J. Chemoth. Inf. Dis. and Malign Suppl 1:480, 1989. e-Pub 1989.
1112. Bettelheim P, Muhm M, Valent P, Geissler K, Hinterberger W, Haas O, Speiser W Sunder Plassman G, Vieder L, Andreeff M, Lechner K. RhuGM CSF in combination with standard induction chemotherapy ("3+7") in patients with de novo acute myeloid leukemia. Molec. Biother 1:61, 1989. e-Pub 1989.
1113. Maslak P, McKenzie S, Scheinberg D, Andreeff M. Mixed lineage features of chronic myelogenous leukemia (CML). ASCO 8:208, 1989. e-Pub 1989.
1114. Steinherz P, Haimi J, Redner A, Meyers P, Andreeff M. Rapid rotation of drugs in an intensive therapy for acute lymphoblastic leukemia The MSK NY II Protocol, with quantitative monitoring of cytoreduction for the selection of optimal therapy. ASCO 8:211, 1989. e-Pub 1989.
1115. Redner A, Haimi J, Steinherz P, Andreeff M. Near haploid leukemia: correlation between kinetic quiescence and failure to respond to chemotherapy. 80th Annual Meeting AACR 30:34, 1988. e-Pub 1988.
1116. Andreeff M, Hegewisch S, Haimi J, Bressler J, Souza L. Cytokine enhanced proliferation and differentiation of human myeloid leukemia. Cell Tissue Kinet 21:62, 1988. e-Pub 1988.
1117. Squires J, Redner A, Andreeff M. P53 expression in human leukemia: Restriction to lymphoid cell lineage and potential prognostic importance in acute lymphoblastic leukemia. AACR 29:454, 1988. e-Pub 1988.
1118. Haimi J, Dolbeare F, Andreeff M. Cell kinetics of low dose cytosine arabinoside therapy in acute non lymphocytic leukemia and myelodysplastic syndromes. AACR 29:27, 1988. e-Pub 1988.
1119. Andreeff M, Kreis W, Miller W, Gee T, Berman E, Kolitz J, Kempin S, Straus D, Reich A, Tafuri A, Espiritu E, Deere M, Clarkson B. Low dose cytosine arabinoside (ARA C) in acute non lymphocytic leukemia (ANLL) and myelodysplastic syndromes (MDS): Analysis of response and response mechanisms. ASCO 7, 1988. e-Pub 1988.
1120. Hegewisch S, Bressler J, Haimi J, Souza L, Welte K, Andreeff M. Induction of differentiation by granulocyte and granulocyte macrophage colony stimulating factor and cytosine arabinoside in the human myeloid leukemic cell line KG 1. AACR 29:368, 1988. e-Pub 1988.
1121. Gabius HJ, Hellmann KP, Bokemeyer C, Andreeff M. Lectins in human hematopoietic cell lines. German Cancer Congress, 1988. e-Pub 1988.
1122. Tafuri A, Haimi J, Redner A, Andreeff M. Effects of hexamethylene bisacetamide on human myeloma cell line: Stathmokinetic and multiparameter flow cytometric analysis. International Congress of Hematology, 1988. e-Pub 1988.
1123. Redner A, Andreeff M. Clinical application of DNA/RNA flow cytometry in pediatric leukemia therapy. Cytometry Suppl 2:9, 1988. e-Pub 1988.
1124. Andreeff M, Hegewisch Becker S, Tafuri A, Haimi J, Bressler J, Godfrey L, Welte K, Redner A. Cytokine modulation of leukemia cell proliferation and differentiation. Cytometry Suppl 2:10, 1988. e-Pub 1988.
1125. Pinkel D, Gray J, Segraves R, Collins C, Yu LC, Eastmond DA, Tenjin H, Andreeff M, Haimi J, Perle MA, Golbus M. Clinical cytogenetics using in situ hybridization for detection of structural and numerical chromosome abnormalities. Cytometry Suppl 2:6, 1988. e-Pub 1988.
1126. McKenzie S, Scheinberg D, Andreeff M, Maslak P, Clarkson B. Cell surface phenotypes of acute leukemias at Memorial Hospital. Cytometry Suppl 2:53, 1988. e-Pub 1988.
1127. Andreeff M, Young C, Clarkson B, Fetten J, Rifkind R, Marks P. Treatment of myelodysplastic syndromes (MDS) with hexamethylene bisacetamide (HMBA). Symposium on Myelodysplastic Syndromes: Biology and Treatment, Houston, 1988. e-Pub 1988.
1128. Andreeff M, Groshen S, Cirrincione C, Gaynor J, B: C. Clinical relevance of acridine orange flow cytometry in hematologic oncology. Cell Tissue Kin 20:243, 1987. e-Pub 1987.
1129. Andreeff M. Adult ALL: An improving outlook. Society of America Medical Conference. Third National Symposium. Leukemia 1:254, 1987. e-Pub 1987.
1130. Andreeff M, Bressler J, Squires J. Oncogene protein expression in fresh human leukemia cells. Cell Tissue Kin 20:251, 1987. e-Pub 1987.
1131. Paietta E, Andreeff M, Papenhausen P, Roberts M, Wiernik PH. Biphenotypic and undifferentiated acute leukemias: in vitro induction of differentiation. ASCO 5:8, 1986. e-Pub 1986.
1132. Haines I, Andreeff M, Mertelsmann R, Chaganti R, Nahmias N, Clarkson BD. Prognostic factors in primary myelodysplastic syndrome (PMDS). ASCO 5:165, 1986. e-Pub 1986.
1133. Andreeff M, Bressler J, Assing G, Squires J. P21RAS and P53 oncogene expression in acute leukemia determined by multiparameter flow cytometry. AACR 27, 1986. e-Pub 1986.
1134. Schwartzberg L, Nahmias N, Gee T, Andreeff M, Clarkson B. Treatment of central nervous system (CNS) relapse in adult acute lymphoblastic leukemia (ALL). ASCO 5:160, 1986. e-Pub 1986.
1135. Andreeff M, Gaynor J, Chapman D, Ellis S, Little C, Gee T, Mertelsmann R, Kempin S, Berman E, Koziner B, McKenzie S, Clarkson B. Prognostic factors in acute lymphoblastic leukemia in adults: The Memorial Hospital Experience. Acute Leukemias. Prognostic Factors and Treatment Strategies 13, 1986. e-Pub 1986.
1136. Andreeff M, Squires J, Bressler J. Expression of p53 oncogene protein in fresh human leukemia cells. J Cell Biochem Suppl 10c:143, 1986. e-Pub 1986.
1137. Kong XB, Andreeff M, Fanucchi MP, Fox JJ, Watanable KA, Vidal P, Chou TC. Cell differentiation effects of 2'fluoro-1-B-D-arabino- furanosyl pyrimidines in HL 60 cells. AACR 27, 1986. e-Pub 1986.
1138. Andreeff M, Slater DE, Bressler J, Furth ME. Cellular oncogene expression measured by flow cytometry in a hematopoietic cell line. Leukemia 2(2), 1985. e-Pub 1985.
1139. Berman E, Arlin AZ, Gee TS, Kempin SJ, Mertelsmann R, Andreeff M, Nahmias N, Clarkson BD. Results of a comparative trial of amsacrine/cytarabine/thioguanine (AAT) and daunorubicin /cytarabine /thioguanine (DAT) in patients with untreated acute non lymphocytic leukemia (ANLL): Results of the L 16M protocol. 3rd Europ. Conf. Oncol(129), 1985. e-Pub 1985.
1140. Berman E, Arlin AZ, Gee TS, Kempin SJ, Mertelsmann R, Andreeff M, Nahmias N, Clarkson BD. Results of a comparative trial of amsacrine/cytarabine/thioguanine (AAT) and daunorubicin /cytarabine /thioguanine (DAT) in patients with untreated acute non lymphocytic leukemia (ANLL): Results of the L-16M protocol. 3rd Europ. Conf. Oncol 129, 1985. e-Pub 1985.
1141. Paietta E, Andreeff M, Papenhausen P, Roberts M, Wiernik PH. Biphenotypic leukemias. XII Symp. Compar. Res. Leukemia and Related Disease, 1985. e-Pub 1985.
1142. Wang E, Tan EM, Andreeff M. Alternative expression of statin, a non proliferation specific protein, and PCNA (cyclin), a proliferation specific protein, during transition from quiescent to replicating state. 25th Annual Meeting, Amer Soc Cell Biol:39, 1985. e-Pub 1985.
1143. Espiritu E, Welte K, Andreeff M. Induction of Leu 11 on lymphoid leukemic cells by OKT 3, PMA and IL 2. Soc. Analyt Cytol. XI:355, 1985. e-Pub 1985.
1144. Schiff RD, Mertelsmann R, Andreeff M, Berman E, Gee TS, Kempin SJ, Berenson S, in transformation CBLDCIR, Proc ASCO PRL. Low dose cytarabine (LD ARA C) in RAEB in transformation (RAEBIT) and poor risk leukemias. ASCO 4:165, 1985. e-Pub 1985.
1145. Andreeff M, Wong G, Koziner B, Espiritu E, Clarkson B. Non B, Non T acute lymphoblastic leukemia (ALL): Evidence for complete B cell differentiation of a quiescent subpopulation and their response to induction therapy. AACR 26:28, 1985. e-Pub 1985.
1146. Kempin S, Meyers J, Lee B, Koziner B, Al Katib A, Straus D, Berman E, Gee T, Andreeff M, Mertelsmann R, Clarkson B. Clinical immunological classification of lymphoplasmacytoid immunocytomas (LPI). ASCO 4:208, 1985. e-Pub 1985.
1147. Bartal AH, Andreeff M, Feit C, Hirshaut Y. Clonal stability of hybridoma clones determined by flow cytometry. AACR 26:286, 1985. e-Pub 1985.
1148. Schiff RD, Mertelsmann R, Andreeff M, Gee TS, Kempin SJ, Koziner BL, Lee BJ, Clarkson BD. Low dose arabinosyl cytosin (LD ARA C) in hematologic malignancies and myelodysplastic syndromes (MDS). Amer Clin Onc 3:206, 1984. e-Pub 1984.
1149. Andreeff M, Hansen H, Cirrincione C, Thaler H, Groshen S, Assing G, Clarkson BD, Melamed MR. Cellular RNA content: a major prognostic factor in adult acute leukemia and non Hodgkin's lymphoma. Intl Conf Analyt Cytol X, 1984. e-Pub 1984.
1150. Andreeff M, Redner A, Groshen S, Clarkson B, Melamed MR. Application of flow cytometry in characterization of lymphomas and leukemias. 13th Europ Congr Cytology, 1984. e-Pub 1984.
1151. Andreeff M, Cirrincione C, Assing G, Melamed MR, Clarkson BD. Analysis of prognostic factors including flow cytometry derived parameters in adult acute non lymphoblastic leukemia (ANLL). Amer Soc Clin Onc 3:195, 1984. e-Pub 1984.
1152. Andreeff M, Higgins PJ, Bressler J, Melamed MR. Cellular oncogene expression measured by flow cytometry in human hematopoietic cell lines. Amer Assoc Cancer Res 25:35, 1984. e-Pub 1984.
1153. Walle A, Al Katib A, Chaganti R, Koziner B, Darzynkiewicz Z, Andreeff M. Genetic and phenotypic heterogeneity of L3 leukemia (FAB) cell populations. Proc Amer Fed Clin Res, 1984. e-Pub 1984.
1154. Gulati S, Shank B, Straus D, Koziner B, Lee B, Mertelsmann R, Kempin S, Andreeff M, Dinsmore R, Gee T, Yopp J, Vega R, Gandola L, O'Reilly R, Clarkson B. Autologous stem cell transplantation (ASCT) for poor prognosis lymphoma. Amer Soc Clin Onc 3:245, 1984. e-Pub 1984.
1155. Berman E, Arlin Z, Daghestani A, Gee T, Kempin S, Mertelsmann R, Andreeff M, Hancock R, Baratz R, Williams L, Clarkson B, Young C. Phase I II study of idarubicin and cytarabine (ARA C) in acute leukemia. Amer Assoc Cancer Res 25:187, 1984. e-Pub 1984.
1156. Andreeff M, Darzynkiewicz Z, Cirrincione C, Groshen S, Melamed MR. Importance of flow cytometric parameters in multi variate analysis of acute leukemia and lymphoma. Symposium Clinical Cytometry:25, 1983. e-Pub 1983.
1157. Walle A, Darzynkiewicz Z, McKenzie S, Higgins PF, Andreeff M. Characterization of nuclear (n) and cellular (c) RNA and DNA content of blood (PB) and marrow (BM) cell of patients with Burkitt type of lymphoma (FAB, L3). Amer Assoc Cancer Res 24:8, 1983. e-Pub 1983.
1158. Redner A, Groshen S, Melamed MR, Andreeff M. Flow cytometry of ALL during induction therapy and multivariate analysis of prognostic factors. Symposium Clinical Cytometry:109, 1983. e-Pub 1983.
1159. Andreeff M, Hansen H, Cirrincione C, Assing G, Melamed MR. Prognostic value of DNA/RNA flow cytometry of B cell non Hodgkin's lymphoma (NHL) in conjunction with four taxonomic systems. Proc Amer Soc Clin Oncol 2:13, 1983. e-Pub 1983.
1160. Walle R, Andreeff M. Multiparameter characterization of cell population of FAB L3 (Burkitt like) leukemia. Symposium Clinical Cytometry:143-44, 1983. e-Pub 1983.
1161. Shank B, Andreeff M, Li D. Cell survival kinetics in peripheral blood and bone marrow during total body irradiation for marrow transplantation. Rad Res Soc Meeting, 1983. e-Pub 1983.
1162. Andreeff M, Kempin S, Arlin Z, Mertelsmann R, Espiritu E, Gee T. High dose cytosin arabinoside (HDARAC) in acute leukemia (AL). Correlation of clinical response and cell kinetics. Amer Assoc Cancer Res 24:166, 1983. e-Pub 1983.
1163. Thongprasert S, Molander D, Andreeff M. Changes in proliferation and RNA content during induction classification of acute non lymphoblastic leukemia (ANLL) determined by multiparameter flow cytometry. Amer Assoc Cancer Res 24:8, 1983. e-Pub 1983.
1164. Gebhard D, Mittelman A, Lee BF, Andreeff M, Koziner B. Clonal excess (CE) light chain expression in blastic phase chronic myeloid leukemia (B1 CML), acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). Amer Assoc Cancer Res 24:126, 1983. e-Pub 1983.
1165. Andreeff M, Darzynkiewicz Z. Chromatin structure in leukemia: Classification of subtypes and cell kinetics during induction therapy. Cell and Tissue Kin:679, 1982. e-Pub 1982.
1166. Andreeff M, Darzynkiewicz Z, Clarkson BD, Miller D, Melamed MR. Role of flow cytometry (FC) of nucleic acid content and chromatin structure in classification and monitoring of acute leukemia (AL) and non Hodgkin's lymphoma. 13th Intl Cancer Congress:589, 1982. e-Pub 1982.
1167. Andreeff M, Shank B, Hiddemann W, O'Reilly R, Clarkson BD, Melamed MR. Effects of chemo and radiotherapy on human hematopoietic cells in vivo. Intern Symposium on Biological Dosimetry: Cytometric Approaches to Mammalian Systems, 1982. e-Pub 1982.
1168. Hiddemann W, Buechner T, Andreeff M, Woermann B, Clarkson BD. Comparison of the therapeutic efficacy of two induction regimens for acute myelocytic leukemia (AML) by accurate quantitation of bone marrow cellularity. Blut 45:219, 1982. e-Pub 1982.
1169. Andreeff M, Clarkson BD, Melamed MR. Use of flow cytometry for characterization and management of human leukemia. Internatl Conf on Analytical Cytology and Cytometry IX and the VIth Internatl Symposium on Flow Cytometry 4, 1982. e-Pub 1982.
1170. Chiao JW, Andreeff M, Freitag W. Relationship of proliferation and differentiation during induced leukemic cell maturation. 13th Intl Cancer Congress:675, 1982. e-Pub 1982.
1171. Walle A, Andreeff M, Clarkson BD, Melamed MR. Density separation of aneuploid blast cells from normal diploid cells in blood of patients with acute leukemia. 13th Intl Cancer Congress 65, 1982. e-Pub 1982.
1172. Andreeff M, Darzynkiewicz Z, Steinmetz J, Melamed MR, Clarkson BD. Determination of chromatin structure in situ in acute leukemia and non Hodgkin's lymphoma by flow cytometry (FC). Amer Assoc Cancer Res 23:29, 1982. e-Pub 1982.
1173. Walle A, Andreeff M, Clarkson BD. Monitoring of submicroscopic levels of aneuploid leukemia cells following induction therapy. Amer Soc Clin Oncol 1:189, 1982. e-Pub 1982.
1174. Hiddemann W, Andreeff M, Buechner T, Woermann B, Arlin Z, Clarkson BD. Quantitation of therapy induced cytoreduction in acute myeloblastic leukemias (AML): A comparison of two induction regiments. Amer Assoc Cancer Res 23:118, 1982. e-Pub 1982.
1175. Walle A, Espiritu E, Andreeff M. Separation of normal and leukemic leukocytes by new density gradient (DG) and identification by flow cytometry (FC). Cell and Tiss Kin, 1982. e-Pub 1982.
1176. Walle A, Andreeff M, Melamed MR, Clarkson BD. Correlations between DNA stemline, RNA content and papaprotein levels in multiple myeloma. Cytometry 2:136, 1981. e-Pub 1981.
1177. Hiddemann W, Buechner T, Andreeff M, Woermann B, Clarkson B. Quantitative Bestimmung der Therapie induzierten Zytoreduktion in Knochenmark bei Patienten mit akuter Leukaemie. Jahrestagung der Deutschen Gessellschaft fuer Haematologie und Onkologie, Onkologie 4:278, 1981. e-Pub 1981.
1178. Hiddemann W, Buechner T, Woermann B, Andreeff M. Quantitation of chemotherapy induced cell kill in acute leukemia. Internatl Soc Hematology. European and African Division, Sixth Meeting 221, 1981. e-Pub 1981.
1179. Feit C, Bartal A, Andreeff M, Hirshaut Y. Dexamethason effect on hybridoma formation. Second Houston Symposium: Hybridomas and Cellular Immortality, 1981. e-Pub 1981.
1180. Hiddeman W, Buechner T, Woermann B, Andreeff M. Quanitation of treatment induced cytoreduction for the management of acute leukemia therapy. Cytometry 2:103, 1981. e-Pub 1981.
1181. Eisert RM, Andreeff M, Eisert WB, Melamed MR. Comparison of acridine orange and ethidium bromide/mithramycin staining for fluorescence analysis of DNA. Cytometry 2:96, 1981. e-Pub 1981.
1182. Andreeff M, Melamed MR, Miller D, Clarkson BD. Near haploid acute lymphoblastic leukemia (ALL): A poor prognosis subgroup identified and monitored by flow cytometry. Cytometry 2:87, 1981. e-Pub 1981.
1183. Andreeff M, Hiddemann W, Melamed MR, Clarkson BD. Subclassification of acute leukemia and treatment monitoring by multiparameter flow cytometry (FC). Cytometry 2:86, 1981. e-Pub 1981.
1184. Andreeff M, Li L, Swartwout S, Broxmeyer HE. Use of flow cytometry and colony forming assays in monitoring differentiation of human promyelocytic leukemia cells (HL-60). Cytometry 2:86, 1981. e-Pub 1981.
1185. Goldenhersh M, Andreeff M, Lynfield R, Safai B. Relationship between density and degree of differentiation of fractionated epidermal cells. Clin Res 29:595, 1981. e-Pub 1981.
1186. Chiao JW, Andreeff M. Reduction of proliferation and RNA content during differentiation of promyelocytes to macrophages induced by T cell product. FASEB, 1981. e-Pub 1981.
1187. Arlin Z, Gee TS, Kempin SJ, Mertelsmann R, Dellaquila C, Andreeff M, Clarkson BD. Treatment of adult nonlymphoblastic leukemia (ANLL) with AMSA in combination with cytosine arabinoside (ARA C) and Thioguanine (TG) (AAT). Amer Assoc Cancer Res, 1981. e-Pub 1981.
1188. Blumenreich M, Andreeff M, Chou TC, Wittes R, Clarkson B, Young C. Kinetic and biochemical modulation of pyrimidine antimetabolites in therapy of acute leukemia. Amer Assoc Cancer Res 22, 1981. e-Pub 1981.
1189. Andreeff M, Miller D, Steinherz P, Kempin S, Straus D, Clarkson B. Hypodiploid acute lymphoblastic leukemia (ALL): A rare entity detected and monitored by flow cytometry. Amer Cancer Res 22, 1981. e-Pub 1981.
1190. Suarez C, Miller D, Steinherz P, Andreeff M. Flow cytometry DNA and RNA determination in 107 cases of childhood acute lymphoblastic leukemia (ALL). Amer Assoc Cancer Res 22, 1981. e-Pub 1981.
1191. Chiao JW, Andreeff M. Differentiation of myelogenous leukemia cells induced by lymphocyte conditioned medium. Amer Assoc Cancer Res 22, 1981. e-Pub 1981.
1192. Andreeff M, Darzynkiewicz Z, Melamed MR, Clarkson BD. Human acute leukemia. Heterogeneity of phenotype, nucleic acid content and chromatin structure. Fifth International Symposium on Flow Cytometry, Rome, 1980. e-Pub 1980.
1193. Andreeff M, Arlin Z, Gee T, Steinmetz J, Melamed MR, Miller D, Clarkson BD. New quantitative determinants in acute leukemias. III. Flow cytometry of DNA and RNA for classification, for detection of biclonality, and as a possible prognostic method. 18th Congress Intern Soc Hematol, 1980. e-Pub 1980.
1194. Hiddemann W, Andreeff M, Buechner T, Gee T, Arlin Z, Steinmetz J, Blumenreich M, Clarkson B. New quantitative determinants in acute leukemia. II. Cell kill kinetics of chemotherapy. 18th Congress Intern Soc Hematol, 1980. e-Pub 1980.
1195. Hiddemann W, Buechner T, Andreeff M, Woermann B, Steinmetz J, Melamed MR, Clarkson B. New quantitative determinants in acute leukemia. I. Bone marrow biopsy for cell kinetic analysis. 18th Congress Intern Soc Hematol, 1980. e-Pub 1980.
1196. Andreeff M, Filippa D, Melamed MR, Clarkson BD. Flow cytometry in the evaluation of non Hodgkin's lymphomas: DNA/RNA measurements in 107 cases. 18th Congress Intern Soc Hematol, 1980. e-Pub 1980.
1197. Andreeff M, Mendelsohn N, Steinmetz J, Acs G, Melamed MR. Proliferation and differentiation of diploid/tetraploid human myeloid leukemia cells (HL 60/4) in vitro. 18th Congress Intern Soc Hematol, 1980. e-Pub 1980.
1198. Andreeff M, Melamed MR, Koziner B, Mertelsmann R, Hiddemann W, Chaganti RSK, Clarkson BD. Clonal and phenotypic heterogeneity in acute leukemia. Modern Trends in Human Leukemia, IV, Wilsede, Germany, 1980. e-Pub 1980.
1199. Andreeff M, Filippa D, Rosen T, Steinmetz J, Gee T, Good RA, Clarkson BD, Melamed MR. Non Hogkin's lymphomas: Classification by DNA/RNA flow cytometry and surface marker analysis. Amer Assoc Clin Oncol 21, 1980. e-Pub 1980.
1200. Hiddemann W, Buechner T, Andreeff M, Arlin Z, Gee T, Woermann B, Steinmetz J, Clarkson B. Bone marrow biopsy a new approach for cell kinetics in acute leukemias. Amer Assoc Cancer Res 21, 1980. e-Pub 1980.
1201. Andreeff M, Gee T, Mertelsmann R, McKenzie S, Steinmetz J, Chaganti R, Koziner B, Clarkson B. Biclonal lymphoblastic and myeloblastic acute leukemia. Amer Assoc Cancer Res 21, 1980. e-Pub 1980.
1202. Blumenreich M, Andreeff M, Murphy ML, Young C, Clarkson B. Phase II study of mM thymidine in acute leukemia with flow microfluorometric analysis of drug induced kinetic alterations in the bone marrow. Amer Assoc Cancer Res 21, 1980. e-Pub 1980.
1203. Hiddemann W, Buechner T, Andreeff M, Woermann B, Melamed MR, Clarkson B. Chemotherapy of acute non-lymphocytic leukemias-new cell kinetic determinants. Fourth Annual Meeting, The Cell Kinetics Society, 1980. e-Pub 1980.
1204. Andreeff M, Hiddemann W, Clarkson BD, Melamed MR. Application of flow cytometry in clinical hematology. Fifth International Symposium on Flow Cytometry. Basic and Applied Histochemistry 24:358, 1980. e-Pub 1980.
1205. Hiddemann W, Andreeff M, Blumenreich M, Clarkson BD. Cell kinetics and cytoreduction rates quantitative determinants for drug effects: Phase II evaluation of high dose thymidine (TdR). Basic and Applied Histochemistry 24:372, 1980. e-Pub 1980.
1206. Hiddemann W, Buechner T, Andreeff M, Woermann B, Arlin Z, Clarkson BD. Cell kinetic monitoring of acute leukemia therapy: Comparison of two different induction therapy regimens for acute non lymphocytic leukemia (ANLL). Basic and Applied Histochemistry 24:373, 1980. e-Pub 1980.
1207. Andreeff M, Filippa D, Steinmetz J, Mertelsmann R, Melamed MR, Good RA, Clarkson B. Malignant lymphomas: Classification and staging by multiparameter analysis. Engineering Foundation Conference, Automated Cytology VII, Asilomar, California, 1979. e-Pub 1979.
1208. Hiddemann W, Andreeff M, Buechner T, Woermann B, Steinmetz JC, Clarkson B. Bone marrow biopsy for cell kinetic analysis of leukemia. Engineering Foundation Conference, Automated Cytology VII, Asilomar, California, 1979. e-Pub 1979.
1209. Andreeff M, Darzynkiewicz Z, Traganos F, Melamed MR. Cell cycle analysis by acridine orange staining and flow cytometry. Fifth Meething of the International Society of Haematology 1:91, 1979. e-Pub 1979.
1210. Woodcock T, Damin L, O'Hehir M, Hansen H, Andreeff M, Young C. Early clinical and pharamacokinetic evaluation of thymidine therapy in patients with advanced cancer. Amer Assoc Cancer Res 20:114, 1979. e-Pub 1979.
1211. Hansen H, Filippa DA, Andreeff M, Fried J, Arlin Z, Clarkson B. Non Hodgkin's lymphoma: Cytokinetic, volumetric, cytofluorometric studies of tumor cells. Correlations with cell surface markers and the Rappaport classification. Amer Assoc Cancer Res 20:339, 1979. e-Pub 1979.
1212. Andreeff M, Arlin Z, Gee T, Koziner B, Mertelsmann R, Broxmeyer H, Melamed MR, Clarkson B. : Acute lymphoblastic and non lymphoblastic leukemia in adults: Rapid remission reduction and identification of new subtype. Fifth Meeting of the International Society of Haematology IV:37, 1979. e-Pub 1979.
1213. Beck J, Miller D, Steinberg P, Andreeff M, Mertelsmann R, Koziner B, Good R, Gupta S. Different stages of cell maturation of childhood leukemias defined by immunological and biochemical markers. Fifth Meeting of the Internatioal Society of Haematology 1:9, 1979. e-Pub 1979.
1214. Andreeff M, Darzynkiewicz Z, Gee T, Arlin Z, Koziner B, Chaganti R, Melamed MR, Clarkson B. Classification and monitoring of adult leukemia by flow cytometry. Fifth Meeting of the International Society of Haematology 1:60, 1979. e-Pub 1979.
1215. Andreeff M, Beck JD, Kapoor N, Steinmetz J, Melamed MR, Gee T, Miller D, Clarkson B. Clonal evolution in actue leukemia. Analysis of subpopulations by velocity sedimentation and multiple markers. Amer Assoc Cancer Res 20:112, 1979. e-Pub 1979.
1216. Andreeff M, Mendelsohn N, Steinmetz J, Acs G, Melamed MR. Induced differentiation of diploid/tetraploid human leukemia cells (HL 60/4) in vitro. Engineering Foundation Conference, Automated Cytology VII, Asilomar, California, 1979. e-Pub 1979.
1217. Beck JD, Andreeff M, Haghbin M, Miller DR, Tan C, Good RA, Gupta S. : Flow cytometric studies and comparison of surface markers expression and morphology in non lymphocytic leukemias of children and young adults. Ped Res 13:429, 1979. e-Pub 1979.
1218. Beck JD, Andreeff M, Haghbin M, Miller D, Steinherz P, Good RA, Gupta S. Characterization of childhood acute leukemias by multiple immunological and biochemical markers. Fed Proc:1273, 1979. e-Pub 1979.
1219. Andreeff M, Darzynkiewicz Z, Melamed MR, Gee T, Clarkson B. Nucleic acid content and chromatin structure of leukemic cells in situ as studied by flow cytometry. Amer Assoc Cancer Res 19:786, 1978. e-Pub 1978.
1220. Andreeff M. Classification of lymphocytes and leukemias by flow cytometry. Sixth Engineering Foundation Conference on Automated Cytology II:1, 1978. e-Pub 1978.
1221. Darzynkiewicz Z, Traganos F, Andreeff M, Sharpless TK, Melamed MR. Recognition of cycling versus quiescent cells by flow cytometry. Cell Tiss Kinet 11:680, 1978. e-Pub 1978.
1222. Andreeff M, Traganos F, Melamed MR, Clarkson B, Darzynkiewicz Z. New approaches in analysis of the cell cycle. Cell Tiss Kinet 11:677, 1978. e-Pub 1978.
1223. Andreeff M, Beck J, Darzynkiewicz ZD, Traganos F, Gupta S, Melamed MR, Good RA. RNA content of human lymphocyte subpopulations. Natl Acad Sci USA 75:1938-42, 1978. e-Pub 1978.
1224. Evenson D, Darzynkiewicz Z, Stainan-Coico L, Andreeff M, Traganos F, Melamed MR. Induction of G2 block and polyploidy in Friend leukemia cells by treatment with Anthracenedione. J Cell Biol 79:7a, 1978. e-Pub 1978.
1225. Akiyama H, Zhao R, Nishida Y, Ostermann LB, Mak PY, Ayoub E, Piya S, Carter BZ, Andreeff M, Ishizawa J. Synergistic Induction of Mitochondria-Regulated Ferroptotic Cell Death in Acute Myeloid Leukemia. Japanese Society of Hematology 2022 - Abstract.
1226. Atluri H, Mullin J, Takahashi K, Loghavi S, Maiti A, Sasaki K, Daver N, Valero YA, Pemmaraju N, Borthakur G, Hammond DE, Chien KS, Ferrajoli A, Short NJ, Abbas HA, Jabbour E, Andreeff M, Ravandi F, Tidwell RSS, Wang X, Konopleva MY, Garcia-Manero G, Kantarjian HM, DiNardo CD. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update - Oral Presentation. ASH 2023.
1227. Akiyama H, Tcheng M, Sharma P, Zhao R, Ostermann LB, Yazdani S, Moayed A, Szulc Z, Oleinik N, Mak PY, Ruvolo V, Carter BZ, Ogretmen B, Borthakur G, Schimmer, AD Andreeff M, and Ishizawa J. Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia. ASH 2023.
1228. Gener-Ricos G, Bewersdorf JP, Loghavi S, Goldberg AD, Famulare C, Issa GC, Borthakur G, Kadia TM, Carter BZ, Patel KP, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C Mutations in Patients with Myeloid Malignancies. ASH 2023.
1229. Wang X, Davis A, Su X, Muftuoglu M, Krejsa C, Mascarenhas J, Andreeff M, and Hoffman R. TL-895, a Highly Selective, Covalent Inhibitor of Bruton’s Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME). ASH 2023.
1230. Issa GC, Cuglievan B, DiNardo CD, MD, MSc, Short NJ, MD, McCall D, MD, Gibson A, DO, Nunez C, MD, Garcia MB, DO, Roth M, MD, Bidikian A, MD, Pike A, RN, Tan S, RN, Kammerer B, BSN, MS, RN, Yilmaz M, MD, Kadia TM, MD, Pemmaraju N, MD, Ohanian M, DO, Daver N, MD, Jabbour E, Borthakur G, MD, Ravandi F, MD, MBBS, Garcia-Manero G, MD, Andreeff M, PhD MD, Kantarjian HM, MD. Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) - Oral Presentation. ASH 2023.
1231. Pourebrahim R, Khazaei S, Ostermann LB, Zhao R, Muftuoglu M, and Andreeff M. Age-Specific Induction of Mutant p53 Drives Clonal Hematopoiesis in Adult Mice Leading to Acute Myeloid Leukemia. ASH 2023.
1232. Yilmaz M, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, Pemmaraju N, Short NJ, Valero YA, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia C, Pike A, Loghavi S, Patel KP, Tang G, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Ravandi F, Andreeff M, and Daver N. Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML - Oral Presentation. ASH 2023.
1233. Ayoub E, Marupud A, Nishida Y, Heinz Montoya R, Mohanty V, Walter W, Bray MR, Patsilevas T, Boettcher S, Issa GC, Chen K, Haferlach T, Borthakur G, Andreeff M. Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage. ASH 2022.
1234. Winter L, Pawlowsky L, Marcinek A, Brauchle B, Muth A, Kazerani M, Petrera A, Kischel R, Emhardt AJ, Rothenberg-Thurley M, Dufour AM, Spiekermann K, Andreeff M, Daver N, Buecklein VL, and Subklewe M. The Battle within: AML´s p53 Strategies to Evade T-Cell Attack. ASH 2023.
1235. Jia Y, Zhang Q, Zhang W, Andreeff M, Jain N, Ma H, Zhang P, Zheng G, Zhou D, Konopleva M. Targeting BCL-XL and BCL-2 by PROTAC 753b effectively eliminates AML cells and enhances efficacy of chemotherapy by targeting senescent cells. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2021.
1236. Akiyama H, Zhao R, Rahhal A, Ayoub E, Nishida Y, Ostermann L, Andreeff M, Ishizawa J. Glutathione-GPX4 Nexus Protects Acute Myeloid Leukemia (AML) Cells From Mitochondrial Protease ClpP-induced Cell Killing. Japanese Cancer Association Abstract 2021.
1237. Carter BZ, Mak PY, Ke B, Bedoy A, Boettcher S, Ostermann LB, Shpall EJ, and Andreeff M. Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML. ASH 2023.
1238. Muftuoglu M, Li L, Basyal M, Ayoub E, Lv J, Bedoy A, Patsilevas T, Bidikian A, IssaGC, Andreeff M. Single-Cell Proteomic Analysis Reveals Menin Inhibition-Induced Proteomic Alterations in AML Patients Treated with Revumenib. ASH 2023.
1239. Munir F, Khazaei S, Calkins PH, Scruggs D, Mizuno H, Ostermann LB, Cuglievan B, Garcia MB, Chen D, Tong Y, Ren Z, Andreeff M, and Nishida Y. Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias. ASH 2023.
1240. Carter BZ, Tao W, Mak PY, Mak D, McGeehan G, Ordentlich P, Andreeff M. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. EHA Abstract 2021.
1241. Yilmaz M, Kantarjian H, Muftuoglu M, Kadia T, Konopleva M, Borthakur G, DiNardo C, Pemmaraju N, Short NJ, Alvarado Y, Montalban-Bravo G, Jurisprudenica C, Pike A, Ohanian M, Jabbour E, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib with Decitabine and Venetoclax (triplet) Is Highly Active in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML). ASCO Abstract 2021.
1242. Khasawneh A, Paran FJ, Oyama R, Maiti A, Abbas HA, Wang B, Desai PN, Hayes K, Harman JR, Su X, DiNardo CD, Andreeff M, Milne TA, Konopleva MY, Tabe Y. Molecular Profiling of Response and Resistance to Venetoclax–Decitabine Therapy in Acute Myeloid Leukemia. ASH 2023.
1243. Carter BZ, Mak PY, Tao W, Ostermann LB, Nishida Y, Boettcher S, Andreeff M. Targeting HSP90-epichaperome in TP53 mutant AML. 18th International p53 Workshop 2022- Weizmann Institute of Science , Rehovot, Israel.
1244. Ayoub E, Li L, Muftuoglu M, Nishida Y, Mohanty V, Leighton JS, Patsilevas T, Basyal M, Bedoy A, Haferlach T, Takahashi K, Chen K, Navin N, Issa GC, Andreeff M. Single-Cell Genomics and Proteomics Reveals Venetoclax-Resistant Monocytic Differentiation of TP53 LOH Clones in TP53 Mutant AML. ASH 2023.
1245. Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann L, Heinz Montoya R, Muftuoglu M, Ruvolo V, Mak PY, Tao W, Carter BZ, Kojima K, Daver N, Lesegretain A, Seki T, Shacham S, Konopleva M, and Andreeff M. Enhanced p53 Activation by MDM2 and XPO1 Disrupts MYC Transcriptional Program and Profoundly Synergizes to Induce Apoptosis in Combination with BCL-2 Inhibition in Ven/HMA Resistant Acute Myeloid Leukemia. 18th International p53 Workshop -2022 - Weizmann Institute of Science , Rehovot, Israel.
1246. Carter BZ, Mak PY, Ke B, Nishida Y, Boettcher S, Bedoy A, Ostermann LB, DiNardo CD, Puzio-Kuter A, Levine A, Andreeff M. Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2. ASH 2023.
1247. Baran N, Han L, Stuani L, Cavazos A, Cooper L, Ramage CL, Kuruvilla VM, Zhang Q, Sabtier M, Boet E, Gay JP, Feng N, Battula VL, Chu-Van E, Castelli F, Carroll M, Konoplev SN, Thakral B, Daver N, Marszalek JR, Ge Y, Andreeff M, J-E S, and Konopleva MY. Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism. ASH 2023.
1248. Sharma P, Ostermann LB, Piya S, Ke B, Baran N, Tyagi A, Muftuoglu M, Basyal M, Zhang Q, Munck J, K-H D, Sims M, Carter BZ, Battula VL, Andreeff M, and Borthaku G. ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission - Oral Presentation. ASH 2023.
1249. Muftuoglu M, Basyal M, Li L, Lv J, Ostermann LB, Zhao R, Ke B Akiyama H, Mak PY, Carter BZ, Deng H, Li Y, Garrison BS, Rajangam KL, and Andreeff M. Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models. ASH 2023.
1250. Haddad FG, Jabbour E, Sasaki K, Nasr L, Huang X, Issa GC, Ravandi F, Garcia-Manero G, Kadia TM, Daver N, Valero YA, Nasnas C, Ohanian M, Short NJ, Masarova L, Zoghbi M, Nasnas PE, Montalban-Bravo G, Skinner J, Pierce S, Andreeff M, and Kantarjian HM. Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML) - Oral Presentation. ASH 2023.
1251. Yamatani K, Watanabe T, Saito K, Maiti A, Yamashita S, Khasawneh A, Paran FJ, Hayes K, Borthakur G, Harman JR, Kimura S, DiNardo CD, Milne TA, Andreeff M, Tabe Y, and Konopleva MY. PPARG and ASS1: Targets of Metabolic Alteration in Venetoclax / Decitabine Resistant Acute Myeloid Leukemia. ASH 2023.
1252. Maiti A, Muftuoglu M, Ignatz-Hoover JJ, DiNardo CD, Ravandi F, Andreeff M, Xiao L, Huang X, Patel KP, Litten JB, Bourk E, Astrow S, Kantarjian HM, Tomlinson BK, Daver N, and Wald D. Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial. ASH 2023.
1253. Nishida Y, Ayoub E, Scruggs D, Khazaei S, Munir F, Ostermann LB, Mak PY, Baozhen K, Carter BZ, Baran N, Maiti A, Mohanty V, Chen K, Navin N, Haferlach T, Ren Z, Tong Y, Chen D, Issa GC, M Andreeff M. Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC - Oral Presentation - Best Of ASH. ASH 2023.

Book Chapters

1. Zeng Z, Konopleva M, Andreeff M. Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells. In: Acute Myeloid Leukemia Methods and Protocols. Humana Press, 75-86, 2017.
2. Kojima K, Andreeff M. TP53. In: Targeted Therapy in Translational Cancer Research, 2016.
3. Booth CH, Mutkus L, Bussard K, Spaeth E, Andreeeff M, Marini FC. Mesenchymal Stem/Stromal cell-Targeted Therapies for Solid Tumors and Hematological Malignancies. In: Targeted Therapy of Acute Myeloid Leukemia, 2015.
4. Carter BZ, Andreeff M. IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia. In: Targeted Therapy of Acute Myeloid Leukemia, 2015.
5. Jacamo R, Spaeth E, Battula V, Marini F, Andreeff. Mesenchymal Stromal/Stem Cells in solid tumors and hematological malignancies: from biology to therapeutic applications. In: "Mesenchymal Stromal Cells: Biology and Clinical Applications". Humana Press, 209-236, 2013.
6. Andreeff M, Quintas-Cardama A. Pathobiology of Acute Myeloid Leukemia. In: HoffmanR, Benz EJ, Hematology, Basic Principles and Practice, sixth edition. Elsevier, 853-862, 2013.
7. Marini F, Studeny M, Dembinski J, Kidd S, Spaeth E, Zeng Z, Ling X, Klopp A, Lang F, Hall B, Andreeff M. Mesenchymal stem/stromal cells (MSC) as cellular vehicles for tumor targeting. In: Gene based therapies for cancer. Springer, 113-139, 2010.
8. Samudio I, Konopleva M, Carter B, Andreeff M. Apoptosis in Leukemias: Regulation and Therapeutic Targeting. In: Cancer Treat Res. 1st. Springer, 197-217, 2010.
9. Andreeff, M, Goodrich DW, Koeffler HP. Cell proliferation and differentiation. In: Cancer Medicine. B. C. Decker, Inc, 2009.
10. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. In: Drug Resist Updat. 4-5, 103-13, 2009.
11. Ueno NT, Andreeff M, Champlin RE. Stem cell transplantation for metastatic and high-risk nonmetastatic breast cancer: A novel treatment approach. In: M. D. Anderson Cancer Care Series: Breast Cancer. Second Edition. Springer, 387-410, 2007.
12. Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. In: Handb Exp Pharmacol. 180, 263-83, 2007.
13. Hall B, Marini F, Andreeff M. The participation of mesenchymal stem cells (MSC) in tumor stroma formation and their application as targeted-gene delivery vehicles. The participation of mesenchymal stem cells (MSC) in tumor stroma formation and their application as targeted-gene delivery vehicles. In: Bone-Marrow Derived Progenitors,” Handbook of Experimental Pharmacology. Springer-Verlag, 265-285, 2007.
14. Marini F, Hall B, Dembinski J, Studeny M, Sasser AK, Andreeff M. Mesenchymal stem cells as vehicles for genetic targeting of tumors. In: Stem Cell Transplantation. Biology, Processing, and Therapy. Wiley-VCH Verlag, 157-175, 2006.
15. Andreeff, M, Goodrich DW, Koeffler HP. Cell proliferation and differentiation. In: Cancer Medicine. B. C. Decker, Inc, 27-40, 2005.
16. Wulf, GG, Wang RY, Brenner MK, Andreeff M, Goodell MA. Leukemia stem cells with efficient drug efflux in acute myeloid leukemia. In: Acute Leukemias IX. Springer, 128-135, 2003.
17. Weidner, DA, Wang RY, Zhao S, Kuehnle I, Kantarjian H, Brenner MK, Goodell MA, Andreeff M. Reduced level of Philadelphia chromosome positive (Ph+) cells in lineage negative side population bone marrow progenitor cells from patients with chronic myeloid leukemia (CML). In: Acute Leukemias IX. Springer, 140-149, 2003.
18. Andreeff, M, Goodrich DW, Pardee AB. Cell proliferation and differentiation. In: Cancer Medicine. B. C. Decker, Inc, 27-39, 2003.
19. Wang, RY, Weidner D, McQueen T, McMannis J, Korbling M, Champlin R, Andreeff M. Quantitative determination of Bcl-2 expression in AML cell lines and in normal and leukemic progenitor cell compartments by laser scanning cytometry: Comparison with flow cytometry and Western blot. In: Acute Leukemias IX. Springer, 239-251, 2003.
20. Andreeff, M, Konopleva M. Mechanisms of drug resistance in AML. In: Clinically Revelant Resistance in Cancer Chemotherapy. Kluwer Academic Publishers, 237-262, 2002.
21. Andreeff, M, Goodrich DW, Pardee AB. Cell proliferation, differentiation and apoptosis. In: Cancer Medicine. B. C. Decker, Inc, 17-32, 2000.
22. Konopleva, M, Rissling I, Andreeff M. CD38 in hematopoietic malignancies. In: Human CD38 and related molecules. Karger, 189-201, 2000.
23. Giles, FJ, Andreeff M, Keating MJ. Acute myeloid leukemia. In: Cancer Treatment. 5th. Mosby, Inc, 1280-1294, 2000.
24. Konopleva, M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M. Apoptosis: Molecules and mechanisms. In: Drug Resistance in Leukemia and Lymphoma III. Plenum Press, 217-236, 1999.
25. Andreeff, M, Goodacre A. Molecular cytogenetic analysis of myeloid leukemias and myelodysplastic syndromes. In: An Introduction to Fluorescent In Situ Hybridization. John Wiley & Sons, Inc, 241-278, 1999.
26. Younes, A, Escudier S, Andreeff M. Fluorescence in situ hybridization of lymphoproliferative malignancies. In: An Introduction to Fluorescent In Situ Hybridization. John Wiley & Sons, Inc, 279-306, 1999.
27. Estey, E, Beran M, Kantarjian H, O’Brien S, Koller C, Cortes J, Kornblau S, David C, Andreeff M, Keating M. Recent studies in AML, RAEB-t, and RAEB at M. D. Anderson Hospital. In: Acute Leukemias VII: Experimental Approaches and Novel Therapies. Springer-Verlag, 824-827, 1998.
28. Keating, MKantarjian H, Gandhi V, O’Brien S, Koller C, Kornblau S, Beran M, Andreeff M, Plunkett W, Freireich E. FLAG-Ida, an effective regimen for high risk AML. In: Acute Leukemias VII: Experimental Approaches and Novel Therapies. Springer-Verlag, 828-833, 1998.
29. Deisseroth, A, Kantarjian H, Andreeff M, Talpaz M, Keating M, Khouri I, Champlin R. Chronic Leukemias. In: Cancer: Principles and Practice of Oncology. 5th. Lippincott-Raven Publishers, 2321-2343, 1997.
30. Tari, AM, Neamati N, Andreeff M, Lopez-Berestein G. Liposomal delivery of P-ethoxy antisense oligonucleotides in chronic myelogenous leukemia. In: Strategies for Oligonucleotide and Gene Delivery in Therapy. Plenum Press, 163-168, 1996.
31. Khouri, I, Kantarjian H, Talpaz M, Andreeff M, M-S L, Champlin R, Deisseroth AB. Chronic myeloid leukemia. In: Clinical Oncology. Churchill, Livingstone, Inc, 2035-2051, 1995.
32. Andreeff M. Acute Myeloid Leukemia. In: Cancer Treatment. W. B. Saunders, 911-922, 1995.
33. Andreeff, M, Drach J, Zhao S, Consoli U, Escudier S, Sanchez-Williams G, Liu Y, Goodacre A, Drach D, Dunne C, Tafuri A, Estey E, Deisseroth A. Cell kinetic, molecular and clinical analysis of growth factor sensitization of myeloid leukemia. In: Hemopoietic Growth Factors, Oncogenes and Cytokines in Clinical Hematology. S Karger, 112-136, 1994.
34. Moore, Jr DF, Andreeff M. The Acute Leukemias. In: Medical Oncology: A Comprehensive Review. PRR, 3-28, 1993.
35. Deisseroth, A, Andreeff M, Champlin R, Kantarjian H, Keating M, Khouri I, Talpaz M. Chronic Leukemias. In: Cancer - Principles and Practice of Oncology. 4th. JB Lippincott Co, 1965-1983, 1993.
36. Andreeff, M, Tafuri A, Bettelheim P, Valent P, Estey E, Lemoli R, Goodacre A, Clarkson B, Mandelli F, Deisseroth A. Cytokinetic resistance in acute leukemia: recombinant human granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, interleukin-3 and stem cell factor effects in vitro and clinical trials with granulocyte macrophage colony stimulating factor. In: Acute Leukemias. Haematology and Blood Transfusion. Springer-Verlag, 108-117, 1992.
37. Andreeff M. Biological characterization and therapy monitoring of leukemia by flow cytometry. In: Flow Cytometry in Hematology. Academic Press, 231-266, 1992.
38. Andreeff, M, Tafuri A, Bettelheim P, Valent P, Estey E, Lemoli R, Goodacre A, Clarkson B, Mandelli F, Deisseroth A. Cytokinetic resistance in acute leukemia: Recombinant human granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, interleukin-3 and stem cell factor effects in vitro and clinical trials with granulocyte macrophage colony-stimulating factor. In: Acute Leukemias-Pharmacokinetics. Haematology and Blood Transfusion. Springer-Verlag, 108-117, 1992.
39. Hittelman, WN, Vyas R, Aglor P, Andreeff M, Vadhan-Raj S. Differentiation therapy in myelodysplasia and leukemia: effects on normal and abnormal elements. In: The Status of Differentiation Therapy in Cancer, Vol. II. Raven Press, 433-440, 1991.
40. Clarkson, B, Berman E, Little C, Andreeff M, Kempin S, Kolitz J, Gabrilove J, Arlin Z, Mertelsmann R, Cunningham I, Castro-Malaspina H, Gulati S, O'Reilly R, Gee T. Update on clinical trials of chemotherapy and bone marrow transplantation in acute myelogenous leukemia in adults at Memorial Sloan-Kettering Cancer Center (MSKCC) 1966 to 1989. In: Acute Myelogenous Leukemia: Progress and Controversies. Wiley-Liss, Inc, 239-272, 1990.
41. Andreeff M. Flow cytometry of leukemia. In: Flow Cytometry and Cell Sorting. A. Liss, Inc, 697-745, 1990.
42. Andreeff, M, Tafuri A, Hegewisch-Becker S. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3 and BCFG) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinosine. In: Acute Leukemias II. Springer-Verlag, 747-762, 1990.
43. Bettelheim, P, Muhm M, Geissler K, Grosichek C, Hinterberger W, Speiser W, Sunder-Plassmann G, Valent P, Lechner K, Andreeff M, Haimi J, Haas O, Maurer D, Schulz G. GM-CSF during remission induction for acute myelogenous leukemia. In: Hematopoietic Growth Factors in Clinical Applications. Marcel Dekker, Inc, 401-420, 1990.
44. Clarkson, B, Gaynor J, Little C, Berman E, Kempin S, Andreeff M, Gulati S, Cunningham I, Gee T. Clinical trials in adults with acute lymphoblastic leukemias at MSKCC. In: UCLA Symposia on Molecular and Cellular Biology, Vol. 108: Acute lymphoblastic Leukemia. A.R. Liss, 231-252, 1990.
45. Clarkson, B, Gaynor J, Little C, Berman E, Kempin S, Andreeff M, Gulati S, Cunningham I, Gee T. Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia. In: Acute Leukemias - Prognostic factors and treatment strategies. Springer-Verlag, 397-408, 1990.
46. Steinherz, PG, Gaynon P, Haimi J, Meyers P, Redner A, Steinherz L, Andreeff M, Hammond D. Improved survival of children with high risk acute lymphoblastic leukemia: Report from the Childrens Cancer Study Group and the Memorial Sloan-Kettering "New York" Protocols. In: Acute Lymphoblastic leukemia. A.R. Liss, 147-156, 1990.
47. Tafuri A, Andreeff M. Cell kinetic modulation of hematological malignancies by cytokines: Recruitment therapy to overcome cytokinetic resistance. In: Hematopoietic Growth Factors in Clinical Applications. Marcel Dekker, Inc, 381-399, 1990.
48. Tafuri A, Andreeff M. Recruitment therapy in acute myeloblastic leukemia: A different approach to improved leukemia treatment. In: Cytokines in Hemopoiesis, Oncology and AIDS. Springer-Verlag, 107-114, 1990.
49. Andreeff M, Squires J, Bokemeyer C, Verbeek W, Bressler J, Redner A. Oncogenes in human leukemia and lymphoma: Chromosomal localization, activation and expression of p21 ras and p53. In: Chemotherapy of Infectious Diseases and Malignancies. Futura Med, 825-837, 1989.
50. Gray, JW, Pinkel D, Trask B, van den Engh G, Segraves R, Collins C, Andreeff M, Haimi J, Perle MA. Application of flow karyotyping and fluorescence in situ hybridization to detection of chromosome aberrations. In: Prognostic Cytometry and Cytopathology of Prostate Cancer. Elsevier Science, 304-313, 1989.
51. Andreeff M, Gaynor J, Chapman D, Little C, Gee T, Clarkson BD. Prognostic factors in acute lymphoblastic leukemia in adults: The Memorial Hospital Experience. In: Haematol Blood Transfus. Springer-Verlag, 111-124, 1987.
52. Berman, E, Gee TS, Kempin SJ, Gulati S, Andreeff M, Gabrilove J, Kolitz J, Reich L, Mayer K, Miller W, Raymond G, Young CW, Clarkson BD. A comparative trial of idarubicin and cytarabine versus daunorubicin and cytarabine in untreated acute non-lymphocytic leukemia. In: 4th International Symposium on Therapy of Acute Leukemia. In: Excerpta Medica. Elsevier Science (Excerpta Medica), 37-41, 1987.
53. Andreeff M, Espiritu E. Flow cytometry in hybridoma technology. In: Hybridoma Formation. Humana Press, 437-445, 1987.
54. Andreeff M, Assing G, Cirrincione C. Prognostic value of DNA/RNA flow cytometry in myeloblastic and lymphoblastic leukemia in adults: RNA content and S-phase predict remission duration and survival in multi-variate analysis. In: Clinical Cytometry. Annals of the New York Academy of Sciences, 387-406, 1986.
55. Andreeff, M, Hansen H, Cirrincione C, Filippa D, Thaler H. Prognostic value of DNA/RNA flow cytometry in B-cell non-Hodgkin's lymphoma; development of laboratory model and correlation with four taxonomic systems. In: Clinical Cytometry. Annals of the New York Academy of Sciences, 368-386, 1986.
56. Koziner, B, Stavnezer J, Al Katib A, Gebhard D, Mittelman A, Andreeff M, Clarkson BD. Surface immunoglobulin light chain expression in pre-B cell leukemia. In: Clinical Cytometry. Annals of the New York Academy of Sciences, 211-226, 1986.
57. Redner, A, Melamed MR, Andreeff M. Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA and CALLA and comparison with conventional cytology. In: Clinical Cytometry. Annals of the New York Academy of Sciences, 241-255, 1986.
58. Andreeff, M, Redner A, Thongprasert S, Eagle B, Steinherz P, Miller D, Melamed MR. Multiparameter flow cytometry for determination of ploidy, proliferation and differentiation in acute leukemia: Treatment effects and prognostic value. In: Tumor Aneuploidy. Springer-Verlag, 81-105, 1985.
59. Clarkson, B, Gee T, Arlin Z, Mertelsmann R, Kempin S, Dinsmore R, O'Reilly R, Andreeff M, Berman E, Higgins C, Little C, Cirrincione C, Ellis S. Current status of treatment of acute leukemia in adults: An overview. In: Therapie der akuten Leukaemien, 1-31, 1984.
60. Alabaster, O, Andreeff M, Spooner C, Clagett K. Flow cytometric measurement of intracellular pH: A dosimetric approach to metabolic heterogeneity. In: Biological Dosimetry. Eisert WS, Mendelsohn ML, 299-309, 1984.
61. Wustrow, TPU, Andreeff M, Good RA. Cell kinetics of the leukemia in AKR mice using flow cytometry. In: Therapie maligner Tumore. Gustav Fischer Verlag, 734, 1983.
62. Gulati, S, Lee B, Mertelsmann R, Koziner B, Straus D, Andreeff M, Hansen H, Gee T, Kempin S, Shank B, Dinsmore R, Flomenberg N, Mayer K, Reich L, Langleben A, Jain K, O'Reilly R, Clarkson B. Autologous stem cell transplant for poor prognosis lymphoma. In: Current Concepts in Medical Oncology II. Memorial Sloan- Kettering Cancer Center, 147-150, 1983.
63. Andreeff, M, Clarkson BD, Good RA, Darzynkiewicz Z, Filippa D, Melamed MR. A taxonomic system for non-Hodgkin lymphomas based on flow cytometric quantitation of nucleic acids in situ. In: Solide Tumoren und Metastasierung. Gustav Fischer Verlag, 589, 1982.
64. Buechner, T, Hiddemann W, Andreeff M. New determinants for classification and therapeutic response in acute leukemia. In: Proceedings of the German Cancer Congress, 607, 1982.
65. Andreeff, M, Filippa D, Melamed MR, Good RA, Clarkson BD. Malignant lymphomas: Classification and staging by automated cytometry. In: Solide Tumoren und Metastasierung. Gustav Fischer Verlag, 590, 1982.
66. Chiao, JF, Freitag WB, Andreeff M. Changes in cellular markers and functions accompanying differentiation in HL60 promyelocytes by lymphocyte conditioned medium. In: Leukemia Marker, 305-308, 1981.
67. Hiddemann, W, Andreeff M, Clarkson BD. Quantitation of chemotherapy induced cytoreduction in acute leukemia. In: Modern Trends in Human Leukemia IV, 73-76, 1981.
68. Darzynkiewicz, Z, Andreeff M, Traganos F, Melamed MR. Proliferation and differentiation of normal and leukemic lymphocytes as analyzed by flow cytometry. In: Flow Cytometry IV, 392-397, 1980.
69. Andreeff M. Cell Kinetics of Tumor Growth. In: Fundamentals-Methods-Experiments. Thieme Medical Publishers, 175 pp, 1977.
70. Andreeff M, Abenhardt W. Synchronized recruitment of resting Ehrlich ascites tumor cells following transplantation. In: International Symposium of Pulse Cytophotometry. European Press, 210-215, 1976.
71. Andreeff M. Effects of different cytostatic agents on cell proliferation and DNA synthesis in Ehrlich ascites tumors. In: Molecular Base of Malignancy. Thieme Medical Publishers, 154-166, 1976.
72. Andreeff M. Cytokinetic analysis of tumor growth. In: Molecular Base of Malignancy. Thieme Medical Publishers, 147-153, 1976.
73. Andreeff M. Methoden zur Zellzyklusanalyse. In: Erkrankungen der Myelopoese, 521-524, 1976.
74. Andreeff M und Bothmann G. Gewinnung von Einzelzellsuspensionen aus soliden Geweben zur fluorometrischen DNS-Bestimmung. In: Impulscytophotometrie, 59-65, 1975.
75. Andreeff M und Haag D. Fluorochromierung mit Acridinorange in der Impulscytophotometrie. In: Impulscytophotometrie, 31-37, 1975.
76. Bothmann, G, Andreeff M, Rummel H. Die Durchflusscytophotometrie: Ein Fortschritt in der Frueherkennung des Ovarial-carcinoms?. In: Impulsecytophotometrie, 154-60, 1975.
77. Andreeff M. Proliferation pattern of ascites tumors under influence of cytostatics. In: Pulse Cytophotometry. European Press, 215-225, 1975.
78. Andreeff, M, Opetz, Gruner B. Age dependent changes of tumor cell kinetics. Pulse cytophotometric and autoradiographic studies. In: Pulse Cytophotometry. European Press, 121-8, 1975.
79. Andreeff M. Teilsynchronisation durch Bleomycin. Untersuchung der DNS-Synthese und Zellzykluskinetik am Ehrlich-Lettre-Ascites-Tumor. In: Bleomycin. Illertissen, 69-78, 1975.
80. Andreeff M. Impulscytophotometrische DNS-Bestimmung proliferierender Systeme. In: Impulscytophotometrie, 73-76, 1975.
81. Andreeff M. Wirkung verschiedener neuer Cytostatica auf die DNA-Reduplikation und die Proliferationskinetik am Modell des Ehrlich-Lettre'schen Ascites-Tumors. In: Verh Dtsch Ges Innere Medizin, 1678-80, 1974.
82. Andreeff M. Nuclear DNA content of muscle cells in experimental myotonia. In: Third Symposium on Neuromuscular Disorders. Janske Lazne, 1973.
83. Andreeff M. Effects of fractionation of ionizing radiation on nucleic acid synthesis in tumor cells, tumor growth and survival of experimental animals. In: Aktuelle Probleme der Klinischen Strahlenbiologie, 1970.

Books (edited and written)

1. Walker AR, et al. Targeted Therapy of Acute Myeloid Leukemia. Springer, 2015.
2. Berger DP, Engelhardt M, Hen H, Mertelsmann R, Andreeff M, Koziner B, Messner HA, Thatcher N. Concise Manual of Hematology and Oncology. Springer, 2008.
3. Andreeff M, Pinkel D. An Introduction to Fluorescence In Situ Hybridization. John Wiley & Sons, Inc, 1999.
4. Andreeff M. Acute Leukemias. Springer-Verlag, 1992.
5. Andreeff M. Clinical Cytometry, 1986.
6. Andreeff M. Cell Kinetics of Tumor Growth. Thieme, 1977.
7. Andreeff M. Impulscytophotometrie. Springer, 1975.

Letters to the Editor

1. Bouligny, IM, Montalban-Bravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, CD, Ravandi, F, Borthakur, G, Pemmaraju, N, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, Kanagal, R, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
2. Rakheja D, Konoplev S, Su M, Wheeler D, Muzny DM, Ruvolo VR, Collins R, Karandikar NJ, Andreeff M, Medeiros LJ, Chen W. High incidence of IDH mutations in acute myeloid leukaemia with cuplike nuclei. Br J Haematol 155: 125-8, 2011.
3. Marini, FC, Studeny M, Andreeff M. Response to Wolf. J Natl Cancer Inst 97: 541-542, 2005.
4. Monaco, G, Konopleva M, Belmont JW, Andreeff M. Correspondence re: S. Tavor et al., Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia. Cancer Res 64: 6832-6833, 2004.
5. Konopleva, M, Zhao S, Xie Z, Andreeff M. Human A1 expression in acute myeloid leukemia (AML). Blood 97: 578-579, 2001.
6. Drach, D, Zhao S, Drach J, Andreeff M. Expression of multidrug resistance gene (MDR1) in normal hematopoietic cells. Blood 81(12): 3480-1, 1993.